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Abstract  
Comorbidity is defined as experiencing an ‘index’ health condition with one or more other 
conditions at the same time. The prevalence of comorbidity, in particular chronic disease 
comorbidity, is set to rise in ageing Western populations and negatively influences patient 
health and health care services. However, our understanding of how specific comorbid 
chronic disease combinations (such as cardiovascular disease and osteoarthritis) interact, the 
subsequent outcomes and how severity influences these remains limited. The aim of this 
thesis was to investigate the consequences of cardiovascular disease and osteoarthritis 
comorbidity on short and long-term physical health change in general practice populations. 
 
A systematic review and secondary data analyses were conducted in order to firstly 
understand the relative influence of individual diagnostic categories (relative morbidity 
severity) on cross-sectional physical health and long-term physical health change over 3-
years. Secondly, a new, novel prospective cohort study investigated the association between 
cardiovascular disease and osteoarthritis comorbidity on the short-term physical health 
change over 4 and 12 months.  
 
The systematic review and secondary analyses established the use of diagnostic categories, 
applied in general practice, as an appropriate method to define relative morbidity severity. In 
the new cohort study, there were cross-sectional associations between increasing 
cardiovascular disease severity and poorer physical health. The addition of osteoarthritis 
comorbidity increased the strength of associations, after adjusting for socio-demographic 
factors. The ‘effect’ of cardiovascular disease and osteoarthritis comorbidity was, however, 
less than additive compared to either the individual cardiovascular disease or individual 
osteoarthritis cohort. There was no significant association between cardiovascular disease 
and osteoarthritis comorbidity and short-term physical health change. 
 
v 
 
This thesis highlights that a specific understanding of disease interactions requires the 
incorporation of condition type and their severity. Such epidemiological approaches offer the 
potential for identifying practical mechanisms by which clinicians might address patients’ 
needs, and how specific chronic diseases interact and influence different patient outcomes. 
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Chapter 1: Introduction 
 
This chapter provides the conceptual framework and rationale for the thesis. It addresses the 
current understanding of chronic diseases and their relationship with ageing, and describes 
the prevalence of experiencing multiple chronic diseases at the same time and the influence 
of this experience on health and health care services. The chapter also describes the concept 
of ‘severity’ in populations and provides the overall rationale for the thesis, presenting the 
aims & objectives. 
 
1.1. Chronic disease & ageing 
Chronic diseases are defined as health conditions which progress slowly, are prolonged in 
duration (≥ 3 months) and are resistant to treatment, or have no cure (Powell et al. 1989). In 
the last century, non-communicable chronic diseases have replaced acute, infectious diseases 
as the primary cause of mortality in the world (Israel, Rosenberg & Curtin 1986), accounting 
for approximately 60% of deaths worldwide, of which 44% were premature deaths (Daar et 
al. 2007). Chronic disease mortality also places a high economic burden on healthcare 
systems. For example, it has been estimated that from 2005 to 2015, the United Kingdom 
(UK) economy will have lost $33 billion (approximately £20 billion) as a result of premature 
deaths due to chronic diseases such as heart disease, stroke and diabetes (World Health 
Organization 2005).  
 
Chronic diseases have important consequences throughout life, and on mortality. In an 
assessment of the global burden of chronic disease by the World Health Organization (WHO), 
Ischaemic Heart Disease (IHD) was the leading cause of death in 2004, but such chronic 
disease is also an important cause of disease-related disability, and this is a similar feature 
across a number of chronic conditions (World Health Organization 2008). Chronic diseases 
have an adverse influence on both physical and mental health (Hopman et al. 2009) and are a 
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challenge for health care systems which are focused on improving the patient’s quality-of-life 
(QOL), as well as prolonging it (U.S. Department of Health and Human Services 2010, Davies 
2011). 
 
Chronic diseases increase with ageing. A recent report from the Department of Health for 
England stated that approximately 15 million people in England (28% of the population) 
have at least one chronic disease. A greater proportion of these chronic diseases were found 
in the elderly - 14% were aged 40 years or under, but 58% were aged 60 years or older 
(Department of Health 2012). The proportion within each age category was also dependant 
on the type of condition, with those aged 60 years or older experiencing hypertension, 
coronary heart disease (CHD) or musculoskeletal (MSK) problems in particular (Table 1.1). 
These findings are comparable with other developed countries. In a Canadian national survey 
conducted in 2005, of those aged 12 years of age or older, approximately 9 million people 
(33%) had at least one or more of seven high prevalence chronic diseases. In the age 
categories 40-59, 60-79 and 80 years or older, the proportions with at least one chronic 
disease increased from 37%, to 71% to 82% respectively (Broemeling, Watson & Prebtani 
2008). In a Dutch sample representative of general practice, a third of all registered patients 
had at least one chronic disease from a possible 29, as age increased from 55-64, 65-74 & 74 
years or more, prevalence of chronic disease increased from 53% to 70% to 86% respectively 
(van Oostrom et al. 2012). 
 
Understanding the adverse influence of chronic diseases is especially important in developed 
countries, where the populations are ageing. In the UK, from 1985 to 2010, the period life 
expectancy at birth of males increased from 72 years to 79 years and for females this 
increased from 77 years to 82 years. By 2035 it is estimated that life expectancy for males 
and females in the UK will have risen further, to 83 & 87 years of age respectively (Office for 
National Statistics 2011a). The population will not only be older, but the proportion in old 
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age will also be greater, as the current number of people in the UK aged 65 years or older is 
predicted to nearly double from 10 million to 19 million by 2050 (House of Commons Library 
2010). Increases in chronic disease in England have already been observed. From 2006/07 to 
2010/11, the number of patients affected by chronic diseases, recorded as part of the Quality 
and Outcomes Framework (QOF), increased (Department of Health 2012). Though overall 
chronic disease prevalence is increasing, the figures will vary from disease to disease and by 
age. A study in Finland predicted that by 2030, though mortality as a result of coronary heart 
disease would decrease in younger age groups, this would increase in the elderly as a result 
of ageing populations (Huovinen et al. 2006). 
 
As the likelihood of experiencing a chronic disease increases with age, so too does the 
likelihood of experiencing multiple chronic diseases at the same time. A report by the 
Department of Health (2012) showed that in England in 2009, the proportion of the 
population with multiple chronic disease increased with age (Figure 1.1). Furthermore, it 
also estimated that the number of patients with multiple chronic diseases in England is likely 
to rise from 1.9 million in 2008 to 2.9 million by 2018. The associated implication is that such 
increases of multiple chronic diseases would place an additional financial burden on the NHS 
and social care services of £5 billion. The report concluded that the current English NHS 
model of chronic disease care is not equipped to deal with such levels of multiple chronic 
diseases in the future (Department of Health 2012). 
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Table 1.1: Proportion (%) of people in England with chronic disease, by age categories 
 Age groups (%) 
Type of chronic disease 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ 
Hypertension <1 <1 <1 <1 3 8 13 16 14 
Coronary Heart Disease  <1 <1 <1 1 2 5 10 13 15 
Stroke & Transient Ischaemic Attacks <1 <1 <1 <1 <1 <1 1 2 2 
Musculoskeletal problems  1 1 3 6 11 19 22 30 37 
Diabetes - <1 1 1 2 5 8 10 8 
Cancer  <1 <1 <1 <1 1 2 2 3 4 
Mental Health 2 2 2 4 4 4 3 3 3 
Asthma 4 4 3 4 4 4 5 5 5 
Chronic Obstructive Pulmonary Disease <1 <1 <1 <1 <1 1 2 2 2 
Source: Adapted from General Lifestyle Survey 2009 (Department of Health 2012) 
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Figure 1.1: Proportion of people with one or more chronic diseases, by age in England 
(Chronic disease defined as Long-Term Condition (LTC), (Department of Health 2012)) 
 
1.2. Multimorbidity & comorbidity 
1.2.1. Definitions 
There are two definitions for patients who experience more than one health condition at the 
same time, comorbidity and multimorbidity. Though these terms are frequently used 
interchangeably in research literature, there is an important distinction between them. 
Comorbidity was the first definition and was presented by Feinstein in 1970 as “any distinct 
additional clinical entity that has existed or may occur during the clinical course of a patient 
who has the index disease under study” (Feinstein 1970). Therefore, to have comorbidity is to 
not only experience a specific disease of primary interest or investigation (index disease), but 
to also experience one or more other health condition(s) at the same time. Comorbidity can 
potentially be the product of any combination of index and additional disease(s) and patients 
may present with either an acute disease (short-term) or chronic (long-term) disease. 
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Experiencing multiple health conditions at the same time is also defined as multimorbidity. 
This is related to the presence of two or more conditions, and in contrast to comorbidity, no 
one condition takes priority. This was defined by van den Akker et al in 1996 as “the co-
occurrence of multiple chronic or acute diseases and medical conditions within one person” (van 
den Akker, Buntinx & Knottnerus 1996). Research related to this definition takes the 
approach of understanding whether the general accumulation of conditions impacts on 
patients in contrast to the focus on a primary condition, as in comorbidity. Using this 
definition allows health care services and clinicians to take a wide, general view of the 
influences of several morbidities and respond to the overall impact on the patient 
appropriately (Fortin et al. 2007). 
 
1.3. Multimorbidity 
1.3.1. Prevalence of multimorbidity 
The extent to which populations experience multiple chronic diseases at the same time is 
important to understand. By first assessing the prevalence in the population, the resulting 
figures provide the basis of establishing likely health needs, and the associated care 
resources. As the interest in multimorbidity and comorbidity has increased, a greater number 
of research studies have measured the prevalence of both. ‘Prevalence’ is the extent to which 
a health condition is present in a given population and is defined as “the total number of 
individuals who have an attribute or disease at a particular time (it may be a particular period) 
divided by the population at risk of having the attribute or disease at that time or midway 
through the period” (Porta et al. 2008). 
 
Guralnik et al in 1989 first described the prevalence of multimorbidity in the United States 
(US) general population. In a sample of those aged 60 years or older, half experienced two or 
more chronic diseases at the same time from a selection of nine chronic diseases. Increasing 
age and female gender were associated with an increased prevalence of multimorbidity 
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(Guralnik et al. 1989). In 1998, van den Akker et al showed that in a Dutch general practice 
sample of over 60,000 patients, multimorbidity (defined as 2 or more conditions) increased 
in women across the age categories from 9% (0-19 years), 19% (20-39 years), 36% (40-59 
years), 65% (60-79 years) to 80% (80 years and over); but prevalence was lower for men 
compared to women (van den Akker et al. 1998). In several more recent studies, similar 
influences of age and gender on multimorbidity prevalence have also been demonstrated; in 
the US population, in a nationally random sample of over a million Medicare beneficiaries, 
which placed the prevalence of multimorbidity at 65% in the population aged 65 years or 
over (Wolff, Starfield & Anderson 2002), in the general population of Canada (Broemeling, 
Watson & Prebtani 2008) and in a study in Dutch general practice (van Oostrom et al. 2012). 
 
Increasing age has a clear impact on the prevalence of multimorbidity. This was most 
recently established in a systematic review by Fortin et al in articles published from 1980 – 
2010, which examined the prevalence of multimorbidity, from both general population (12 
articles) and primary care studies (8 articles). In the articles which had examined all age 
ranges, prevalence was approximately 20% or lower in those aged 40 years or under, a sharp 
increase during middle age was observed, which subsequently plateaued after 70 years to a 
prevalence of around 75% (Fortin et al. 2012). An issue raised by the Fortin et al review was 
that prevalence across studies was wide, mainly as a result of varied methodologies but the 
influence of age was consistent. Salisbury et al used two different methods to define 
multimorbidity (a count of the chronic diseases which are present in the QOF and the John 
Hopkins University Adjusted Clinical Groups (ACG) system) in samples from UK general 
practice and found that multimorbidity was common in the UK regardless of the defining 
measure and increasing prevalence was associated with older age (Salisbury et al. 2011). 
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In another systematic review by Marengoni et al (which included approximately half of the 
articles which were also in the Fortin et al review), a greater prevalence of multimorbidity 
was again associated with age. However, this also highlighted an influence of female gender 
and a low socioeconomic status as being associated with increased prevalence of 
multimorbidity (Marengoni et al. 2011). An association between deprivation status and 
multimorbidity was also shown by Barnett et al. A large, cross-sectional study assessed the 
prevalence of multimorbidity in a sample which included a third of the Scottish population, 
defined as having 2 or more of a selection of 40 chronic diseases. 55% of those with at least 
one morbidity also had multimorbidity and this increased with age, 2% for those aged 
between 0-24 years, 11% for 25-44 years, 30% for 45-64 years, 65% for 65-84 years and 
82% for those aged 85 years or older. This study also demonstrated that compared to the 
most affluent individuals, those living in the most deprived areas not only experienced more 
multimorbidity, but 10-15 years earlier in life (Barnett et al. 2012). 
 
1.3.2. Consequences of multimorbidity 
Fortin et al also undertook a systematic review to examine the influence of multimorbidity on 
QOL in primary care. The 30 studies included all used a simple, though varied count of 
chronic diseases and all were cross-sectional. These studies found that increasing 
multimorbidity was associated with poorer QOL. This was more apparent in the physical than 
psychological and social domains (Fortin et al. 2004). More recently, an extensive systematic 
review was conducted by Marengoni et al. They identified articles which had considered the 
influence of multimorbidity on; (i) disability and functional status, (ii) mortality, (iii) health 
care utilization or (iv) QOL. The review concluded that multimorbidity had a negative 
influence on each of these factors, but that there was a need to investigate the influence of 
multimorbidity prospectively and on longer-term outcomes (Marengoni et al. 2011). 
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1.3.3. Longitudinal consequences of multimorbidity 
A recent systematic review conducted by France et al found there were only five studies 
which had examined the influence of multimorbidity longitudinally (ranging from 1 to 2 years 
follow-up). This review demonstrated that in these five studies which had examined the 
influence of multimorbidity longitudinally, multimorbidity was associated with increased 
healthcare use and costs, inpatient admissions and mortality (France et al. 2012). 
 
1.3.4. Current status of multimorbidity research 
Despite a wide range of prevalence estimates in the literature, primarily as a result of varied 
methodologies (Fortin et al. 2012), there is a clear argument that in general practice, 
multimorbidity is ‘the rule rather than the exception’. Multimorbidity is associated with 
increased age (van den Akker et al. 1998, Laux et al. 2008), but is not just experienced by the 
elderly (Mercer et al. 2009). It is also clear that deprivation is an important factor in the 
prevalence of multimorbidity, with the most vulnerable in society at greatest risk (Uijen, van 
de Lisdonk 2008, Barnett et al. 2012). 
 
The high prevalence of multimorbidity means that there are larger societal impacts. The 
burden of multimorbidity is reflected in high healthcare costs (Glynn et al. 2011), and high 
consultation rates in general practice (Salisbury et al. 2011). Those with multimorbidity also 
have poorer QOL (Fortin, 2004; Heyworth, 2009) and physical function (Kadam, Croft & 
North Staffordshire GP Consortium Group 2007). 
 
The science of multimorbidity is still emerging and gaps in the research conducted remain, 
especially that of the natural history (Marengoni et al. 2011), and prospective research into 
the longer-term outcomes of multimorbidity in general practice is very limited (France et al. 
2012). Multimorbidity research needs to address a lack of assessment by disease severity 
(Mercer et al. 2009) and influence of multimorbidity on QOL over time (Fortin et al. 2004).  
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1.4. Comorbidity 
1.4.1. Prevalence of comorbidity 
Schellevis et al showed that in general practice patients; the observed prevalence of 
comorbidity was significantly higher in those with one of five specified common chronic 
diseases (osteoarthritis, hypertension, chronic ischaemic heart disease, diabetes mellitus and 
chronic nonspecific lung disease) than those without one of these five. Having an existing 
chronic disease placed the patients at greater risk of comorbidity. Within the sample, OA and 
diabetes mellitus were the most common comorbidity in the five chronic diseases (Schellevis 
et al. 1993). Kadam et al also demonstrated increased prevalence of comorbidity in those 
with existing chronic disease in two separate studies conducted in UK general practice. After 
adjusting for age, sex and social class in both, i) OA patients were more likely to have 
comorbidity than age-matched controls (Kadam, Jordan & Croft 2004) and ii) in a case-
control study, those with diabetes, anxiety or upper respiratory tract infections were each 
associated with a greater risk of comorbidity compared to controls (Kadam, Jordan & Croft 
2005). 
 
Prevalence of comorbidity is also influenced by age. In a Dutch study of HF patients from 
general practice aged 65 years or older, both cardiovascular disease (CVD) and non-CVD 
comorbidities increased with age (van der Wel et al. 2007). Another study of HF patients, 
stratified by several different comorbidities, found that the prevalence of discordant (non-
CVD) comorbidities was greater and increased at a faster rate than concordant comorbidities 
in the oldest old (Ahluwalia et al. 2011). 
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The prevalence of comorbidity varies across specific chronic disease combinations. In a study 
of seven chronic diseases in the Canadian population, half of those with hypertension had 
other comorbidity, and in comparison of the population with diabetes, three quarters had 
comorbidity (Broemeling, Watson & Prebtani 2008). Caughey et al conducted a systematic 
review of comorbidity studies in Australia which had examined the prevalence of different 
chronic disease comorbid combinations. Prevalence varied across different disease pairings, 
for example, in a sample with arthritis, over 50% had hypertension, 20% had CVD and 14% 
had diabetes. In a sample with asthma, over 60% had arthritis, 20% had CVD and 16% had 
diabetes (Caughey et al. 2008). In prevalence analysis performed on a large sample in Canada 
and adjusted for age, gender, race, education, income and Body Mass Index (BMI), the most 
common comorbidity for those with arthritis was CVD (20%), followed by 18% with diabetes 
and 13% with respiratory disease (Slater, Perruccio & Badley 2011). Most recently, in a 
sample of over 50,000 nationally representative patients from Dutch general practice, the five 
most common combinations with 10 chronic diseases were examined. Diabetes, CHD and OA 
were the most prevalent comorbidities within the ten most common chronic diseases (Table 
1.2). Gender and age adjusted odds ratios (OR) demonstrated the prevalence of the majority 
of comorbid pairings occurred more than would be expected by chance. Across the ten index 
conditions, the top 5 accounted for only approximately 30% of comorbidity (van Oostrom et 
al. 2012). 
  
 
1
2
 
Table 1.2: Five most prevalent comorbidities of ten index chronic diseases 
Index chronic 
disease 
Comorbidity top 5 and prevalence (%)  % Contribution  
to comorbidityǂ 
 1  2  3  4  5   
                 
Diabetes CHD  (30.0)  OA (22.7)  Neck/back  (20.3)  Heart failure (18.1)  COPD (17.2)  31.5 
CHD Diabetes (33.5)  Heart failure (25.5)  OA (23.0)  Neck/back  (20.8)  Cancer (16.7)  32.8 
OA Neck/back  (26.8)  Diabetes  (26.0)  CHD (23.6)  Visual disorder (16.4)  Cancer (16.0)  33.5 
COPD Asthma  (32.4)  CHD (27.4)  Diabetes  (25.8)  Heart failure (24.0)  OA (20.5)  29.9 
Neck/back OA (31.5)  Diabetes  (27.3)  CHD (25.2)  COPD (17.0)  Cancer (15.5)  35.8 
Cancer Diabetes (25.6)  CHD (24.4)  OA (22.8)  Neck/back  (18.8)  COPD (18.3)  33.1 
Stroke Diabetes  (32.4)  CHD (26.0)  OA (21.0)  Heart failure (20.2)  COPD (17.5)  27.8 
Depression OA (24.7)  Diabetes (24.6)  CHD (22.8)  Neck/back  (22.3)  COPD (18.0)  26.4 
Heart failure CHD (42.0)  Diabetes (33.3)  COPD (29.4)  OA (24.5)  Stroke (18.0)  30.4 
Anxiety disorder Depression (38.0)  Diabetes (22.3)  Neck/back  (22.2)  CHD (20.7)  OA (19.8)  31.4 
Adapted from van Oostrom (van Oostrom et al. 2012). Diabetes = Diabetes mellitus, CHD = Coronary heart disease, OA = Osteoarthritis, COPD = Chronic Obstructive 
Pulmonary Disease, Neck/back = Chronic neck or back disorder. ǂContribution of top 5 to all comorbidity with the specific chronic disease
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1.4.2. Consequences of comorbidity 
In 2001, Gijsen et al conducted a systematic review identifying studies which had examined 
the consequences of comorbidity. This showed that overall comorbidity influences several 
health outcomes, including mortality, physical functioning and QOL. Nearly all of the studies 
which had defined comorbidity through ‘counts’ (the summing of diseases an individual has) 
or through a ‘comorbidity index measure’ (combining the number and severity of conditions) 
found significant consequences. However, in those articles examining comorbid ‘pairs’ (an 
index condition with a defined comorbidity), not all chronic disease combinations had a 
significant influence on a range of outcomes (Gijsen et al. 2001). 
 
Varying patient burden subsequently influences health services, with regard to prevention, 
complexity of treatment and service utilization (Gijsen et al. 2001, Fortin et al. 2007). The 
high prevalence of comorbidity in populations is reflected by high levels of general practice 
consultation. For several conditions, including hypertension, IHD and HF, patients with a high 
level of comorbidity had more consultations for the comorbidities than the index condition 
and therefore required a greater proportion of resources (Starfield et al. 2003). 
 
1.4.3. Consequences of interaction 
By examining the consequences of specific chronic disease combinations, the interaction of 
such comorbid disease pairs can be assessed. Interaction is the “interdependent operation of 
two or more causes to produce, prevent or control an effect” (Porta et al. 2008, Greenland 
2009). The consequences of different chronic disease comorbidity combinations may vary 
from that which may be expected when combining the individual consequences of each 
disease. Outcomes may be antagonistic, that is the actual effects of two factors occurring 
together is smaller than that which might be expected from combining the individual effects 
of each factor in the absence of the other (Rothman 1974). Interaction may also take the form 
of an additive effect, which is the actual effects of two factors occurring together, being the 
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sum of the individual effects that would be produced by each of the factors in the absence of 
the others (Ahlbom, Alfredsson 2005). Interaction may also result in a synergistic effect, 
which is “a situation in which the actual effects of two or more factors is greater than the sum of 
their individual effects” (Porta et al. 2008). 
 
Several studies have examined different consequences of interaction between specific 
chronic disease comorbidity. In 1999, Fried et al examined the association between different 
chronic disease combinations and physical disability. Using a cross-sectional sample of 
women aged 65 years or older, they showed that certain chronic disease combinations were 
synergistically associated with different aspects of disability when compared to the influence 
of the individual diseases (Fried et al. 1999). In 2005, Rijken et al examined the influence of 
different comorbid chronic disease combinations from a nationally representative cross-
sectional sample of Dutch general practice on physical health. They found that overall, having 
a select chronic disease and any other chronic disease comorbidity was associated with 
significantly worse physical health then those without comorbidity. However, when 
examining specific chronic disease combinations and adjusting for age and gender, they 
showed that some chronic diseases interact to have a synergistic effect on physical health 
(CVD & arthritis) and some do not (arthritis & diabetes mellitus) (Rijken et al. 2005). Wee et 
al found that the QOL of diabetes mellitus patients from the general population in Singapore 
was diminished as a result of comorbidity, but the extent of interaction varied depending on 
whether the comorbidity was with hypertension, heart disease or MSK illness.  Here an 
additive effect was observed of diabetes comorbidity of hypertension or MSK illness but an 
antagonistic effect with heart disease (Wee et al. 2005). 
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1.4.4. Longitudinal consequences of comorbidity 
Of the 78 articles included in the review by Gijsen et al, 24 had examined QOL, 14 of these had 
examined specific disease pairs, but only 1 had examined the consequence of comorbid 
chronic disease pairs prospectively in the general population (Ettinger et al. 1994) and 1 in 
general practice (Sherbourne et al. 1996). Both of these US studies found that physical health 
decline was more likely in those with specific comorbid combinations than those with the 
same index diseases but without comorbidity. Other isolated prospective studies, outside of 
this review have also shown that comorbidity (measured as either counts or using an index 
measure) was associated with declines in physical health (Bayliss et al. 2004, White et al. 
2011).  
 
Long-term comorbidity is also associated with increased mortality. In a 14-year longitudinal 
study, Caughey et al showed that the elderly (≥ 65 years of age) who had 3 or more chronic 
diseases were at greater risk of mortality, but survival was determined by the specific 
comorbid combinations (Caughey et al. 2010). Nüesch et al demonstrated the impact of CVD 
comorbidity on mortality of OA patients. A sample drawn from general practices in the 
southwest of England was also prospectively followed for an average of 14 years. They found 
that patients with OA had a significantly higher risk of mortality than the general population 
and that this was particularly pronounced in those with a history of CVD (standardised 
mortality ratio 1.71 (95% CI 1.49 to 1.98)). This paper recommended that patients presenting 
with OA in general practice should be examined for CVD risk factors (Nuesch et al. 2011). 
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1.4.5. Current status of comorbidity research 
Chronic disease comorbidity is common and occurs more frequently than could be expected 
by chance (van Oostrom et al. 2012). The prevalence of comorbidity is frequently high, and 
increases with age, but figures vary across different disease combinations. Chronic disease 
comorbidity is associated with increased mortality, increased health care utilisation and 
negative impact on health. Most comorbidity research which has examined these 
consequences has typically been cross-sectional, has not considered the severity of the 
conditions included and has frequently defined the presence of comorbidity as a ‘count’ of 
other morbidities with the index condition rather than as comorbid combinations (Huntley et 
al. 2012). 
 
Few research studies have examined the impact of specific combinations of chronic disease 
comorbidity on patient physical health and even fewer have examined the interaction of 
these over time in general practice populations. For clinicians to effectively treat and manage 
patients with chronic disease comorbidity, it is important to understand how comorbidity 
affects the patient over the course of that index condition. Furthermore, from diagnosis of a 
disease, the impact of that condition or the patient’s perceived impact will most likely change 
over time. Change in physical health over time may improve or worsen and this course may 
be altered by the combinations of disease that are present in the patient. In summary, current 
evidence in comorbidity literature has had very few studies on specific chronic disease 
interaction and prospective investigation of outcomes. 
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1.5.  The concept of ‘severity’ 
The ‘severity’ of a health condition will frequently influence its clinical management. By 
understanding the ‘state’ of a given condition, this can provide additional insight into a 
particular outcome and subsequent clinical decision-making. For example, severity of 
radiographic OA, as defined by the Kellgren & Lawrence scale, is an indicator of disease 
progression through joint space narrowing (Bruyere et al. 2003). Therefore, knowledge of 
severity can add to the information forming treatment and management choices.  
 
The ‘severity’ of comorbidity and multimorbidity is an important, but infrequently examined 
area of research. For patients in general practice, having more than one morbidity at the 
same time is increasingly common and often necessitates more complex care (Kadam 2012). 
Multiple morbidities are a particular concern for patients with chronic diseases, who have 
been shown to experience more additional morbidity than other disease groups (Schellevis et 
al. 1993, Kadam, Jordan & Croft 2004). Previous research has frequently defined comorbidity 
or multimorbidity by a ‘morbidity count’, with increasing severity indicated by an increasing 
number of morbidities. Where such a definition of severity has been used, increasing severity 
is associated with poorer health outcomes (Bayliss et al. 2004, Kadam, Croft 2007), but such a 
simplistic definition of severity introduces certain limitations.  
 
Though an increased number of morbidity counts may reflect poor health outcomes, it 
remains unclear where the mechanisms of this may lay, as which diseases are present, and 
the contribution of each disease to patient health, remains unclear. Therefore, to clearly 
understand how different morbidities interact and the subsequent patient outcomes, the 
need exists to define clearly the severity of each condition present. Such an approach to 
measuring severity would quantify additional morbidity numbers, whilst retaining 
information on each condition, of which both sets of data are of importance for the clinician. 
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1.5.1. Forms of severity  
The consensus now is that definitions of comorbidity or multimorbidity need to move beyond 
simply counting and including conditions. However, the term ‘severity’ can be applied in 
different ways and can depend on whose perspective is considered; the patient’s, the 
clinician’s or disease occurrence at a population level. Three ways in which the term ‘severity’ 
can be approached are as follows: 
 
(i) ‘Health severity’, the severity of one’s own health, perceived by an individual 
(whether they have a condition or not) at a given point in time. This concept of 
‘severity’ relates to an overall outcome, which may be disease specific or relate to the 
multimorbidity a patient experiences, or to other factors such as age, gender and 
deprivation. 
 
(ii) ‘Disease severity’, differing experiences of health by individual patients who have 
been classified as having the same disease or symptom, e.g. when two individuals, 
both with heart disease, require different levels of treatment. This concept of severity 
relates to the consequences and complications of the disease an individual patient 
might experience.  
 
(iii) ‘Relative morbidity severity’, the severity of one disease population relative to 
another disease population i.e. heart failure population on average would be 
associated with ‘more’ adverse outcomes than the population with hypertension. This 
concept of ‘severity’ is important as it allows the comparison of populations and the 
population experience of the particular disease. 
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1.5.2. Defining ‘relative morbidity severity’ 
Relative morbidity severity presents an opportunity to examine the severity of different 
morbidity groups at the population level, either as several separate morbidities or in 
comorbid combination. Assessment of the relative severity of morbidities requires a uniform 
method of defining morbidity groups, clinical diagnosis applied in general practice provides 
an epidemiological method to achieve this. Due to the lack of measures of morbidity severity 
in general practice (Kadam et al. 2008), Kadam et al developed an index to assess morbidity 
severity in general practice based on the coded information applied to the patient during 
consultation. This morbidity index forms the basis of the ‘relative morbidity severity’ concept, 
it is utilised to construct morbidity groups, which then allows relative comparisons. 
 
1.5.2.1. Kadam morbidity index 
In 2006, Kadam et al developed a Morbidity Index, to define ‘morbidity severity’ in general 
practice (Kadam, Jordan & Croft 2006). The first stage involved working with General 
Practitioners (GP) to develop criteria with which to classify morbidity in general practice. 
Through six meetings with a group of clinically active GPs, a morbidity classification was 
developed which was based on four separate criteria. Morbidity could be defined by its: 
 
i) chronicity and threat 
ii) time course, 
iii) health care use  
iv) impact on patients’ Activities of Daily Living (ADL)  
 
A morbidity can be applied to one of four categories within the ‘chronicity and threat’ criteria 
it may be acute, acute-on-chronic, chronic or life-threatening. For ‘time course’, categories 
relate to one-off, recurrent, progressive or permanent. The remaining two classifications are 
continuous, so for ‘health care use’ a morbidity can range from 1 (low – consultation 
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requiring advice only) to 9 (high – inpatient or high-tech care required) and ‘impact on 
patients ADL’ is scaled from 1 (low impact) to 9 (high impact). In the second stage of this 
development work, 44 GPs completed a consensus study, when 188 common and randomly 
selected morbidities from a national database were classified by the four criteria. This 
resulted in morbidities being placed according to ‘severity’ within each criterion. 
 
In 2008, Kadam et al tested the internal and external validity of using morbidity as a severity 
classification. This tested whether the clinically-defined severity categories were associated 
with poor physical health (Kadam et al. 2008). Using data from both UK (internal validity) 
and Dutch (external validity) general practices, the associations between morbidity severity 
and physical functioning were investigated and showed that morbidity severity was 
associated with older age, being female and more deprived and poor physical function.  
 
This work demonstrated that clinical morbidity in populations can be ordered by ‘morbidity 
severity’ and that routine consultation can provide the diagnostic data which can be used as 
an indicator of physical health at an epidemiological level. The practical consequence of the 
Kadam morbidity index is that comorbidity and multimorbidity need not be defined by 
individual conditions, but by groups of morbidities that share similar attributes particularly 
in relation to overall health. This approach provides insight into the burden of morbidity, but 
at the loss of individual disease or condition information. Epidemiological studies have 
shown the population impact of individual diseases on physical health, but the general 
practice impact of individual chronic diseases relative to one another remains to be 
established. This is an important gap if the comorbidity and multimorbidity definitions are to 
re-focus on combinations of individual and specified conditions.  
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1.5.2.2. Morbidity selection and relative severity ordering 
Development of the morbidity index by Kadam et al had been achieved by classifying 
morbidities across each of the four severity categories. Here the association had been 
examined between increasing severity in each category (i.e. acute, acute-on-chronic, chronic 
or life threatening, within the ‘chronicity and threat’ category) and several variables. This 
work, though classifying morbidity to the severity categories, did not consider the relative 
severity of morbidities with any variables. 
 
The research by Kadam et al can inform the investigation into relative morbidity severity in 
two specific ways. Firstly, this can provide evidence for the inclusion of morbidities, based on 
common prevalence. Here common morbidities, including many chronic diseases, consulted 
for in UK general practice were used. Secondly, the morbidity index has classified the severity 
of morbidities based on four criteria, providing a method to define a priori order of relative 
severity of morbidities. A summary of the work of Kadam et al and how this was used to 
examine relative morbidity severity is displayed in Figure 1.2. 
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Figure 1.2: Relative morbidity severity methods informed by previous research 
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1.5.2.3. Exemplar chronic disease spectrums 
By defining severity of one morbidity relative to another, and when considering several 
conditions, this approach can form a ‘severity spectrum’. Relative morbidity severity can be 
considered within the same chronic disease by forming ‘spectrum’ of several morbidities 
which influence the same bodily system. To examine the role of relative morbidity severity in 
this thesis, two specific chronic diseases were selected, cardiovascular disease and 
musculoskeletal disorders, and spectrum formed for each.  
 
As individual chronic diseases, both CVD & MSK are common reasons for consultations in UK 
general practice (Jordan et al. 2013). Each chronic disease includes a range of conditions 
which, whist influencing the same body system, differ in their influence on the patient. These 
form severity spectrums of morbidities which can share an aetiological link (i.e. hypertension 
is a risk factor for heart failure) or act separately (i.e. no causal link between osteoarthritis 
and rheumatoid arthritis). Separately, each of these two chronic disease spectrums will 
influence their respective bodily systems. However, these chronic diseases have also been 
shown to commonly co-occur (van der Wel et al. 2007) and may also share certain risk 
factors (Guh et al. 2009, Conaghan, Vanharanta & Dieppe 2005). For these reasons, CVD & 
MSK provide a good basis for consideration of relative morbidity severity and for comorbid 
examinations of interactions. 
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1.5.2.4. The concept of ‘disease or disorder’ spectrum 
Chronic diseases can include several different conditions and each may vary in its impact on 
the patient. For example, the term ‘cardiovascular disease’ incorporates a range of conditions 
from hypertension, ischaemic heart disease, peripheral vascular disease and stroke. Another 
example is ‘musculoskeletal disorders’, which incorporates a range of conditions from pain 
symptoms, site-specific pain, specific degenerative and inflammatory diagnostic conditions. 
So each chronic disease represents a range or ‘spectrum’ of labels. The importance of 
understanding the spectrum is that this perspective provides the link to the concept of 
‘severity’. The different stages within each chronic disease spectrum might provide a possible 
staging of the ‘relative severity’ of the condition, and the work by Kadam et al provides 
support for this type of hypothesis or approach. 
 
However, the main caveat to the spectrum approach is to understand whether or how the 
groups of conditions are related to each other. Chronic disease may include a number of 
potentially interlinking diseases affecting the same system and pathogenesis (for example 
cardiovascular disease), or a series of potentially related chronic disorder (e.g. 
musculoskeletal disorders). In the spectrum of musculoskeletal disorder, the common feature 
is the pain symptom, but conditions such as osteoporosis, OA and rheumatoid arthritis (RA) 
may have distinct pathogenesis. 
 
In investigating comorbidity and multimorbidity, the concepts of ‘severity’ and ‘spectrums’ 
provides the basis for extending the definitions, to answer the questions how different 
morbidities at different stages of development, are incorporated in epidemiological 
definitions and potential application to clinical practice.   
 
 
 
 25 
 
1.6. General practice populations 
General practice provides the ideal setting to examine the influence of specific combinations 
of chronic diseases on the physical health of the population. In the UK approximately 98% of 
the population are registered with a general practice (Bowling et al. 1999). General practice is 
frequently the first point-of-contact for any individual with a non-emergency health condition 
or symptom and so functions as the primary level of health care in the UK. The management 
and treatment of chronic diseases accounts for a large proportion of National Health Service 
(NHS) resources and a large proportion of this is used at the general practice level, with 50% 
of GP appointments being related to chronic diseases (Office for National Statistics 2011b). 
In UK general practice, Read codes are used to classify the morbidity or symptom with which 
a patient presents to the health professional in a standardised way. This computerised coding 
of consultations provides the ability to monitor symptoms and conditions. Due to the 
substantial burden of chronic diseases, the monitoring of these is of particular importance. 
This may be performed through chronic disease registers at a local level, with general 
practices being able to observe patients with particular conditions of importance in their 
region. Monitoring is also conducted at a national level in the UK through the Quality and 
Outcomes Framework (QOF). The QOF was introduced in 2004 to ensure that a selection of 
the most prevalent and resource intensive diseases in the UK are recorded accurately and 
process of care was measured, and practices reimbursed based on coding diseases of interest. 
 
As a result of this standardised and regular monitoring policy, general practice is positioned 
at the front-line to deal with comorbidity (van den Akker, Buntinx & Knottnerus 1996, 
Starfield et al. 2003), but must question how to effectively treat and manage patients who are 
experiencing different diseases at the same time. Current disease guidelines are limited in 
their ability to deal with multiple conditions (Boyd et al. 2005), but to achieve such guidelines 
we need to understand how specific comorbid disease influence different aspects of health. 
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1.7. Measuring health 
With life expectancy increasing, and the prevalence of chronic diseases also rising, the 
expanding focus for health care is to ensure patients retain a quality-of-life (QOL) which they 
find acceptable for as long as possible (Belloc, Breslow & Hochstim 1971). Chronic diseases 
can lead to a multitude of systematic or localised biological, physiological, psychological 
and/or sociological changes in the patient. QOL is a subjective measure of these factors, 
acting as a proxy by providing an indicator of how the disease impacts on different aspects of 
a patient’s life. QOL is an important indicator of the burden of chronic disease (Scott, Garrood 
2000) and use of these measures has increased steadily in recent decades. This has resulted 
in a greater importance placed on QOL as well as a shift to provide more autonomy to 
patients and focus treatment and management around their preferences, rather than purely 
on clinical decisions. 
 
1.7.1. General physical health 
The WHO defines health as "a state of complete physical, mental and social well-being and not 
merely the absence of disease or infirmity" (Division of Mental Health and Prevention of 
Substance Abuse 1997). However, there is a growing awareness in Western society of the 
importance of physical activity for general health. Regular physical activity has proven to be 
effective in the prevention of several chronic conditions (U.S. Department of Health and 
Human Services 1996). Retaining or improving general physical health can improve multiple 
aspects of the patient’s daily life and potentially reduce further aspects of health decline. 
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Measures of physical health may be disease-specific or general. Disease-specific tools will 
measure aspects of physical health which are specific to the disease of interest, for example 
chest pain in CVD patients. Such measures are frequently used to assess the severity of a 
condition on the patient. General measures of health relate to common experiences of 
patients, no matter the disease, for example, difficulty in walking a mile. The major benefit of 
such generic measures is the ability to compare the physical health of patients across 
different disease groups. 
 
Though psychological health is an important aspect of general health, the impact of chronic 
disease on psychological health has been shown to be less than the impact on physical health. 
Rijken et al found that those with more than one of several chronic diseases had no worse 
psychosocial health than those with just one of the chronic diseases (Rijken et al. 2005). It has 
been demonstrated that though some aspects of physical health decline with increasing age 
and the presence of chronic disease, mental health decline is less distinctive. This may be the 
result of psychological adjustment (Singer, Hopman & MacKenzie 1999, Hopman et al. 2009) 
and that general physical health is more likely to be affected by chronic disease over time 
than psychological health.  
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1.8.  Rationale for the thesis 
Populations, particularly those in the developed world are ageing. This has led to the 
increasing prevalence of chronic disease, and in-turn, the increasing prevalence of patients’ 
experiencing more than one chronic disease at the same time. Though research is developing 
our knowledge in this area, our understanding of the consequences of comorbidity & 
multimorbidity longitudinally remains limited, as does the role of severity within both. 
 
General practice provides an opportunity to examine chronic disease populations. Patient 
groups with these long-term conditions frequently consult and are readily identifiable 
through computerised general practice systems. Standardised consultation coding in UK 
general practice allows for the selection of specific conditions of large samples, as the 
majority of the UK population are registered with a general practice. Data from general 
practice also presents an opportunity to define morbidity groups for epidemiological 
research and add further to comorbidity & multimorbidity research by examining the role of 
severity in multiple chronic disease experience. An outcome which is influenced in all chronic 
disease groups is general physical health and this is a major factor on patient QOL. 
 
CVD & MSK are chronic diseases which occur individually and together commonly in general 
practice and will be examined across the thesis. However, the specific focus will be on two 
chronic disease examples, Cardiovascular Disease (CVD) and Osteoarthritis (OA), and on the 
concept of comorbidity. CVD and OA are two of the most common and debilitating chronic 
diseases, combined CVD & OA is one of the most frequently observed comorbid combinations 
(Guccione et al. 1994, van der Wel et al. 2007). Though the likelihood of CVD & OA co-
occurrence increases with increasing age, ageing does not completely account for the 
observed prevalence of CVD & OA comorbidity, which is greater than that which would be 
expected by chance (Kadam, Croft 2007, van Oostrom et al. 2012). 
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In addition to their common occurrence both individually or together, there are other shared 
factors between these conditions which suggest an important relationship, including shared 
causal mechanisms (i.e. obesity (Guh et al. 2009) or vascular (Conaghan, Vanharanta & 
Dieppe 2005)) and shared consequences (i.e. diminished physical health). In particular, 
conditions which influence the same consequences, but through different mechanism, may be 
of particular importance (Kriegsman, Deeg & Stalman 2004). The commonality of CVD & OA 
also presents a feasible base to conduct an epidemiological investigation into the 
consequences of specific comorbid combinations. A relationship between CVD & OA is clear, 
but the specific influences of this comorbid combination remain largely unexplored. 
 
This rationale raises five specific questions: 
 
1) Do individual chronic diseases in general practice populations vary in their influence on 
overall health? 
This question is important, because to understand comorbidity or multimorbidity fully, we 
need to first understand the individual disease effects on outcomes. 
 
2) Can relative morbidity severity act as a marker of physical health? 
This question is important in establishing the use of consultation data as a means of defining 
morbidity and whether relative severity is associated with physical health 
 
3) Can relative morbidity severity act as a marker of physical health change? 
This question is important to understand how individual morbidities influence physical 
health over a long-term period 
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4) How do specific chronic disease comorbidity combinations interact to influence health?  
This question is important because specific comorbidity combinations may have different 
effects, and may also be dependent on the focus of outcome. 
 
5) How does chronic disease and chronic disease comorbidity influence health over time?  
This question is important because specific comorbidity combinations may cause greater or 
faster deterioration in health. 
 
The underlying hypothesis is that those with comorbidity will have poorer and more rapidly 
deteriorating physical health than those with individual conditions. Furthermore, that 
increasing severity will influence any association. By understanding the consequences of this 
common comorbid disease pair on the physical health of general practice populations, this 
provides new information for comorbidity researchers and clinicians. 
 
1.8.1. Specific hypotheses 
The thesis has been framed as following. First investigations are focused on understanding 
cardiovascular disease and musculoskeletal disorder spectrums separately, and in relation to 
overall physical health. Second investigations are focused on the specific relationship 
between cardiovascular disease groups and the addition of osteoarthritis, and the influence 
of this specific combination on physical health over time. The following five are key 
hypotheses: 
 
Hypothesis 1 
The association between individual chronic disease and physical health will vary between 
different chronic diseases 
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Hypothesis 2 
Diagnostic labels applied in general practice are markers of ‘relative morbidity severity’ and are 
associated with physical health 
 
Hypothesis 3 
Increasing relative morbidity severity is associated with greater change in long-term physical 
health 
 
Hypothesis 4 
CVD and OA comorbidity is associated with worse physical health than index CVD without OA 
and index OA without CVD 
 
Hypothesis 5 
CVD and OA comorbidity is associated with more rapid and severe physical health change over 
short-term than index CVD without OA and index OA without CVD 
 
1.9. Aim & objectives 
1.9.1. Aim 
To investigate the consequences of cardiovascular disease and osteoarthritis comorbidity on 
short and long-term physical health in general practice. 
 
1.9.2. Objectives 
1) To review the current evidence on the associations between conditions in the 
cardiovascular disease and musculoskeletal disorder spectrums, and physical health in 
general populations 
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2) To examine the association between individual chronic disease spectrum and physical 
health in general practice populations 
3) To examine the association between individual chronic disease spectrum and long-term 
physical health change (3-year) in general practice populations 
4) To develop a new study investigating the relationship between cardiovascular disease 
groups and comorbid osteoarthritis, and examine the short-term change in physical 
health over time (monthly and 12-months). 
 
1.10. Thesis overview 
The following is a brief overview of several aspects of the thesis. Described below is i) the 
content of each chapter of the thesis, ii) a summary of each study included in the thesis, 
reported in Box 1.1 and iii) a summary of each analytical component included the thesis, 
reported in Box 1.2. 
 
Chapter 2 will present the background literature for the thesis. This will describe the 
prevalence, causes and consequences of CVD and OA. This will also describe the current 
understanding of comorbidity research related to CVD and OA, including research covering 
their relationship as comorbidities. 
 
Chapter 3 describes the methods which have been used in the five main studies that are 
presented in the thesis. This chapter provides consideration and justification for the inclusion 
of these methods.  
 
Chapter 4 is a systematic review which examines the influence of individual chronic diseases 
on physical health. This presents the current understanding of the relative influence of 
several different chronic diseases on physical health in general practice and the general 
population. 
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Chapter 5 tests the use of diagnostic labels as markers of relative morbidity severity for 
chronic diseases. The cross-sectional analysis of an existing data set allowed examination of 
the association between relative morbidity severity and physical health. 
 
Chapter 6 describes a cohort study examining the influence that relative morbidity severity 
has on (long-term) physical health change over 3 years. Here the influence of comorbid 
counts is also examined. 
 
Chapter 7 describes the protocol of the Comorbidity Cohort (2C) study, a newly designed 
study which examines the influence of the combined comorbidity of CVD & OA on the physical 
health of general practice patients and how it changes over the short-term. This includes a 
pilot study and methods of the main study and sampling techniques.  
 
Chapter 8 describes the cross-sectional analysis of the 2C study, examining the association 
between CVD & OA comorbidity and physical health. 
 
Chapter 9 describes longitudinal analysis of the influence of CVD & OA comorbidity on 
(short-term) physical health change from baseline to 4-month follow-up and from baseline to 
12-month follow-up. 
 
Chapter 10 will discuss the overall findings of the thesis, how this research relates to existing 
research and its research and clinical implications. This will address both the strengths and 
limitations of the thesis and then draw together the conclusions made from the thesis. 
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Box 1.1: Summary of analyses in thesis (for related key findings please see Box 10.1) 
Study Analysis Brief description (Dataset, aim, publications) 
 
1 Systematic review  Original work for thesis. 
 To examine the influence of individual chronic 
disease on physical health  
 Publication planned for 2013 
 
2 Secondary, cross-
sectional  
 Performed for thesis using a specific subsample of data 
from the NorStOP population survey, collected by other 
Centre staff prior to commencing the thesis. 
 To examine the association between ‘relative 
morbidity severity’ and physical health 
 Published in Journal of Clinical Epidemiology 
 
3 Secondary, cohort   Performed for thesis using a specific subsample of data 
from the NorStOP population survey collected, by other 
Centre staff prior to commencing the thesis.  
 To examine the association between ‘relative 
morbidity severity’, comorbidity and long-term 
physical health change 
 Published in Quality of Life Research 
 
4 Primary,  
cross-sectional  
 Original work for thesis. New, 12-month prospective 
cohort study of comorbidity in general practice.  
 To examine the association between CVD & OA 
comorbidity and physical health 
 Study protocol published in BMC Health Services Research 
 Baseline analysis prepared for submission 
 
5 Primary, cohort   Original work for thesis. Prospective analysis of health 
change at two different time-points  
 To examine the association between CVD & OA 
comorbidity and short-term physical health change 
 Publication planned for 2013 
  
 
3
5
 
Box 1.2: Overview of the analytical components of the thesis (for related sample socio-demographic characteristics please see Table 9.1) 
Chapter Study Dataset Analysis Design Sample description n 
       
5 2 NorStOP Secondary Cross-sectional  Responders to baseline survey with a PCS score who had consulted within  
2-year period for at least one morbidity (Study sample) 
 
7,779 
6 3 NorStOP Secondary Cohort  Responders to baseline and 3-year follow-up surveys with a PCS score from 
both and who had consulted within 2-year period for at least one morbidity 
 
4,672 
7 4 2C Primary Descriptive  Eligible study sample who were mailed the 2C study 
 
9,676 
8 4 2C Primary Cross-sectional  Responders to baseline questionnaire with PCS score  
 
5,176 
9 5 2C Primary Cohort  Responders to baseline and 12-month follow-up questionnaire with PCS 
score 
 
3,266 
9 5 2C Primary Cohort Responders to baseline and 4-month follow-up questionnaire with PCS 
score 
 
2,167 
9 5 2C Primary Cohort Responders to baseline, 4-month follow-up and 12-month follow-up 
surveys  with PCS score 
1,919 
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1.11. Summary 
Understanding the consequences of chronic diseases to patient health is increasingly 
important as the prevalence of these conditions increases in ageing populations. 
Furthermore, the increasing prevalence of patients who experience several chronic diseases 
at the same time demands the attention of research, of particular importance is the 
consequences of specific chronic disease interactions and the role of disease severity.  
 
This thesis will add to comorbidity research, using a new and novel cohort study, it will 
examine the consequences of experiencing two common chronic diseases (CVD & OA) on 
physical health and how this may change in the short-term. Such information will add to the 
limited understanding of prospective comorbid interactions in general practice populations. 
The next chapter will provide a background to the current understanding of CVD and OA, 
both as individual chronic disease and chronic disease comorbidity. 
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Chapter 2: Background Literature 
 
The previous chapter described the importance of investigating and understanding chronic 
disease comorbidity. Two important and commonly occurring chronic diseases are 
Cardiovascular Disease (CVD) and Osteoarthritis (OA). This chapter will present background 
literature on each of these chronic diseases individually, the prevalence and consequences of 
comorbidity with each of these and current research which has examined cross-sectional and 
longitudinal CVD & OA comorbidity. This will conclude by presenting the evidence gap which 
this thesis will fill. 
 
2.1. Cardiovascular disease 
Cardiovascular diseases (CVD) are a group of disorders of the heart and circulatory system. 
Many different acute and chronic conditions are classified within CVD, which the World 
Health Organization (WHO) divides into; i) coronary heart disease (CHD): disease of the 
vessels supplying blood to the heart; ii) cerebrovascular disease: disease of the vessels 
supplying blood to the brain; iii) peripheral artery disease: disease of the vessels supplying 
blood to the arms and legs; iv) rheumatic heart disease: damage to the heart from rheumatic 
fever; v) congenital heart disease: abnormalities of the heart from birth and vi) deep vein 
thrombosis and pulmonary embolism, characterised by blood clots in these vessels (World 
Health Organization - Europe 2012).  
 
Cardiovascular diseases encompass a range of conditions including peripheral vascular 
disease, atrial fibrillation and stroke, but common conditions include hypertension, Ischaemic 
Heart Disease (IHD) and Heart Failure (HF).  
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Blood pressure is highly variable within populations (Parati et al. 1998), and hypertension 
occurs when the hydrostatic pressure that the blood exerts on the vessels in which it flows 
around the circulatory system becomes elevated over a prolonged period of time (Chambers, 
Wakley & Iqbal 2001). Hypertension is a risk factor for further CVD, but there is no definitive 
point at which this elevated blood pressure begins to cause other conditions (Carretero, 
Oparil 2000). However, hypertension is typically defined as blood pressure of greater than 
140 mm Hg (millimetres of mercury) systolic (highest) pressure and 90 mmHg diastolic 
(lowest) pressure (Chobanian et al. 2003, National Institute for Health and Clinical Excellence 
2011a). 
 
Ischaemic Heart Disease (IHD), also known as Coronary Heart Disease (CHD) or Coronary 
Artery Disease (CAD), is a reduction in blood flow to the heart and its consequences. Reduced 
blood flow results from limited capacity of the vessels supplying the cardiac muscle, caused 
by disease, often atherosclerosis (plaque build-up) which has narrowed the lumen. The 
reduction in blood flow to the heart predominantly leads to two clinical conditions, angina or 
Myocardial Infarction (MI) (Mathers et al. 2004). Angina is recurring chest pain as a result of 
reduced blood flow to the heart and onset is linked to exertion or stress (Scirica 2009). MI is 
also a result of interrupted blood supply to the heart muscle but in this case necrosis of the 
heart cells occurs due to prolonged ischemia. MI is characterised by sudden chest pain (and 
typically pain in the left arm), shortness of breath, nausea, palpitations, anxiety and can result 
in death (Antman et al. 2000). 
 
Heart Failure (HF) occurs when the heart is unable to provide the body with a sufficient 
supply of blood. This occurs when there are functional or structural abnormalities with the 
heart. This becomes particularly apparent during moments of exertion and symptoms may 
include shortness of breath, general tiredness and swelling of the feet and ankles due to fluid 
retention and is also a cause of death (AbouEzzeddine, Redfield 2011). 
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2.1.1. Prevalence of cardiovascular disease 
An estimated 57 million people died globally in 2008, 17.3 million (30%) of these deaths (the 
leading cause) were attributed to CVD (World Health Organization 2012a). Though mortality 
rates due to CVD in the UK have continued to decline in the last 40 years, CVD continues to be 
the main cause of mortality in this country, accounting for approximately a third (170,000) of 
all deaths in England & Wales (Scarborough et al. 2010). The related financial burden to the 
UK economy was placed at an estimated £30.7 billion, just under half (47%) of these costs 
incurred through direct health expenditure, a quarter (27%) through lost productivity and a 
quarter (26%) through informal patient care (Scarborough et al. 2010). As mortality rates 
from CVD have decreased in recent decades in the UK, the number of people living with CVD 
morbidity long-term has increased (Scarborough et al. 2011).  
 
In 2010, an estimated 30% of the population aged 16 years or older in England (NHS 
Information Centre 2011), 32% in Scotland (National Statistics 2012) and 30% in the USA 
(Yoon, Ostchega & Louis 2010) had hypertension. Each of these national surveys found the 
prevalence of hypertension to be higher in men than women and also increased with age. 
Though from 1998/99 to 2003, each report had recorded increases in the prevalence of 
hypertension, from 2003 to 2010/11 prevalence had remained relatively consist. 
 
A report by Scarborough et al in 2010 for the British Heart Foundation (BHF) approximated 
the number of people living with CHD in the UK at 2.7 million (Scarborough et al. 2010). CHD 
has been declining in the UK since the 1980s (Unal, Critchley & Capewell 2004)                                                                                              
and by an estimated 3-4% per year from 1999-2007 (Pearson-Stuttard et al. 2012). However, 
it continues to be a major cause of deaths in England, more than any other single disease and 
was responsible for 65,000 deaths in 2010 (British Heart Foundation 2012).  
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Though CVD has been declining in recent decades in the UK, HF has increased in prevalence 
(Stewart et al. 2003). In 2009, using information from the General Practice Research 
Database (GPRD), the prevalence estimates for HF in England, were 0.9% (67,721) and 0.7% 
(77,511) for men & women respectively and in Scotland, 1.0% & 0.8% (Scarborough et al. 
2010). Most recently a large epidemiological study conducted in Scottish general practices 
placed the overall prevalence of HF in Scotland at 1.1% (Barnett et al. 2012). 
 
2.1.2. Risk factors for cardiovascular disease 
There are several factors associated with increased risk of CVD. These can be termed as those 
which can potentially be changed (modifiable) and those which cannot (non-modifiable). 
Two important non-modifiable risk factors for CVD are ageing and gender. With increasing 
age comes an increasing risk of experiencing CVD (Lakatta, Levy 2003). Prevalence (existing 
cases) and incidence (new cases) of CVD have been shown to increase with increasing age for 
hypertension (Lewington et al. 2002, Lakatta, Levy 2003), CHD (Odden et al. 2011) and HF 
(Ho et al. 1993, Gott et al. 2006). Gender is also a risk factor for CVD, with men in general 
being at a greater risk of CVD than women. However, the reduced CVD risk afforded by being 
a woman decreases with increasing age (Azad, Bierman 2007). In a Finnish sample, Pekka et 
al found that i) incidence of CHD and ii) related mortality were 3 and 5 times higher 
respectively for men than women. However, the advantage of being a woman was lost as age 
increased, likely related to the menopause (Jousilahti et al. 1999). 
 
Modifiable risk factors for CVD include several aspects related to lifestyle choice, including 
weight and smoking. Obesity, excess body weight resulting in a Body Mass Index (BMI) ≥30, 
is an increasing problem worldwide and its prevalence has more than doubled since 1980 
(World Health Organization 2012b). A systematic review by Guh et al examined the incidence 
of comorbidities related to being overweight or obese and showed obesity to be a risk factor 
for all CVD (Guh et al. 2009, Sowers 2003). Obesity has been independently associated with 
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increased prevalence of hypertension (Redon et al. 2008) and nearly a quarter (23%) of the 
global burden of IHD has been attributed to obesity (World Health Organization 2012b). 
Smoking is also a risk factor for the development of IHD (Manson et al. 1990). Smokers have 
twice the risk of dying from CHD or stroke compared with those who have never smoked 
(U.S. Department of Health and Human Services 1990).  
 
The presence of other health conditions is also a potentially modifiable risk factor for CVD. 
Hypertension is one of the most important preventable causes of morbidity and mortality in 
the UK (National Institute for Health and Clinical Excellence 2011a). Hypertension has been 
shown to be a risk factor for the development of several diseases, particularly other CVD (UK 
Faculty of Public Health, National Heart Forum 2005) and better detection of hypertension 
has been shown to reduce CHD (Levene et al. 2010). A large audit of approximately 50% of 
patients in the UK, discharged with a primary diagnosis of HF found hypertension (53%) and 
IHD (47%) to be the most commonly contributing causes, with a quarter of these patients 
having both hypertension and IHD (National Institute for Cardiovascular Outcomes Research 
2012). Diabetes is also a risk factor for CVD. Those with diabetes come to a higher risk of CVD 
15 years earlier compared to those without diabetes (Booth et al. 2006). 
 
2.1.3. Burden of cardiovascular disease  
2.1.3.1. Mortality 
In the UK and many other developed countries, mortality rates of CHD have steadily 
decreased in recent decades (Unal, Critchley & Capewell 2004). From 1995 to 2010, the age-
standardised mortality rate of those aged 75 years or under in Scotland fell by 61% 
(Information Services Division Scotland 2011). However, CHD continues to be a large 
contributor to mortality, and in 2009 was the cause of 18% and 12% of UK deaths in men and 
women respectively (Scarborough et al. 2011). For HF patients the risk of mortality remains 
high, with annual mortality at approximately 30% (Cleland et al. 2011). 
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2.1.3.2. Physical health 
Morbidity outcomes present information on the burden experienced by CVD patients. By 
conducting secondary analysis of several Dutch datasets (15,000 patients), Sprangers et al 
showed the negative impact which overall CVD has on physical health compared to the 
‘average’ general population scores. Furthermore, that physical health of those with 
hypertension was better than those with ‘heart conditions’ (Sprangers et al. 2000). 
Hypertension has been shown to have a negative influence on physical health in general 
practice (Schmidt et al. 2008) and in the general population of several countries (Alonso et al. 
2004). Once diagnosed with IHD, patients’ physical health has been shown to be particularly 
affected. Buckley et al found that in a sample from 37 general practices across the west and 
north-west of Ireland, patients with Angina alone or other IHD had poorer physical health 
after 4 ½ years (Buckley, Murphy 2009). 
 
The impact of HF is typically examined in younger males within secondary care. This limits 
the generalisability of such results to older patients seen in primary care. HF is negatively 
associated with physical health (Jenkinson et al. 1997a, Martin et al. 2007, Hopman et al. 
2009, Peters-Klimm et al. 2010) and the impact on physical health is more severe compared 
to several other conditions, such as hypertension and IHD (Hobbs et al. 2002). Morbidity 
experienced by HF patients is substantial and impacts on the patient’s ability to undertake 
aspects of life. In a group of elderly Swedish primary care HF patients, there was an impact on 
the ability to achieve a number of Activities of Daily Living (ADL) (Norberg, Boman & Lofgren 
2008). HF patients are also limited in their ability to undertake exercise, which raises the 
question of the impact of HF on physical health through sedentary lifestyle (National Institute 
for Cardiovascular Outcomes Research 2012). It is clear that HF is strongly associated with 
diminished physical capacity and health.  
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2.1.3.3. Psychological health 
Prolonged, debilitating illness is likely to result in psychological distress and CVD, particularly 
hypertension, has been linked to cognitive dysfunction (Vicario et al. 2012). Data from a 
national survey conducted in the UK assessed the cognitive function of participants aged 60-
74 with or without vascular disorders. Vascular disorders were specifically associated with 
lower cognitive function (Begum et al. 2009). The incidence of depression was examined 
prospectively in CVD patients in UK general practice by Tyrer et al in 1999. This study 
showed patients were more likely to develop depression within a year of a CVD event, 
compared to those without a CVD event (Tyrer, Lawrenson & Farmer 1999). Shah et al 
reviewed literature of the relationship between IHD and subsequent depression and found 
several studies which supported an association with recorded depression post-IHD 
development (Shah et al. 2004). In 2002 MacMahon & Gregory conducted a systematic review 
of articles which had examined psychological factors in patients with HF. They found that 
psychological factors, particularly anxiety, were typically neglected in this disease group, but 
where depression had been examined, the prevalence of this was high (MacMahon, Lip 2002).  
 
2.1.4. Management and treatment of cardiovascular disease 
The basis for management and treatment of different CVD in UK general practice is defined by 
the National Institute for Health and Clinical Excellence (NICE) clinical guidelines. 
Management or treatment allocation is based on a tiered system, ranging from simple but 
effective choices to the most complex, and often expensive options. Due to the variety of CVD, 
a wide range of options exists for use by the clinician and only a selection is mentioned here. 
 
For the majority of (non-emergency) CVD conditions, initial management is often based on 
modifiable changes to lifestyle, which can reduce symptoms, the risk of disease progression 
and improve patient QOL. These changes can include help and advice in improving diet (i.e. 
reduced intake of salt and saturated fats), smoking cessation and increasing physical activity. 
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Pharmacological management of CVD is frequently a treatment option i.e. nitrates for angina 
(National Institute for Health and Clinical Excellence 2011b). As well as the prescription of 
various medicines, the adherence to these is also of importance. Surgical interventions are 
also available, for example revascularisation for angina patients. 
 
For the majority of these management and treatment options recommended in the NICE 
guidelines, reference is frequently made to consider CVD patient comorbidities prior to 
treatment. However, NICE guidelines provide little or no information on how different 
comorbidities may influence the patients and therefore how these particular patients should 
be managed.  
 
2.2. Osteoarthritis 
Osteoarthritis (OA) is characterised by the presence of joint pain and stiffness which 
frequently results in physical disability (Breedveld 2004). OA is typically classified in two 
ways, symptomatically, through patient reported symptoms or radiographically, through 
alterations in the joint pathology determined by imaging (Kokebie, Block 2008). Either or 
both of these changes may be present to define OA. Those who have symptomatic OA 
frequently experience joint pain and stiffness, with onset of pain and pain severity being 
important reasons for consulting general practice (Bedson et al. 2007). Radiographic OA is 
typified by the structural changes which can occur, including: the degradation of articular 
cartilage and joint space narrowing. As a result of damage or excessive joint loading, changes 
can occur as the joint healing process is activated. This can lead to the development of 
osteophytes (Abramson, Attur 2009) and presence of mild synovitis (Birchfield 2001). The 
knee, hip and hand are the joints most frequently affected (Bijlsma, Berenbaum & Lafeber 
2011). 
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2.2.1. Prevalence of osteoarthritis 
OA is the commonest form of joint disorder in the world (Arden, Nevitt 2006). By 2020 it is 
expected that OA will be one of the top ten leading causes of burden for women in the 
developed world (Murray, Lopez 1997). In the UK, OA is the commonest chronic disease and 
overall prevalence is estimated at 13% of patients aged 45 years or older registered with a GP 
(Bedson, Jordan & Croft 2005). The prevalence of OA in UK general practice is similar to that 
of other developed countries, with the prevalence of a Norwegian local community sample 
estimated at 12.8% (Grotle et al. 2008) and 14.3% of Australians consulting their general 
practice for OA in the course of one year (Knox et al. 2008). 
 
Prevalence of OA is associated with age. Across two separate UK general practice databases 
(Royal College of General Practitioners Weekly Returns Service (RCGP WRS 2001) & 
Consultations in Primary Care Archive (CiPCA 2001)), around 20% and 17% respectively of 
65-74 year olds registered with a general practice consult about OA annually, increasing to 
25% and 20% respectively in those aged 75 years or more (Jordan et al. 2007). Prevalence is 
also dependent on the joint location of OA. Pereira et al conducted a meta-analysis of articles 
which had examined the prevalence of OA. A total of 63 articles were included for OA of the 
hand, knee or hip. OA was defined by, self-report (patient asked if they had ever been 
informed that they had OA by a health professional), symptomatic or radiographic 
definitions. Despite heterogeneity of studies, this study demonstrated that the hands were 
the most prevalent location of OA across the three joints (43%), followed by the knee (24%) 
and then the hip (11%) (Pereira et al. 2011). 
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2.2.2. Risk factors for osteoarthritis 
A systematic review by Blagojevic et al examined the findings of 85 cohort and case-control 
studies which had examined risk factors associated with developing knee OA. This review 
found the factors which were consistently associated with knee OA to be: older age, previous 
knee trauma, obesity, having hand OA and being female (Blagojevic et al. 2010).  
 
The influence of age on developing OA can come as a result of age-related mechanical factors, 
i.e. changes in gait or age-related changes in joint pathobiology, such as enzyme breakdown 
of the cartilage (Abramson, Attur 2009). Changes in joint mechanics and loads are also 
related to several risk factors. Previous injury and additional loading as a result of excess 
body weight may result in altered joint mechanics. Obesity is associated with an increased 
risk of developing OA (Felson et al. 1988). A meta-analysis by Guh et al in 2009 found that 
there was a significant association between obesity and the risk of joint replacement due to 
OA (Guh et al. 2009). Being obese also increases the risk of hand OA (Carman et al. 1994). 
Therefore, factors other than direct increases in joint loading (i.e. of the knee or hip) may be 
influencing this disease. Women are also at a greater risk of having OA (Brandt et al. 2003). 
 
2.2.3. Burden of osteoarthritis 
OA impacts on physical, emotional and social aspects of patients’ lives and is one of the 
leading causes of pain worldwide (National Institute for Health and Clinical Excellence 2008). 
The aspects of health to assess for OA patients include the influence on symptoms, disability 
and QOL. In 2000, the WHO classified OA as having the fourth greatest burden on QOL of any 
major disease (Reginster, Khaltaev 2002).  
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2.2.3.1. Pain 
OA is associated with pain (Grotle et al. 2008) and continues to be an important influence on 
patients. Though the presence of osteophytes and joint space narrowing have been 
independently associated with pain in hand OA (Kortekaas et al. 2011), there also remains 
evidence that patients without radiographic OA experience joint pain (Oka 2009).  
 
Symptomatic OA and knee pain continue to increase. Nguyen et al showed that age and BMI-
adjusted prevalence of symptomatic OA and knee pain in OA patients from a US population 
sample (Framington Osteoarthritis Study) substantially increased over a 20 year period 
(Nguyen et al. 2011). Such increases in joint pain have important consequences on patient 
health. A prospective cohort study conducted in the population aged 50 years or older in 
North Staffordshire, UK, showed that those who developed knee pain over a 3-year period 
experienced significant reductions in their physical functioning (Jinks, Jordan & Croft 2007). 
Pain is an important consequence of OA, in its own right and due to its subsequent impact on 
other factors of health. 
 
2.2.3.2. Physical health 
Adverse influences of OA have been shown for multiple aspects of physical health, including; 
activities of daily living (Sadosky et al. 2010), fatigue (Zautra et al. 2007) and physical 
functioning (Stratford, Kennedy & Woodhouse 2006). OA has also been shown to negatively 
influence general physical health (Picavet, Hoeymans 2004, Rannou et al. 2007, Loza et al. 
2009). Picavet et al examined the association between self-reported knee or hip OA on the 
physical health of a random sample of the Dutch general population. These results showed 
that those with OA had poorer physical health compared to the average general population. 
Rannou et al found a similar association between those consulting for either knee or hip OA 
in the general practice population of France.  
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2.2.3.3. Psychological health 
Hopman et al examined the association between five chronic conditions from 10 different 
studies from the Canadian population and changes in physical and mental health compared to 
normative population data. Using data from two studies of knee & hip OA patients waiting for 
joint replacement surgery, they found large differences between the physical health (PCS 
scores) of these patients and normative data, but little difference in mental health (MCS 
score) (Hopman et al. 2009). However, other research has shown an association between OA 
and diminished psychological health. Rosemann et al showed that the point prevalence of 
depressive symptoms in general practice patients with OA was increased compared to 
general practice patients of the same age (Rosemann et al. 2007). Experience of pain is 
associated with depression (Chou 2007) and Hawker et al showed that over a 2-year period, 
fatigue and disability as a result of OA subsequently predicted depressed mood (Hawker et al. 
2011). 
 
2.2.3.4. Mortality 
Though the impact of OA on morbidity has been long established, any direct influence on 
mortality has not been determined (Watson, Rhodes & Guess 2003). Though there is often an 
increased risk for those with OA of premature death, this has been linked to factors such as 
the presence of comorbid conditions and medication side-effects (Hochberg 2008). However, 
others have shown that persons with OA have increased mortality compared with the general 
population and that also having CVD as a comorbid disease is a factor for increased risk 
(Nuesch et al. 2011). 
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2.2.4. Management & treatment of osteoarthritis 
Pain, stiffness and lack of functioning are frequently the initial symptoms related to OA and 
therefore primary treatment goals are to reduce or improve these. Over the long-term, 
minimising the progression of OA and ensuring that patients maintain, or improve their QOL 
is the ultimate goal (Bijlsma, Berenbaum & Lafeber 2011). The basis of the management and 
treatment of OA in UK general practice is based on NICE guidelines. NICE have produced 
evidence-based guidelines for the management and treatment of OA (National Institute for 
Health and Clinical Excellence 2008). Treatment options are suggested based on a tiered 
system of care, with simpler, more cost effective strategies, such as exercise and weight loss 
leading to more complex and expensive options, such as joint replacement. In 2012, 
Kingsbury & Conaghan showed that (in general) NICE guidelines for OA are followed in the 
NHS, but lack of time and resources mean that care can be sub-optimal (Kingsbury, Conaghan 
2012). An important consideration about the guidelines for OA, as with many other diseases, 
is that they do not provide options of specific management and treatment where comorbidity 
is present. Therefore, their effectiveness as aids to the GP or nurse is potentially limited in a 
substantial proportion of the consulting public.  
 
2.3. Comorbidity 
Comorbidity is common in patients with CVD (Rijken et al. 2005), with patients often 
experiencing more than one cardiovascular disease (Caughey et al. 2008). Non-
cardiovascular comorbidity with CVD is also common. For example around a third of people 
with heart failure will also have diabetes mellitus (Braunstein et al. 2003). Similarly, there is 
evidence of high levels of comorbidity in those with OA (Kadam, Croft 2007). Several research 
studies have investigated the prevalence and impact of comorbid OA, in particular with CVD 
and found this to be a common combination of conditions (van Dijk et al. 2008, van Oostrom 
et al. 2012). 
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2.3.1. Cardiovascular disease comorbidity 
2.3.1.1. Prevalence 
In 2005 Rijken et al examined the prevalence of chronic disease comorbidity in the Dutch 
general practice population. They showed that of the patients with CVD, 57% had chronic 
disease comorbidity, the highest prevalence rate of the six chronic diseases they had studied 
(Rijken et al. 2005). Bolen et al at the Center for Disease Control (CDC), US, found that in a 
large US sample the prevalence estimate for arthritis in those with heart disease was 57% 
and that in these comorbid patients, physical inactivity was 30% higher than for those with 
heart disease only (Center for Disease Control 2009). In a Canadian population-based study 
of a representative sample aged 20 years or older, over a third (38.3%) of patients who 
reported having CVD as the index condition (CVD defined as high blood pressure, heart 
disease or stroke) also reported having arthritis. The prevalence of this comorbidity was 
second only to diabetes, and the risk of activity limitation was significantly increased by the 
presence of arthritis, even after adjustment for covariates (Slater, Perruccio & Badley 2011).  
 
The high prevalence of hypertension in populations means that a variety of different 
comorbidities are common alongside this condition. Gurnalik et al found that 24% of the US 
general population had both hypertension and arthritis and 8% had both hypertension and 
heart disease. The high prevalence rate of hypertension and heart disease had been 
hypothesised, based on the relationship of hypertension as a known risk factor for heart 
disease. However, the authors found the prevalence of comorbidity between hypertension 
and arthritis to be greater than expected. Though they concluded that this could have been 
related to detection bias (people with one disease may be more willing to respond to surveys 
and report other conditions), they suggested that this could also be a reflection of some 
biological factor (Guralnik et al. 1989). Loza et al examined the prevalence of hypertension 
alongside the wider disease construct of ‘rheumatic diseases’. In a Spanish general population 
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sample, they also found the observed prevalence of hypertension to be significantly greater 
than the expected prevalence in those who also had a rheumatic disease (Loza et al. 2008). 
 
Prevalence of comorbidity is high in patients with CHD. Boyd et al examined the prevalence of 
CHD comorbidities, using comorbid conditions which were most likely to alter the clinical 
course or the clinicians’ ability to effectively treat CHD. Using a nationally representative 
sample of the US general population aged 45 years or older, they showed that common CHD 
comorbidities were arthritis (57%), heart failure (29%) and diabetes mellitus (25%) (Boyd et 
al. 2011). Similar prevalence of CHD comorbidities was also shown in a Dutch general 
practice population, with the three most common CHD comorbidities being diabetes mellitus 
(34%), heart failure (26%) and OA (23%) (van Oostrom et al. 2012). 
 
Experiencing comorbidity with HF is a frequent occurrence and both CVD and non-CVD 
comorbidity introduce complications to the care of HF patients (Lang, Mancini 2007). A 
frequent comorbidity prevalent with HF is Chronic Obstructive Pulmonary Disease (COPD). In 
2004, Hawkins et al also observed the high prevalence of COPD alongside HF, with 24% of a 
Scottish general practice population having both of these conditions. Furthermore, of these 
patients with HF, no matter whether they had COPD or not, half of the sample also had 
hypertension or angina. This presence of HF & COPD increased rates of consultation and 
multiple medication prescription added confusion for the clinician (Hawkins et al. 2010).  
 
Van der Wel et al examined the presence of comorbidities in HF patients aged 65 years or 
older, sampled from Dutch general practices. That HF patients experience multiple conditions 
was evident, with over 80% experiencing four or more comorbidities. Of these, non-CVD 
comorbidities were just as prevalent as those which were cardiovascular. Of those aged 65-
74, some of the most common comorbidities were hypertension (40%), angina (36%) & MI 
(33%) (van der Wel et al. 2007). A high prevalence of HF comorbidity was also observed in a 
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sample of over 30,000 US Medicare patients. In those aged 65 years or older with a previous 
diagnosis of HF, over half had a history of hypertension (61%) or coronary artery disease 
(CAD) (56%), diabetes (38%) and COPD (33%) were also common. Recently another study 
using data from the US found that in a sample of over 9,000 Medicare patients with non-
hospitalized HF, 28% also had arthritis. Only Ischaemic heart disease (65%) and diabetes 
(34%) were more commonly occurring comorbidities (Ahluwalia et al. 2012). 
 
2.3.1.2. Consequences 
CVD comorbidity is associated with poorer patients’ outcomes, both of morbidity and 
mortality (Glynn et al. 2008). Verbrugge et al found that in a survey conducted in the US 
population, patients with disability from both arthritis and heart disease had poorer self-
rated health compared with those who had either arthritis disability or heart disease 
disability. Furthermore, those patients with such a combination of comorbidity had greater 
difficulties than those patients with other disease (Verbrugge, Juarez 2008). Griffith et al also 
found that in an older Canadian population (65 years or older), of those with arthritis and 
heart problems, the population attributable risk for functional disability, was high (Griffith et 
al. 2010). In CVD patients, comorbidity has also been shown to be detrimental to physical 
health. In a sample of the general population from China, Wang et al found that individual 
hypertension impacted negatively on physical health (as measured by the Short-Form 36 (SF-
36)) and subsequently that the addition of comorbidity with hypertension had a further, 
significantly detrimental influence on physical heath (Wang et al. 2009).  
 
HF comorbidity places additional burden on multiple aspects of QOL, including physical and 
psychological health (Peters-Klimm et al. 2010) and is also associated with increased 
mortality (Ahluwalia et al. 2012). Glynn et al observed that 43% of patients with CVD from a 
UK general practice sample experienced chronic kidney disease, diabetes or both and that the 
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risk of mortality was increased in those with CVD and either one of these two other chronic 
diseases (Glynn et al. 2008). 
 
2.3.1.3. Longitudinal consequences on physical health 
A summary of prospective studies examining CVD comorbidity (& OA comorbidity) is 
provided in Table 2.1. In 1996, Sherbourne et al conducted an observational study over two 
years to examine the longitudinal association between comorbid anxiety with hypertension 
or heart disease and patient QOL, as measured using the SF-36. In a sample of Health 
Maintenance Organisation (HMO) patients drawn from practices from several US cities, they 
showed that the physical health of those with hypertension & anxiety comorbidity was 
significantly worse after two years than for those with index hypertension. Though those 
with heart disease & anxiety comorbidity had worse physical health than those with heart 
disease, this effect was not as great. This difference of worse health of hypertension 
comorbidity than heart disease comorbidity was attributed to the poorer QOL at the baseline 
measurement of the heart disease patients, though a small sample of heart disease patients 
also limited the strength of findings (Sherbourne et al. 1996). 
 
Bayliss et al also examined the influence of hypertension comorbidity on change in physical 
health (Physical Component Summary (PCS) score) longitudinally. In a US sample drawn 
from both primary and secondary care, and defining comorbidity by counts of several specific 
chronic diseases, comorbidity was examined as a predictor of physical health decline after 
four years. Compared to patients with hypertension, the odds of physical health decline were 
examined for those patients with hypertension and i) one comorbid chronic disease, ii) two 
comorbid chronic diseases, iii) three comorbid chronic diseases or iv) four or more comorbid 
chronic diseases. Though the odds of physical health decline after four years were increased 
with increasing number of additional comorbid chronic disease, this was only significant in 
those with four conditions or more (Bayliss et al. 2004). 
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Further examination of hypertension comorbidity was conducted by Maatouk et al. A study 
conducted with patients aged 50-74 from German general practices, found that in this sample 
of 4,203 patients who had hypertension diagnosed by the physician; the most prevalent 
comorbidities from a select list were; circulatory disorders (19%), diabetes (17%) and 
coronary heart disease (17%). This study recorded physical health (measured using the PCS 
score of the SF-12) at baseline and at five-year follow-up. They found that most comorbidity 
were predictors of worse physical health after five years in those with hypertension 
(Maatouk et al. 2012). 
 
Kriegsman et al examined the influence of chronic disease comorbidity and subsequent 
change in physical functioning over a 3-year time-period. In a Dutch sample of patients aged 
between 55–85 years, the odds of experiencing a decline in physical functioning over 3-years 
in cardiac disease patients were over 2½ times greater with the addition of arthritis 
(Kriegsman, Deeg & Stalman 2004).  
  
 
5
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Table 2.1: Prospective studies examining the influence of cardiovascular disease comorbidity or osteoarthritis comorbidity on physical health 
change in general practice 
Authors, year Country Follow-up 
(years) 
Index disease(s) Health setting Comorbidity Outcome 
       
Ettinger et al, 1994 US 10 OA General population Hypertension 
Heart disease 
 
Physical function 
Sherbourne et al, 1996 US 2 Hypertension 
Heart disease 
 
Family practice Anxiety Physical function (SF-36) 
Bayliss et al, 2004 US 4 Hypertension 
 
Primary & secondary care Countsǂ PCS score (SF-36) 
Kriegsman et al, 2004 Netherlands 3 Cardiac Disease 
Arthritis 
 
General population Arthritis 
Cardiac Disease 
Physical function (ENI) 
Peters et al, 2005 UK 7 OA General practice Hypertension 
CVD 
 
New Zealand score* 
 
White et al, 2011 US 2.5 OA 
 
General population Index measure Physical function 
Maatouk et al, 2012 Germany 5 Hypertension General practice Circulatory disorder 
CHD 
PCS Score (SF-12) 
CHD = Coronary Heart Disease, Comorbidity index measure = Standardised measure for combining the number and severity of conditions, CVD = Cardiovascular 
Disease, ENI = Edwards-Nunnally Index, UK = United Kingdom, US = United States, OA = Osteoarthritis, PCS = Physical Component Summary score, SF-36 = Short-
Form 36, ǂthe summing of comorbid diseases an individual has, *This tool was developed for surgical prioritisation and is measure of pain & disability. 
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2.3.2. Osteoarthritis comorbidity 
2.3.2.1. Prevalence 
In a study of patients from general practices in the Netherlands, Schellevis et al showed that 
those with OA and aged under 65 years had the most comorbidity (28%) compared to those 
with one of four other chronic disease (hypertension, chronic ischaemic heart disease, 
diabetes mellitus and chronic nonspecific lung disease) (Schellevis et al. 1993). Gabriel et al 
in 1999 showed that those with OA were more likely to experience comorbidity than age and 
sex-matched controls without a previous diagnosis of arthritis (Gabriel, Crowson & O'Fallon 
1999). This was supported by Kadam et al in 2004, using data from UK general practice. They 
compared the prevalence of comorbidity between 11,000+ OA cases and 11,000+ non-OA 
matched controls aged 50 and over. After adjusting for age, gender and social class, those 
with OA were over twice as likely to have high levels of comorbidity as controls (Kadam, 
Jordan & Croft 2004) . Most recently a study by van Oostrom et al in a Dutch general practice 
sample, found the five most common OA comorbidities to be chronic neck or back disorders 
(27%), diabetes mellitus (26%), CHD (24%), visual disorders (16%) and cancer (16%) (van 
Oostrom et al. 2012). 
 
2.3.2.2. Consequences 
Comorbidity experienced by patients with OA has been shown to influence multiple aspects 
of the patient life. In 2007, Kadam et al demonstrated the importance of OA comorbidity on 
patients’ QOL. They examined a sample of OA patients aged 50 years and older from general 
practice and found that the presence of comorbidity was negatively associated with physical 
functioning, measured using the SF-12. Furthermore, higher comorbid counts were 
associated with worse physical health (Kadam, Croft 2007). A similar finding was also found 
by Kauppila et al. who found that in a sample of patients with severe OA (scheduled for 
arthroplasty), physical functioning (measured by the SF-36) was significantly worse as the 
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number of comorbid diseases increased (Kauppila et al. 2008). In another sample of OA 
patients, Reichmann et al examined the role of several factors on the health-status of patients 
with radiographic knee OA. In this sample, they found a trend between increasing morbidity 
count and declining overall health status, established through a single self-report question 
(Reichmann et al. 2009). 
 
A study that investigated the influence of a specific comorbid pairing on physical health was 
conducted by Miksch et al. Using a sample from German primary care; the SF-36 scores of 
patients with diabetes were compared to those with diabetes and OA comorbidity. This study 
found that those with OA and diabetes had a significantly worse PCS score compared to those 
with diabetes only (Miksch et al. 2009). This cross-sectional study showed that the specific 
addition of OA to a chronic disease can have a detrimental influence on the patients’ 
experience of physical health. Tinetti et al in 2011 examined the cross-sectional interaction 
between different comorbid pairs on several universal outcomes. Over 5000 Medicare 
patients in the US, with one of five chronic diseases (HF, COPD, OA, depression, cognitive 
impairment) were included in the sample. OA & depression was one of the four significant 
interactions, this pairing demonstrating a synergistic effect on limiting the Activities of Daily 
Living (ADL) above that seen for those with individual OA or depression (Tinetti et al. 2011). 
Another specific comorbidity examined in those with OA was joint pain. In a Dutch sample 
recruited from a hospital rheumatology department, those with the specific comorbid 
combinations of OA and one or more joint-pain comorbidity had worse physical functioning 
(as measured using the SF-36) than those OA patients without joint-pain comorbidity 
(Hoogeboom et al. 2012). 
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2.3.2.3. Longitudinal consequences on physical health 
OA comorbidity has also been shown to influence change in physical health over time. Using 
participants from the US general population who had, or had a high risk of developing, 
symptomatic OA, White et al found that those who developed a new comorbidity or 
widespread pain in the preceding 30 months were at risk from greater functional decline 
(White et al. 2011). 
 
2.3.3. Cardiovascular disease & osteoarthritis comorbidity 
2.3.3.1. Prevalence 
Cardiovascular disease and osteoarthritis are chronic diseases which commonly occur on 
their own in different individuals in general population samples. A proportion of the 
population with CVD will develop OA as comorbidity and vice versa, a proportion of a 
population with OA will develop CVD. Development of such a comorbid combination is more 
frequent than would naturally be expected when two diseases exist in a population (van 
Oostrom et al. 2012) and therefore other drivers may influence the presence of both these 
conditions at the same time. Singh et al in 2002 showed that OA patients experienced more 
risk factors for CVD than those without OA (Singh et al. 2002). 
 
Schellevis et al found hypertension to be a frequent comorbidity with OA in the Dutch 
population aged 65 years or older and registered with a general practice (Schellevis et al. 
1993). Saltman et al also found that in a large Australian general practice sample that 7.8 
patients per 1000 consulted for both hypertension and OA over a 1½ year period. This was 
the third most common combination of the 10 most frequently managed problems (Saltman, 
Sayer & Whicker 2005).  In US patients aged 35 years or older with OA, 40% were estimated 
to have hypertension, compared to 25% of the general population without arthritis (Singh et 
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al. 2002). In a further study using a US sample with severe hip OA, the prevalence of 
hypertension in OA patients was 65% (Marks, Allegrante 2002).  
 
An association between IHD and OA was demonstrated by Kalichman et al in 2005. Within a 
sample selected solely from a single village in Russia, the comorbidity of patients with 
radiographically defined hand OA was recorded. A significant association was found between 
OA and diagnosis of IHD. This was the only significant association found with hand OA among 
several other chronic diseases (Kalichman et al. 2006). For HF patients, the prevalence of 
comorbidity is high. One of the most common non-cardiovascular comorbidity is OA. From a 
random sample of 5% of Medicare beneficiaries in the US population, over 120,000 HF 
patients, aged 65 years or older were identified. Of these, 16% also had OA and this was the 
7th most common non-cardiovascular comorbidity experienced by this sample (Braunstein et 
al. 2003). Van der Wel et al also examined the prevalence of non-cardiovascular 
comorbidities in HF patients. In a sample of 269 patients from Dutch general practice aged 65 
years or older, the prevalence of OA in this HF sample significantly increased with age (van 
der Wel et al. 2007). Chan et al found that in a Hong Kong general practice sample with knee 
OA, the commonest non-MSK comorbidity was cardiovascular disease (33%) (Chan et al. 
2009). 
 
2.3.3.2. Consequences 
There are several research needs when considering MSK conditions (including OA) when 
combined with other diseases, including the consequences for the patient (Siebens 2007). 
Two Dutch studies have examined the cross-sectional impact of CVD & OA comorbidity on the 
physical health of populations. Furthermore, these have considered how different diseases 
may impact on the patient relative to one another. Van Dijk et al examined the cross-sectional 
impact of specific comorbidities in OA patients from rehabilitation centres and two hospitals 
on their physical functioning. Within this sample over half had a cardiac disease (54%), as 
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defined by the Cumulative Illness Rating Scale (CIRS). Those OA patients with cardiac disease, 
classified as moderate or severe had a significantly worse physical functioning status (as 
measured by the SF-36) than those with OA but no cardiac disease (van Dijk et al. 2008). 
 
A further Dutch study, using a sample of general practice patients with early OA also 
examined the influence of comorbidity on the physical health of this sample. The cross-
sectional analysis showed that the prevalence of i) hypertension and ii) severe heart disease, 
MI or stroke were 20% and 1% respectively. Univariate analysis showed a negative influence 
of these comorbidities on physical health and that this was worse for the severe heart disease 
category than hypertension. However, though this study found comorbidity count to be 
significantly associated with worse physical health, neither of these two CVD conditions were 
independently linked after regression analysis, adjusting for age, gender, social status and 
severity of radiographic OA (Wesseling et al. 2012). 
 
2.3.3.3. Longitudinal consequences on physical health 
Ettinger et al investigated the impact of knee OA on physical functioning in a US sample aged 
between 45-74 years old. This study found that there was a stronger association with poor 
physical functioning after 10 years for those who also had comorbid heart disease, after 
adjustment for age, gender, race, education and follow-up time (Ettinger et al. 1994). In a 
study conducted over a 7 year period, Peters et al investigated factors associated with 
changes in pain and disability in OA patents. In a UK general practice sample stratified by age, 
gender and clustering of practices, those with hip OA & CVD comorbidity experienced greater 
deterioration in pain & disability after 7 years than those without CVD comorbidity, those 
with knee OA & hypertension also experienced greater deterioration compared to the index 
OA group (Peters et al. 2005). 
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2.4. Evidence gaps 
Cardiovascular disease (CVD) is a common chronic disease and prevalent across the 
developed world. This chronic disease is a major cause of mortality, resulting in much 
premature death. CVD also influences morbidity, impacting on all aspects of patients’ health 
and subsequently placing a large demand on the health care systems which must manage and 
treat these conditions. Management of CVD is orientated around the reduction of risk factors, 
but once the disease has developed pharmacological treatment is often utilised. Patients with 
CVD frequently experience comorbidity and this has a negative influence on patients’ health 
and health care resources. 
 
Osteoarthritis (OA) is also a common chronic disease and increases with ageing. This has risk 
factors common to CVD, including ageing and obesity as well as more unique factors such as 
previous joint damage. This is a major cause of morbidity in the developed world, frequently 
causing pain and diminished physical and mental health. OA management is orientated 
around reduction in weight, increased physical activity and exercise and the prescription of 
analgesics and Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) until joint replacement is 
necessary. OA comorbidity is also common and has been shown to be detrimental to physical 
health in particular, especially as severity of comorbidity increases. 
 
The presence of comorbidity with CVD and OA increases the mortality and morbidity 
experience of each condition. The general presence of comorbidity is, in the main, negative. 
However, when specific disease pairs have been examined, these have not always resulted in 
significant influences on patient health. The influence of many specific disease pairs on 
aspects of heath remains unclear, but understanding such combinations is critical for the 
tailoring of health care systems to the growing proportion of the general practice population 
who have chronic disease comorbidity. 
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The chapter has demonstrated the health issues around CVD and OA and how their high 
prevalence results in the increased morbidity or premature death of a substantial proportion 
of the population of developed countries such as the UK. It has also highlighted the frequent 
presence of comorbidity with both of these chronic diseases and their specific common 
occurrence. What remains unclear is the extent to which the specific combination of these 
two conditions (CVD & OA) influences the specific outcomes of patients, particularly their 
physical health, and how such an influence may change over time. With the determination of 
the need for such comorbidity research now established, the next chapter will highlight some 
of the specific methods which must be considered to undertake this research objective and 
how they will be addressed within the thesis. 
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Chapter 3: Methods 
 
Chapter 1 provided a rationale for undertaking this thesis and Chapter 2 has positioned the 
thesis in the context of the existing background literature and current understanding of 
chronic disease and comorbidity research. Chapter 3 now details the methods used in the 
thesis to undertake the different studies. Decisions were required on the methods used, 
including those which would be recurrent themes throughout several chapters. This chapter 
highlights the areas where methodological choices were made and provides evidence to 
support their use. 
 
3.1. Thesis outline 
There are two main investigations to this thesis. The first relates to understanding individual 
chronic disease and physical health. This was conducted in order to understand the role of 
relative morbidity severity, defined as diagnostic categories within individual chronic 
diseases, and their influence on cross-sectional physical health and long-term physical health 
change. The second investigation relates to understanding the association between chronic 
disease comorbidity and physical health. This was conducted using a new comorbidity cohort 
study to understand the influence of CVD & OA comorbidity on cross-sectional physical health 
and short-term physical health change.  
 
3.2. Systematic review 
Included in the first investigation was a systematic review. This was chosen in order to 
summarise the evidence about the influence of individual chronic diseases on physical health. 
To be able to understand the association between comorbidity and the physical health of 
patients, one must first understand the influence which individual conditions have on the 
physical health experience. Without such knowledge it remains difficult to differentiate the 
actual contribution of each condition to a patients’ physical health when in combination. 
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In chapter 2, for three CVD of interest and for OA, a review of the background literature 
presented current evidence about the influence of each of these diseases on the physical 
health experience of general practice populations. This highlighted that such diseases, when 
considered in isolation, have a negative impact on the physical health of patients. However, 
the extent to which the same disease influences patients’ health varies across different 
studies and a general consensus for each disease remains elusive. This is the case for several 
different conditions. No research has attempted to a) systematically review studies of the 
same disease which have each examined physical health outcomes or b) compare the relative 
influence of several different, individual chronic diseases on the physical health of patients. 
Therefore, this thesis initially reports on a systematic review which was undertaken to both 
fill the research gap by collating existing research relating to the impact of individual chronic 
disease upon physical health, and to provide a context for the comorbidity study of discussed 
later in the thesis. 
 
3.3. Epidemiological methods 
Epidemiology is “the study of the distribution and determinants of disease frequency” 
(MacMahon 1970) in a given population. Epidemiology considers the frequency (incidence & 
prevalence), distribution (samples within a population getting a disease) and determinants 
(outcomes of exposure) of disease in human populations (Hennekens 1987). 
 
Throughout this thesis two methods of epidemiological study were used, descriptive and 
observational studies. Descriptive, specifically cross–sectional studies were used in both 
investigations 1 & 2 and assess the presence or absence of the exposure and outcome, 
providing information on the frequency of either at a single time-point. This method of 
research is important to identify the existence of associations between factors. However, 
cross-sectional design is limited by its inability to infer any causal relationship between 
exposure and outcome, but this can be examined using observational studies.  
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There are two forms of observational study, case-control studies and cohort studies. A case-
control study is that which examines a group of cases - those with an outcome of interest, 
against a group of controls - those without the outcome of interest, and retrospectively 
examines each groups past exposure to a particular factor. Though case-control studies 
provide a relatively quick and easy method to examine a research question, particularly for 
small samples of cases with rare conditions, this design is limited. Being retrospective this 
introduces observation bias in the recalling of information about the exposure and the 
formation of groups may be influenced by selection bias (Lewallen, Courtright 1998). 
 
In investigation 2 of the thesis, a cohort study was used to examine the prospective 
association between comorbidity and physical health. Cohort studies assemble samples based 
on a common factor e.g. patients who have had the same exposure or with the same disease 
and follow them over time to compare if those ‘exposed’ have different outcomes to the 
‘unexposed’ (Thadhani, Tonelli September 2006). The strengths of cohort studies include the 
temporal sequence of outcomes from the exposure and the ability to consider multiple 
outcomes of interest for a single exposure. The aim of observational research is to infer the 
findings from a sample to the wider populations from which the sample was drawn. However, 
the generalisability of a sample to its original population may be limited by factors which lead 
to incorrect inferences being made. Errors in interpreting results may be introduced through 
i) chance, ii) bias or iii) confounding. 
 
That any observed results are a factor of chance, rather than the tested association is 
introduced by the inherent variability within a sample. To reduce the possibility that a result 
occurs by chance can be addressed pre-data collection, by the use of a sufficient sample size, 
as variability is typically reduced by a larger sample or post-data collection, by testing for 
statistical significance of results. A measure frequently reported for statistical tests is the p 
value, this determines the probability that an event has occurred by chance if there is no 
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relationship between an exposure and outcome. A related measure to the p value is 
confidence intervals, which provide all the information to decide if an association is 
significant. Confidence intervals indicate the reliability of an estimate. This provides a range 
about an observed sample value in which we have confidence (usually to 95%) that the true – 
but unknown – value of the population will be within. Furthermore, if this does not cross an 
indicator value, (i.e. does not cross 0) then that is considered statistically significant 
(Hennekens 1987). 
 
Bias relates to the introduction of systematic aspects of error of the study design which 
influence the results. For example, this could be a difference in the method of data collection 
used between different cohorts (measurement bias, “the systematic variation of measurement 
from the true values” (Porta et al. 2008)). Bias can be limited by the careful design and 
consistent execution of a study (Grimes, Schulz 2002). Finally, observed results could be 
explained by confounding. Confounding, is an explanation for study findings actually being 
the result of a third factor, which is associated with the exposure, but also independently 
affects the outcome. This can be addressed within both the design phase, such as using 
stratification or in analysis using multivariate analysis to adjust for these factors (Hennekens 
1987). 
  
This thesis conducted analysis using two epidemiological datasets. The first was an existing 
Centre dataset on which secondary analysis was conducted and the second was a new cohort 
study. Both of these studies were designed to link collected survey data with general practice 
clinical records from consenting patients. The strength of this linkage epidemiology is the 
combination of multiple aspects of the patients’ medical history, including consultations, 
prescriptions and referrals, with self-reported survey health measures of interest. 
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3.4. Chronic disease or disorder spectrums 
The role of severity on influencing physical health, in either individual or comorbid chronic 
disease is considered throughout this thesis. Relative morbidity severity is tested through a 
priori spectrums by the ordering of GP diagnostic labels based on their severity. The focus of 
this thesis was across two different chronic conditions, cardiovascular disease (CVD) and 
musculoskeletal (MSK) disorders. The concept of relative morbidity severity spectrums is 
applied to both of these throughout the thesis, but within this work the CVD spectrum is 
referred to as a disease spectrum and the MSK spectrum, a disorder spectrum. 
 
In the MSK disorder spectrum, MSK diagnostic labels can range from pain symptoms that are 
regional (Parsons et al. 2007) or widespread (Croft et al. 1993), to pathology that is localised 
such as OA (Arden, Nevitt 2006), or to more systemic conditions such as rheumatoid arthritis 
(RA) (Reginster 2002). Notably the pain symptoms could either be self-limiting (Jordan, Jinks 
& Croft 2006) or be part of an established chronic disease such as OA (Dieppe et al. 2000). 
The experience of pain is a shared factor amongst these conditions but the causal process 
may be different and one condition within the spectrum is not a risk factor for another. The 
CVD spectrum is different to MSK in that current evidence has more clearly focused on a 
linked pathway in relation to development of CVD spectrum (Ara 2004, Player et al. 2007). 
Therefore, hypertension may be a preceding risk factor to myocardial infarction, which in 
turn can progress to end-stage heart failure in some individuals (Krum, Gilbert 2003).  
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3.4.1. Defining chronic spectrums 
A variety of CVD and MSK conditions are prevalent in the general population and general 
practice populations. To test the relative severity of these different cardiovascular morbidity 
or musculoskeletal morbidity, several conditions were selected from each chronic disease for 
inclusion in the different studies. The selection of CVD and MSK conditions was different in 
each study depending on the research question, therefore the chronic disease spectrums 
examined varied in each study (Table 3.1).  
 
The choice of CVD and MSK conditions examined within the systematic review was based on 
selecting common conditions of wide ranging severity. By selecting conditions with varied 
severity this allowed the examination of the influence of differing severity on physical health. 
The choice of common conditions, from those within the morbidity index developed by 
Kadam et al, and seen within general practice and the general population was to examine 
conditions which influence the health of large proportions of populations and practically to 
allow a review of sufficient literature to clearly understand the role of two different chronic 
spectrums on physical health. 
 
Expanding on the systematic review, secondary analysis was conducting using an existing 
Centre dataset to examine the association between relative morbidity severity and physical 
health in a general practice sample. This data was from an epidemiological study with linkage 
between patients’ survey data and (with consent) consultation records. Focusing the study 
question on a single dataset using multiple general practice populations from the local area, 
meant a larger spectrum of conditions for both CVD and MSK could be examined than was 
practical for the systematic review. Using consultation records the most commonly occurring 
CVD and MSK could be identified and placed in a hierarchical order using the severity order 
defined by the Kadam Morbidity Index. Examining more conditions within each spectrum 
than in the systematic review allowed a more rigorous testing of this concept of severity. 
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Table 3.1: Summary of cardiovascular disease and musculoskeletal disorder spectrums used in each study 
  Chronic disease spectrum  
Study Analysis CVD MSK Justification of morbidity choices 
     
1 Systematic  
review 
Hypertension 
Ischaemic heart disease 
Heart failure 
Lower back pain 
Osteoarthritis 
Rheumatoid arthritis 
 Each spectrum covers a wide severity range 
 This wide range provides initial  opportunity to examine 
how morbidities influence physical health relatively 
 These frequently investigated morbidities provide an 
opportunity for systematic review   
     
     
2 & 3 Secondary  
analysis 
Hypertension 
Atrial fibrillation 
Ischaemic heart disease 
Angina 
Myocardial infarction 
Heart failure 
Soft tissue disorder 
Soft tissue pain 
Peripheral enthesopathies 
Unspecified joint disorder 
Lower back pain 
Neck pain 
Osteoarthritis 
Osteoporosis 
Inflammatory polyarthrophy 
 These spectrums expand on systematic review  
 Allow test within same population sample  
 Additionally available labels allow further examination of 
relative severity 
 Allowed examination of influences of relative morbidity 
severity longitudinally 
     
     
4 & 5 Primary 
 analysis 
Hypertension 
Ischaemic heart disease 
Heart failure 
 
OA  CVD spectrum covers a wide severity range  
 Specific focus on OA allows a feasible test of interaction 
 
 70 
 
For the 2C study, OA was chosen as the comorbidity to examine with CVD. From the general 
practice sample, those patients who had previously consulted for OA were purposively 
selected for invitation to the study. OA in this sample was not limited to the method of 
diagnosis (symptomatic or radiographic) or by the joint location. This wide definition of a 
distinct disease type provided the ability to consider OA comorbidity against a spectrum of 
CVD conditions in a focused way, rather than subdivision by either the definition or joint 
location of OA. The choice of CVD was again a reflection of examining a wide spectrum of 
severity against common CVD, in which the prevalence of OA comorbidity is also high. 
 
The basis for a priori ordering of the CVD & MSK spectrums within this work was based 
around the previous work of Kadam (Kadam et al. 2008). Table 3.2 is an adapted table from 
this work and demonstrates the severity ordering of studied CVD and MSK morbidities in this 
study. This ordering was used to guide that within the thesis. 
 
3.4.2. Mutually exclusive categories 
Each spectrum is formed from several diseases or disorders being placed in the a priori order 
of their relative morbidity severity. The sample of each disease category was formed from 
patients who have previously consulted for that condition. However, many patients will have 
consulted for several of the conditions of interest within the same chronic spectrum. 
 
To retain patients in more than one disease category would remove the ability to compare 
diseases independently with each other for a proportion of the study sample. Therefore, each 
disease category was designed to be mutually exclusive by using a hierarchical classification. 
This means that if an individual had consulted for more than one of the specified diagnostic 
categories within the same chronic disease, they were classified by their ‘most severe’ 
category. For example, a patient with a previous consultation for hypertension and heart 
failure would be placed in the heart failure category. 
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3.5. Measuring health in populations 
3.5.1. General population surveys 
A frequently used tool for the collection of information from samples is the general 
population survey. This involves the distribution of standard and structured questions to a 
study sample. This could be in an electronic format, but predominantly remains a paper 
questionnaire format which can be given directly to the sample or mailed to their home 
address. The survey can be formed from open or closed questions, but in large scale 
epidemiological studies these are frequently closed questions. Surveys can be constructed 
from non-validated outcome measures but the use of validated outcome measures provides 
the reassurance of the quality of the data collected and reduces the risk of introducing 
measurement bias. Surveys are an important research tool as they reach a large study sample 
through a relatively simple (though potentially costly and labour intensive) process and are 
generally acceptable to patients, though this may be affected by certain content, length of 
survey or frequency of requests. 
 
 
 
 
 
 
 
 
 
 
  
 
7
2
 
Table 3.2:  Previous morbidity severity ordering (Kadam et al. 2008)   
   Morbidity classifications (51% consensus) 
Read code Study terms GPs 
n 
1. Chronicity & threat 2. Time course 3. Healthcare use 4. Impact on 
patient activities 
       
 CVD      
G20 High blood pressure 44 chronic permanent medium low 
G57 Atrial fibrillation 44 chronic permanent medium medium 
G33 Angina pectoris 44 chronic progressive high high 
G34 Ischaemic heart disease 12 undefined progressive high high 
G58 Congestive heart failure 44 chronic progressive medium high 
       
 MSK      
N22 Tenosynovitis 44 acute recurrent low medium 
N24 Pain in limb 44 acute one-off low undefined 
N21 Rotator cuff shoulder syndrome 44 acute recurrent medium medium 
N09 Knee joint pain 44 undefined recurrent medium medium 
N14 Back pain 44 acute-on-chronic recurrent medium medium 
N11 Cervical spondylosis 44 acute-on-chronic progressive medium medium 
N05 Generalised osteoarthritis 44 chronic progressive medium high 
N33 Osteoporosis 12 chronic progressive medium undefined 
N04 Rheumatoid arthritis 18 chronic progressive high high 
 
CVD: Cardiovascular disease, MSK: Musculoskeletal, GP: General Practitioner requested to order morbidities by severity 
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3.5.2. Short-Form health surveys 
The Short-Form (SF) series of generic health surveys measure general health, including both 
physical and mental health. The SF surveys are available in different formats, with the 
predominately used instruments containing 36 questions (SF-36) and the shorter survey 
with a subset of 12 questions (SF-12). Both the SF-36 & SF-12 contain eight subscales, 
measuring: physical functioning, role-physical, bodily pain, general health, vitality, social 
functioning, role-emotional and mental health. Upon completion of the SF survey, each 
subscale is scored from 0 (worst health) to 100 (best health). The scoring system for these 
measures also contains a method of imputation, Missing Score Estimation (MSE). This can 
estimate a missing value within a subscale, where several other required questions for that 
subscale have been answered.  This process does not compromise the validity of the measure 
and is therefore potentially beneficial as reduces any loss of data (Liu et al. 2005).  
 
Both SF surveys also form aggregate scores based on calculations using the eight subscales. 
Two summary scores, the Physical Component Summary (PCS) score and the Mental 
Component Summary (MCS) scores can be calculated from the SF-36 and SF-12. These scores 
are normalised to the general US population mean of 50 (SD 10), scores below 50 indicate 
worse physical or mental health than the normative data (Ware et al. 2002). These summary 
scores allow the comparison of the consequences of different disease groups and samples on 
general physical and mental health. 
 
The SF-12 was developed to be completed quicker than the SF-36, but retain the validity and 
reliability of its parent measure. It is a widely used measure of QOL, which has been shown to 
be valid in assessing the general health of chronic disease groups (Cunillera et al. 2010), 
simple for patients to complete and produce results comparable to the SF-36. The Short 
Form-12 (SF-12) Health Survey (Ware, Kosinski & Keller 1996) was the primary outcome 
used to measure self-reported physical health throughout this thesis. 
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3.5.2.1. Measuring health of chronic diseases with the SF-12 
The general health of different chronic disease groups has frequently been measured using 
the SF-12. For example in CVD samples, including hypertensive (Cunillera et al. 2010) and 
heart failure (Daamen et al. 2012) patients, and MSK samples with conditions including; LBP 
(Carmona et al. 2001), OA (Loza et al. 2009) and RA (Kahn et al. 2007). 
 
Summary scores provide an opportunity to compare the general health of different disease 
groups. Different values across groups provide an indication of varying health states. Crilley 
in 2001 found that MI patients from the UK (who had, had an MI two years earlier), had 
poorer PCS scores than a ‘normative’ comparison group of a similar age, both for those aged 
65 and under, or 65 and over. They found that the SF-12 correlated well with measures of 
chest pain and that this was a useful measure to assess the physical health of MI patients 
(Crilley, Farrer 2001). Research by Failde in 2009 found that the SF-12 could be used to 
discriminate between those with MI and those with angina. This had also been possible in the 
SF-36 and demonstrates the same measurement qualities between the parent and daughter 
measure (Failde et al. 2009). Furthermore, Gandhi et al examined the psychometric 
properties of the SF-12 summary scores in OA & RA trial populations and found the SF-12 to 
be a psychometrically sound tool in assessing both arthritis groups and that this measure was 
significantly correlated with clinical variables (Gandhi et al. 2001).   
 
3.5.2.2. Measuring health change in chronic diseases with the SF-12 
Capturing the responsiveness to changes in health is important in an outcome measure being 
used to assess health over time. Hurst et al in 1998 examined the responsiveness to short-
term change of the SF-12 PCS score in 240 RA patients who completed the SF-12 three 
months apart. Responsiveness was assessed by comparing the standardised response mean 
(SRM) of the SF-12 with the SF-36 in patients who reported improvement in their arthritis 
(Hurst, Ruta & Kind 1998). The validity of the SF-12 PCS score was closely correlated with the 
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SF-36 PCS, as were the change scores. More recently, Müller-Nordhorn et al compared the SF-
12 & SF-36 in coronary heart disease patients from 18 rehabilitation centres from across 
Germany using SRM. Their findings demonstrated the SF-12 to be a responsive measure of 
change in physical health over 6 and 12 months (Muller-Nordhorn, Roll & Willich 2004). 
 
The SF-12 has also been utilised to examine longer-term change in physical health in chronic 
disease groups. In 2009, Pisinger et al examined how the physical health of patients with 
Ischaemic Heart Disease altered over a five year time-period. They found that in the sample 
of 7,500+ patients from the Danish population, the PCS score could distinguish change in 
physical health of an intervention and a control group (Pisinger et al. 2009). Furthermore, in 
2012, Maatouk et al examined the association between several variables in hypertension 
patients and SF-12 PCS score 5 years after diagnosis. They found the PCS score in 
hypertensive patients to be a predictor of PCS scores five years later (Maatouk et al. 2012).  
 
3.5.2.3. Strengths & limitations of the SF-12 
The SF-12 is a widely used and valid outcome measure of general health. Furthermore, being 
a general measure of health it can be used to compare outcomes from different disease 
categories. This is particularly beneficial in comparing comorbid disease groups, which may 
have very different specific disease symptoms, but will also influence general aspects of 
health. 
 
There are several limitations of the SF-12. Muller-Nordhorn (2004) & Lim (1999) found that 
the proportion of missing data for the SF-12 could reach up to approx. 20% (Lim, Fisher 
1999, Muller-Nordhorn, Roll & Willich 2004). Consideration must also be made of the 
proportion of the responders who have the highest scores (ceiling effect) or the lowest scores 
(floor effect). Work done by the developers of the SF-12 (QualityMetric) considered these 
ceiling and floor effects in the 2009 general US population, stratified by age, gender and 
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disease specific populations. This showed that ceiling effects were high across the physical 
subscales for the younger age groups ≤44 years of age, particularly for males. For the 
subscales of Social Functioning and Role Emotional, older adults (particularly males) aged 
55≥ years of age had high floor effect. In this general population, chronic disease showed low 
to medium floor or ceiling effects (Ware et al. 2002). Furthermore, disease specific health 
measures may be more responsive to change than the SF-12 (Bennett et al. 2003). 
 
3.5.3. Physical health 
The WHO defines health as "a state of complete physical, mental and social well-being and not 
merely the absence of disease or infirmity" (Division of Mental Health and Prevention of 
Substance Abuse 1997). The aspect of patients’ QOL which this thesis focuses on is physical 
health. There is a growing awareness in Western society of the importance of physical 
activity for general health. Regular physical activity has proven to be effective in the 
prevention of several chronic conditions (U.S. Department of Health and Human Services 
1996). Retaining or improving general physical health can improve multiple aspects of the 
patient’s daily life and potentially reduce further aspects of health decline. 
 
This thesis focuses purely on physical health and does not address the issue of psychological 
health. Though psychological health is an important aspect of general health, the impact of 
chronic disease on psychological health has been shown to be less than the impact on 
physical health. Rijken et al found that those with more than one of several chronic diseases 
had no worse psychosocial health than those with just one of the chronic diseases (Rijken et 
al. 2005). It has been demonstrated that, though aspects of physical health decline with 
increasing age and the presence of chronic disease, mental health can remain stable. This 
suggests that there may be a process of psychological adjustment (Singer, Hopman & 
MacKenzie 1999, Hopman et al. 2009) and that general physical health is more likely to be 
affected by chronic disease over time than psychological health. However, clearly it is 
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possible that the morbidities chosen for investigation in this thesis do have important links 
with mental health, and there is certainly other literature that stresses the importance of 
mental health in multimorbidity. However, pragmatically and scientifically, the choice was to 
focus on physical health in this thesis. 
 
3.6. Conducting research in general practice  
Throughout this thesis, samples were formed using individuals who were registered with a 
general practice and had previously consulted their GP. The formation of study samples 
based on consultation history is possible as general practices use computerised recording 
systems to maintain a record of each patient’s visit, logging the reason for consultation in a 
standardised way. 
 
A visit to general practice is marked by the application of a label summarising the main 
presenting complaint. This label, usually attributed by the GP, determines the course of health 
care management or treatment (Jutel 2009). For example, routine chronic disease clinics, 
which monitor individual patients with conditions such as ischaemic heart disease (van 
Lieshout et al. 2009) have their respective labels which provide key signposts for the health 
care management pathway of the patient (Campbell et al. 2005). This computerised recording 
of health conditions through the application of specific diagnostic labels not only provides a 
standardised recording mechanism for general practice records, but also provides the 
opportunity to define chronic disease at a population level for research. Though marker 
systems/tests are available in general practice to define a condition, these are not always 
performed or indeed required for the GP to apply a diagnostic label. Therefore, the presence 
of the label itself provides the marker of disease or symptom and can subsequently be used to 
define disease categories. 
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3.6.1. Diagnostic labelling in general practice 
In UK general practice, the ‘Read code’ system is used to classify the morbidity with which a 
patient presents to the health professional in a standardised way. Read codes are a 
computerised coding classification, initially developed by Dr James Read in the 1980s, and 
provide an alphanumerically coded method of recording clinical and administrative data. The 
original version used a four-level hierarchical system to classify morbidity, symptoms or 
processes, but limitations with this lead to development of a five-level version in 1990 and a 
subsequent revision between 1992 and 1995, which forms the current version (Version 3) 
used today. Read codes are divided into chapters, chapters 0-9 form ‘process codes’ (e.g. 
histories, laboratory procedures etc.), whilst chapters A-Z are ‘diagnosis codes’. Each chapter 
is composed of five hierarchical levels of coding classifications, with each sub-level providing 
more and more information (Table 3.1). The Read code system was developed as a 
collaboration between the National Health Service Centre for Coding and Classification 
(NHSCCC) and medical professionals (Harding, Stuart-Buttle 1998).  
 
Table 3.1: Example of five-levels of coding in a cardiovascular Read code chapter  
Chapter level Read code Read term 
1 G…. Circulatory system disease 
2 G3… Ischaemic heart disease 
3 G30.. Acute myocardial infarction 
4 G301. Anterior myocardial infarction OS 
5 G3011 Acute anteroseptal infarction 
 
Morbidity data is collected routinely by practices in actual consultations using Read codes. In 
2004, Jordan et al reviewed the literature which had examined the quality of morbidity 
coding using Read codes by general practices. Their systematic review found 24 articles 
which had considered the quality of computerised coding in comparisons to other methods, 
such as paper records or diagnostic testing.  Overall, though they found the quality of coding 
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to be mixed and some limitations (i.e. patient discusses multiple problems during a 
consultation but only one problem coded), they stated that the potential does exist for good 
quality consultation coding within general practices (Jordan, Porcheret & Croft 2004). 
 
One of the conclusions drawn from the work by Jordan et al was that general practices would 
benefit from training to further improve their coding. In 2004, Porcheret et al investigated 
the influence of assessment, feedback and training on the quality of coding in several general 
practices. As part of the development of a local (North Staffordshire) initiative to create a 
network of general practices involved in research they investigated the impact of focused and 
monitored training in coding. They found that though there were varied levels of coding 
quality initially across different practices, training and support improved or maintained 
coding and they concluded that, with the right infrastructure, morbidity data from 
consultation can be used in epidemiological research in primary care (Porcheret et al. 2004). 
 
3.6.2. Chronic disease registers 
In addition to the improvements in data coding and quality in groups of local general 
practices, a relatively recent change to the method of resource allocation to general practice 
by the NHS has meant improved coding practice nationally. The Quality and Outcomes 
Framework (QOF) was introduced in 2004 to ensure that a selection of the most prevalent 
and resource intensive diseases in the UK are recorded accurately. Financial reimbursements 
are applied to the coding of these diseases of interest to provide an indicator programme for 
the status and continued monitoring of these conditions. Improvement in the coding of 
consultations, both nationally and locally (in relation to Staffordshire & Cheshire, UK) shows 
Read codes to be an accurate method of defining chronic disease. 
 
Chronic disease registers based on consultation coding in general practice are important for 
health services to monitor disease in the population and to plan for service provision in the 
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future. However, consultation coding also presents an opportunity for epidemiological 
research. With the majority of the UK population registered with a general practice, large 
samples of patients, across many different disease types are potentially accessible to address 
many research questions. 
 
3.7. Summary 
This chapter has defined the methods used in the thesis and reported in the next 6 chapters. 
In chapter 4, systematic review methods were used. Chapters 5 to 9 are based on large 
consultation-survey linkage studies from general practice. The core epidemiological methods 
used were cross-sectional (chapters 5 and 7) and cohort design (chapters 6, 8 & 9), and using 
logistic and linear regression statistical methods.  
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Chapter 4: The associations between chronic disease 
spectrum and physical health: A systematic review 
 
The influence of individual chronic disease on physical health has been extensively examined. 
This chapter describes a systematic review to examine the relative influence of several 
different conditions from two chronic diseases (Cardiovascular Disease (CVD) and 
Musculoskeletal (MSK) disorders) on physical health. Examining the role of individual 
chronic disease in physical health will provide a context in which to understand the impact of 
combinations of chronic diseases, and hence comorbidity on physical health. 
 
4.1. Introduction 
The presence of a chronic disease will frequently be detrimental to patients’ health, impacting 
on quality-of-life (QOL), including physiological and psychological health (Lyons, Lo & 
Littlepage 1994). There has been extensive research examining the associations between 
individual chronic diseases and patients’ health. However, the magnitude of this experience 
may vary from disease to disease. For example, both hypertension and lower back pain (LBP) 
will impact on physical health, but the impact of these two conditions on patient populations 
will vary (Lima et al. 2009). Direct comparisons of the literature are possible, both between 
the same or different conditions, through use of the same measure of general health, but the 
lack of quantifiable or systematic comparisons of how different individual chronic diseases 
impact on patient health limits any comparisons.  
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Understanding individual chronic diseases and their association with patients’ experience of 
health is important for general practice. Examining the associations between disease and 
health, for one disease relative to another, can better inform clinicians about how different 
patient populations are being affected. Such information may provide a basis for 
interventions which delay the progression of, or prevent, poor health. In striving for evidence 
based health care, comparisons are required to be able to apply such findings to clinical care. 
 
Current research has frequently examined associations with patient health of a multitude of 
different chronic diseases, including CVD and MSK disorders. However, the literature on this 
topic has not been collectively reviewed and as a result there is a gap in the knowledge of 
how different chronic diseases impact on physical health in relation to one another, which a 
systematic review can fill. International use of the Short-Form (SF) Health Survey across 
many different health conditions provides the opportunity to gather extensive data on how 
different chronic diseases impact on physical health. The collation of such information allows 
for a better understanding of the association between different chronic diseases and physical 
health through the synthesis of data. This also provides the opportunity to examine how 
individual conditions influence health both within the same chronic disease spectrum and 
between different chronic disease spectrums. 
 
General practice forms the front line service in the care of chronic diseases in the United 
Kingdom (UK). Providing a clearer understanding of the relative influence of chronic diseases 
on the physical health of the general population (potential consulters) or general practice 
population (consulters) would allow clinicians to make more informed decisions regarding 
the provision of resources for more tailored treatment or management by adding to the 
evidence of how to approach different disease populations.  
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4.2. Aim & objectives 
4.2.1. Aim 
The aim of this systematic review was to examine current evidence on the association 
between individual chronic diseases and physical health. This would examine the presence of 
either of two chronic disease spectrums, i.e. CVD or MSK disorders, on the physical health 
experienced by the general population or general practice populations. 
 
4.2.2. Objectives  
Two specific objectives using systematic review methods were: 
1. To examine whether physical health differs within a chronic disease spectrum.  
2. To examine whether physical health differs between chronic disease spectrums.  
 
4.3. Methods 
A systematic review of research articles was conducted. Medical literature databases were 
searched to identify articles which included study samples defined with one of two chronic 
diseases and which had reported a physical health outcome in the general population or a 
general practice population. Selection of articles was based on standardised inclusion and 
exclusion criteria. Final inclusion of an article within this review required agreement of in the 
majority of the review team. From each article specific information was extracted, and from 
this, data was then analysed. 
 
 
 
 
 
 
 84 
 
4.3.1. Chronic disease spectrums: Categories 
This systematic review compared several different conditions within two chronic disease 
spectrums, CVD spectrum and MSK spectrum. Three empirically chosen common conditions 
were examined within each spectrum. For CVD, the three conditions chosen were 
Hypertension, Ischaemic Heart Disease (IHD) and Heart Failure (HF). For MSK disorders, the 
three conditions chosen were Lower Back Pain (LBP), Osteoarthritis (OA) and Rheumatoid 
Arthritis (RA). 
 
These two spectrums were formed on the basis of relative morbidity severity as described in 
Chapter 3. The choice of the three conditions within each spectrum was based on their 
common prevalence and their substantial influence on the health of general practice 
populations. By a priori hypothesising that there were differences in the association between 
each disease and physical health, this provides the test in which to investigate the concept of 
chronic disease spectrums and the idea that each disease label is a marker of severity. The 
selected disease categories were placed in an a priori order based on the consensus of GPs 
(morbidity index) and ranged from those considered relatively ‘less severe’ to the patient (i.e. 
hypertension for CVD and LBP for MSK) to disease categories defined as ‘moderately severe’ 
(i.e. IHD for CVD and OA for MSK), and to ‘most severe’ (i.e. HF for CVD and RA for MSK). 
 
The three cardiovascular diseases selected and OA are discussed in greater detail in Chapter 
2. In addition to OA, the MSK spectrum was formed from the common conditions of LBP and 
the inflammatory condition of RA. All these MSK conditions have been shown to be associated 
with poor physical functioning (Delitto et al. 2012, Ware Jr. et al. 1998). The syndrome of LBP 
can present as either localised or diffuse pain in the lower region of the back. LBP is the most 
common MSK condition in the UK, with a one-month period prevalence of 29% (Macfarlane 
et al. 2012). Despite the high prevalence of LBP, 90% of patients show some improvement by 
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8 weeks (Speed 2003) and though a common problem the impact on activity limitation is low 
(Kent, Keating 2005). 
  
RA is a chronic, systemic inflammatory disease which affects the joints and results in their 
degradation. In the UK, the prevalence of RA is approximately 1% (Symmons et al. 2002) and 
patients can experience disability at any time of their life. There is no known cure for RA so 
treatment and management are very much based on improving patients’ QOL. Physical health 
in particular can be severely diminished and RA can have a greater impact than other MSK 
conditions (Picavet, Hoeymans 2004).  
 
4.3.2. Literature databases 
Research literature was available from different database sources (Medline, EMBASE and 
CINAHL). Each database contains a different catalogue of articles from journals depending on 
their specific field. Medline (Medical Literature Analysis and Retrieval System Online) is an 
American-based database and was chosen as this provides a large selection of articles, dating 
from the 1950s and pertaining to the life, biomedical and health sciences. EMBASE, a 
European database provides access to biomedical articles and also provides an additional 
focus on articles with a pharmaceutical nature. CINAHL (Cumulative Index to Nursing and 
Allied Health Literature) focuses on topics which are based in, or orientate around nursing 
and the allied health professions. The use of three literature databases, with varied resources 
of published biomedical information provided sufficient breadth to capture the majority of 
articles which would be of interest to this review. Searches using these three databases were 
run through the National Health Service (NHS) evidence webpage 
(https://www.evidence.nhs.uk/). Once articles had been identified from the three databases, 
these articles were exported into the bibliographic management software, RefWorks 
(Proquest LLC, Michigan, USA). 
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4.3.3. Article inclusion criteria 
Selection of an article into the final review was based on inclusion criteria (Table 4.1). Study 
samples were aged 18 years or older, as the selected chronic diseases predominantly affect 
the adult population (Alder et al. 2005).  These adult samples had to have been recruited 
either from the general population or general practice and defined as having one of the six 
study diseases of interest (hypertension, IHD, HF, LBP, OA or RA). Disease status could be 
defined either from; the practitioner (i.e. clinical diagnosis), the patient (i.e. their GP had 
previously told them that they have a condition) or a clinical indicator (i.e. high blood 
pressure). Within this systematic review, articles which included patients who had been 
defined as having IHD, angina or myocardial infarction (MI) were all defined within the IHD 
category for this review.  
 
Only observational studies (including cross-sectional, case-control or cohort studies) were 
included in the review. The primary outcome of interest for this review was the Physical 
Component Summary (PCS) score from the Short-form 12 or 36. Therefore, an article was 
required to have used the Short-form 12 (SF-12) or Short-form 36 (SF-36) health surveys to 
generate this score. If an article had used one of these measures and either 1) provided the 
PCS score for the disease group of interest or 2) provided data from the eight SF subscales 
which could be used to calculate the PCS score, then it was included. Though the SF-12 is a 
shortened version of the SF-36, these measures have been shown to be comparable when 
examining the QOL of hypertension (Cote et al. 2004), RA (Hurst, Ruta & Kind 1998), HF 
(Jenkinson et al. 1997a), MI (Mols, Pelle & Kupper 2009), spinal disorder (Lee et al. 2007) and 
OA (Gandhi et al. 2001) patients. 
 
 
 
 
 87 
 
Table 4.1: Inclusion criteria for articles into the final systematic review  
Inclusion criteria Specification  
Age Aged 18 years or older 
Study type Observational studies  
Population General population or general practice sample  
Disease Study includes patients with at least one of the six diseases of interest  
Outcome measure SF12 or SF36 with PCS score or scores for all eight subscales  
 
 
4.3.4. Article exclusion criteria 
Articles which specifically sampled all patients aged 17 years or under were excluded, as 
were articles which were published before 1990. The SF scales were developed in the late 
1980s and not used prior to the 1990s (Ware, Sherbourne 1992). Randomised control trials 
(RCT) were excluded. Due to the selective nature by which RCT samples are chosen, such 
studies would not provide a true representation of the general population or those who 
consult general practice. In articles including both baseline cross-sectional data and follow-up 
longitudinal data from observational studies, only the baseline cross-sectional data was 
included into this systematic review. Whilst longitudinal data could be important, the scope 
of the review was not extended to cohort data which had different periods of follow-up, 
assessment of interventions and which assessed change over time. Finally, any articles which 
were written in a language other than English were excluded as there was no facility available 
for translation. 
 
4.3.5. Search strategies 
This systematic review implemented nine search strategies in total, generated by three 
disease specific searches, which were applied to the three literature databases. The disease 
specific search strategies related to 1) “cardiovascular”, 2) “musculoskeletal” and 3) “chronic” 
disease terms (Appendix 4.1). Each disease specific search strategy used defined 
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terminology to indicate which articles should be extracted from the databases for inclusion in 
this review. This terminology was grouped by i) outcome, ii) setting and iii) population. 
“Outcome” relates to any term in an article regarding the outcome measure of interest, 
“setting” refers to the terms used to search for articles which match the systematic review’s 
health care setting of interest and “population” relates to the disease type being searched for 
i.e. ‘CVD’, ‘MSK’ or ‘chronic diseases’.  
 
The search terminology was based on Medical Subject Headings (MeSH) and keywords. MeSH 
terms are a standard vocabulary used by literature databases to index research articles 
within a database. By using these, articles can be selected which have a common theme or 
link (i.e. all those articles which are classified as having ‘cardiovascular’ content). ’Exploded’ 
MeSH terms were used for the study search strategies, this allowed for the greatest number 
of articles related to a term to be included by wider search terms being utilised. Individual 
keywords were then used to provide more tailored and specific search terms to complement 
the broader MeSH terms. 
 
4.3.6. Screening and selection of articles 
This stage comprised title screening, abstract screening, and final article selection, using a 
total of three reviewers (JAP, KPJ, UTK). The first reviewer (JAP) screened all articles by their 
title, removing unsuitable and duplicate articles based on this information. After exclusion by 
title, the first reviewer selected articles based on abstract content meeting the required 
inclusion criteria. Two second reviewers (UTK & KPJ), who were blinded to the decision of 
the first reviewer, then screened half of the articles each. In cases of disagreement on the 
inclusion or exclusion of an article between the first reviewer and one of the second 
reviewers, the article was passed to the other second reviewer for arbitration. After this 
process the first reviewer then read all remaining articles in full to decide on the final articles 
to be included in the review. Again, second reviewers assessed half of the papers each and 
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arbitration of queried papers was conducted by the other second reviewer. Once the final list 
of included articles was compiled, the first reviewer examined each article’s reference list for 
any further articles which could be included in the review but which had been missed by 
database searches. Final inclusion of these was based on agreement with the second 
reviewers. 
 
The selection of articles was based on the consensus between reviewers; no standardised 
measure of quality assurance (QA) was used. Articles using observational studies can be very 
different in design, but of no less importance to the overall picture of the systematic review. 
Though several QA checklists do exist for observational studies, these vary in content and no 
research has compared these directly (Mallen, Peat & Croft 2006). 
 
4.3.7. Data extraction 
The final articles included in the review underwent structured data extraction (Table 4.2). In 
the instances where an article was included in the review but the required data were not 
reported, the corresponding author was contacted and the data requested from them directly. 
 
Data of interest included: the lead author and year of publication; the number of participants 
which formed the study sample, along with their mean age (Standard Deviation (SD)) (or age 
range of the study sample if the mean was not available). Further data included the health 
care setting of these studies, either general population or general practice, and how the 
disease of the study sample had been defined. Within this review, no restrictions were placed 
on the country of origin from which the study sample came, but this information was 
recorded for subsequent synthesis of PCS data, based on the normative data of that country’s 
population (see section 4.3.8). 
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Data on the primary outcome measure, the SF health survey was also recorded. Firstly, 
whether the SF-12 or SF-36 had been used and secondly, the mean PCS score and a measure 
of distribution around that mean; standard deviation (SD), standard error of the mean (SE) or 
confidence intervals (CI) were extracted. However, if the mean PCS score was not present, but 
the mean score for each of the eight SF subscales was, then this information was used to 
produce the required PCS score using standard formula, as described by the developers 
(Ware, Kosinski & Keller 1994). 
 
Table 4.2: Data extracted from each article in the final systematic review 
Data type Description of data 
Author, year The first author of the article, the year of its publication 
 
Sample size (n) The size of the sample upon which analyses were performed for that 
article 
 
Age The mean age (Standard Deviation (SD)) of the study sample.  
N.B. If this was not available, age range or minimum age were 
extracted if available 
 
Country The country from which the study sample were selected 
 
Health setting The healthcare setting from which the sample was selected  
i.e. general population or general practice 
 
Case definition Description of the method used within the study to define the 
disease category of interest 
 
Outcome measure  SF12 or SF-36 
 
PCS score The mean Physical Component Summary (PCS) score calculated by 
the article for their study sample, together with measure of variation 
(SD, Standard Error (SE) or 95% Confidence Intervals (95% CI)) 
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4.3.8. Data analysis & standardisation 
First, descriptive analysis was performed on the extracted characteristics. Secondly, PCS 
scores for each study were converted to a z-score. A z-score is a value which is generated by 
standardising a PCS score using national normative SF data. This value indicates the extent to 
which the health of the disease sample deviates from the health of the general population of 
the country in which the disease sample were selected. This is in contrast to the use of PCS 
scores, which is a score indicating the extent to which the health of the disease sample 
deviates from the health of the general United States (US) population. The use of z-scores can 
potentially account for any variation introduced in to the findings when comparing samples 
with the same disease, but from different countries because of similarities or differences with 
the US. 
 
Much of the literature examining the association between chronic diseases and physical 
health recorded by the SF, are in worldwide settings. The generic nature of the SF surveys 
means that it has been used to assess the general health of the populations of many different 
countries. A comparison of health across countries has been achieved through the creation of 
a summary scoring method by the developers of the SF (QualityMetric) by providing a 
standard US reference population. 
 
Calculation of a PCS score from any country is based on the average PCS score of the US 
population acting as the standard (Ware, Kosinski & Keller 1994). Therefore, comparisons 
between studies are made with the same point of reference, the physical health of the average 
American population. However, drawing conclusions based on a PCS score, means that the 
observed association of a disease with self-reported physical health in each study sample will 
always be influenced by how different or similar the population of the country is from the 
general US population. The aim of this systematic review, however, was to collate data on the 
association between disease category and physical health, but with studies originating from 
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many different countries, the approach needed to take account of each individual country’s 
normative national population SF data. 
 
The method of producing z-scores provided a practical opportunity to better assess how 
physical health of a person with a given disease differs from the expected physical health of 
an ‘average’ person for that country. This analysis was based on a methodological construct 
used in a previous systematic review undertaken by van der Waal et al in 2005, which 
converted PCS scores to z-scores to compare OA patients across different countries (van der 
Waal et al. 2005). This method was also used by Salaffi in 2009 to standardise SF PCS scores 
with the general population from the study country of interest (Salaffi et al. 2009). 
 
Each PCS score was converted to a z-score. This is calculated using the mean PCS score from 
the general population of the same country as the study sample (a ‘normative national 
population’). If the normative PCS score of the general population for a country was not 
identified during the review process or through citation searches, then the PCS score from the 
most comparable country was used. Choice of the alternative country was based on socio-
demographic similarities to the country from which the study sample had come from. For 
example, in the absence of a mean PCS score of a representative sample of the Japanese 
general population to compare against a Japanese study sample, then the normative PCS 
score for the Chinese population was used. 
 
Once the ‘normative’ population had been chosen for each study sample (Gandek et al. 1998, 
Hopman et al. 2000, Lam et al. 2005, Demiral et al. 2006) included in the final review 
(Appendix 4.2) then the z-score could be generated. To calculate this score the difference 
between the mean PCS score of the study sample and the mean PCS score of the relevant 
normative sample was divided by the standard deviation of the mean PCS score of the 
normative national population (Figure 4.1) (van der Waal et al. 2005). The resultant output 
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from this calculation can be interpreted as the number of standard deviations of the mean 
study sample physical health score away from that of the normative national population of 
the country in question. For each study the mean z-score were displayed graphically and the 
mean of all study z-scores for the same disease was subsequently calculated.  
 
z-score = x¯ 1 - x¯ 2 
                  σx¯ 2 
 
Figure 4.1: Equation to generate a z-score. 
x¯ 1 = Mean PCS score of the study sample, x¯ 2 = Mean PCS score of normative sample, σx¯ 2 = 
Standard deviation of the mean PCS score of the normative sample 
 
Two sensitivity analyses were conducted. The first assessed any variation in conclusions 
when using the SF-12 or SF-36, by stratifying by these two measures. The second considered 
whether any differences between diseases observed across different populations, were also 
observed in a single study (Alonso et al. 2004) which looked at several diseases within the 
same population. 
 
4.4. Results (Search strategy outputs) 
4.4.1. Articles 
From the three literature databases a total of 3,384 unique articles were identified. From title 
screening, 196 articles were retained. After abstract screening, 104 of the 196 were retained, 
61 were excluded by both the first and second reviewers, and there was disagreement for 31 
articles. Through arbitration, 11 of these 31 articles were retained, leaving 115 articles to be 
reviewed in full. 
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Of the 115 articles selected on the basis of abstract, upon full article screening 72 did not 
meet the inclusion criteria for this review and were subsequently excluded (Table 4.3). An 
agreement on inclusion or exclusion could not be met by the first and second reviewers for a 
further 20 articles. Three of these were retained after arbitration. This resulted in 26 full 
articles from the database searches being included in the systematic review. With the 
inclusion of a further 8 articles sourced through the reference lists of the 26 articles and 
agreed upon by all reviewers, this resulted in 34 articles finally being included in the 
systematic review (Figure 4.2). 
 
Table 4.3: Reasons for the exclusion of articles when reviewed in full 
Reason for exclusion  Number excluded 
Disease definition did not meet inclusion criteria 26 
Short Form health survey data unavailable  22 
Sample not from the general population or general practice 17 
Different outcome measure used  10 
Non-observational study design 6 
Same data set used in another review article 5 
Article unavailable 3 
Total 89 
 
4.4.2. Studies 
For the CVD spectrum, this review identified 21 studies for hypertension (13 countries), 16 
studies for ischaemic heart disease (11 countries) and 15 studies for heart failure (10 
countries). For the MSK spectrum, this review identified 10 studies for lower back pain (9 
countries), 13 studies for osteoarthritis (9 countries) and 6 studies for rheumatoid arthritis 
(5 countries). 
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Figure 4.2: Stages of article selection 
 
7,853 articles found through systematic 
search 
3,384 articles assessed by title 
4,469 duplicate articles removed 
196 articles reviewed by title & abstract 
61 articles excluded 
31 articles queried between reviewers 
11 articles included after arbitration 
115 articles reviewed in full 
26 articles selected 
3,188 articles removed 
8 additional articles sourced 
34 articles included in final review 
 3 articles included after arbitration 
20 articles queried between reviewers 
104 articles included 
72 articles excluded 23 articles included 
 96 
 
4.5. Results (Study characteristics) 
4.5.1. Characteristics of cardiovascular diseases 
4.5.1.1. Characteristics of the hypertension studies 
21 studies (from 14 articles) examined the influence of hypertension on physical health for a 
combined sample of 16,507 (Appendix 4.3). These studies were based in 13 different 
countries, nine European, two from the Americas and two from Asia. Fourteen of the 21 
studies used samples from general populations, with study sample mean ages ranging from 
42.9-69.9 years. The remaining 7 studies drew their samples from general practice and study 
sample mean ages ranged from 58.1 – 68.1 years old. Fourteen studies defined hypertension 
using a self-report checklist of diseases; here the participant was requested to indicate 
whether they had ever been diagnosed with any of a series of health problems (including 
hypertension) by their healthcare professional. Three studies based the definition on the 
clinical records containing a previous diagnosis for hypertension and two used 
clinical/physical examination at the time of consultation. 
 
4.5.1.2. Characteristics of ischaemic heart disease studies 
10 studies (from 5 articles) examined the influence of IHD on physical health for a combined 
sample of 1,668 (Appendix 4.4). The majority of studies (8) included samples from the 
general population, the mean ages of these ranging from 55–66.6 years of age. These studies 
were from six European, one American and one Asian country, with all defining IHD through 
use of a patient self-report chronic disease checklist. The remaining studies used samples 
from general practices across regions of Ireland and England. The mean ages of these samples 
were 65.0 & 69.4 years of age respectively and IHD was defined through the review of 
medical records. Both of these studies excluded patients with angina from their samples. 
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Three studies examined the influence of angina on physical health, for a combined sample of 
1,092 (Appendix 4.4). Each of these studies selected their samples from general practice, 
using multiple general practices from across specific geographical areas. Two were based in 
England, with sample mean ages of 68.0 and 70.2 respectively and the other in Ireland, with a 
mean age of 67.2 years. All three studies reviewed clinical records and selected patients 
based on a previous diagnosis for angina. 
 
Three studies examined the influence of MI on physical health for a combined sample of 545 
(Appendix 4.4). Two selected their samples from general practice, using multiple general 
practices from different geographical areas of England. The mean ages of these samples were 
67.2 and 68.9 years respectively and both were defined by reviewing clinical records and 
selecting patients with a previous diagnosis for MI. The remaining study sampled from the 
Spanish general population, this had a mean age of 67.3 years and MI was defined by the 
patient stating on a self-report checklist that they had previously diagnosed with this 
condition. 
 
4.5.1.3. Characteristics of heart failure studies 
15 studies (from 8 articles) examined the influence of HF on physical health for a combined 
sample of 2,830 (Appendix 4.5). Approximately half of these studies included samples from 
the general population from six European, one America and one Asian country. HF was 
defined through use of a self-report chronic disease checklist and the mean ages of these 
study samples ranged from 57.4-67.9 years. Five studies examined the physical health of HF 
patients in samples drawn from general practice, with ages ranging from 72.7-76.5 years, 
three of these samples were from England and two from the US.  These five studies based 
inclusion on a previous diagnosis of HF in the patients’ records. The remaining two studies 
(from Sweden and Germany) used samples from a variety of sources, including general 
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practice, medical centres and HF clinics. Mean age ranged from 64-78 years and HF in these 
samples was defined through clinical tests. 
 
4.5.2. Characteristics of musculoskeletal disorders 
4.5.2.1. Characteristics of lower back pain studies 
Ten studies examined the influence of lower back pain (LBP) on physical health for a 
combined sample of 4,477 (Appendix 4.6). These studies were based in nine different 
countries, six European and three from the Americas. Four studies used samples from the 
general population, with mean ages ranging from 50.7-69.6 years. Six studies drew their 
samples from general practice, with mean ages ranging from 48.9-81.0. Five studies used self-
report checklists to define LBP with the remaining five defining this by a previous 
consultation recorded in the clinical records or presentation of pain in the lower back region 
at the time of consultation. 
 
4.5.2.2. Characteristics of osteoarthritis studies 
Thirteen studies (from ten articles) examined the influence of OA on physical health for a 
combined sample of 9,414 (Appendix 4.7). These studies were based in nine different 
countries, six European, one in the US and two in Asia. Five studies used samples from 
general populations where mean ages ranged from 60-67 years. The eight remaining studies 
drew their samples from general practice (including outpatient’s clinics), with mean ages of 
these samples ranging from 61.6–71.0 years. Seven studies defined the presence of OA by the 
experience of symptomatic or radiographic signs, with four of these using the American 
College of Rheumatology (ACR) classification. The remaining six studies defined OA through 
either a self-report checklist (three studies) or a previous diagnosis in the patients’ records 
(three studies).  
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4.5.2.3. Characteristics of rheumatoid arthritis studies 
Six studies examined the influence of RA on physical health for a combined sample of 2,970 
(Appendix 4.8). These studies were based in four different countries, three European and 
one in the US. Two studies used a general population sample, with mean ages of 57.6 and 66 
years respectively. The remaining four studies drew their samples from general practice 
(including outpatient’s clinics) or selected patients from county-level RA registers, and had 
mean ages ranging from 53.9 – 66 years old. Two studies defined the presence of RA by the 
previous diagnosis of RA, two used a diagnosis based on American Rheumatism Association 
(ARA) criteria and two used a self-report disease checklist. 
 
4.6. Results  
The purpose of this analysis was to synthesise the studies from two a priori hypothesised 
chronic disease spectrums, comparing whether there were differences in physical health 
within the same chronic disease spectrum, by disease category or between chronic disease 
spectrums. 
 
4.6.1.  Cardiovascular disease spectrum 
With one exception (Aydemir, Ozdemir & Koroglu 2005), all hypertension studies reported 
that the PCS score was below that of the general US population (below 50), ranging from 49.4 
(best) to 38.4 (worst). When these PCS scores were converted to z-scores, all but one study 
sample indicated physical health scores below that of the normative national population, 
ranging from -0.15 to -1.22 standard deviation (SD) (Table 4.4). The mean of these scores 
was -0.68, representing a physical health status for those with hypertension, 0.7 SD below the 
normative national population.  
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Table 4.4: Physical health of hypertension  
Author by disease, year  n Mean age (SD) PCS score 
Mean (SD) 
Z-score 
     
Hypertension     
(Alonso et al. 2004) 665 53.5 (17.3) 44.6 (11.3) -0.66 
 448 59.4 (15.7) 44.3 (10.8) -1.08 
 618 60.6 (14.4) 43.3 (11.3) -1.11 
 599 56.9 (16.2) 44.2 (11.5) -0.66 
 308 52.6 (15.8) 44.3 (11.9) -0.74 
 489 54.2 (18.3) 45.8 (10.9) -0.42 
 316 57.1 (16.0) 43.9 (12.1) -0.88 
 
 
502 58.7 (13.0) 44.9 (10.5) -1.08 
(Aydemir, Ozdemir & Koroglu 
2005)                                                                                                                                                                   
938 58.1 (11.2) 52.7 (22.4) 0.54 
(Cunillera et al. 2010) 
 
917 61.08 (18.5) 43.2 (14.2) -0.80 
(Erickson, Williams & Gruppen 
2001)                                                                                                                                                              
 
125 59.0 (11.2) 49.4 (9.3) -0.15 
(Hobbs et al. 2002) 
 
1203 65.0 (10.0) 47.2 (10.7) -0.35 
(Johnson, Coons 1998) 
 
81 N/A 44.0 (10.8) -0.72 
(Lam et al. 2005) 
 
271 N/A 48.1 (9.4) -0.65 
(Lima et al. 2009) 
 
941 69.9 (12.3) 45.8 -0.53 
(Mena-Martin et al. 2003) 
 
104 59.3 (12.9) 46.0 (11.1) -0.51 
(Prior, Kadam 2011)   
 
1606 68.1 (9.5) 38.4 (12.2) -1.22 
(Quercioli et al. 2009)  
 
218 64.8 (12.8) 46.4 (8.9) -0.81 
(Schmidt et al. 2008) 
  
4252 N/A 41.8 (10.4) -0.91 
(Wang et al. 2008) 
 
217 61.5 (13.2) 42.9* -0.80 
(Ware, Kosinski & Keller 1994)                                                                                1689 58.4 43.7 (10.3) -0.76 
     
*PCS score was not available in original article but was calculated from available SF subscales; PCS = 
Physical Component Summary score; SD = Standard deviation; N/A: Not available 
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For the 16 studies detailing the physical health scores in those with IHD (including angina 
and MI), all PCS scores were worse than the general US population, ranging from 43.1 to 31.7. 
When converted to z-scores, this represented a range from -0.75 to -1.96 (Table 4.5), mean 
of -1.37. For all 15 studies examining HF, all PCS scores were worse than the general US 
population, ranging from 42.8 to 28.9. The z-scores for HF ranged from -1.11 to -2.14 (Table 
4.6) below the normative national population, a mean of -1.72. 
 
Z-score ranges were compared for each of the three disease categories of the CVD spectrum 
(Figure 4.3). The first 10 of the 20 hypertension studies (with the exception of Aydemir et al 
(Aydemir, Ozdemir & Koroglu 2005) had a z-score outside the range of the other two 
conditions. The first 6 of 16 IHD studies had physical health scores covering the same range 
of scores observed for the hypertension study samples, the last half (8) of the IHD studies had 
z-scores which covered the same range of z-scores for the HF study samples (with the 
exception of (Alonso et al. 2004) [Netherlands]). Four HF study samples with the worst z-
scores were outside the range of the other two conditions.  
 
4.6.1.1. Comparing cardiovascular disease studies 
For each of the three CVD, z-scores were also examined when only using those studies which 
had used the SF-36. The majority of studies across each CVD category had used the SF-36. 
There was little difference in mean z-scores for each CVD whether using the SF-12 & SF-36 or 
only the SF-36 to measure physical health (Table 4.7, Appendix 4.9). 
 
Results from studies within the CVD spectrum were compared to one article which had 
examined hypertension, IHD & HF in the same samples (Alonso et al. 2004). When comparing 
the results from the several different countries Alonso et al have examined, higher z-scores 
(better physical health) were observed in those with hypertension than IHD or HF. Those 
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with IHD had better physical health than those with HF in all but two of the countries (Japan 
& France) (Figure 4.4). This overall pattern reflected that observed in this review. 
 
Table 4.5: Physical health of ischaemic heart disease 
Author by disease, year  
 
n Age 
Mean (SD) 
PCS score  
Mean (SD) 
Z-score 
     
IHD     
(Alonso et al. 2004) 141 60.5 (16.3) 37.1 (12.4) -1.46 
 104 66.6 (16.2) 37.5 (10.2) -1.95 
 103 65.6 (15.2) 36.6 (10.8) -1.96 
 289 64.1 (14.3) 38.3 (11.2) -1.26 
 47 64.1 (11.2) 40.7 (11.6) -1.13 
 190 55 (20.6) 42.0 (12.0) -0.83 
 78 63.9 (11.8) 37.6 (12.8) -1.61 
 
 
100 59.3 (14.5) 41.9 (10.8) -1.50 
(Buckley, Murphy 2009) 
 
449 65.0 (9.1) 42.0 (9.0) -0.86 
(Prior, Kadam 2011) 257 69.4 (8.3) 33.4 (10.8) -1.71 
     
Angina     
(Buckley, Murphy 2009) 
  
275 67.2 (9.01) 39.4 (9.4) -1.12 
(Hobbs et al. 2002) 
  
531 68.0 (9.6) 40.7 (11.1) -0.99 
(Prior, Kadam 2011) 286 70.2 (8.5) 31.7 (9.8) -1.87 
     
Myocardial Infarction     
(Cunillera et al. 2010)  
 
105 67.3 (15.0) 38.1 (15.1) -1.32 
(Hobbs et al. 2002) 
  
396 67.2 (9.7) 43.1 (11.2) -0.75 
(Prior, Kadam 2011) 44 
 
68.9 (9.44) 34.7 (11.4) -1.58 
IHD: Ischaemic Heart Disease; PCS: Physical Component Summary score;  
SD = Standard deviation 
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Table 4.6: Physical health of heart failure 
Author by disease, year  n Age 
Mean (SD) 
PCS score  
Mean (SD) 
Z-score 
     
Heart failure     
(Alonso et al. 2004) 83 64.7 (11.4) 31.0 (10.6) -2.10 
 127 66.7 (13.2) 37.1 (11.1) -2.00 
 142 68.0 (12.6) 36.8 (10.9) -1.93 
 250 64.4 (14.3) 36.6 (11.4) -1.43 
 91 63.5 (12.8) 37.6 (11.5) -1.46 
 170 62.2 (17.5) 39.4 (12.4) -1.11 
 35 65.3 (12.5) 35.1 (12.6) -1.91 
 
 
50 57.4 (14.7) 42.8 (10.9) -1.37 
(Brostrom et al. 2004) 223 75 (9): males 
78 (9): females 
  
34.7* -1.77 
(Faller et al. 2007)  231 64 (13) 36.1 (10.6) -1.49 
(Gott et al. 2006) 
  
542 76.5 32.6* -1.79 
(Hobbs et al. 2002) 
  
399 72.7 (9.5) 35.97 (10.1) -1.45 
(Prior, Kadam 2011) 
  
139 76.5 (8.2) 28.98 (9.0) -2.14 
(Sidorov et al. 2003) 
 
268 75.2 33.8 (10.8) -1.81 
(Wyrwich et al. 2007) 80 50+ 32.2* -1.98 
*PCS score was not available in original article but was calculated from available SF subscales PCS: 
Physical Component Summary score; SD = Standard deviation 
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Figure 4.3: Z-scores of studies with a defined cardiovascular disease in descending order  
Hyp = Hypertension, IHD = Ischaemic health disease, HF = Heart failure. Black markers indicate those articles for which a PCS score was calculated from the eight SF 
subscales. White markers indicate those studies which used the SF-12; red, blue and yellow markers indicate studies which used the SF-36. SD = Standard Deviation 
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Table 4.7: Cardiovascular disease and musculoskeletal disorders spectrum z-scores 
 Studies using SF-12 or SF-36  Studies using SF-36 only 
 Number of studies Z-score range Mean z-score (SD)  Number of studies Z-score range Mean z-score (SD) 
        
Cardiovascular disease        
Hypertension 21 0.54 to -1.22 -0.68 (0.4)  15 0.54 to -1.11 -0.61 (0.4) 
Ischaemic heart disease 16 -0.75 to -1.96 -1.37 (0.4)  12 -0.75 to -1.96 -1.29 (0.4) 
Heart failure 15 -1.11 to -2.14 -1.72 (0.3)  12 -1.11 to -2.10 -1.64 (0.3) 
        
Musculoskeletal disorder        
Lower back pain 10 -0.71 to -2.17 -1.38 (0.6)  4 -0.72 to -2.17 -1.31 (0.7) 
Osteoarthritis 13 -1.07 to -2.56 -1.86 (0.4)  5 -1.07 to -2.56 -1.92 (0.7) 
Rheumatoid arthritis 6 -1.09 to -2.46 -1.70 (0.5)  3 -1.46 to -2.46 -1.89 (0.5) 
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Figure 4.4: Article which has examined hypertension, ischaemic heart disease and heart failure in the same sample, across several countries  
Hyp=Hypertension, IHD = Ischaemic health disease, HF = Heart failure. Jap = Japan, Net = Netherlands, Ger = Germany, USA = United States of America, Nor = 
Norway, Den = Denmark, Ita = Italy and Fra = France (Alonso et al. 2004).  
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4.6.2. Musculoskeletal disorder spectrum 
All studies describing PCS scores in people with MSK disorders, reported that the PCS scores 
were below that of the average US population (below 50). PCS scores for the LBP studies 
ranged from 44 (best) to 29 (worst). When these PCS scores were converted to z-scores, the 
scores ranged from -0.71 to -2.17, with a mean of -1.38, therefore a SD of approximately 1.4 
below the normative national population (Table 4.8). For all 13 studies describing physical 
health scores in people with OA and physical health, PCS scores ranged from 39.8 to 31.7. The 
z-scores of these samples ranged from -1.07 to -2.56 and the mean of these was -1.86 (Table 
4.9). Studies describing physical health scores in people with RA, PCS scores, ranged from 
40.6 to 32.9, and the z-scores ranged from -1.09 to -2.46 (Table 4.9), with a mean of -1.70 
(Figure 4.5). 
 
Table 4.8: Physical health of lower back pain 
Author by disease, year  
 
n Age 
Mean (SD) 
PCS score 
Mean (SD) 
Z-score 
     
Lower back pain     
(Carmona et al. 2001) 
 
325 ≥20 32.4 -1.90 
(Cunillera et al. 2010) 
  
1277 50.7 (21.4) 44 (13.6) -0.71 
(Depont et al. 2010)  796 52.9 (11.3) 36.2 (8.6) -2.00 
(Ekman et al. 2005) 
  
302 48.9 (14.2) 35.2 (4.7) -1.71 
(Hicks et al. 2008)  140 81.0 (5.5) 
 
43.9 -0.73 
(Lima et al. 2009) 
  
621 69.6 (10.7) 44 -0.72 
(Prior, Kadam 2011) 
  
650 64.4 (10.0) 37.6 (12.1) -1.30 
(Salaffi et al. 2005) 
  
127 ≥18 40.1 (9.8) -1.61 
(Suarez-Almazor et al. 2000) 
  
46 49.9 (14.8) 29.3 (8.1) -2.17 
(Wang et al. 2008) 193 51.1 (15.2) 41.9*  -0.90 
     
*PCS score was not available in original article but was calculated from available SF subscales PCS: 
Physical Component Summary score; SD = Standard deviation; N/A: Not available 
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Table 4.9: Physical health of osteoarthritis and rheumatoid arthritis 
Author by disease, year  
 
n Age 
Mean (SD) 
PCS score 
Mean (SD) 
Z-score 
     
Osteoarthritis     
(Carmona et al. 2001) 
  
233 ≥20 31.7 (27.3-36.1) -1.97 
(Carmona et al. 2001) 
  
136 ≥20 35.5 (31.1-39.8) -1.58 
(Loza et al. 2009) 1071 71 (9) 
 
35.1 (8.7) -1.62 
(Picavet, Hoeymans 2004) 
 
547 64 
 
39.8 -1.62 
(Picavet, Hoeymans 2004) 354 67 
 
37.4 -1.39 
(Prior, Kadam 2011) 850 68.9 (9.7) 
 
33.15 (11.0) -1.73 
(Rannou et al. 2007) 2540 67 (10) 
 
32.0 (8.4) -2.53 
(Rannou et al. 2007) 
  
1581 67 (10) 31.8 (8.4) -2.56 
(Salaffi et al. 2005) 
  
193 ≥18 36.6 -2.06 
(Slatkowsky-Christensen et al. 
2007) 
 
190 61.6 
 
36.3* -1.60 
(Ware Jr. et al. 1998) 
  
994 60.8 38.9 (10.1) -1.26 
(Woo et al. 2004) 
  
574 N/A 36.6* -2.22 
(Zakaria et al. 2009)  151 65.6 (10.8) 37.5* -2.10 
     
     
Rheumatoid arthritis     
(Kahn et al. 2007) 490 54 (11)  
 
37 (9) -1.46 
(Picavet, Hoeymans 2004)  
 
156 66 36.1 -1.46 
(Salaffi et al. 2009) 
  
693 53.9 (12.9) 33.6 (6.4) -2.46 
(Slatkowsky-Christensen et al. 
2007) 
  
194 61.1 
 
32.9* -1.97 
(Uhlig et al. 2007) 
 
936 61.3 (14.1) 
 
35 (12) -1.74 
(Ware Jr. et al. 1998) 
  
501 57.6 40.6 (10.5) -1.09 
*PCS score was not available in original article but was calculated from available SF subscales PCS: 
Physical Component Summary score; SD = Standard deviation 
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Figure 4.5: Z-score of studies with a defined musculoskeletal disorder in descending order 
LBP = Lower Back Pain, OA = Osteoarthritis, RA = Rheumatoid Arthritis. Black markers indicate those articles for which a PCS score was calculated from the eight 
SF subscales. White markers indicate those articles which used the SF-12. SD = Standard Deviation 
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Study samples ordered by descending z-score 
LBP (Mean -1.38, SD 0.6)
OA (Mean -1.86, SD 0.4)
RA (Mean -1.70, SD 0.5)
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4.6.2.1. Comparing musculoskeletal disorder studies 
For each of the three MSK, z-scores were also examined when only using those studies which 
had used the SF-36. The majority of studies across each MSK disorder had used the SF-12. 
There was little difference in mean z-scores for each MSK disorder whether using the SF-12 & 
SF-36 or only the SF-36 to measure physical health (Table 4.7, Appendix 4.13). 
 
4.6.3. Comparing cardiovascular disease & musculoskeletal disorder 
spectrums  
With one exception, the study samples from all six chronic diseases had physical health 
scores below normative national population levels. 81 samples in total were included in this 
systematic review across the six disease categories. Approximately half of all the 
hypertension study samples had a mean z-score higher than that for any study from the other 
disease categories, ranging between 0.54 to -0.66 (nine studies). The two remaining CVD 
categories and the majority of studies from the three MSK conditions covered similar ranges 
of z-scores, from -0.71 to -2.14 (67 studies). The lowest z-scores were observed across all 
three MSK conditions, ranging from -2.17 to -2.56 (five studies) (Figure 4.6). 
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Figure 4.6: Comparison of z-scores of both cardiovascular disease and musculoskeletal disorder studies in descending order  
Hyp=Hypertension, IHD = Ischaemic health disease, HF = Heart failure. LBP = Lower Back Pain, OA = Osteoarthritis, RA = Rheumatoid Arthritis, SD = Standard 
Deviation 
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Study samples ordered by descending z-score 
Hyp (Mean -0.68, SD 0.4)
IHD (Mean -1.37, SD 0.4)
HF (Mean -1.72, SD 0.3)
LBP (Mean -1.38, SD 0.6)
OA (Mean -1.86, SD 0.4)
RA (Mean -1.70, SD 0.5)
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4.7. Discussion 
4.7.1. Overall findings 
A total of 81 observational samples, from across 17 different countries and with a combined 
sample of 39,503 were selected for this systematic review. Results show that these specific 
chronic diseases are associated with poor physical health in general and general practice 
populations. Patients with a diagnosis of any of the six disease categories of interest had 
worse physical health than that experienced by normative national populations. Within both 
the cardiovascular and musculoskeletal chronic disease spectrums, the strength of 
association between conditions and physical health varied. On average, samples with 
hypertension had better physical health than those with ischaemic heart disease (IHD), and 
those with IHD had better physical health than those with heart failure (HF). Those with 
lower back pain had better physical health then those with OA or RA, but the two latter 
disease categories experienced similar physical health. Between chronic disease spectrums, 
the influence of select disease categories on physical health is similar, despite these diseases 
affecting very different body systems. 
 
4.7.2. Cardiovascular disease spectrum 
Increasing disease severity within the CVD spectrum was associated with worse physical 
health. On average, hypertension samples had ‘better’ physical health than IHD samples; 
those with IHD had ‘better’ physical health than those with HF. The hypothesis was that these 
a priori disease categories would reflect the stages or ‘severity’ of the cardiovascular 
spectrum and the systematic review supports these findings. 
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Whilst the systematic review covered studies from different geographical regions and health 
settings, additional support to the comparison of these three CVD is provided by the Alonso et 
al study. Investigating these three CVD conditions in the same population in eight different 
counties, Alonso et al found that in six of the eight countries, those with hypertension had 
better mean physical health scores than those with IHD and those with IHD had better mean 
physical health scores than those with HF, mirroring the findings of this review (Alonso et al. 
2004). 
 
The role of several factors may be influencing the observation of poorer physical health with 
increasing relative morbidity severity. A partial explanation for differences across the 
spectrum findings may be age. Age may be a confounder as increasing age is associated with 
increased prevalence of CVD (Lakatta, Levy 2003) and poorer physical health (Alonso et al. 
2004). Comparing the PCS scores of each disease category against age-matched normative 
data may have presented a different influence of each condition on physical health. The 
normative data used to produce the z-scores was based on the average general population, 
across all age ranges. However, normative PCS scores alter when stratified by age. For 
example, the PCS score for the general US population is 50, when categorised by age, the 
mean PCS score decreases (worse health) from 47.4 to 44.7 to 40.0 as age increases from 55-
64, 65-74 & 75 years or older respectively (Ware, Kosinski & Keller 1994). The age ranges 
observed for hypertension, IHD and HF observed within this review ranged from 52-70, 55-
70 and 57-78 years of age respectively.  
 
Though this review did not account for the confounding presence of factors upon the physical 
health of these samples, other research would suggest that though these findings could be 
influenced, relative impact would likely remain even after adjustment for factors such as age, 
gender, deprivation or comorbidity. Research by Bardage et al found a negative impact of 
hypertension on physical health even after adjustment. Using a Swedish general population 
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sample (aged 21-84), they found that people with hypertension had worse physical health 
than normotensives in the same population (as measured by the SF-36) and that this 
association remained after adjusting for age, gender, socio-demographic factors and 
comorbidity (Bardage, Isacson 2001).  In more recent research, when all comorbidity was 
adjusted for in a Spanish primary care population, the negative impact of hypertension 
observed on physical health in comparison to the ‘average’ population was also retained 
(Pinto-Meza et al. 2009). 
 
These findings showed that people with hypertension experience worse physical health than 
the average general population, but better health than those with IHD. This was in-line with 
research undertaken by Lyon et al in 1994. In a primary care sample from West Glamorgan, 
Wales, their study found that hypertension patients had worse physical functioning, 
measured by the SF-36 subscale, compared to those without hypertension, but better 
physical functioning than those with either angina or MI (Lyons, Lo & Littlepage 1994). 
 
However, there are also clear overlaps in the physical health experience across the three CVD 
conditions. Individual people with hypertension may experience a health status that is 
equivalent health to a person with IHD, and a person with IHD may experience equivalent 
health to a person with HF. Hypertension is a known risk factor for IHD (Vaccarino et al. 
2011) and IHD a known risk factor for HF (He et al. 2001). This may go some way to 
explaining the overlapping of physical health states in some study samples, as people may be 
making transitions from one stage of CVD to another. 
  
4.7.3.  Musculoskeletal disorder spectrum 
Hypothesised relative morbidity severity in the MSK spectrum was not associated with worse 
physical health across the full spectrum. Though these three disease categories clearly have 
an impact on the physical health experienced, the a priori disease severity spectrum was not 
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reflected in the reported mean physical health scores. Though LBP did fit the hypothesis and 
showed the best average physical health score of the three selected MSK conditions, on 
average those with OA experienced slightly poorer physical health than those with RA. This 
finding is contradictory to our hypothesis and other research. Previous research by Picavet et 
al had examined several MSK conditions in the same population and found that the physical 
health of those with RA was worse than OA (Picavet, Hoeymans 2004). Using the wider 
definition of ‘inflammatory rheumatic diseases’, Salaffi found that in a sample of the 
consulting population in Italy these had worse health (though marginally) than those with 
OA. This also demonstrated that those with LBP had better physical health than either those 
with OA or RA (Salaffi et al. 2005). Using a case-control design, Kolahi et al examined the 
physical health of healthy controls and case groups with OA, RA or fibromyalgia (Kolahi et al. 
2011). In a matched sample of women aged 35-55, those with RA had significantly worse 
physical health (as measured with the SF-36) than those with OA. 
 
The findings for the MSK spectrum, as considered for the CVD spectrum, may be confounded 
by age. Within this study, and comparable to other research (Hameed, Gibson 1996, Scott et 
al. 1998), the age of the OA samples was typically older than that of the RA samples. 
Therefore, the poorer health observed in the OA samples may be associated with this factor 
as well as the disease.  
 
The construct of this spectrum was based on three disorder categories, though all are MSK in 
nature, these lack a direct aetiology. Instead, these are all based around the experience of 
pain (Woolf, Vos & March 2010) and therefore this may also go some way to explaining the 
relatively similar physical health scores in the MSK spectrum.  
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4.7.4. Comparing cardiovascular disease with musculoskeletal disorder 
This review selected two chronic diseases, different in their pathology and patient outcomes 
and compared the impact of these conditions on general physical health. For the CVD 
categories, relative morbidity severity in relation to poorer physical health was shown, but 
not for the selected MSK conditions. The differences that were found when comparing these 
two chronic disease spectrums may be related to the pathology of these diseases. The CVD 
spectrum was based on three disease categories linked by shared aetiology, where there is a 
clear aetiological path (for some, but not all patients) from the development of hypertension, 
to IHD and then to HF. For the selected MSK conditions, although there might be shared pain 
experience, they do not represent aetiological links through shared pathology. However, the 
selected MSK conditions still provide the basis for comparing different conditions and their 
association with poor physical health. 
 
Despite the different role of relative morbidity severity within these two chronic disease 
spectrums, conversely, equivalent average physical health scores were observed between 
these different disease categories. All six disease categories included studies which had 
observed a physical health score from -1 to a -1.5 z-score, also the mean scores of different 
disease types were comparable, e.g. IHD -1.37 and LBP -1.38; HF -1.72 and RA -1.70. Such 
comparison of two chronic diseases spectrums demonstrates the similar experience of 
patients with very different diseases. Improvements to patient health may not only come 
from disease focused management or treatment but also a focus on improving physical 
health, no matter the perceived impact of one disease over another.  
 
4.7.5. Individual disease categories 
Though hypertension is thought of as a health problem of relative ‘low’ severity, all studies 
included in this review (with one exception) had worse physical health than the normative 
national populations. Those with hypertension experiencing better physical health than those 
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with IHD or HF may be expected, but those with hypertension having poorer physical health 
than the normative national population is notable. Wensing et al examined the impact of 
several chronic conditions on patient health, using the SF-36. In a Dutch general practice 
population, aged 18 years or older, they found an association between several different 
chronic conditions and worse health, but they found the reported health from those with 
hypertension to be no different to those without the condition (Wensing, Vingerhoets & Grol 
2001). A potential reason for the poor health of the hypertension category could be the 
influence of the samples’ age, as increasing age is a risk factor for both prevalence of 
hypertension and diminished physical health.  
 
The role of ‘other morbidity’ may also act as a confounder. Previous research has argued that 
hypertension can be asymptomatic and that the experience of poor health is more likely to be 
a symptom of other morbidities (Miksch et al. 2009). Therefore, the poor physical health 
observed for the hypertension categories may be influenced by other diseases. However, 
though those in this disease category may well have other comorbidities, it remains that, on 
an epidemiological level, those previously defined with ‘hypertension’ have worse physical 
health. 
 
The study by Aydemir et al was the only one to find an association between hypertension and 
improved physical health status. Though this study had a large sample size from several 
regions in Turkey and a mean age comparable to the other studies, this result would appear 
to be somewhat of an outlier. This study was the only one to define hypertension using the 
Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 
Pressure 7 (JNC VI) classification. Though this measure may be a reason for the variation in 
these results, potentially as a result of detecting more mild cases of hypertension, it does 
define hypertension with the same diastolic and systolic values (Chobanian et al. 2003) as 
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used by the NICE guidelines (National Institute for Health and Clinical Excellence 2011a) and 
therefore this is unlikely.  
 
The IHD category included three separate definitions, that of IHD, angina or MI. Though the 
latter two disease categories can be classified within the former, use of the three definitions 
was examined as a potential source of variance related to the diagnostic labels applied in 
general practice amongst these samples. This difference in definitions was not reflected in a 
consistent influence on the z-scores recorded, with scores from all three covering the entire 
observed z-score range for all the IHD disease categories. 
 
Of the studies which had examined the association between HF and physical health, Brostrom 
in 2004 had recruited their sample from several hospital wards in addition to several 
primary care health centres from across Sweden (Brostrom et al. 2004). Despite the potential 
that recruitment from such an environment may have included patients with more severe HF, 
the z-scores from this sample were comparable to the other HF studies. 
 
A generalised approach to OA was used within this review. OA could be radiographic or 
symptomatic and could be defined in a specific joint or by the general presence of OA. Seven 
of the included thirteen studies examined a specific joint; one of these examined knee OA 
(Zakaria et al. 2009) and six studies, across three articles, had each examined OA in two 
different joints, knee & hip (Picavet, Hoeymans 2004), knee & hip (Rannou et al. 2007) and 
knee and hand (Carmona et al. 2001). Physical health scores from either a particular joint or 
general OA from across all the OA studies had no discernible difference. 
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4.7.6. Systematic review design  
4.7.6.1. SF-12 vs. SF-36 
Two versions of the SF health survey were used as the outcome measures of physical health 
in this review, the SF-12 & SF-36. Though the SF-12 is derived from the SF-36, the reduction 
in questions from 36 to 12 suggests a potential change in the data captured. Since the 
development of the SF-12, much research has compared these two versions, finding the 
outputs between the two to be comparable (Jenkinson et al. 1997b, Gandhi et al. 2001, Mols, 
Pelle & Kupper 2009). However, to ensure that the results from studies which had used the 
different measures were comparable, for each disease category, z-scores were examined both 
for i) all studies or ii) studies using the SF-36 only. Findings were similar. 
 
4.7.6.2. Available PCS score vs. calculated PCS score 
To generate z-scores for all studies, it was necessary to have the PCS score for each study. For 
eight studies, only the subscales of the SF measures were available in the published article, 
therefore the PCS scores were calculated for these studies from the subscales. When the 
results from studies for which PCS scores had been manually calculated, rather than using 
those provided by the authors, were compared graphically with the other studies, no 
perceived difference in these scores existed. Standardised methods, as outlined in the user’s 
manuals by the developers of the SF surveys were utilised to produce these scores and this 
has introduced no variance into this review. 
 
4.7.7. Strengths and limitations 
4.7.7.1. Strengths 
One of the strengths of this systematic review lies in stating a priori hypotheses based on the 
notion of relative morbidity severity. Ordering diseases within the same chronic disease 
spectrum has allowed the testing of the hypothesis of severity, based on categorisation by 
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disease. This test also included studies based on clear standardised procedures and included 
international research. A further strength of the methods was the use of z-scores as a method 
of standardising physical health status to the respective national populations. The z-score 
approach provided estimates, not only for physical health but also for the disease categories. 
This approach allows for the fact that different countries may have different approaches to 
diagnosis for any of the six conditions. It has also demonstrated the use of z-scores for future 
research and brought about the comparison of two common chronic diseases where little 
comparison has been applied before. Finally, the effort to contact authors to acquire data and 
therefore be able to include a greater number of studies into this review also adds to the 
strength of the findings. A total of 20 authors were contacted requesting additional data from 
their original articles, 17 of these responded with 12 providing the additional information 
requested 
 
4.7.7.2. Limitations 
Though six conditions were included in this review, there were many other CVD and MSK 
conditions that could have been selected. Other limitations are that research articles which 
were not written in English were not included in this systematic review. Ideally any article 
which possessed the required inclusion criteria, regardless of language would have been 
included. However, there was no facility to translate articles and therefore we were unable to 
include wider non-English literature. 
 
For the articles which were selected for the review, no standardised quality assurance (QA) 
measure was used to assess their final inclusion or to assess variation between studies. As 
stated earlier in this chapter (section 4.3.6 Screening), it was decided that there was no 
measure of QA superior to that of assessment by the review team. Though, the selection of 
articles into this review was based on rigorous assessment of the sourced literature by those 
involved in this review, lack of a measure of QA may have introduced selection bias 
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pertaining to the articles included and therefore is a potential source of some of the variation 
seen between conditions 
 
The approach to calculating the z-scores could also have introduced limitations. For several 
studies, no national normative data was available for which to generate the z-scores. The 
scores for samples from Brazil (Lima et al. 2009), Ireland (Buckley, Murphy 2009), Malaysia 
(Zakaria et al. 2009) and Japan (Alonso et al. 2004) were calculated using normative data 
from the USA, UK, China and China respectively. Though, in the circumstances where no 
national normative data was available this method was thought superior to that of using the 
US population norms, it should be noted that the production of normative data for these, and 
other countries would be beneficial for the future strength of this method. 
 
This systematic review has solely focused on the physical health (PCS score) of study samples 
rather than alongside available psychological health (Mental Component Summary (MCS) 
score). Though the psychological aspect of health is important to general health and related 
to physical health, it was not the primary interest of this work. Chronic disease has been 
shown to be associated with diminished physical health, as measured by the SF12. However, 
psychological health status can remain high and relatively stable (Hopman et al. 2009). It is 
also accepted that other measures of general physical health are available and that these 
findings are specific to the Short-Form health surveys. 
 
Finally, this review has not conducted as yet a formal meta-analysis, which for example might 
take account of age, or pool articles of matching characteristics. This review would benefit 
from these analytic methods as PCS scores were summarised only by means across studies 
and so this does not take into account the different sizes of the studies and within study 
variation. 
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4.7.8. Research implications 
This systematic review supports the definition of relative morbidity severity, the ordering of 
samples for epidemiological research based on previously applied or present disease 
categories as defined by health care professionals. This method of defining morbidity severity 
could be applied to further research in the association of different individual conditions with 
other outcome measures or in assessing the impact of certain comorbid combinations and 
outcomes of interest. 
 
Other issues which may be of benefit for other research to consider is that to conduct this 
review it was necessary to contact the corresponding authors of 20 articles to try to gain the 
required data, including both socio-demographic information as well as outcome measure 
data. Though corresponding authors were extremely helpful and often supplied the data 
requested, this highlights the improvements that could be made in the fullness of data 
reporting in observational studies.  
 
Finally, the summary score methods of the SF health survey are effective methods for the 
comparison of different studies. However, with the increasing number of studies from 
different countries which provide normative data for a population, the use of z-scores is 
increasing possible. Whether a study decides to use PCS/MCS scores or z-scores depends on 
several considerations. If a study wishes to compare the impact of disease(s) within the same 
sample or country and then make direct comparison with the wider available research using 
the SF then using the summary measure is recommended. However, if the aim of a study is to 
use summary measures to assess the impact of a disease across samples from distinctly 
different geographical areas, in isolation of the inherent variability which exists across 
different populations then z-scores offer this opportunity. The choice of which summary 
measure used may also be influenced by the country in which this is being studied. In the 
example for hypertension presented in Appendix 4.10, when comparing z-scores generated 
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with normative national population data or USA normative data, some countries show more 
variation in these scores than others. 
 
4.8. Conclusions 
Chronic diseases are associated with worse physical health than the normative population. 
This systematic review shows quantitative distinctions between conditions both within the 
same chronic disease spectrum and between chronic disease spectrums. The severity of CVD 
is an influence on physical health; however, those with MSK disorders can also experience 
similar impacts on physical health. These (at times) very distinct chronic diseases, have less 
distinct impacts on physical health and it may be more appropriate to make health status the 
locus around which treatment and management is orientated rather than the specific disease. 
 
By understanding how individual chronic diseases influence physical health, this chapter 
provides a context against which to examine how chronic diseases may interact in 
comorbidity. This systematic review has now presented the potential to examine conditions 
within and between chronic disease spectrums. However, limitations relating to the 
additional adjustment for confounders such as age, means that to validate the use of relative 
morbidity severity as a method to assess physical health requires specific analysis to gain a 
better understanding of how different conditions relate to one another in the same 
population. 
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Chapter 5: Association between relative morbidity severity 
and physical health: NorStOP cross-sectional study 
 
This chapter examines the association between relative morbidity severity and physical 
health in a general practice population. Chapters 1 and 4 support the ordering of diagnostic 
labels based on the perceived understanding of severity. The systematic review 
demonstrated that, in two different chronic disease spectrums, the presence of a particular 
condition influences the physical health of the patient, even when the definition of the 
disease/disorder varies. However, the question was now extended as to whether, in the same 
population, the application of different diagnostic labels within the cardiovascular and 
musculoskeletal spectrums by the GP reflects the physical health of different patient 
populations relative to one another. 
 
5.1. Introduction 
The interest of this thesis is focussed on patient registers in general practice, and therefore 
this study utilised an existing large general practice consultation-survey linkage data set for 
secondary analysis to answer specific questions. Such analysis has the advantages of similar 
patient characteristics across all morbidity groups and the ability to adjust for confounding 
factors such as age, gender and deprivation status. Finally, to be able to test chronic disease 
spectrums as a definition of relative morbidity severity, several diseases and disorders were 
required within each spectrum. This study took a more extensive view of CVD and MSK 
categories than in the Chapter 4 systematic review and included more diagnostic categories 
within each of these chronic disease spectrums. 
 
By undertaking secondary analysis on an existing consultation-survey linked dataset (North 
Staffordshire Osteoarthritis Project (NorStOP)), this cross-sectional study examined the 
association between relative morbidity severity and patient self-reported physical health for 
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two chronic disease spectrums (cardiovascular disease (CVD) and musculoskeletal (MSK) 
disorders) from a general practice population. In doing so, this work developed and tested an 
innovative way to define morbidity severity in relation to other morbidity, using routinely 
collected clinical data from general practice populations.  
 
5.2. Aim and objectives 
5.2.1. Aim 
For the two specific chronic diseases of CVD and MSK, the aim was to examine the cross-
sectional association between relative morbidity severity and self-reported physical health. 
 
5.2.2. Objectives 
Using two examples of chronic disease spectrums, there were two distinct questions:  
1) do different diagnostic labels which form the stages of a disease spectrum in 
cardiovascular disease reflect the associated physical health of the corresponding 
patient group?  
2) do different diagnostic labels which form the stages of a disorder spectrum in 
musculoskeletal disorders reflect the associated physical health of the 
corresponding patient group? 
 
5.3. Methods 
5.3.1. Study design 
Using an existing consultation-survey linkage dataset (NorStOP), the study hypotheses were 
investigated in a cross-sectional general practice population aged 50 years and over. These 
participants had completed a baseline survey that was subsequently linked, with consent, to 
their clinical records from the two years before the baseline survey. Patients were selected 
for this analysis based on recorded consultations for CVD or MSK conditions in the two years 
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preceding the baseline survey. A 2-year time-period would be sufficient to identify chronic 
disease patients who would consult general practice at least once in this time period. Chronic 
disease patients frequently consult general practice (Schellevis et al. 1994), and as previous 
consultation is associated with future consultation (Jordan, Ong & Croft 2003), even those 
diagnosed with a chronic disease preceding the 2-year period would likely consult in such a 
study-defined time-period.  
 
5.3.2. Study population 
5.3.2.1. North Staffordshire Osteoarthritis Project (NorStOP) 
NorStOP (funded by the Medical Research Council (MRC)) is a study of joint pain and general 
health in the general population. A questionnaire was mailed to all registered patients aged 
50 years and older from six general practices based in North Staffordshire, United Kingdom 
(UK). Study practices are part of the Primary Care Research West Midlands North (PCR 
WMN) network, a research partnership between the Arthritis Research UK Primary Care 
Centre, Keele University and the NHS. This collaborative network was developed to facilitate 
high quality primary care research by dove-tailing academic and clinical research bodies.  
 
The populations at these partner practices are representative of the wider population of the 
North Staffordshire area. These practices routinely use the Read classification (Harding, 
Stuart-Buttle 1998) to code clinical encounters with their patients and as part of their 
commitment to the Network, are required to code at least 95% of consultations. The study 
had been given ethical approval by the North Staffordshire Research Ethics Committee (REC) 
and as part of this application had also requested to use patients’ medical records to link with 
survey responses. 
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The NorStOP survey was sent to 20,214 patients registered at the six practices. 13,986 
patients (69%) responded and non-responders showed similar socio-demographic 
characteristics to previous surveys (Thomas et al. 2004). From the responding population, 
10,432 (51.6%) patients had consented to the review of their computerised clinical records, 
and of these consenters, 8,962 (44.3%) had had any morbidity consultation in the two years 
before the baseline survey (Figure 5.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Flowchart on selection of study population from the overall NorStOP population. 
 
The outcome of interest was the Short-Form 12 (SF-12) health survey, and specifically the 
summary scores. 7,779 patients (56% of survey responders who had consented to record 
review and had an SF-12 score) had completed the Physical Component Summary (PCS) and 
Mental Component Summary (MCS) items. This group formed the study sample and their 
survey data was linked to the morbidity data coded by GPs for the previous two years. 
Population mailed for the North Staffordshire 
Osteoarthritis Project (NorStOP) 
= 20,214 
Responders to baseline NorStOP questionnaire 
= 13,986 (69%) 
Responders to baseline NorStOP questionnaire who 
consented to medical record review 
= 10,432 (52%) 
Responders to baseline NorStOP questionnaire who consented to medical 
record review and had consulted in the previous two years 
= 8,962 (44%) 
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5.3.3. Defining two chronic disease spectrums 
All those patients who had consulted for any CVD or MSK disorders in the two years before 
the baseline survey were identified from the study sample of 7,799. This study was primarily 
interested in a specific selection of Read codes (Table 5.1). Several codes from both the CVD 
and MSK chapters were selected based on existing work by Kadam et al who had identified 
the 56 commonest morbidities in England and Wales and asked GPs to grade these by 
severity (Kadam, Jordan & Croft 2006). The a priori order of relative morbidity severity 
defined as exclusive diagnostic categories was based on the Kadam Morbidity Index. 
 
Six cardiovascular “disease” categories were selected: (i) hypertension (least severe), (ii) 
atrial fibrillation, (iii) ischaemic heart disease, (iv) angina, (v) myocardial infarction and (vi) 
heart failure (most severe). Nine musculoskeletal “disorder” categories were selected: (i) soft 
tissue disorder (least severe), (ii) soft tissue pain, (iii) peripheral enthesopathies, (iv) joint 
disorders, (v) back pain, (vi) neck pain (vii) osteoarthritis, (viii) osteoporosis and (ix) 
inflammatory polyarthropathy (most severe).  
 
Of the CVD categories used in this analysis, all were described in Chapter 2, with the 
exception of atrial fibrillation (AF). AF is the commonest form of arrhythmia, the irregular 
contraction of the heart. This arrhythmia reduces the capacity of the heart to expel blood and 
limits the capacity for efficient contraction of all four chambers. AF can result in the 
formation of blood clots and therefore is a risk factor for Stroke (National Institute for Health 
and Clinical Excellence 2006). Prevalence of AF in the UK is approximately 2% (Davis et al. 
2012) and its presence can be a risk factor for further conditions, such as stroke and is 
strongly associated with heart failure (Bilato et al. 2009). A systematic review, including 
several observational studies found a mixed influence of AF on quality-of-life (QOL) of 
patients. Studies showed both no impact of AF on QOL when compared to matched controls 
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and also diminished health in those with AF (measured by the SF-36), though this latter 
sample were not compared to a control sample (Lane, Lip 2009). 
 
Table 5.1: Study specific Read codes  
Read Term Read code (3rd level) 
  
Cardiovascular disease  
Hypertension G20 
Atrial Fibrillation G57 
Ischaemic Heart Disease G3. 
Angina G33 
Myocardial Infarction G30 
Heart Failure G58 
  
Musculoskeletal disorders  
Soft tissue disorder N22 
Soft tissue pain N24 
Peripheral enthesopathies N21 
Unspecified joint disorders  N09 
Back pain N14 
Neck pain N11 
Osteoarthritis N05 
Osteoporosis N33 
Rheumatoid Arthritis* N04 
Polymyalgia Rheumatica* N20 
*N04 & N20 were combined to create inflammatory polyarthropathy 
 
Of the MSK categories used in this analysis, back pain, OA and RA are described in Chapters 2 
& 4. The MSK spectrum was formed from several other common symptom and diagnostic 
categories with wide ranging influences on the patient. Soft tissue disorders were defined as 
the ‘least severe’ category of the MSK spectrum. Such a diagnostic label would be applied to 
the patient upon consultation for symptoms localised in the soft tissues (i.e. muscles) around 
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a joint. Soft tissue pain is distinct from soft tissue disorder by virtue of specific reference to 
pain. Peripheral enthesopathies cover a range of conditions which impact upon the location 
of ligament, tendon and articular capsule attachment to the bones and occur within the 
peripheral joints of the body, including conditions such as adhesive capsulitis of the shoulder 
(Frozen shoulder) and achilles tendonitis (Falsetti et al. 2009). Such conditions are often 
related to overuse and are identified when the patient presents with pain or inflammation. 
Conditions such as frozen shoulder (Gartsman et al. 1998, Baums et al. 2007) and achilles 
tendonitis (Martin et al. 2005) have been shown to have a negative impact on physical health 
as measured by the SF-36. 
 
Unspecified joint disorders are those for which the patient consults general practice with 
symptoms related to a joint but for which a clear cause cannot be applied by the clinician. 
Neck pain is a common health problem and one regularly presented in general practice. 
Osteoporosis is defined by the excessive reduction in bone mass density. This is more 
commonly observed in women, especially after the menopause. The presence of osteoporosis 
increases the chance of fractures, particularly in joints such as the wrist and hip and impacts 
on the physical health experienced by these patients (Cortet et al. 2011). The final MSK 
category was defined as inflammatory polyarthropathy, formed from a combination of those 
who had previously consulted for either RA or polymyalgia rheumatic (PMR). These were 
combined primarily due to low numbers of consulters for both conditions, but these are both 
also serious MSK disorders based on joint inflammation. PMR is the most common 
inflammatory condition in older people in the UK, with patients’ predominantly experiencing 
pain or stiffness in the shoulders and/or pelvis (Dasgupta et al. 2010). Both RA and PMR are 
associated with poor quality of life measures (Barraclough et al. 2008, Hutchings et al. 2007, 
Picavet, Hoeymans 2004). 
 
 131 
 
The remaining patients from the study sample formed a comparator reference group. These 
were patients who had not consulted for one of the study specific Read codes (CVD or MSK) 
and this population represents the wider consulting sample, providing a context against the 
two chronic diseases of interest. 
 
5.3.4. Cross-sectional measures 
5.3.4.1. Physical health status 
The Short Form-12 (SF-12) Health Survey (Ware, Kosinski & Keller 1996) was used to 
measure self-reported physical health. The primary outcome of interest in this study was the 
PCS score. 
 
5.3.4.2. Socio-demographic status 
Age, gender and deprivation status were also obtained. These are known confounders, with 
older age and being female both shown to increase prevalence and incidence of chronic 
disease (Arden, Nevitt 2006) and age and deprivation to be associated with physical health 
status, and therefore important to consider as potential confounders. The level of deprivation 
in populations has also been shown to be associated with chronic disease and an area level 
measurement of deprivation is more strongly associated with QOL than individual 
deprivation. (Breeze et al. 2005). 
 
The level of neighbourhood deprivation for each patient within this study was quantified 
using the Index of Multiple Deprivation (IMD) 2004 (Office of the Deputy Prime Minister 
2004). The IMD is a multi-dimensional measure of area-level deprivation in England. 
Deprivation status is based on the allocation of a patient to a Lower Layer Super Output Area 
(LSOA), based on their home postcode. LSOAs are consistent boundary areas in England, each 
containing an approx population of 1,500 people. An overall IMD score is derived from this 
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information; this is a weighted score of seven sub-domains relating to: income; employment; 
health; education, skills and training; barriers to housing and access to local services; crime; 
and living environment. These are all aspects of patients’ lives which are individually or 
cumulatively related to deprivation.  This measure has been shown to be valid in assessing 
the deprivation status of all areas of England (Jordan, Roderick & Martin 2004). 
 
5.3.4.3. Psychological health status 
The Mental Component Summary (MCS) score of the SF-12 was used as a measure of 
psychological health status. Though there is some correlation with the PCS score, this 
measure of health has been shown to be a valid and reliable measure of psychological health 
(Ware, Kosinski & Keller 1996). Psychological health has been shown to be associated with 
poor physical health (Lin et al. 2003) and the psychological impact of chronic diseases has 
been associated with poor patient outcomes (Jordan et al. 2008). As such, the confounding 
effect of psychological health on physical health was included in this analysis. 
 
5.3.4.4. Morbidity counts 
In addition to the diagnostic categories of interest within the two spectrums, the issue of 
comorbidity was also considered. For patients who had consented to medical record review, 
the frequency and detail of previous consultations was available as a measure of comorbidity. 
Several studies have utilised a count of morbidities to define comorbidity (Kadam, Croft & 
North Staffordshire GP Consortium Group 2007, Heyworth et al. 2009), and within this study 
it provided an initial and pragmatic consideration of this increasingly important variable. 
Morbidity count was defined as number of unique conditions for which the patient consulted 
in the two years prior to baseline. 
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5.3.5. Statistical analysis 
The mean PCS score (with 95% confidence intervals) for each diagnostic category within the 
two spectrums was first presented graphically. The PCS score was dichotomised around its 
study sample mean (39.80, Standard Deviation 12.5). Within each chronic disease spectrum, 
each of the exclusive diagnostic categories were summarised by age, gender, deprivation 
status (IMD), psychological health status (MCS dichotomised by the mean score: 48.59, SD 
11.4)) and morbidity count. Morbidity count categorised individuals in the two year period of 
observation into consulters for: (i) one morbidity only, (ii) 2-4 morbidities, (iii) 5-8 
morbidities, (iv) 9-13 morbidities and (v) 14 or more morbidities. These counts refer to at 
least one consultation for any given morbidity and do not include repeat consultations for the 
same morbidity. Age was categorised into four groups: 50-59 years, 60-69 years, 70-79 years 
and 80 years and over, and IMD deprivation status categorised based on the quartile score 
from category 1 (affluent) to category 4 (deprived). Unadjusted associations between 
diagnostic categories and physical health for both chronic disease spectrums were estimated 
using Odds Ratios (OR) (with 95% confidence intervals) using logistic regression with the 
hypertension group as the reference for the CVD spectrum and the soft tissue disorder group 
the reference for the MSK spectrum. 
 
Associations were then adjusted separately for: (i) age, gender and deprivation status, (ii) 
age, gender, deprivation and psychological health status and (iii) all factors and morbidity 
counts. Adjusting in stages allowed each set of confounders to be considered for their own 
impact on the association between diagnostic categories and physical health. A statistical 
linear trend in the estimates within the ordered spectrums was assessed. Statistical 
significance in analyses was defined as p<0.05, all hypothesis testing was 2-tailed, and 
analyses were performed using the Statistical Package for the Social Sciences (SPSS, Chicago, 
Illinois, Version 15.0). 
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Finally, the exclusive group categorisation within both CVD and MSK spectrums was checked 
for potential of comorbid inclusion of the other less severe categories. For example, was the 
selection of heart failure as the most severe CVD group, in fact reflecting the inclusion of all 
the other CVD categories? Specifically, was poorer physical health a reflection of comorbidity 
rather than the individual condition? Therefore, cross-tabulated tables for the six diagnostic 
categories within the CVD spectrum and the nine diagnostic categories within the MSK 
spectrum are presented. 
 
5.4. Results 
5.4.1. Characteristics of study population 
13,986 patients responded to the baseline NorStOP survey. From the baseline survey 
responders, patients ‘dropped out’ if they had: i) not consented to medical record review, ii) 
had not consulted for a morbidity in the two years prior to the health survey and iii) had not 
completed the SF-12 health survey within the baseline questionnaire sufficiently to provide a 
PCS or MCS score (Table 5.2). This resulted in a study analysis sample of 7,799 (55.8% of 
survey responders). 
 
At each stage of ‘drop-out’, the proportion of patients in each age category remained 
consistent, over 60% of patients at each stage were aged 69 years or younger. There were 
more women than men in the study sample; this was true at each phase of ‘drop-out’.  
Of the 13,986 survey responders, the greatest proportion was from the most deprived 
category. However, these more deprived original responders were subsequently less likely to 
consent to record review or consult over the two years. Therefore, deprivation status was 
proportionate across each category for the study sample. In each ‘drop-out’ stage patients 
were more likely to have a good rather than poor psychological health status. There was no 
difference in morbidity counts between those who had consulted and those who had 
consulted and completed the SF-12. 
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Table 5.2: Characteristics of survey responders and subsequent stages of patient ‘drop-out’  
Study factor Category Survey 
respondersa 
13986 
N (%) 
Consenters to record 
reviewb 
10432 (74.6) 
n (%) 
Morbidity 
consultersc 
8962 (64.1) 
n (%) 
Study 
sampled 
7799 (55.5) 
n (%) 
      
Age 50 – 59 4387 (31.4) 3345 (32.1) 2764 (30.8) 2538 (32.5) 
 60 – 69 4224 (30.2) 3213 (30.8) 2776 (31.0) 2456 (31.5) 
 70 – 79 3585 (25.6) 2654 (25.4) 2354 (26.3) 1974 (25.3) 
 80+ 1790 (12.8) 1220 (11.7) 1068 (11.9) 831 (10.7) 
      
Gender Male 6154 (44.0) 4818 (46.2) 4028 (44.9) 3552 (45.5) 
 Female 7832 (56.0) 5614 (53.8) 4934 (55.1) 4247 (54.5) 
      
Deprivation status Category 1 (affluent) 3264 (23.3) 2601 (24.9) 2237 (25.0) 1996 (25.6) 
 Category 2 3334 (23.8) 2552 (24.5) 2205 (24.6) 1969 (25.3) 
 Category 3 3463 (24.8) 2534 (24.3) 2210 (24.7) 1904 (24.4) 
 Category 4 deprived) 3922 (28.0) 2742 (26.3) 2308 (25.7) 1928 (24.7) 
      
Psychological  
health status 
Good 7138 (59.7) 5482 (60.1) 4555 (58.4) 4555 (58.4) 
Poor 4817 (40.3) 3637 (39.9) 3242 (41.6) 3242 (41.6) 
      
Morbidity count 1  - - 841 (9.4) 736 (9.4) 
 2-4 - - 2197 (24.5) 1969 (25.3) 
 5-8 - - 2146 (24.0) 1866 (23.9) 
 9-13 - - 1686 (18.8) 1447 (18.6) 
 14> - - 2092 (23.3) 1781 (22.8) 
 
aNumber of patients responding to questionnaire survey: deprivation status based on n=13,983 and psychological health status based on n=11,955; bPatients who 
responded to survey and consented to medical record review: deprivation status based on n=10,429 and psychological health status based on n=9,119; 
cResponding patients who consulted within 2-year period for at least one morbidity: deprivation status based on n=8,960 and psychological health status based on 
n=7,797; dResponding patients who consulted within 2-year time period for at least one morbidity and completed the SF-12: deprivation status based on n=7,797 
and psychological health status based on n=7,797. 
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5.4.2. Characteristics of study sample 
In the study sample of 7,799, there were 2,447 (31.4%) patients who had consulted for one of 
the specified CVD diagnostic categories and 3,321 (42.6%) patients who had consulted for 
one of the specified MSK disorder categories, with 1,037 (13.3%) of these having consulted 
for a category in both chronic disease spectrums. There were 3,068 (39.3%) patients, who 
had not consulted for any one of the study specific CVD or MSK diagnostic categories. 
 
5.4.3. Characteristics of cardiovascular disease categories 
Of the 2,447 CVD consulters (Table 5.3), just under half were men and half aged 70 years and 
over. This group had a higher proportion that were deprived and had a good psychological 
health status, with 42% consulting for 14 or more morbidities in the two year time period, 
before the baseline survey. 
 
The greatest number of consulters was 1,606 (65.6%) for hypertension, followed by 286 
(11.7%) for angina and 257 (10.5%) for ischaemic heart disease. The lowest numbers were 
observed for myocardial infarction (44 (1.8%)). There were more women than men in the 
hypertension and atrial fibrillation categories, but the situation was reversed for the other 
diagnostic categories. Over half of the hypertension, atrial fibrillation, ischaemic heart disease 
and angina consulters were in the two most deprived groups. Those with myocardial 
infarction and heart failure were in the more affluent areas. The heart failure group had the 
poorer psychological health status and two thirds of these had consulted for 14 morbidities 
or more. This diagnostic category also had the highest proportion of those aged 80 years or 
over (41%). 
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Table 5.3: Characteristics of cardiovascular disease categories 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study factor Category Hypertension 
 
n=1606 
Atrial 
fibrillation 
n=115 
Ischaemic heart 
disease 
n=257 
Angina 
 
n=286 
Myocardial 
infarction 
n=44 
Heart 
failure 
n=139 
  No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) 
        
Age group  
(years) 
50-59  353 (22.0) 11 (9.6) 38 (14.8) 44 (15.4) 11 (25.0) 5 (3.6) 
60-69  546 (34.0) 34 (29.6) 91 (35.4) 91 (31.8) 9 (20.5) 26 (18.7) 
70-79  507 (31.6) 44 (38.3) 99 (38.5) 104 (36.4) 18 (40.9) 51 (36.7) 
80+  200 (12.5) 26 (22.6) 29 (11.3) 47 (16.4) 6 (13.6) 57 (41.0) 
        
Gender Male  669 (41.7) 51 (44.3) 170 (66.1) 152 (53.1) 36 (81.8) 72 (51.8) 
Female 937 (58.3) 64 (55.7) 87 (33.9) 134 (46.9) 8 (18.2) 67 (48.2) 
        
Deprivation  
status 
Category 1 (affluent) 345 (21.5) 27 (23.5) 51 (19.8) 49 (17.1) 15 (34.1) 35 (25.2) 
Category 2 321 (20.0) 24 (20.9) 59 (23.0) 54 (18.9) 14 (31.8) 41 (29.5) 
Category 3 406 (25.3) 39 (33.9) 65 (25.3) 100 (35.0) 6 (13.6) 33 (23.7) 
Category 4 (deprived) 533 (33.2) 25 (21.7) 82 (31.9) 83 (29.0) 9 (20.5) 30 (21.6) 
        
Psychological  
heath status 
Good 939 (58.5) 59 (51.8) 135 (52.5) 125 (43.7) 23 (52.3) 54 (38.8) 
Poor 667 (41.5) 55 (48.2) 122 (47.5) 161 (56.3) 21 (47.7) 85 (61.2) 
        
Morbidity  
count 
1 17 (1.1) 2 (1.7) 4 (1.6) 1 (0.3) 0 (0) 1 (0.7) 
2-4 182 (11.3) 16 (13.9) 37 (14.4) 23 (8.0) 5 (11.4) 6 (4.3) 
5-8 371 (23.1) 18 (15.7) 59 (23.0) 54 (18.9) 7 (15.9) 15 (10.8) 
9-13 404 (25.2) 23 (20.0) 69 (26.8) 73 (25.5) 8 (18.2) 24 (17.3) 
14> 632 (39.4) 56 (48.7) 88 (34.2) 135 (47.2) 24 (54.5) 93 (66.9) 
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5.4.4. Characteristics of musculoskeletal disorder categories 
Of the 3,321 MSK disorder consulters (Table 5.4), over half were women and half aged 69 
years or under. The level of deprivation was consistent across this group and most had a good 
psychological status, with 34% consulting for 14 or more morbidities in the two year time 
period before the baseline survey. 
 
The highest number of exclusive consulters was 850 (25.6%) for osteoarthritis, followed by 
650 (19.6%) with back pain and then 556 (16.7%) with soft tissue pain. Only 102 (3%) 
patients had consulted for an inflammatory polyarthropathy. With the exception of 
peripheral enthesopathies, more women had consulted than men in any of the other MSK 
categories. There were no distinct differences in relation to deprivation status, but neck pain, 
osteoporosis and inflammatory polyarthropathy categories reported poor psychological 
health status. Over 40% of consulters with neck pain, osteoarthritis, osteoporosis or 
inflammatory polyarthropathy categories had the highest morbidity count of 14 or more. 
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 Table 5.4: Characteristics of musculoskeletal disorder categories 
 
Study factor Category Soft tissue  
disorder 
n=62 
Soft tissue 
 pain 
n=556 
Peripheral 
enthesopathies 
n=259 
Joint 
disorder 
n=467 
Back pain 
 
n=650 
Neck pain 
 
n=262 
OA 
 
n=850 
Osteoporosis 
 
n=113 
Inflammatory 
polyarthropathy 
n=102 
  No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) 
           
Age group  
(years) 
50-59 22 (35.5) 166 (29.9) 104 (40.2) 186 (39.8) 258 (39.7) 72 (27.5) 166 (19.5) 25 (22.1) 15 (14.7) 
60-69 15 (24.2) 188 (33.8) 90 (34.7) 138 (29.6) 191 (29.4) 93 (35.5) 288 (33.9) 37 (32.7) 36 (35.3) 
70-79 18 (29.0) 146 (26.3) 55 (21.2) 101 (21.6) 139 (21.4) 71 (27.1) 263 (30.9) 36 (31.9) 29 (28.4) 
80+ 7 (11.33) 56 (10.1) 10 (3.9) 42 (9.0) 62 (9.5) 26 (9.9) 133 (15.6) 15 (13.3) 22 (21.6) 
           
Gender Male  18 (29.0) 239 (43.0) 131 (50.6) 187 (40.0) 316 (48.6) 118 (45.0) 306 (36.0) 15 (13.3) 33 (32.4) 
Female 44 (71.0) 317 (57.0) 128 (49.4) 280 (60.0) 334 (51.4) 144 (55.0) 544 (64.0) 98 (86.7) 69 (67.6) 
           
Deprivation  
status 
Category 1(affluent) 17 (27.4) 138 (24.8) 68 (26.3) 99 (21.2) 155 (23.8) 73 (27.9) 227 (26.7) 33 (29.2) 21 (20.6) 
Category 2 15 (24.2) 111 (20.0) 74 (28.6) 127 (27.2) 160 (24.6) 66 (25.2) 233 (27.4) 28 (24.8) 24 (23.5) 
Category 3 15 (24.2) 148 (26.6) 58 (22.4) 131 (28.1) 166 (25.5) 61 (23.3) 178 (20.9) 31 (27.4) 39 (38.2) 
Category 4 deprived) 15 (24.2) 159 (28.6) 59 (22.8) 110 (23.6) 169 (26.0) 62 (23.7) 212 (24.9) 21 (18.6) 18 (17.6) 
           
Psychological 
health status 
Good 37 (59.7) 307 (55.2) 169 (65.3) 260 (55.7) 353 (54.3) 126 (48.1) 425 (50.0) 47 (41.6) 44 (43.1) 
Poor 25 (40.3) 249 (44.8) 90 (34.7) 207 (44.3) 297 (45.7) 136 (51.9) 425 (50.0) 66 (58.4) 58 (56.9) 
           
Morbidity  
counts 
1 4 (6.5) 27 (4.9) 13 (5.0) 18 (3.9) 25 (3.8) 4 (1.5) 11 (1.3) 1 (0.9) 1 (1.0) 
2-4 16 (25.8) 113 (20.3) 54 (20.8) 91 (19.5) 124 (19.1) 38 (14.5) 94 (11.1) 11 (9.7) 9 (8.8) 
5-8 19 (30.6) 129 (23.2) 69 (26.6) 127 (27.2) 152 (23.4) 55 (21.0) 178 (20.9) 17 (15.0) 17 (16.7) 
9-13 16 (25.8) 130 (23.4) 52 (20.1) 95 (20.3) 145 (22.3) 55 (21.0) 233 (27.4) 26 (23.0) 17 (16.7) 
14> 7 (11.3) 157 (28.2) 71 (27.4) 136 (29.1) 204 (31.4) 110 (42.0) 334 (39.3) 58 (51.3) 58 (56.9) 
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5.4.5. Characteristics of comparator category 
Of the 7,799 patients who formed the study sample, 3,068 (39.9%) had consulted for a Read 
code other than one of the study specific CVD or MSK codes (Table 5.5). Overall this group of 
patients were younger than both the CVD and MSK categories, with over two thirds aged 69 
years or younger. Over half of consulters were women and more consulters in this group had 
an affluent deprivation status. As with the CVD and MSK categories, consulters were more 
likely to have a ‘good’ rather than ‘poor’ psychological health status, though the proportion of 
these was greater than for the two disease groups. 
 
Under half (41.7%) of the comparator group had consulted for 5 or more other morbidities in 
the two years before the baseline survey. This compares with 88.0% and 80.4% of the 
patients from the CVD and MSK categories respectively who had consulted for 5 or more 
other morbidities. 
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Table 5.5: Characteristics of comparator category 
Study factor Category Comparator 
category 
n=3068 
No (%) 
Total CVD 
n=2447 
No (%) 
Total MSK 
n=3321 
No (%) 
     
Age group  
(years) 
50-59 1250 (40.7) 462 (18.9) 1014 (30.5) 
60-69 918 (29.9) 797 (32.6) 1076 (32.4) 
70-79 646 (21.1) 823 (33.6) 858 (25.8) 
80+ 254 (8.3) 365 (14.9) 373 (11.2) 
     
Gender Male  1462 (47.7) 1150 (47.0) 1363 (41.0) 
Female 1606 (52.3) 1297 (53.0) 1958 (59.0) 
     
Deprivation 
status 
Category 1(affluent) 840 (27.3) 522 (21.3) 831 (25.0) 
Category 2 842 (27.5) 513 (21.0) 838 (25.2) 
Category 3 714 (23.3) 649 (26.5) 827 (24.9) 
Category 4 (deprived) 671 (21.9) 762 (31.1) 825 (24.8) 
     
Psychological  
health status 
Good 1933 (63.0) 1335 (54.6) 1768 (53.2) 
Poor 1134 (37.0) 1111 (45.4) 1553 (46.8) 
     
Morbidity 
counts 
1 607 (19.8) 25 (1.0) 104 (3.1) 
2-4 1181 (38.5) 269 (11.0) 550 (16.6) 
5-8 718 (23.4) 524 (21.4) 763 (23.0) 
9-13 329 (10.7) 601 (24.6) 769 (23.2) 
14> 233 (7.6) 1028 (42.0) 1135 (34.2) 
aThe “Comparator category” represents those without a study specific (cardiovascular or 
musculoskeletal) Read code. CVD = Cardiovascular disease, MSK = Musculoskeletal  
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5.4.6. Association between cardiovascular diseases and physical health 
The mean PCS scores with 95% confidence intervals for those with a consultation for CVD are 
shown in Table 5.6 and Figure 5.2. Mean PCS scores decreased across the hypothesised 
relative morbidity severity spectrum, ranging from 38.38 (95% CI: 37.8, 39.0) for 
hypertension to 28.98 (95% CI: 27.5, 30.5) for consulters with heart failure (trend p<0.001). 
The estimated Odds Ratio (OR) for poor PCS score compared to the hypertension group were 
as follows (unadjusted vs. adjusted for age, gender, deprivation status, psychological health 
status and morbidity count): atrial fibrillation (1.8 vs. 1.5), ischaemic heart disease (2.6 vs. 
3.0), angina (3.6 vs. 3.2), myocardial infarction (2.5 vs. 2.8) and heart failure (6.1 vs. 3.5). 
These estimates diminished when adjusted (Table 5.7), but the trend in the association 
between the ordered diagnostic categories and poorer physical health remained significant 
(p<0.001).  
 
5.4.7. Association between musculoskeletal disorders and physical health 
The mean PCS scores with 95% confidence intervals for this group are shown in Table 5.6 
and Figure 5.3. Mean PCS scores decreased across the hypothesised relative morbidity 
severity spectrum, and ranged from 44.85 (95% CI 42.2, 47.5) for soft tissue disorder to 
28.79 (95% CI 26.8, 30.8) for consulters with inflammatory polyarthropathy (trend p<0.001). 
The estimated ORs were as follows (unadjusted vs. adjusted for age, gender, deprivation 
status, psychological health status and morbidity count): soft tissue pain (2.8 vs. 2.6), 
peripheral enthesopathies (1.6 vs. 1.8), joint disorder (2.7 vs. 2.7), back pain (3.0 vs. 3.0), 
neck pain (4.4 vs. 3.8), osteoarthritis (6.6 vs. 5.4), osteoporosis (7.2 vs. 5.3) and inflammatory 
arthropathy (14.2 vs. 9.8). These estimates diminished when adjusted (Table 5.7), but the 
trend in the association between the ordered diagnostic categories and poorer physical 
health remained significant (p<0.001). 
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Table 5.6: Mean Physical Component Summary scores for cardiovascular disease and 
musculoskeletal diagnostic categories 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aThe “Comparator group” represents those without a study specific (cardiovascular or 
musculoskeletal) Read code. PCS = Physical Component Summary score 
 
 
 
 
Group Sample  PCS 
 No. (%) Mean (95% CI) 
   
Study sample 7799 (100) 39.80 (39.5, 40.1) 
   
Comparator groupa 3068 (39.3) 43.73 (43.3, 44.2) 
   
Cardiovascular disease   
Hypertension 1606 (65.6) 38.38 (37.8, 39.0) 
Atrial fibrillation 115 (4.7) 35.18 (33.3, 37.1) 
Ischaemic heart disease 257 (10.5) 33.36 (32.0, 34.7) 
Angina 286 (11.7) 31.68 (30.5, 32.8) 
Myocardial Infarction 44 (1.8) 34.71 (31.2, 38.2) 
Heart failure 139 (5.7) 28.98 (27.5, 30.5) 
   
Musculoskeletal disorders   
Soft tissue disorder 62 (1.9) 44.85 (42.2, 47.5) 
Soft tissue pain 556 (16.7) 38.73 (37.7, 39.8) 
Peripheral enthesopathies 259 (7.8) 41.96 (40.5, 43.4) 
Joint disorder 467 (14.0) 38.70 (37.6, 39.8) 
Back pain 650 (19.8) 37.59 (36.7, 38.5) 
Neck pain 262 (7.9) 34.75 (33.3, 36.2) 
Osteoarthritis 850 (25.6) 33.15 (32.4, 33.9) 
Osteoporosis 113 (3.4) 32.22 (30.0, 34.4) 
Inflammatory polyarthropathy 102 (3.1) 28.79 (26.8, 30.8) 
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Figure 5.2: Mean Physical Component Summary scores for study specific categories from the 
cardiovascular disease spectrum 
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Figure 5.3: Mean Physical Component Summary scores for study specific categories from the 
musculoskeletal disorder spectrum 
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Table 5.7: Associations between diagnostic categories and poor physical health by cardiovascular disease and musculoskeletal disorder 
aNumber of patients in the study sample with at least one morbidity consultation for this diagnostic category in the 2-year time period of observation; bNumber of 
patients classified by study defined exclusive severity categories; cBased on Physical Component Summary (PCS) score from SF-12; dDeprivation score as measured 
by Index of Multiple Deprivation (IMD)24; eBased on Mental Component Summary (MCS) score from SF-12; fMorbidity count is the number of different morbidities 
consulted for in a 2-year period before health survey; *Reference group. 
  Adjusted OR (95% CI) 
Diagnostic category Total 
numbera 
Exclusive  
numberb (%) 
Physical 
healthc 
Unadjusted  
Odds Ratio (95% CI) 
Age, Gender &  
Deprivation 
statusd 
Age, Gender, 
Deprivation statusd  
& MCSe 
Age, Gender,  
Deprivation statusd, 
MCSe & Morbidity countf Good Poor 
 
        
Cardiovascular disease 
        
Hypertension  1824 1606 (88.0) 736 870 1.0* 1.0* 1.0* 1.0* 
Atrial fibrillation  168 115 (68.5) 37 78 1.78 (1.1, 2.6) 1.63 (1.1, 2.5) 1.55 (1.0, 2.4) 1.51 (1.0, 2.3) 
Ischaemic heart disease 357 257 (72.0) 64 193 2.55 (1.8, 3.4) 2.78 (2.0, 3.8) 2.74 (2.0, 3.8) 2.98 (2.1, 4.1) 
Angina  327 286 (87.5) 55 231 3.55 (2.6, 4.8) 3.62 (2.6, 5.0) 3.30 (2.4, 4.6) 3.18 (2.3, 4.4) 
Myocardial infarction  50 44 (88.0) 11 33 2.53 (1.2, 5.0) 3.17 (1.6, 6.4) 3.02 (1.5, 6.3) 2.81 (1.3, 6.0) 
Heart failure  139 139 (100.0) 17 122 6.07 (3.6, 10.1) 5.02 (3.0, 8.5) 4.35 (2.5, 7.5) 3.54 (2.1, 6.1) 
Musculoskeletal disorder 
        
Soft tissue disorder  119 62 (52.1) 43 19 1.0* 1.0* 1.0* 1.0* 
Soft tissue pain  1119 556 (49.7) 251 305 2.75 (1.6, 4.8) 2.91 (1.6, 5.2) 2.97 (1.6, 5.5) 2.62 (1.4, 4.9) 
Peripheral enthesopathies  462 259 (56.1) 152 107 1.59 (0.9, 2.9) 1.95 (1.1, 3.6) 2.11 (1.1, 4.0) 1.79 (0.9, 3.4) 
Joint disorder  836 467 (55.9) 214 253 2.67 (1.5, 4.7) 3.09 (1.7, 5.6) 3.17 (1.7, 5.8) 2.73 (1.5, 5.1) 
Back pain  876 650 (74.2) 279 371 3.00 (1.7, 5.3) 3.47 (1.9, 6.2) 3.53 (1.9, 6.5) 2.99 (1.6, 5.5) 
Neck pain  325 262 (80.6) 89 173 4.39 (2.4, 8.0) 4.95 (2.7, 9.2) 4.77 (2.5, 9.1) 3.76 (2.0, 7.2) 
Osteoarthritis  882 850 (96.4) 218 632 6.56 (3.7, 11.5) 6.74 (3.8, 12.1) 6.86 (3.8, 12.5) 5.38 (2.9, 9.9) 
Osteoporosis  118 113 (95.8) 27 86 7.20 (3.6, 14.4) 7.77 (3.8, 15.9) 7.34 (3.5, 15.3) 5.34 (2.5, 11.3) 
Inflammatory 
polyarthropathy  
102 102 (100.0) 14 88 14.22 (6.5, 31.1) 13.90 (6.2, 31.0) 13.37 (5.9, 30.4) 9.77 (4.2, 22.5) 
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5.4.8. Comparison between cardiovascular disease and musculoskeletal 
disorder categories 
The overall mean PCS score for the CVD group was 36.3 (Standard Deviation 12.0) and the 
figure for the MSK disorder group was 36.6 (SD 12.2). Consulters with hypertension had a 
lower PCS score 38.38 (95% CI: 37.8, 39.0) than patients who had consulted with symptoms 
of a soft tissue disorder 44.85 (95% CI 42.2, 47.5). For the hypothesised ‘most severe’ 
categories, the PCS scores were 28.98 (95% CI: 27.4 – 30.4) for heart failure and 28.79 (95% 
CI 26.7, 30.8) for inflammatory polyarthropathy. Other diagnostic categories within both the 
spectrums also showed similar PCS scores, for example ischaemic heart disease 33.36 (95% 
CI 32.0, 34.7) was comparable to osteoarthritis 33.15 (95% CI 32.4, 33.9). 
 
5.4.9. Comparison between diagnostic label consulters and exclusive 
diagnostic categories  
Each exclusive CVD diagnostic category was formed from over two thirds of the patients who 
had consulted for that condition (Table 5.8). For example, 72% of patients who consulted for 
ischaemic heart disease in the two years before the baseline survey were categorised into the 
ischaemic heart disease group. This was a result of either: that being the only condition for 
which they had consulted or the only other study specific conditions which had also been 
consulted for were hypertension or atrial fibrillation which were defined as less severe. 
 
As a consequence, 28% of patients who consulted for ischaemic heart disease in the two 
years before the baseline survey were not categorised into exclusive ischaemic heart disease. 
These patients had consulted for one of the other three, ‘more severe’ study defined 
categories (angina, myocardial infarction or heart failure) and therefore were classified 
under one of these conditions. 
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In general, the proportion of patients lost from one CVD category because they were allocated 
to a more ’severe’ CVD category was low, ranging from 0.5% - 8.9%. However, for the 
exclusive heart failure category there was a higher proportion of those who had also 
consulted for atrial fibrillation (16.1%) and myocardial infarction (12.0%). 17.4% of 
consulters for ischaemic heart disease were defined into the exclusive angina category. 
 
Each exclusive MSK diagnostic category was formed from at least half of the patients who had 
consulted for that condition, except for soft tissue pain (Table 5.9). As with the CVD 
categories, in general, the proportions of patients consulting for one category but being 
moved to another category was low, ranging from 0.3% - 10.8%. However, those patients 
who were allocated to the exclusive osteoarthritis category, had consulted for higher 
proportions of all the ‘less severe’ conditions. This ranged from 15.0% who had also 
consulted for back pain to 25.6% who had also consulted for joint pain.  
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Table 5.8: Number of consulting patients within each exclusive cardiovascular disease category   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bold = Number of patients (%) consulting for the disease which forms this exclusive label cohort; Italic = Number of patients (%) consulting for this disease but who have 
subsequently been classified into another, more severe exclusive label cohort 
 
 
 
 
 
 
  Consulted for  
  Hypertension (%) 
 
n = 1824 
Atrial fibrillation (%) 
 
n = 168 
Ischaemic heart  
disease (%) 
n = 357 
Angina (%) 
 
n = 327 
Myocardial 
infarction (%) 
n = 50 
Heart failure (%) 
 
n = 139 
    
  E
xc
lu
si
v
e 
ca
te
go
ri
es
 
 
Hypertension 1606 (88.0) - - - - - 
Atrial fibrillation  27 (1.5) 115 (68.5)  - - - - 
Ischaemic heart disease 62 (3.4) 10 (5.6) 257 (72.0) - - - 
Angina 96 (5.3) 12 (7.1) 62 (17.4) 286 (87.4) - - 
Myocardial infarction  10 (0.5) 4 (2.4) 18 (5.0) 12 (3.7) 44 (88.0) - 
Heart failure 23 (1.3) 27 (16.1) 20 (5.6) 29 (8.9) 6 (12.0) 139 (100) 
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Table 5.9: Number of consulting patients within each exclusive musculoskeletal category   
  Consulted for 
  Soft tissue 
disorder (%) 
n = 119 
Soft tissue 
pain (%) 
n = 1119 
Peripheral 
enthesopathies (%) 
n = 462 
Joint disorder 
(%) 
n = 836 
Back pain 
(%) 
n = 876 
Neck pain 
(%) 
n = 325 
Osteoarthritis 
(%) 
n = 882 
Osteoporosis 
(%) 
n = 118 
Inflammatory 
polyarthropathy (%) 
n = 102 
           
E
xc
lu
si
v
e 
ca
te
go
ri
es
 
Soft tissue 
disorder 
62 (52.1) - - - - - - - - 
Soft tissue pain 7 (5.9) 556 (49.7) - - - - - - - 
Peripheral 
enthesopathies 
5 (4.2) 75 (6.7) 259 (56.0) - - - - - - 
Joint disorder 4 (3.4) 88 (7.9) 42 (9.1) 467 (55.9) - - - - - 
Back pain 7 (5.9) 121 (10.8) 46 (9.9) 80 (9.5) 650 (74.2) - - - - 
Neck pain 11 (9.2) 53 (4.7) 25 (5.4) 36 (4.3) 49 (5.6) 262 (80.6) - - - 
Osteoarthritis 19 (16.0) 173 (15.5) 76 (16.5) 214 (25.6) 132 (15.0) 55 (16.9) 850 (96.4) - - 
Osteoporosis 1 (0.8) 33 (2.9) 10 (2.2) 20 (2.4) 33 (3.8) 7 (2.2) 17 (1.9) 113 (95.8) - 
Inflammatory 
polyarthropathy 
3 (2.5) 20 (1.8) 4 (0.9) 19 (2.3) 12 (1.4) 1 (0.3) 15 (1.7) 5 (4.2) 102 (100) 
Bold = Number of patients (%) consulting for the disease which forms this exclusive diagnostic category; Italic = Number of patients (%) consulting for this disease 
but who have subsequently been classified into another, more severe exclusive category 
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5.5. Discussion 
The study results confirm the a priori hypothesis that, at the population level, diagnostic 
labels applied in general practice reflect relative morbidity severity as these are associated 
with physical health. This is true within categories of cardiovascular diseases and 
musculoskeletal disorders. Factors such as age, gender, deprivation, psychological status, and 
morbidity counts in a 2-year time period do not fully explain these associations. Whilst 
diagnostic variability exists in general practice (Crombie, Cross & Fleming 1992, Bertakis, 
Azari & Callahan 2004), these results support the concept that groups of consulters with the 
same diagnostic label, as recorded in clinical encounters can be grouped into exclusive 
measures of severity.  
 
Findings for the selected CVD categories showed that exclusive consulters with heart failure 
are most likely to have poorer physical health compared to hypertension only consulters 
(Alonso et al. 2004), and that consulters with an exclusive category of angina (Soto et al. 
2005) will differ in physical health compared with atrial fibrillation consulters (Thrall et al. 
2006). All those with a CVD category had poorer physical health than the study comparator 
group (Erickson, Williams & Gruppen 2001). Whilst only six diagnostic categories for CVD 
were selected, they were based on potentially illustrating the idea that the different 
categories convey the stages of disease pathology development in populations (Bardage, 
Isacson 2001, Faller et al. 2007). Of the CVD spectrum, only MI did not follow the 
hypothesised a priori order of poorer physical health with increasing relative morbidity 
severity, here the small sample size (n = 44) may limit the inference for this disease category, 
suggested by the wide confidence intervals.  
 
Findings for the selected MSK disorders showed that consulters with exclusive inflammatory 
polyarthropathy have poorer physical health compared to those who consult for the 
symptoms of soft tissue disorders (Salaffi et al. 2005). All MSK diagnostic categories, except 
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soft tissue disorders, had poorer physical health than the comparator group. In the MSK 
group there were nine separate categories and they had been selected on the basis of 
potentially illustrating the idea that different categories convey a spectrum of relative 
morbidity severity disorders that may be inter-related in populations. So the selected 
categories related to non-specific symptoms (soft tissue disorder, soft tissue pain), specific 
regional symptoms (peripheral enthesopathies, joint disorders, back pain, neck pain) and 
pathology (osteoarthritis, osteoporosis, inflammatory polyarthropathy). It is possible, for 
example, that the exclusive consulters with neck pain may be part of the symptom complex of 
inflammatory polyarthropathy (Reiter, Boden 1998) or that OA may include people who also 
had a joint disorder diagnosis, Bedson et al showed that in a case-control study, OA cases 
from general practice were more likely to have a history of ‘knee-related disorders’ than 
controls (Bedson, Jordan & Croft 2005). In contrast to the hypothesis for the clear 
pathological links between different CVD (Iseki et al. 2000, al-Roomi, Heller & Wlodarczyk 
1990), here the hypothesis is related to undifferentiated and differentiated stages of illness 
within the same spectrum of MSK disorders. So whilst there were distinct hypotheses for the 
two examples chosen, the study findings are consistent in reflecting the overall idea that 
diagnostic labels can act as a measure of the corresponding physical health severity.  
 
Whilst specific examples were chosen for the study, the analyses allowed the comparison of 
physical health for consulters with different, but exclusive diagnostic categories between the 
disease and disorder spectrums (Sprangers et al. 2000, Wang et al. 2008). Consulters with 
angina or heart failure have comparable poor health to consulters with osteoarthritis, 
osteoporosis or inflammatory polyarthropathy. Consulters for osteoarthritis have poorer 
physical health than back pain consulters (Salaffi et al. 2005). Age, gender, deprivation and 
psychological status do not explain these associations, and even the co-occurrence of other 
morbidity did not explain the associations between the severity of diagnostic categories and 
self-reported physical health. 
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5.5.1. Strengths and limitations 
5.5.1.1. Strengths 
This secondary analysis was conducted using a large sample (20,000+) from the general 
population of a specific geographical area of the UK (North Staffordshire). The good response 
rate for this survey (70%) from a large number of patients registered in general practice 
suggests the generalisability of these study findings to the local region. This study also 
supports the concept of using diagnostic labels to define severity for epidemiological research 
in general practice populations. This work expands and supports the argument for chronic 
disease spectrums outlined by the systematic review in Chapter 4.  
 
The interpretation of study results is based on the notion of relative morbidity severity that 
relates to the population of consulters with a diagnostic category. Previous evidence has 
highlighted that there is variation in the diagnostic coding by GPs in primary care (Crombie, 
Cross & Fleming 1992, Hamilton et al. 2003). However, this study provides the evidence that 
the clinical judgement that underpins the application of diagnostic labels (and arguably the 
decision-making process), at least at a population level can distinguish between different 
severities of physical health.      
 
5.5.1.2. Limitations 
Since the study measurement was based on the consulting population, this study did not 
include people who had one of the study disease categories but did not consult during the 
study period. However, with a 2-year time window of observation, this study would have 
captured most consulters as these conditions are persistent and chronic in duration. This 
study was also based on people who had agreed to participate in the health survey, consented 
to the record review and had consulted, which introduces the possibility of other selection 
issues (Jordan, Porcheret & Croft 2004, Willis 2008). However, overall response to the survey 
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was high (69%) and previous analyses have shown that such a bias is unlikely (Dunn et al. 
2004, Boardman et al. 2005). 
 
Spectrums for each chronic disease were formed through the a priori ordering of exclusive 
diagnostic categories. These categories were formed by defining patients by their ‘most 
severe’ consultation of the selected study categories in the two years prior to the baseline 
survey. Constructing exclusive diagnostic categories on the most severe category consulted 
for raises the question that those in the more severe groups may have worse physical health 
as a result of an increased number of morbidities, rather than for just the condition by which 
they were defined. However, internal comparisons remain valid as they were based on a 
priori hypotheses and though the use of ‘exclusive’ groups categorised patients by their most 
severe consultation, the adjustment by morbidity counts reduces the explanation of multiple 
morbidity as a marker of poor physical health. Finally, other CVD and MSK conditions could 
have been chosen and other diagnostic categories will require further validation against 
physical health measures. 
 
5.5.2. Clinical relevance 
Such empirical findings from a large population-based study of general practice provide the 
basis for clinical identification of populations with relatively poor physical health, the 
implication being that this may aid clinical management (Brown et al. 1999). Potential 
benefits may include an improved ability for the GP to provide more selective or staged 
treatment referral mechanisms depending on the diagnostic label, or developing 
management approaches that use information from diagnostic labels as proxy measures of 
physical health. This method may also provide the basis of an epidemiological construction of 
the stages of disease that populations may develop and pass through over time. 
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5.6. Conclusion 
Using the examples of cardiovascular disease and musculoskeletal disorders, this study 
shows that exclusive diagnostic labels can be used as a basis for indicating population 
severity as measured by physical health. These findings were not explained by socio-
demographic factors or other morbidity. In general practice populations, this method 
provides the evidence for using diagnostic labels as a basis for developing decision aids for 
the potential provision of public health interventions. Furthermore, this presents an 
opportunity for the epidemiological investigation of change in chronic disease or disorders 
over time. 
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Chapter 6: Associations between relative morbidity 
severity, comorbidity and long-term physical health 
change: NorStOP cohort study 
 
Chapters 4 and 5 have shown that conditions within the cardiovascular disease (CVD) and 
musculoskeletal (MSK) disorder spectrum are associated with poor physical health. As the 
severity of select conditions within either of these chronic disease spectrums increases, 
physical health generally gets worse. 
 
However, cross-sectional analyses of chapter 5 provided only a ‘snap-shot’ of the influence of 
these conditions on physical health and also did not consider the role of comorbidity. The 
very nature of chronic disease means these conditions are experienced over the long-term 
and frequently alongside other conditions, it is therefore important to understand how 
conditions influence physical health change over the long-term, relative to one another, and 
how the presence of comorbidity may influence this. 
 
6.1. Introduction 
With disease management often being a continual process, an understanding of how different 
chronic diseases influence change in health over time is important (Burstrom, Johannesson & 
Rehnberg 2007). As the numbers of patients living with chronic diseases are increasing 
(Hazell et al. 2009), it is essential to understand how these conditions relate to physical 
health over time and whether their influence on health is distinct to each type of chronic 
disease. Such information would not only enhance health professionals’ understanding of 
how chronic diseases influence physical health relative to one another, but also highlight the 
relationships between the development of a long-term condition and providing optimum 
quality-of-life (QOL) for the patient. 
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As outlined in the previous chapters, CVD and MSK disorders include several disease and 
symptom conditions, which can form spectrums based on relative severity of morbidity. 
However, it is not clearly understood how the different conditions within the same chronic 
disease spectrum influence health relative to one another longitudinally. Previous cohort 
studies have shown the influence that individual CVD (Brown et al. 1999, Boini et al. 2006) 
and MSK disorders (Roux et al. 2005, Dervin et al. 2003) have on deterioration of physical 
health over time. Brown in 1999 used the SF-36 to measure perceived general health of 
patients hospitalised due to acute myocardial infarction (MI) and found that four years after 
the event, the general health of those aged 65 years or younger remained impaired. Boini et al 
found that after approximately 2.5 years, those with coronary artery diseases had diminished 
physical functioning and general health (Boini et al. 2006). However, studies of individual 
conditions within chronic diseases over different time periods provide only variable, time 
dependant information on how physical health deteriorates. It remains unclear how 
conditions influence health change in relation to one another. 
 
In contrast, studies investigating the association between different conditions within chronic 
disease spectrums and their impact on physical health have mostly been cross-sectional for 
CVD (Stewart et al. 1989) and MSK disorders (Rabenda et al. 2007, Yilmaz et al. 2008). These 
studies have shown an adverse influence of chronic diseases on physical health, for example, 
a study by Alonso et al found that in comparison to general populations, patients with 
different categories of CVD had progressively worse physical health (Alonso et al. 2004). 
However, it is currently unclear if across a number of conditions within a chronic disease, the 
degree of poor health remains the same or changes over time. Longitudinal observational 
research comparing the relative influence of different chronic diseases on physical health 
remains limited, especially how conditions of differing severities in the same chronic disease 
spectrum relate to long-term physical health change in general practice populations. 
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In the current chapter, two further specific objectives for CVD and MSK cohorts in general 
practice populations aged 50 years and over and long-term health were investigated. First 
objective was to investigate whether relative morbidity severity influenced self-reported 
physical health change over three years. It was hypothesised, for both CVD and MSK 
disorders, that those patients recorded in general practice with the more severe exclusive 
diagnostic categories in either chronic disease spectrum would show greater deterioration of 
health over three years. Second objective was to investigate whether comorbidity influenced 
self-reported physical health change over three years. Expanding on the adjustment in the 
association between chronic disease and physical health by morbidity counts in Chapter 5, 
this work examines the influence of comorbidity as a potential and separate influence on 
physical health change over the longer-term time-period of three years. 
 
6.2. Aim & objectives 
6.2.1. Aim 
To investigate the association between individual chronic disease spectrum and long-term 
physical health change (3-year) in general practice populations. 
 
6.2.2. Objectives 
The two objectives using the NorStOP consultation-survey linkage data were: 
1. To examine whether higher morbidity severity is associated with greater physical 
health change over three years,  
2. To examine whether relative morbidity severity and comorbidity are associated with 
physical health change over three years. 
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6.3. Method 
6.3.1. Study design 
This study was an extension of that performed in Chapter 5. The design of the North 
Staffordshire Osteoarthritis Project (NorStOP) meant that after three years from the baseline 
survey, a repeat survey was sent to baseline responders. The baseline study sample formed 
the cohort, and linked data to patients who had also completed the 3-year follow-up survey. 
Out of the baseline sample of 7,799 patients, with consultation-survey linkage data, there 
were 4,672 (59.9%) patients who had also responded to the 3-year follow-up survey. Patients 
remained in their same CVD or MSK category as for the cross-sectional analysis in Chapter 5, 
i.e. based on their consultations to primary care in the two years prior to baseline. Change in 
physical health was measured using the SF-12. Specifically, the interest was in the change in 
Physical Component Summary (PCS) score from baseline to 3-year follow-up. The same 
socio-demographic characteristics (age, gender and deprivation measured by IMD) were also 
used in the NorStOP cohort analysis.  
 
6.3.1.1. Comorbidity: Count measure 
Comorbidity was examined as a specific influence on physical health change over 3-years. 
Consultations coded as morbidities in general practice were used to measure comorbidity. 
Comorbidity count levels were constructed based on the number of different morbidities 
consulted for in the two year time-period before the baseline survey. These 2-year 
comorbidity counts (before the baseline) refer to at least one consultation for any given 
morbidity, including the CVD or MSK categories, but do not include any repeat consultations 
for the same morbidity. Comorbidity counts were categorised as low or high level. 
 
 
 
 160 
 
6.3.2. Statistical analysis 
As previously, age was categorised into four groups: 50-59 years, 60-69 years, 70-79 years 
and 80 years and over, and deprivation status into four groups from category 1 (affluent) to 
category 4 (most deprived). Psychological health status was dichotomised into ‘good’ or 
‘poor’, using the mean baseline MCS score (48.59, SD 11.4) from the cross-sectional study 
sample. Comorbidity level was also dichotomised using the mean count, with individuals 
defined as either consulting with low (≤7) or high (≥8) morbidity counts in the two year 
period before the baseline survey. Within both the CVD and MSK spectrums, each cohort 
were summarised by age, gender, deprivation status, and psychological health status and 
comorbidity levels. The change in mean PCS score for each cohort was the primary outcome 
of interest. 
 
For each diagnostic cohort within the CVD and MSK spectrums, change in physical health 
over three years was first examined using paired t-tests. Associations between cohort and 
physical health change were then examined using multiple linear regression. Multiple linear 
regression was used to consider the influence of several factors in the relationship between 
each disease category and change in physical health score. Adjustments were made 
separately for: (i) age, gender and deprivation status, (ii) age, gender, deprivation status and 
baseline psychological health status (MCS score) and (iii) all factors and baseline physical 
health status (PCS score). This final adjustment was then stratified by ‘low’ or ‘high’ 
comorbidity levels. All analyses were performed using SPSS version 15.0 (SPSS Inc., Chicago, 
Illinois). 
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6.4. Results 
6.4.1. Overall findings 
The 4,672 patients who had responded to the 3-year follow-up survey were younger than 
non-responders. Response was slightly higher from those who were more affluent; those who 
had a ‘good’ psychological health status and a low morbidity count (Table 6.1). Of the 4,672, 
there were 1,371 (29%) patients who had consulted for one of the six CVD cohorts and 1,972 
(42%) patients who had consulted for one of the nine MSK cohorts, with 561 (12%) of these 
having consulted for both chronic conditions. There were 1,890 (41%) patients who had 
consulted for neither a CVD or MSK diagnostic category in the two years prior to the baseline 
survey. 
 
6.4.2. Comparison between baseline-only responders and study sample 
Of the baseline study population of 7,799 patients, there were 3,127 (40%) patients who had 
participated only in the baseline survey and 4,672 (60%) patients who had responded to both 
baseline and 3-year follow-up survey. Of the 3,127 baseline-only responders, 1,076 (34%) 
patients had consulted for CVD categories, 1,349 (43%) for MSK categories and 476 (15%) 
for both CVD and MSK categories. The remaining baseline-only responders of 1,178 (38%) 
had consulted for neither CVD nor MSK categories. Of the 4,672 who had responded to both 
surveys, 1,371 (29%) had consulted for CVD categories, 1,972 (42%) for MSK categories, 561 
(12%) for CVD & MSK and 1,890 (40%) for either CVD or MSK. Therefore, the proportions of 
patients consulting in each group were similar between those who only responded at 
baseline and those who responded at baseline and 3-year follow-up (Figure 6.1).  
 
Those who responded to both surveys, for either CVD or MSK were younger than those 
responding to the baseline-only. More females with CVD had responded to baseline-only than 
males, but the gender response was equal in the 3-year follow up sample with CVD. The 
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gender distribution in those with MSK was similar at both stages. Those responding at 
baseline-only or at both time points with CVD had a greater proportion that were deprived. 
This was the same for MSK baseline-only responders but not those at 3-year follow-up, of 
whom the greater proportion was most affluent. In both CVD and MSK groups, those 
responding to baseline and 3-year follow-up had better psychological health status compared 
to the baseline-only sample. There was little difference in comorbidity levels in the CVD or 
MSK samples between baseline-only responders and cohort sample used in this analysis 
(Table 6.2). 
 
For both chronic disease spectrums, the proportions of baseline-only responders for each 
diagnostic category were similar to those who responded to both baseline and 3-years 
follow-up questionnaire. For example, of those responding to baseline-only, 10.7% were 
classified in the ischaemic heart disease category. A similar proportion of those responding to 
baseline and 3-years follow-up (10.4%) were also classified into the ischaemic heart disease 
category. For no disease category was the proportion of patients responding after three years 
markedly different from those responding to baseline-only. 
 
6.4.3. Characteristics of cardiovascular disease cohorts 
Over half of CVD cohort samples were aged 69 years or younger in each of the six cohorts, 
with the exception of the heart failure cohort, who had a greater proportion of older patients 
(Table 6.3). More women than men consulted for hypertension, atrial fibrillation and heart 
failure and there were no specific deprivation patterns across the different categories. For 
each cohort, except heart failure, more patients had a ‘good’, rather than ‘poor’ psychological 
health status at baseline survey, with over two-thirds having high comorbidity levels in the 
two years before the baseline survey. 
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Table 6.1: Comparison of study population by sub-groups in the selection process 
 
 
 
  Sub-groups 
Risk factor Category Survey  
respondersa 
 Consenters to  
record reviewb 
 Morbidity  
consultersc 
 PCS score  
at baselined 
 Cohort Study  
Samplee 
 Number (%) 13986  10432 (74.6)  8962 (64.1)  7799 (87.0)  4672 (52.1) 
           
Age 50 – 59 (%) 4387 (31.4)  3345 (32.1)  2764 (30.8)  2538 (32.5)  1750 (37.5) 
 60 – 69 (%) 4224 (30.2)  3213 (30.8)  2776 (31.0)  2456 (31.5)  1609 (34.4) 
 70 – 79 (%) 3585 (25.6)  2654 (25.4)  2354 (26.3)  1974 (25.3)  1049 (22.5) 
 80+ (%) 1790 (12.8)  1220 (11.7)  1068 (11.9)  831 (10.7)  264 (5.7) 
           
Gender  Male (%) 6154 (44.0)  4818 (46.2)  4028 (44.9)  3552 (45.5)  2536 (54.3) 
 Female (%) 7832 (56.0)  5614 (53.8)  4934 (55.1)  4247 (54.5)  2136 (45.7) 
           
Deprivation status Category 1 (affluent) (%) 3264 (23.3)  2601 (24.9)  2237 (25.0)  1996 (24.7)  1302 (27.9) 
 Category 2 (%) 3334 (23.8)  2552 (24.5)  2205 (24.6)  1969 (25.2)  1232 (26.4) 
 Category 3 (%) 3463 (24.8)  2534 (24.3)  2210 (24.7)  1904 (24.4)  1090 (23.3) 
 Category 4 (deprived) (%) 3922 (28.0)  2742 (26.3)  2308 (25.0)  1928 (24.7)  1046 (22.4) 
           
Psychological health status Good (48.60>) 7138 (51.0)  5482 (52.5)  4555 (50.8)  4555 (58.4)  2973 (63.6) 
 Poor (48.59<) 4817 (34.4)  3637 (34.9)  3242 (36.2)  3242 (41.6)  1699 (36.4) 
           
Morbidity count Low (7<) 5157 (36.9)  5157 (49.4)  4737 (52.9)  4192 (53.8)  2579 (55.2) 
 High (8>) 4225 (30.2)  4225 (40.5)  4225 (47.1)  3607 (46.2)  2093 (44.8) 
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Figure 6.1: Sample flowchart 
Baseline responders only (dashed line) and those responding at baseline and 3-years follow-up (solid line). For each of these responder groups, those who 
consulted for a CVD, MSK or neither CVD nor MSK condition in the two years prior to baseline survey are displayed. Those who consulted for both a CVD & MSK 
disorder, in the two years prior to baseline are also shown (circles). Proportions are of 7,799  
Responders to the general population study baseline questionnaire that consented to medical record review 
and had consulted in the previous two years  
= 7,799 
Consulted for  
CVD 
= 2,447 (31.4%) 
Consulted for  
MSK 
= 3,321 (42.6%) 
Consulted for neither  
CVD or MSK 
= 3,068 (39.3%) 
Eligible population: Responders to general population study baseline and 3-years follow-up questionnaire 
that consented to medical record review and had consulted in the previous two years 
= 4,672 (59.9%) 
Consulted for  
CVD & MSK 
= 1,037 
Consulted for  
CVD 
= 1,371 (17.6%) 
Consulted for  
MSK 
= 1,972 (25.3%) 
Consulted for neither  
CVD or MSK 
= 1,890 (24.2%) 
Consulted for  
CVD & MSK 
= 561 (7.2%) 
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Table 6.2: Characteristics of the baseline-only responders and the study sample 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CVD: cardiovascular disease; MSK: musculoskeletal disorder; aBased on Index of Multiple Deprivation (IMD); bBased on Mental Component Summary (MCS) score 
from SF-12;  cBased on number of consultations in the two years prior to the baseline survey; dParticipants who responded to the baseline survey only; 
eParticipants who responded to the baseline survey and the follow-up survey three years later 
Study factor Category Cardiovascular diseases  Musculoskeletal disorders 
  Baseline-onlyd 
n=1076 
Study samplee 
n=1371 
 Baseline-onlyd  
n=1349 
Study samplee 
n=1972 
  No. (%) No. (%)  No. (%) No. (%) 
       
Age group (years) 50-59  157 (14.6) 305 (22.2)  296 (21.9) 718 (36.4) 
60-69  267 (24.8) 530 (38.7)  377 (27.9) 699 (35.4) 
70-79  401 (37.3) 422 (30.8)  430 (31.9) 428 (21.7) 
80+  251 (23.3) 114 (8.3)  246 (18.2) 127 (6.4) 
       
Gender Male  470 (43.7) 680 (49.6)  532 (39.4) 831 (42.1) 
Female 606 (56.3) 691 (50.4)  817 (60.6) 1141 (57.9) 
       
Deprivation statusa Category 1 (affluent) 195 (18.1) 327 (23.9)  287 (21.3) 544 (27.6) 
Category 2 208 (19.3) 305 (22.3)  315 (23.4) 523 (26.5) 
Category 3 303 (28.2) 346 (25.3)  367 (27.2) 460 (23.3) 
Category 4 (deprived) 370 (34.4) 392 (28.6)  380 (28.2) 445 (22.6) 
       
Psychological health statusb Good 508 (47.3) 827 (60.3)  598 (44.3) 1170 (59.3) 
Poor 567 (52.7) 544 (39.7)  751 (55.7) 802 (40.7) 
       
Comorbidity levelc Low (<7) 307 (28.5) 382 (27.9)  453 (33.6) 782 (39.7) 
High (>8) 769 (71.5) 989 (72.1)  896 (66.4) 1190 (60.3) 
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Table 6.3: Characteristics of cardiovascular disease cohorts 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aBased on Index of Multiple Deprivation (IMD); bBased on Mental Component Summary (MCS) score from SF-12;  
cBased on number of consultations in the two years prior to the baseline survey 
 
Study factor Category Hypertension 
 
n=936 
Atrial  
fibrillation 
n=58 
Ischaemic  
heart disease 
n=142 
Angina 
 
n=152 
Myocardial  
infarction 
n=24 
Heart  
failure 
n=59 
  No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) 
        
Age group (years) 50-59  242 (25.9) 9 (15.5) 23 (16.2) 24 (15.8) 5 (20.8) 2 (3.4) 
60-69  367 (39.2) 23 (39.7) 61 (43.0) 60 (39.5) 8 (33.3) 11 (18.6) 
70-79  260 (27.8) 17 (29.3) 50 (35.2) 57 (37.5) 9 (37.5) 29 (49.2) 
80+  67 (7.2) 9 (15.5) 8 (5.6) 11 (7.2) 2 (8.3) 17 (28.8) 
        
Gender Male  413 (44.1) 27 (46.6) 101 (71.1) 88 (57.9) 22 (91.7) 29 (49.2) 
Female 523 (55.9) 31 (53.4) 41 (28.9) 64 (42.1) 2 (8.3) 30 (50.8) 
        
Deprivation statusa Category 1 (affluent) 220 (23.5) 14 (24.1) 32 (22.5) 33 (21.7) 10 (41.7) 18 (30.5) 
Category 2 199 (21.3) 14 (24.1) 37 (26.1) 30 (19.7) 6 (25.0) 19 (32.2) 
Category 3 229 (24.5) 18 (31.0) 34 (23.9) 51 (33.6) 3 (12.5) 11 (18.6) 
Category 4 (deprived) 287 (30.7) 12 (20.7) 39 (27.5) 38 (25.0) 5 (20.8) 11 (18.6) 
        
Psychological health statusb Good 587 (62.7) 34 (58.6) 89 (62.7) 76 (50.0) 15 (62.5) 26 (44.1) 
Poor 349 (37.3) 24 (41.4) 53 (37.3) 76 (50.0) 9 (37.5) 33 (55.9) 
        
Comorbidity levelc Low (≤7) 277 (29.6) 13 (22.4) 46 (32.4) 34 (22.4) 6 (25.0) 6 (10.2) 
High (≥8) 659 (70.4) 45 (77.6) 96 (67.6) 118 (77.6) 18 (75.0) 53 (89.9) 
 167 
 
6.4.4. Characteristics of musculoskeletal disorder cohorts 
Over half of MSK cohort samples were aged 69 years or younger in all of the nine cohorts 
(Table 6.4). More men than women consulted for peripheral enthesopathies or back pain 
and there were no specific patterns of deprivation across different cohorts. Except for the 
inflammatory polyarthropathy category, more patients had a ‘good’, rather than ‘poor’ 
baseline psychological health status, with over half of patients (except soft tissue disorder) 
having high comorbidity levels in the two years before the baseline survey. 
 
6.4.5. Association between cardiovascular cohorts and physical health 
status       
Absolute physical health change in individual cohorts over the three years was only 
significant (p<0.001) for hypertension, with the PCS score deteriorating by -0.86 (95% CI -
1.4, -0.3) over three years (Table 6.5). In multivariable analysis, increasing disease severity 
was associated with greater relative deterioration of long-term physical health, particularly 
for the most severe cohorts (Table 6.6). For example, the atrial fibrillation cohort showed an 
actual (unadjusted) improvement in physical health after three years of 0.96 relative to 
change in the hypertension cohort, but when adjusted for age, gender, deprivation status, 
MCS score and baseline PCS score, physical health in this cohort deteriorated relatively by -
0.43. Adjusting for baseline PCS was related to the longitudinal physical health change, with 
adjustment for this factor resulting in decreases in physical health in CVD cohorts. 
Associations for more severe CVD cohorts compared with the reference cohort 
(hypertension) on physical health change were as follows (unadjusted vs. full adjustment): 
atrial fibrillation (0.96 vs. -0.43), ischaemic heart disease (1.02 vs. -0.92), angina (1.42 vs. -
0.45), myocardial infarction (-0.48 vs. -2.31) and heart failure (0.23 vs. -2.09).  
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Table 6.4: Characteristics of musculoskeletal disorder cohorts 
aBased on Index of Multiple Deprivation (IMD); bBased on Mental Component Summary (MCS) score from SF-12;   
cBased on number of consultations in the two years prior to the baseline survey 
 
Study factor Category Soft tissue  
disorder 
n=47 
Soft tissue 
 pain 
n=309 
Peripheral 
enthesopathies 
n=166 
Joint 
disorder 
n=282 
Back pain 
 
n=391 
Neck pain 
 
n=156 
Osteoarthritis 
 
n=509 
Osteoporosis 
 
n=55 
Inflammatory 
polyarthropathy 
n=57 
  No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) 
           
Age group (years) 50-59 18 (38.3) 102 (33.0) 74 (44.6) 129 (45.7) 191 (48.8) 57 (36.5) 119 (23.4) 16 (29.1) 12 (21.1) 
60-69 12 (25.5) 127 (41.1) 58 (34.9) 90 (31.9) 114 (29.2) 59 (37.8) 194 (38.1) 23 (41.8) 22 (38.6) 
70-79 14 (29.8) 63 (20.4) 29 (17.5) 44 (15.6) 69 (17.6) 33 (21.2) 151 (29.7) 13 (23.6) 12 (21.1) 
80+ 3 (6.4) 17 (5.5) 5 (3.0) 19 (6.7) 17 (4.3) 7 (4.5) 45 (8.8) 3 (5.5) 11 (19.3) 
           
Gender Male  15 (31.9) 130 (42.1) 84 (50.6) 119 (42.2) 202 (51.7) 66 (42.3) 188 (36.9) 6 (10.9) 21 (36.8) 
Female 32 (68.1) 179 (57.9) 82 (49.4) 163 (57.8) 189 (48.3) 90 (57.7) 321 (63.1) 49 (89.1) 36 (63.2) 
           
Deprivation 
statusa 
Category 1  
(affluent) 
12 (25.5) 82 (26.5) 47 (28.3) 69 (24.5) 105 (26.9) 50 (32.1) 145 (28.5) 19 (34.5) 15 (26.3) 
Category 2 12 (25.5) 65 (21.0) 55 (33.1) 83 (29.4) 101 (25.8) 40 (25.6) 139 (27.3) 17 (30.9) 11 (19.3) 
Category 3 12 (25.5) 83 (26.9) 29 (17.5) 68 (24.1) 97 (24.8) 32 (20.5) 107 (21.0) 10 (18.2) 22 (38.6) 
Category 4 
(deprived) 
11 (23.4) 79 (25.6) 35 (21.1) 62 (22.0) 88 (22.5) 34 (21.8) 118 (23.2) 9 (16.4) 9 (15.8) 
           
Psychological 
health statusb 
Good 32 (68.1) 193 (62.5) 114 (68.7) 177 (62.8) 236 (60.4) 87 (55.8) 273 (53.6) 31 (56.4) 27 (47.4) 
Poor 15 (31.9) 116 (37.5) 52 (31.3) 105 (37.2) 155 (39.6) 69 (44.2) 236 (46.4) 24 (43.6) 30 (52.6) 
           
Comorbidity 
levelc 
Low (≤7) 24 (51.1) 147 (47.6) 79 (47.6) 129 (45.7) 169 (43.2) 51 (32.7) 157 (30.8) 14 (25.5) 12 (21.1) 
High (≥8) 23 (48.9) 162 (52.4) 87 (52.4) 153 (54.3) 222 (56.8) 105 (67.3) 352 (69.2) 41 (74.5) 45 (78.9) 
 169 
 
6.4.6. Association between musculoskeletal cohorts and physical health 
status 
There was no significant change in absolute physical health score within the MSK spectrum, 
even for the most severe cohort (Table 6.5). In multivariable analysis, increasing disease 
severity was not associated with greater relative deterioration of long-term physical health. 
More severe cohorts within the MSK spectrum (Table 6.6) compared to the reference cohort 
(soft tissue disorder) were as follows (unadjusted vs. full adjustment): soft tissue pain (1.41 
vs. -0.63), peripheral enthesopathies (2.58 vs. 0.78), joint disorder (1.09 vs. -1.21), back pain 
(1.56 vs. -1.22), neck pain (2.77 vs. -0.66), osteoarthritis (2.09 vs. -1.54), osteoporosis (2.98 
vs. -0.04), inflammatory polyarthropathy (3.59 vs. -1.09). 
 
6.4.7. Association between comorbidity and physical health status 
Within all CVD cohorts, those with a higher comorbidity level showed greater mean 
deterioration in physical health over three years than those with lower comorbidity levels, 
with the exception of ischaemic heart disease (Table 6.7). Furthermore, increasing disease 
severity, compared to the reference category (hypertension), was associated with an adjusted 
increasing trend in deteriorating physical health for those with high comorbidity. 
Associations between disease severity and change in physical health by comorbidity levels 
were as follows (low comorbidity levels vs. high comorbidity levels): atrial fibrillation (2.84 
vs. -1.41), ischaemic heart disease (-1.17 vs. -0.88), angina (1.04 vs. -0.99), myocardial 
infarction (-1.88 vs. -2.28) and heart failure (-0.99 vs. -2.54). Within the MSK spectrum, there 
was no association between comorbidity and change in long-term physical health (Table 
6.7). 
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Table 6.5: Mean Physical Component Summary scores for cardiovascular disease or musculoskeletal cohorts 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aNumber of patients classified by study defined exclusive diagnostic categories, bPhysical Component Summary (PCS) score of the SF-12 recorded in the baseline 
survey; cPhysical Component Summary (PCS) score of the SF-12 recorded in the follow-up survey, three years after the baseline survey; dChange in PCS score after 
three years, calculated by subtracting the 3-year follow-up PCS score from the baseline PCS score. *Signifies a significant change in physcial health from baseline to 
3-year follow-up, negative change score indicates worse PCS score at 3 years 
Chronic 
Disease 
Cohort Samplea Baseline PCSb 3-year follow-up PCSc Change in PCSd 
  No. (%) Mean (95% CI) Mean (95% CI) Mean (95% CI) 
      
CVD Hypertension 936 (68.3) 39.94 (39.1, 40.7) 39.08 (38.3, 39.8) -0.86 (-1.4, -0.3)* 
 Atrial fibrillation 58 (4.2) 34.96 (32.3, 37.7) 35.05 (32.0, 38.1) 0.09 (-2.5, 2.7) 
 Ischaemic heart disease 142 (10.3) 34.88 (32.9, 36.8) 35.04 (33.1, 37.0) 0.16 (-1.2, 1.5) 
 Angina 152 (11.1) 33.44 (31.9, 34.9) 34.00 (32.4, 35.6) 0.56 (-0.7, 1.8) 
 Myocardial Infarction 24 (1.8) 35.77 (30.4, 41.1) 34.43 (30.2, 38.7) -1.34 (-6.2, 3.6) 
 Heart failure 59 (4.3) 29.43 (27.3, 31.5) 28.80 (26.6, 31.0) -0.63 (-2.9, 1.7) 
      
MSK Soft tissue disorder 47 (2.4) 46.24 (43.6, 48.9) 44.52 (41.5, 47.5) -1.72 (-4.1, 0.7) 
 Soft tissue pain 309 (15.7) 40.40 (39.0, 41.8) 40.08 (38.7, 41.5) -0.32 (-1.4, 0.8) 
 Peripheral enthesopathies 166 (8.4) 42.77 (41.0, 44.5) 43.63 (42.0, 45.2) 0.86 (-0.4, 2.1) 
 Joint disorder 282 (14.3) 40.52 (39.1, 41.9) 39.89 (38.5, 41.3) -0.63 (-1.6, 0.3) 
 Back pain 391 (19.8) 39.21 (38.0, 40.4) 39.04 (37.9, 40.2) -0.17 (-1.1, 0.7) 
 Neck pain 156 (7.9) 36.12 (34.1, 38.1) 37.17 (35.3, 39.0) 1.05 (-0.4, 2.5) 
 Osteoarthritis 509 (25.8) 34.01 (33.0, 35.0) 34.37 (33.5, 35.3) 0.36 (-0.4, 1.1) 
 Osteoporosis 55 (2.8) 36.35 (33.2, 39.5) 37.60 (34.3, 40.9) 1.25 (-1.3, 3.8) 
 Inflammatory polyarthropathy 57 (2.9) 29.81 (26.9, 32.7) 31.68 (29.0, 34.3) 1.87 (-0.4, 4.2) 
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Figure 6.2: Mean change over 3 years in physical component summary score (95% confidence interval) for cardiovascular disease and 
musculoskeletal disorder cohorts 
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Table 6.6: Associations between cohorts and physical health change, by cardiovascular disease or musculoskeletal disorder 
 
aNumber of patients in the study sample with at least one consultation for this diagnostic category in the 2-year time period of observation; bNumber of patients 
classified by study defined exclusive diagnostic categories; cDicotomy based on the mean Physical Component Summary (PCS) score of SF-12 from previous cross-
sectional study [21]; dDeprivation score as measured by Index of Multiple Deprivation (IMD); eBased on Mental Component Summary (MCS) score from SF-12; 
fPhysical Component Summary (PCS) score from SF-12. negative change score indicates worse PCS score at 3 years relative to reference group 
    Adjusted linear regression.  
Mean (95% CI) 
Cohort Total 
numbera 
Exclusive  
numberb 
 (%) 
Unadjusted  
linear regression.  
Mean (95% CI) 
Age, Gender &  
Deprivation 
statusd 
Age, Gender, 
Deprivation statusd  
& Baseline MCS scoree 
Age, Gender,  
Deprivation statusd, 
MCSe & Baseline PCS scoref 
       
Cardiovascular disease       
Hypertension  1047 936 (89.4) Ref  Ref Ref Ref 
Atrial fibrillation  84 58 (69.0) 0.96 (-1.4, 3.3) 1.05 (-1.3, 3.4) 1.18 (-1.2, 3.5) -0.43 (-2.5, 1.7) 
Ischaemic heart disease 202 142 (70.3) 1.02 (-0.6, 2.6) 0.88 (-0.7, 2.5) 0.95 (-0.6, 2.5) -0.92 (-2.3, 0.5) 
Angina  168 152 (90.5) 1.42 (-0.1, 3.0) 1.42 (-0.1, 3.0) 1.73 (-0.2, 3.3) -0.45 (-1.8, 0.9) 
Myocardial infarction  25 24 (96.0) -0.48 (-4.1, 3.1) -0.73 (-4.4, 2.9) -0.58 (-4.2, 3.0) -2.31 (-5.5, 0.9) 
Heart failure  59 59 (100.0) 0.23 (-2.1, 2.6) 0.65 (-1.8, 3.1) 1.09 (-1.3, 3.5) -2.09 (-4.2, 0.0) 
       
Musculoskeletal disorder       
Soft tissue disorder  87 47 (54.0) Ref Ref Ref Ref 
Soft tissue pain  634 309 (48.7) 1.41 (-1.3, 4.1) 1.23 (-1.5, 3.9) 1.39 (-1.3, 4.1) -0.63 (-3.0, 1.8) 
Peripheral enthesopathies  301 166 (55.1) 2.58 (-0.3, 5.4) 2.21 (-0.7, 5.1) 2.28 (-0.6, 5.1) 0.78 (-1.7, 3.3) 
Joint disorder  482 282 (58.5) 1.09 (-1.6, 3.8) 0.80 (-1.9, 3.5) 0.94 (-1.8, 3.6) -1.21 (-3.6, 1.2) 
Back pain  511 391 (76.5) 1.56 (-1.1, 4.2) 1.12 (-1.6, 3.8) 1.37 (-1.3, 4.0) -1.22 (-3.6, 1.1) 
Neck pain  192 156 (81.3) 2.77 (-0.1, 5.7) 2.60 (-0.3, 5.5) 2.92 (0.1, 5.8) -0.66 (-3.2, 1.9) 
Osteoarthritis  524 509 (97.1) 2.09 (-0.6, 4.7) 2.19 (-0.4, 4.8) 2.50 (-0.1, 5.1) -1.54 (-3.9, 0.8) 
Osteoporosis  59 55 (93.2) 2.98 (-0.5, 6.4) 3.27 (-0.2, 6.7) 3.53 (0.1, 6.9) -0.04 (-3.1, 3.0) 
Inflammatory polyarthropathy  58 57 (98.3) 3.59 (0.2, 7.0) 3.69 (0.3, 7.1) 4.20 (0.8, 7.6) -1.09 (-4.1, 2.0) 
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Table 6.7: Associations between cohorts and change in physical health by cardiovascular disease or musculoskeletal disorder, stratified by low or 
high comorbidity levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aNumber of patients classified by study defined exclusive diagnostic categories; bPatients with ≤7 different consultations in the two years prior to the baseline 
survey; cPatients with 8≥ different consultations in the two years prior to the baseline survey; dReference category 
    Adjusted linear regression 
Chronic Disease Cohorts Samplea  Unadjusted  
linear regression 
Low comorbidity levelb High comorbidity levelc 
  No. (%) Mean (95% CI) Mean (95% CI) Mean (95% CI) 
      
CVD Hypertension 936 (68.3) Ref  Refd Refd 
 Atrial fibrillation 58 (4.2) 0.96 (-1.4, 3.3) 2.84 (-1.9, 7.5) -1.41 (-3.7, 0.9) 
 Ischaemic heart disease 142 (10.3) 1.02 (-0.6, 2.6) -1.17 (-3.9, 1.6) -0.88 (-2.5, 0.8) 
 Angina 152 (11.1) 1.42 (-0.1, 3.0) 1.04 (-2.1, 4.2) -0.99 (-2.5, 0.5) 
 Myocardial Infarction 24 (1.8) -0.48 (-4.1, 3.1) -1.88 (-8.8, 5.0) -2.28 (-5.9, 1.3) 
 Heart failure 59 (4.3) 0.23 (-2.1, 2.6) -0.99 (-8.0, 6.0) -2.54 (-4.8, -0.3) 
      
MSK Soft tissue disorder 47 (2.4) Ref Refd Refd 
 Soft tissue pain 309 (15.7) 1.41 (-1.3, 4.1) -0.28 (-3.7, 3.2) -1.09 (-4.5, 2.3) 
 Peripheral enthesopathies 166 (8.4) 2.58 (-0.3, 5.4) -0.27 (-3.9, 3.4) 1.52 (-2.0, 5.1) 
 Joint disorder 282 (14.3) 1.09 (-1.6, 3.8) -0.72 (-4.2, 2.8) -1.60 (-5.0, 1.8) 
 Back pain 391 (19.8) 1.56 (-1.1, 4.2) -1.28 (-4.7, 2.1) -1.25 (-4.6, 2.1) 
 Neck pain 156 (7.9) 2.77 (-0.1, 5.7) 0.21 (-3.7, 4.1) -1.13 (-4.6, 2.4) 
 Osteoarthritis 509 (25.8) 2.09 (-0.6, 4.7) -1.07 (-4.5, 2.4) -1.79 (-5.1, 1.5) 
 Osteoporosis 55 (2.8) 2.98 (-0.5, 6.4) 1.05 (-4.2, 6.4) -0.41 (-4.4, 3.5) 
 Inflammatory polyarthropathy 57 (2.9) 3.59 (0.2, 7.0) -1.87 (-7.5, 3.7) -1.08 (-5.0, 2.8) 
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6.5. Discussion 
This chapter has shown that within the CVD spectrum, increasing relative morbidity severity 
of diagnostic categories was associated with deteriorating long-term physical health after 
adjusting for baseline physical health and socio-demographic characteristics. However, the 
magnitude of such physical health was small. Such an association was not observed within 
the MSK disorder spectrum and physical health. These findings were also independent of 
baseline psychological health status. After adjusting for the baseline physical health status, all 
cohorts showed a non-significant, relative deterioration in physical health. Within the CVD 
cohort, in those with higher levels of comorbidity, increasing severity was associated with 
greater deterioration in long-term physical health, but such associations were not observed 
for CVD cohorts with lower comorbidity levels.  
 
These findings suggest that health care professionals may need to identify more severe CVD 
patients with higher levels of comorbidity to target health care and potentially prevent the 
likelihood of long-term worsening in physical health. In contrast, for MSK cohorts there was 
little influence of disease severity and comorbidity levels on long-term physical health 
change. Here the potential implication for long-term health, as defined within the study 
spectrum, could be that patients are assessed according to the respective MSK category. 
Change in health in such populations may not be an important indicator of the likely levels of 
musculoskeletal health needs. 
 
6.5.1. Cardiovascular disease findings  
Previous studies have shown the adverse influence of individual CVD on long-term physical 
health change (Brown et al. 1999). Boini et al found that in a general population, people with 
coronary artery disease were likely to have poorer physical health when followed-up around 
three years later (Boini et al. 2006). However, this chapter was interested in the influence of a 
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range of conditions within the same chronic disease spectrum, which constitutes one 
definition of ‘severity’. 
 
Previous cross-sectional studies have shown that hypertension, myocardial infarction, 
ischaemic heart disease and congestive heart failure are associated with progressively poorer 
physical health (Stewart et al. 1989, Alonso et al. 2004). In-line with this previous work, this 
study found that increasing severity influenced the long-term relative deterioration in 
physical health, with the myocardial infarction & heart failure cohorts showing greater 
deterioration relative to the hypertension cohort over three years. This adds to research 
knowledge by showing that across the CVD spectrum in general practice populations there 
are differing influences on long-term physical health change, reflecting the importance of 
‘severity’ as indicated by diagnostic categories that constitute the stages of a chronic disease. 
Higher comorbidity levels were also a separate influence on long-term physical health change 
within the CVD spectrum, with such levels showing greater relative deterioration in physical 
health change. This supports the concept that comorbidity needs be considered as a separate 
issue in the clinical management of patients. 
 
6.5.2. Musculoskeletal disorder findings 
The influence of the spectrum of MSK cohorts on long-term change in physical health was 
distinct to those of the CVD cohorts. There was no association between increasing severity of 
MSK cohort and long-term change in physical health. Previous longitudinal studies have 
investigated specific and single MSK categories which showed long-term deterioration in 
physical health (Roux et al. 2005, Ringen et al. 2008, Arvidsson et al. 2008, Woo, Leung & Lau 
2009), but these studies have not compared the relative influence of different MSK cohorts 
within a spectrum over time. An explanation for these findings for the MSK cohorts may 
relate to the chosen reference category, soft tissue disorder. This cohort had the largest 
(unadjusted) mean PCS change across the two time points of all the MSK disorders and 
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therefore relating all other PCS score change to this reference condition may have limited the 
ability to observe comparable change in the other cohorts. Finally, another explanation for 
this may be that patients are adapting to long-term MSK and therefore their perception of 
health varies more in those who are older and with more serious and longer term problems 
(Galenkamp et al. 2012). However, this is an unlikely explanation for the lack of long-term 
MSK effects on physical health, as previous cross-sectional analyses had shown that the more 
‘severe’ MSK cohorts had poorer health at baseline relative to the reference cohort and this 
argument could also apply to the CVD cohorts where an association was found. 
 
Comorbidity levels also showed a lack of influence on long-term physical health change 
within the MSK cohorts. Whilst a previous cross-sectional study has shown the synergistic 
adverse influence of OA and comorbidity on physical health (Kadam, Croft 2007) more 
detailed long-term studies of MSK-specific outcomes and comorbidity may be required.  
 
6.5.3. Comparing the chronic disease spectrums  
Part of the reason for the differences observed for the CVD spectrum compared to the MSK 
spectrum within this study may be because the CVD cohorts share a pathological link in 
aetiology (Bardage, Isacson 2001, Faller et al. 2007), compared to the categories within the 
MSK spectrum. MSK cohorts encompass a range of ‘pain disorders’ which may represent 
diffuse symptom disorders such as neck or back pain or be distinct pathological processes i.e. 
osteoarthritis (OA) or rheumatoid arthritis (RA). MSK cohorts in this study were based on an 
inter-linking spectrum of disorders, albeit with an a priori order, that influences the pain 
expression through different physiological mechanisms and subjective patient experience. 
These findings create the caveat that the definition of MSK spectrum may be too varied and 
broad (from symptoms to discrete pathologic entities), but that it provides one basis for 
understanding the range of pain spectrum. 
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6.5.4. Strengths and limitations 
6.5.4.1. Strengths 
This study expands on the limited research investigating the influence of different conditions 
within two common chronic disease spectrums on long-term physical health change. This 
large prospective study allows comparisons to be made between several conditions within 
chronic diseases as seen in routine general practice and also how each of these conditions 
influences physical health over a long-term time-period. Physical health was measured with a 
widely used and validated measure of general health (Jenkinson et al. 1997b) and this work 
further investigated the potential impact of comorbidity in primary care, which is an 
increasingly important clinical issue in ageing populations (Gijsen et al. 2001). 
 
6.5.4.2. Limitations 
Limitations in the baseline survey have been addressed in the previous chapter. Thomas et al 
described how baseline three-year responders were more likely to be female, with exclusions 
more likely from the oldest patient categories and non-response by those in the younger age 
categories (Thomas et al. 2004). In addition to the survey and consultation record consent 
selection issues, we also considered ‘drop-out’ bias from the CVD and MSK cohorts, i.e. those 
participants who only took part in the baseline survey but not the 3-years follow-up survey. 
Comparatively, the study sample with both baseline and follow-up measurements was 
younger, more affluent and had improved psychological health status compared to those only 
responding at baseline. This sub-sampling reduces the generalisability of findings, and how 
severity influences long-term physical health change, may not be as applicable to older 
patients with the CVD or MSK of interest from the more deprived sections of the population, 
but will still allow the test of internal comparisons of the cohorts. 
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In considering the influence of comorbidity on physical health change, the method of defining 
comorbidity is also important. Using the count of morbidities in the two years prior to 
baseline survey was a relatively crude measure and may have only provided a crude measure 
of comorbidity in physical health (Fortin et al. 2006). Either using a standardised measure of 
comorbidity or defining comorbidity by specific, chronic combinations of disease may 
provide better clarification of the role of this important factor in long-term physical health 
change.  
 
A further limitation was study attrition over the three-year follow-up period. The number of 
participants in some disease groups was low and hence reduced the power of the study to 
detect small differences compared to the reference groups. Furthermore, there was little 
absolute change over three years and this may be influenced by any floor effect in the PCS 
score. As physical health at baseline was already poor, these patients may have i) adjusted to 
their current heath state or ii) the SF-12 may be unable to record further change as the 
patient has little potential for further deterioration. It is unclear whether the small relative 
changes seen would equate to ‘clinically’ important changes in physical health. 
 
Finally, the strength of association between relative morbidity severity in both the CVD & 
MSK spectrums and physical health change could also be related to unobserved confounding 
issues, other than those factors considered in the study. Factors could include psychosocial 
influences, such as environment or occupation (Hunt et al. 2008) or reduced physical activity 
which may influence the relationship between MSK disorders and overall physical health 
(van Dijk et al. 2010). 
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6.6. Conclusion 
Over a three year period, higher CVD severity and high levels of comorbidity were associated 
with a greater relative deterioration in physical health. In contrast, such findings were not 
observed for the MSK spectrum. Our results suggest that health professionals should consider 
that CVD severity and comorbidity may need to be addressed together in the management of 
long-term changes in physical health. Further research on how each chronic disease, 
comorbidity and QOL of general practice populations changes over time is still required. An 
improved understanding of both relative morbidity severity and comorbidity will allow 
clinicians to provide more tailored treatment and management. 
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Chapter 7: Comorbidity Cohort (2C) study – Methods of 
pilot and main studies, results of pilot study and 
recruitment of main study population 
 
Current evidence has shown the importance of the associations between chronic diseases and 
poor physical health, which may also influence health over the long-term. However, in 
understanding the association between chronic disease and physical health, the thesis 
ambition was then to focus on comorbidity. In the previous chapter the comorbidity count 
measure was used, but with its inherent limitations. In addition, the literature has also 
presented the limited understanding of how chronic diseases interact to influence physical 
health when experienced together. Therefore, to examine the influence of specific comorbid 
chronic disease combinations on physical health over time required the design of a novel 
study which hypothesised the comorbidity interaction, and which also incorporated the 
‘severity’ concept. 
 
This chapter will detail the methods and sampling frame of a new study - the Comorbidity 
Cohort (2C) study. The methods will be discussed across three main themes, i) the initial 
study design, ii) a pilot study including its results and subsequent changes to main study 
design, and iii) the final study design and sample. The initial design of the 2C study will be 
detailed in full, describing the selection of the study population from a wider population, the 
outcome measures used and also the practical processes involved in implementing such a 
study. The pilot study will then be described; this will detail how the 2C study design was 
tested to examine the rigour of certain methods. This will also include the results drawn from 
this smaller study and the implications for the main study. This chapter will conclude by 
stating the amended methods of the 2C study, informing on how the final methods were 
reached, along with details of the study sample composition. 
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7.1. Introduction 
The Comorbidity Cohort (2C) study is a purposively designed cohort study. This was 
developed to expand on the concepts examined in the earlier chapters of this thesis. 
Examining the influence of chronic disease comorbidity in general practice patients can 
expand our understanding of a) how prevention and treatment options may be influenced by 
disease interactions, b) how the presence of multiple conditions impacts on patient health 
and c) how health services may need to adapt in the future to deal with the ever increasing 
presence of comorbidity. In addition the 2C study focuses on short-term health outcomes, to 
provide an alternative context for the longer-term physical health change perspective 
considered in the previous chapter. 
 
Research examining the influence of chronic disease comorbidity on general practice patients 
continues to be an expanding area of interest. Research has considered the prevalence of 
comorbidity in varied chronic disease populations (Caughey et al. 2008, Hudon, Fortin & 
Soubhi 2008), the impact of comorbidity on the health experience of general practice 
populations (Verbrugge, Lepkowski & Imanaka 1989, Guccione et al. 1994, Rijken et al. 2005) 
and there are a multitude of measures of comorbidity tools which have been developed to 
facilitate measurement of comorbidity (de Groot et al. 2003, Sarfati 2012). Despite this 
increasing interest in comorbidity many questions remain unanswered. 
 
The influence of comorbidity is of particular relevance in the study of populations with 
cardiovascular disease (CVD) and osteoarthritis (OA). These conditions commonly co-occur 
(van Oostrom et al. 2012), share certain pathological processes such as obesity (Guh et al. 
2009, Blagojevic et al. 2010) and their specific comorbid pairing has been shown to influence 
cross-sectional physical health. Studies which have examined the existence of CVD & OA 
together have in large part been cross-sectional (Caporali et al. 2005, van Dijk et al. 2008, 
Wesseling et al. 2012). These few studies which do exist have either used the wide concept of 
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cardiac disease (Caporali et al. 2005) or been in a secondary care setting (van Dijk et al. 
2008). Prospective research which has examined CVD & OA has been over long time-periods 
(Ettinger et al. 1994). 
 
Limited epidemiological CVD & OA comorbidity research needs to be built upon to assess the 
longitudinal relationship between specific comorbid combinations of CVD & OA and the 
resulting physical health of patients. The 2C study expands on previous research by 
examining in UK general practice i) the interaction between CVD & OA and the subsequent 
influence on physical health and changes in physical health and ii) the influence of relative 
morbidity severity and comorbidity on short-term physical health and changes in physical  
health.  
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7.2. Aim & objectives 
7.2.1. Aim 
The aim of the 2C study is to examine the influence of cardiovascular disease severity and 
comorbid osteoarthritis on short-term health and health care outcomes over a 12 month 
time-period. 
 
7.2.2. 2C study – Overall objectives 
The specific objectives are to: 
1) To investigate the interaction between cardiovascular disease severity and 
comorbid osteoarthritis and overall health over short-term (monthly and 12-
months) 
2) To investigate the interaction between cardiovascular disease severity and 
comorbid osteoarthritis and diseases-specific health over short-term (monthly 
and 12-months) 
3) To investigate the interaction between cardiovascular disease severity and 
comorbid osteoarthritis and healthcare outcomes over short-term (monthly and 
12-months) 
 
7.2.3. 2C study - PhD Objectives 
The PhD objectives of the 2C study are: 
1) To examine the baseline association between cardiovascular disease severity and 
comorbid osteoarthritis and physical health  
2) To examine the prospective association between cardiovascular disease severity and 
comorbid osteoarthritis and physical health change over 4 and 12 months 
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7.3. Initial study design  
The Comorbidity Cohort (2C) study is a prospective cohort study linking survey and medical 
records. Patients from general practice were selected based on review of their medical 
records from the three years preceding study commencement. In a general practice 
population, patients who had previously consulted for CVD or OA were mailed a self-report 
survey to acquire information on these patients’ opinions of their health. The primary 
component of the study was provision of the same survey at two time points, baseline and 
then another repeat survey twelve months later. A further component to the design 
(requiring additional consent) was the provision of a shorter questionnaire each month in-
between baseline and 12-month follow-up (months 2-11). With consent, survey information 
was then linked to patients’ medical records. Prior to commencing the main study, a pilot 
study was employed to test the study design (Figure 7.1). 
 
7.3.1. Ethics 
The use of any information provided by, or about, National Health Service (NHS) patients can 
only be used with ethical approval. Such approval for the 2C study was gained from the 
Cheshire Research Ethics Committee (REC) (REC reference number: 09/H1017/40). This was 
provided after study review and on the basis that patients would consent to taking part in the 
study and that data would be anonymised and stored securely (Appendix 7.1). 
  
 
1
8
5
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1: Comorbidity Cohort (2C) study design 
Sample selection based on 3-year  
historical GP record review 
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7.4. Participants 
7.4.1. Study population  
Seven general practices were selected from the Stoke-on-Trent (five practices) and North 
Staffordshire (two practices) Primary Care Trusts (PCT). These practices had an approximate 
combined registered population of 53,300 patients, with 28,500 of these being aged 40 years 
or older. The chronic diseases of CVD and OA predominantly occur from mid-life and 
therefore the minimum age of 40 was used when selecting the study population. Sampling 
above this minimum age is likely to provide the ability to capture the majority of relevant 
patients. 
 
The study practices are part of a local research network, the Primary Care Musculoskeletal 
Research Consortium. These practices, supported by the Primary Care Research West 
Midlands North (PCR WMN) network, cover a wide range of socio-economic groups and 
include practices that actively participate in routine collection of clinical data using computer 
records for the purposes of epidemiological study. These practices use Read codes in 95% of 
consultations. They are also contracted to allow the Centre access to their clinical records in 
order to facilitate initial contact with patients by researchers, unless patients have 
specifically requested to be exempt from Centre research. 
 
Demographic information required to be able to contact participants was collected for 
patients aged 43 years and older from these seven practices. This age threshold was used to 
select potential patients for the study sample as records would be searched from the three 
years prior to the baseline questionnaire mail-out, therefore those aged 43 or older would 
include those who were aged 40 three years earlier. 
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7.4.2. Disease cohorts 
From the general practice registers, the study population was constructed from purposive 
sampling of patients who could be categorised into one of eight disease cohorts based on 
patients’ consultation history in the three years (November 2006 – November 2009) 
preceding the baseline questionnaire. These cohorts consisted of patients who had no CVD or 
OA (reference group), four index (individual) groups; those with hypertension but no OA, 
ischaemic heart disease but no OA, heart failure but no OA or patients with OA but no CVD. 
Finally, three comorbid groups consisted of those with hypertension and OA, those with 
ischaemic heart disease and OA and those with heart failure and OA (Table 7.1).  
 
Table 7.1: Study disease cohorts  
Study groups  ID Disease categories 
Reference group -CVD-OA No cardiovascular disease or osteoarthritis 
   
4 Index groups 
+Hyp –OA Hypertension, but no osteoarthritis  
+IHD-OA Ischaemic heart disease but no osteoarthritis 
+HF-OA Heart failure but no osteoarthritis 
-CVD+OA Osteoarthritis but no cardiovascular disease 
   
3 Comorbid groups 
+Hyp +OA Hypertension and osteoarthritis  
+IHD+OA Ischaemic heart disease and osteoarthritis  
+HF+OA Heart failure and osteoarthritis  
CVD = Cardiovascular disease, OA = Osteoarthritis, Hyp = Hypertension,  
IHD = Ischaemic heart disease, HF = Heart failure 
 
The construction of these disease cohorts was based on the identification of a series of Read 
codes from the Practice records. Read codes were used at the third hierarchical level, 
including specific condition codes (i.e. N05 = OA) and several operative codes (i.e. 7K3 = knee 
joint operations) (Table 7.2). This level of coding provided the clear distinction for each 
 188 
 
health condition without being so wide as to incorporate conditions not of interest or too 
specific as to miss patients with relevant health complaints. 
 
Table 7.2: Read codes used to define disease cohorts 
Disease  Read Code Read Code description 
Cardiovascular disease G20 Hypertension 
 G3. Ischaemic heart disease 
 G58 Heart Failure 
 792 Coronary artery operations 
(used for the IHD cohort) 
Osteoarthritis N05 Osteoarthritis 
 7K2 Hip joint operations 
 7K3 Knee joint operations 
    
7.4.3. Study sample 
The sample size was initially based on identifying a 2 point difference at 12 months (effect 
size of 0.2) between patients with index OA and those with CVD & OA comorbidity on the 
primary outcome of the SF-12 Physical Component Summary (PCS) score assuming a 
standard deviation of 10. To identify a 2 point difference, with a power of 80% and a 2-tailed 
significance level of 5%, 394 patients per group (index OA group and each CVD & OA 
comorbidity group) would need to respond at 12 months. However, a higher prevalence of 
index OA was expected than CVD & OA comorbidity. For example, based on a ratio of 2 index 
OA patients for every 1 CVD & OA comorbidity patient, 590 subjects would be required in the 
index OA group and 295 in each CVD & OA comorbidity group.  
 
Recruiting a study sample of sufficient size required estimating the number of general 
practices which would be needed to ensure enough patients from each disease cohort were 
available for invite to the study. To estimate these values, the expected prevalence of each 
disease cohort in the local area was used. These were based on previous prevalence rates 
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from the Morbidity Statistics in General Practice 1991-1992 (McCormick, Fleming & Charlton 
1995) (Table 7.3) and disease. Estimated response was then based on estimations (based on 
the NorStOP dataset (Thomas et al. 2004) of a 70% response of patients to the baseline 
survey and of 70% of these patients responding to the twelve month follow-up questionnaire.  
 
Table 7.3: Estimated disease prevalence from national data 
ID Disease cohort Estimated disease prevalence (%)  
0 -CVD –OA 71.9 
1 +HYP –OA 21.3 
2 +IHD –OA 4.0 
3 +HF –OA 1.7 
4 -CVD +OA 3.4 
5 +HYP +OA 2.8 
6 +IHD +OA 1.1 
7 +HF +OA 0.3 
 
From this it was estimated that the registered populations at seven general practices would 
include enough patients for each disease cohort. The number of patients originally estimated 
to be invited into the 2C study and the estimated numbers retained after 12 months can be 
found in Table 7.4. The expected number of patients in the HF + OA group would be low but 
an anticipated sample size of 50 at 12 months would allow identification of a difference of 4 
points on the SF-12 PCS scale compared to the index OA cohort (power 80%, significance 
level 5%). 
 
The general practices which were included in the 2C study were not of equivalent size, 
ranging from a Practice with a registered population aged 40 years or older of 1,132 to a 
Practice with 8,790 patients aged 40 years or older. For the majority of disease cohorts, all of 
the patients fulfilling the disease criteria were invited. However, where numbers of patients 
exceeded that required for the disease category, due to high prevalence, then patients were 
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selected at random, weighted by practice population size. Random sampling was done for the 
hypertension and no OA group (1000 to be selected) and reference cohort (1500 to be 
selected). All those patients who were available for the disease cohort were included into an 
SPSS file (SPSS, Chicago, Illinois, Version 15.0) and using a randomisation application a 
specific number of IDs were selected by the software. 
 
Table 7.4: Number of patients invited into the 2C study at baseline  
ID Disease cohort Number invited 
into the study 
Estimated number remaining  
after twelve months 
0 -CVD -OA 1,500 700 
1 +Hyp -OA 1,000 500 
2 +IHD -OA 1,200 600 
3 +HF -OA 480 240 
4 -CVD +OA 1,000 500 
5 +Hyp +OA 800 400 
6 +IHD +OA 300 150 
7 +HF +OA 100 50 
 Total 6380 3140 
 
7.5. Survey design 
Collection of health data from the study sample was achieved through the use of postal 
questionnaire survey methods. Two questionnaire formats were implemented in the 2C 
study. Full patient health data was collected i) at baseline (Appendix 7.2) and then twelve 
months later (Appendix 7.3) and ii) at monthly intervals between these two time-points 
(Appendix 7.4). The primary focus of the 2C study was to gain a comprehensive 
understanding of health, including general and specific measures from the study sample 
twelve months apart. The second focus was for the study sample to also complete a much 
shorter questionnaire on a monthly basis, between the baseline and 12-month time points. 
This would provide understanding of short-term health changes experienced by the sample. 
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Patients who consented to take part in the 2C study agreed to the use of their health 
questionnaire data at baseline and to being sent a repeat questionnaire twelve months later. 
Therefore, baseline responders were sent the 12-month follow-up questionnaires only if they 
had agreed at baseline. Other exclusions were patients who had died during follow-up, left 
the practice or removed themselves from further participation in the study. Additional 
consent was required to receive the monthly questionnaires and also to access the patient 
records. 
 
The baseline and monthly questionnaires included generic and specific measures of health 
(Appendix 7.5). The range of measures will be addressed in brief, but physical health was 
the primary outcome of interest for this thesis, and therefore this will be detailed in this 
section. 
 
7.5.1. Baseline and 12-month follow-up questionnaires 
The full and main questionnaire was designed to acquire information on a range of health 
measures. The questionnaires were constructed using validated measures, and in English 
language versions. In addition several questions were included, predominantly to understand 
personal and demographic information i.e. gender (‘Are you Male or Female?’) or age (‘What 
is your date of birth’?). The measures used within this questionnaire were chosen to obtain 
information on four main areas of health. First area, were measures of general health. Second 
area, were measures of cardiovascular-specific health. Third area, were measures of pain and 
OA-specific health. Fourth and final area, were measures related to symptoms of chronic 
disease. 
 
 
 
 
 192 
 
7.5.1.1. Measures of general health 
The measurement of general health in patients to assess the impact of a disease is important. 
Though a disease may have a specific symptom profile, the impact of a disease on the overall 
well-being of patients is an important indicator to the clinician of progression of a disease or 
the patient’s improvement. Measuring general health also provides the opportunity to 
compare different diseases, which is not possible using a specific measure which has been 
tailored for a specific condition. 
 
Physical health was the primary outcome of interest for this study. The Short-Form 12 (SF-
12) health questionnaire is a widely used measure of general health which has been shown to 
be a valid measure for both physical and mental aspects (Hopman et al. 2009). Several other 
general health measures were included in the baseline and 12-month follow-up. The Hospital 
Anxiety and Depression (HAD) score was incorporated to provide an independent 
measurement of psychological health, in addition to the Mental Component Summary (MCS) 
score was also derived from the SF-12.  
 
7.5.1.2. Measures of cardiovascular disease 
CVD-specific measures included the: Seattle Angina Questionnaire (Spertus et al. 1995, 
Garratt et al. 2001), Kansas City Cardiomyopathy questionnaire (Green et al. 2000), Rose 
angina questionnaire (Luepker, World Health Organization. 2004) and symptoms of 
palpitations (Lok, Lau 1996) and dizziness (Nazareth et al. 2006). 
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7.5.1.3. Measures of osteoarthritis 
OA-specific measures included the: Knee injury and Osteoarthritis Outcome Score (KOOS – 
physical function component) (Perruccio et al. 2008), Hip injury and Osteoarthritis Outcome 
Score (HOOS – physical function component) (Davis et al. 2008) and pain scale, pain manikin 
(Lacey et al. 2005) and joint pain measures. 
 
7.5.1.4. Measures of chronic disease symptoms 
Other measures were included which have been linked in previous chronic disease literature 
in relation to the symptoms of tiredness and sleep. Measures included to record these 
included the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale (Cella et 
al. 2005) and the Medical Outcomes Study (MOS) Sleep measure (Hays et al. 2005). 
 
7.5.2. Monthly questionnaire 
Due to the high frequency with which patients would be receiving this questionnaire, content 
was reduced to several key measures from the baseline questionnaire. These four sections 
included measures of i) general health (SF-12), ii) physical activity, iii) body pain and iv) 
cardiovascular symptoms (Appendix 7.5).  
 
Though the aim was to achieve as high a response rate as possible from those consenting to 
receive the monthly questionnaires, the burden to patients was also considered. Therefore, 
the mailing process was designed to remove patients from the monthly mailing after three 
consecutive non-responses, though these patients would still receive the 12-month follow-up 
questionnaire unless they had explicitly requested to be withdrawn.  
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7.6. Recruitment process 
Patients selected from the general practices, which formed the study sample, were recruited 
by an initial letter of invitation (Appendix 7.6), accompanied by the baseline questionnaire, 
patient information sheet (Appendix 7.7) and a return envelope. This initial invitation letter 
carried the letterhead from the patient’s own practice; this is standard practice by the Centre 
and provides the patient with a recognisable point of reference to associate with the project, 
though all points of contact for the patient would be at the Centre. 
 
After two weeks, reminder postcards (Appendix 7.8) were mailed out to non-responders. If 
after a further two weeks (a total of one month after initial mail-out), no response had been 
received from a patient they were sent a repeat of the initial mail-out pack (Appendix 7.9). 
Patients were included into the study upon receipt of their completed baseline questionnaire, 
including their signed consent.  
 
By dividing the study design into two components this reduced the burden to patients where 
possible. Patients were provided with the opportunity to take part in all components of the 
study, but separating the survey into the main and monthly components allowed patients to 
select their level of involvement. Such a design provides the opportunity to all those invited 
to take part in the monthly component of study if they so wish, whilst retaining as many 
patients as possible in the primary construct to collect data at baseline and 12-month follow-
up (Figure 7.2). 
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Figure 7.2: 2C study mailing structure 
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7.7. 2C pilot study 
When using surveys to conduct observational research, two important issues which may 
influence the quality of data collected are i) selection bias and ii) measurement error. 
Selection bias relates to any bias which may influence the interpretation of data as a result of 
differences between those in the sample who did, and those who did not, complete the 
survey, e.g. a greater proportion of the sample who completes the survey are elderly. Such 
bias limits the generalisability of study results to the wider population from which the sample 
was drawn. Measurement error, specifically systematic error, occurs when the use of a 
measurement technique introduces a constant error into the data collected, e.g. the study 
sample consistently misses or incorrectly completes a particular measure or question but 
which is not a result of random error. 
 
The 2C study was based on two different questionnaire formats sent to a large sample at 
multiple time-points. It was therefore important to ensure that the methods used were 
appropriate to ensure the quality of the final data from the main, larger study and that any 
bias or error was minimised. Use of a pilot study, which mirrored the methods to be used in 
the main study, allowed for these methods to be tested on a smaller, more practical scale to 
allow estimation of any influences on the main study design. The pilot study took place prior 
to the undertaking of the 2C study to test aspects relating to i) patients acceptability of 
participating in such a high frequency survey and ii) the content of the questionnaire. 
 
 
 
 
 
 197 
 
7.7.1. Aim and objectives 
The aim of the pilot study was to assess the appropriateness of the proposed design of the 2C 
study in a single general practice. This included two objectives, 1) to examine the response 
rates to both the baseline questionnaire and single monthly questionnaire by patients across 
each disease cohort and 2) to assess the completion rates of each question within the baseline 
questionnaire and monthly questionnaire. 
 
7.7.2. Study design 
The 2C pilot study replicated the main 2C design as closely as possible, but due to the 
longitudinal follow-up, there were impracticalities of implementing exactly the same pilot 
design with this smaller sample. Two changes were made to the methods. Firstly a reminder 
system was not used and therefore non-responders at baseline were not sent reminder 
postcards or a repeat copy of the baseline questionnaire. Secondly, the study sample were 
sent the baseline questionnaire and (for those who consented) only one monthly follow-up 
questionnaire. This allowed for the estimation of the numbers likely to consent to be 
contacted on a monthly basis, but did not require a prolonged period of time to implement. 
 
7.7.2.1. Study sample  
Patients were selected from a single general practice based within the Stoke-on-Trent 
Primary Care Trust (PCT). This practice had a registered population of 7,905, of which 4,107 
(52%) patients were aged 43 years or older. After exclusion of patients who were already 
involved in other Centre studies, 4,057 (51%) patients remained available for the pilot 
sample.  
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From this single practice, a sample size of 500 patients was selected. On the basis of a 3-year 
record review, random samples of 125 patients were selected for patients without  CVD or OA 
(reference group), 125 patients with OA but no CVD, 125 patients with CVD but no OA, and 
125 patients with CVD and comorbid OA. Of the latter 250 patients, all those with heart 
failure, with or without OA, were selected, a random sample of those with hypertension with 
or without OA and those with IHD with or without OA were selected. 
 
7.7.3. Recruitment 
The only changes to the recruitment documents in the pilot study was to the consent form 
within the baseline questionnaire, which requested consent to a single, shorter questionnaire 
being sent after one month and other documents were only amended to state that the survey 
was a pilot study. 
 
7.7.4. Data analysis 
To assess the response rate for the 2C study, the proportion of the sample responding to the 
baseline questionnaire was examined in total, then stratified by disease cohort. From those 
responding at baseline the proportions consenting to i) follow-up at one month and ii) 
medical record review was also examined. 
 
From data acquired from both the baseline and one-month follow-up questionnaires, the 
completion rate of each question were assessed. These were examined by establishing the 
proportion of each question which contained either missing data (e.g.  no answer provided) 
or an ambiguous response (e.g. checking two answer boxes where only one was required). 
This assessed the extent to which each question was successfully completed. 
 
 
 199 
 
7.7.5. Results 
7.7.5.1. Survey response 
Of the 500 patients invited to take part in the 2C pilot study, 155 (31%) completed the 
baseline questionnaire. Only 3 patients with both heart failure and OA were identified at the 
practice and these numbers raised questions regarding the availability of patients for this 
disease cohort. Response to the remaining disease cohorts ranged from 25% of those with 
heart failure but no OA to 38% for those with OA but no CVD (Table 7.5). 
 
Of those patients who had responded at baseline, 139 (90%) consented to receive the 1-
month follow-up questionnaire, and of these 107 (77%) subsequently returned a complete 
one-month follow-up questionnaire. 133 (86%) of those who had responded to baseline 
consented to allowing the review of their medical records.  
 
Table 7.5: 2C pilot study patients who responded to the baseline questionnaire 
Disease cohorts Number mailed Baseline responders (%) 
-CVD –OA 125 32 (26) 
+Hyp –OA 25 9 (36) 
+IHD –OA 72 19 (26) 
+HF –OA 28 7 (25) 
-CVD +OA 125 47 (38) 
+Hyp +OA 83 26 (31) 
+IHD +OA 39 13 (33) 
+HF +OA 3 2 (67) 
Total 500 155 (31) 
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7.7.5.2. Questionnaire completion 
For the majority of measures in the baseline questionnaire, at least 90% of the responding 
sample answered each question. These measures tended to be these which were validated, of 
which the EQ-5D, SF-12 and MOS sleep measure were completed to a particularly high 
degree. At the minimum, 99%, 97% and 96% of patients completed these measures 
respectively. One measures for which the proportion of missing or ambiguous answers was 
higher was the Short Questionnaire to Assess Health Enhancing Physical Activity (SQUASH), a 
measure of physical activity.  
 
Measures within the monthly questionnaire were also completed well; with (one exception) 
at least 90% of the responding sample answering each question. For the SF-12, it was 
possible to calculate the PCS and MCS scores for 94% of those who responded to the one-
month questionnaire. 
 
7.7.6. Discussion 
The response of pilot general practice patients to the baseline survey was consistent for the 
majority of the disease categories. It is evident that those who had responded at baseline, 
were highly likely to also take part in the monthly component of the 2C study and consent to 
record review. Successful completion of the majority of survey measures within both the 
baseline and monthly questionnaires demonstrated the acceptability of the questionnaires to 
patients, but also demonstrated several areas which required minor amendment to improve 
rates of completion. 
 
An important consideration of the study design arose from the initial identification of the 
study sample. The presence of patients with heart failure, either with or without OA, was 
much lower than that expected based on previous rates of prevalence for this condition. 
Though this could have been a localised issue with this Practice, either as a result of actual 
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low prevalence or high mortality rates, it was decided to increase the recruitment of patients 
with heart failure in two ways. Firstly, additional heart failure related Read codes were 
introduced to the sample identification process. Originally it was considered that using the 
‘heart failure’ Read code (G58) would allow sampling to capture heart failure patients, but the 
limited numbers actually found suggested that this code may not be used as much as thought, 
therefore an additional code was used to ensure any differences in local general practice 
coding techniques did not result in missing these patients. Secondly, three additional general 
practices were added to the main study to increase the denominator population and 
therefore increase the number of available patients with heart failure. 
 
The increase in the number of practices from which to recruit would also increase the 
number of patients available in each disease cohort, and likely increase the chance of 
increased number of responders at baseline. Response at baseline was low for all disease 
cohorts, but such a response rate is likely without any reminder system in place and previous 
Centre research has demonstrated response rates of approximately 70%+ when reminders 
follow; the first round response of 31% was typical of previous Centre studies. The pilot 
study did demonstrate the encouraging response to the monthly questionnaire consent 
question. This may well be an over estimation as patients may be more likely to respond to 
the request to complete one questionnaire after one month rather than for the next ten 
months, but this would suggest that those who respond to baseline will be highly likely to 
also consent to the monthly follow-up stage of the 2C study. This was also the case for those 
consenting to record review, and again is similar to the proportion consenting in previous 
Centre surveys. 
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The baseline and monthly questionnaire formats were completed well and demonstrate the 
appropriate design of these two questionnaire formats. For the majority of survey measures, 
patients had no problem completing questions and where a question was missed or 
completed incorrectly this was for only 10% or less of the sample, depending on the question.  
 
Small minor clarifications, aesthetic changes were made to both questionnaires for the main 
2C study. The only more substantial change was made to the format of the SQUASH within the 
baseline questionnaire to simplify the answer options. For example, where the question had 
originally asked for ‘hours’ and ‘minutes’ performing an exercise activity, this was change to a 
single option of ‘time per day’. 
 
7.7.7. Conclusion 
This pilot study demonstrated that the methods proposed for the main 2C study were 
acceptable to both researchers and participants. Overall, conducting the larger, longitudinal 
survey-linkage study would be logistically plausible and would successfully acquire the 
required information, from the required patient groups. The pilot study did highlight that the 
2C study design would require an increase in initial study sample size, to account for a lower 
than expected prevalence of heart failure patients in the local area; it also highlighted the 
need to clarify several survey questions. These amendments would lead to a refinement of 
the design of the 2C study. 
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7.8. 2C study design amendments 
Two solutions were employed to address the low prevalence of heart failure patients. Firstly, 
the number of practices was increased from seven to ten. This new study population had a 
combined registered practice population of approximately 90,000, of which approximately 
46,000 (51%) would be aged 40 years or over. Based on the proportions responding in each 
disease cohort from the pilot study, new estimates were made of the total sample to approach 
and the numbers required within each disease cohort (Table 7.6) 
 
Table 7.6: Post-pilot estimated number of patients to be invited into the 2C study at baseline, 
based on the estimated loss to follow-up after twelve months 
Disease cohort Number invited 
into the study 
Estimated number remaining  
after twelve months 
-CVD -OA 2700 608 
+Hyp -OA 1500 473 
+IHD -OA 1600 504 
+HF -OA 680 214 
-CVD +OA 1350 425 
+Hyp +OA 1100 347 
+IHD +OA 420 132 
+HF +OA 130 41 
Total 9480 2744 
 
The second method to increase the number of the HF disease cohorts was to expand the 
number of Read codes used to search for HF patients, to ensure that none were missed as a 
result of variations in labelling methods used by local general practices during consultation. 
Therefore, patients were also selected for the 2C study if they had been labelled as having a 
New York Heart Association (NYHA) functional classification score. The NYHA classification is 
a clinical measure which classifies the extent of heart failure (New York Heart Association 
(NEW YORK). Criteria Committee. 1964), categorising the patients into one of four severity 
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groups. If the general practice records indicated that a patient had been classified by any one 
of these four categories then they would be invited to take part in the 2C study (Table 7.7). 
 
Table 7.7: Final selection of Read codes upon which the 2C study sample was selected  
Disease  Read Code Read Code description 
Cardiovascular disease G20 Hypertension 
 G3. Ischaemic heart disease 
 G58 Heart Failure 
 662f NYHA classification – class I 
 662g NYHA classification – class II 
 662h NYHA classification – class III 
 662i NYHA classification – class IV 
 792 Coronary artery operations 
Osteoarthritis N05 OA 
 7K2 Hip joint operations 
 7K3 Knee joint operations 
Italics: Additional Read codes introduced after pilot study 
 
 
7.9. Final study sample 
10,064 patients were initially identified to form the study sample to be invited to take part in 
the 2C study. 138 patients were excluded by Practices prior to the baseline mailing of the 
health survey. Patients were excluded based on Read codes indicating a serious or 
debilitation condition (i.e. terminal illness of mental health). Patients who formed this pre-
mailout exclusion group were from across all eight disease cohorts and from all ten practices. 
The proportion unavailable from the index heart failure and comorbid heart failure and OA 
cohorts was approximately double that of the other disease categories, 3.5% and 5.9% 
respectively compared with proportions ranging from 1.0% to 1.8% for the other six disease 
cohorts (Appendix 7.10).  
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9,926 patients were therefore invited to participate in the 2C study (Figure 7.4). During the 
mail-out period a further 250 patients were excluded. Patients were given four months from 
the date of mail-out to respond to the survey, those who were unable to respond were 
designated as exclusions. This group consisted of those who had died or left the practice, 
were withdrawn by someone else (e.g. a family member), had never received the survey as it 
was returned to the Centre as undelivered due to the incorrect address or was completed by 
the incorrect person. As with the pre-mailout period, exclusions were more likely for those 
with heart failure, with or without OA, than the other groups. Therefore, the eligible study 
population for the 2C study consisted of 9,676 patients. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4: Baseline sampling frame 
 
250 excluded during mailing 
 
184 deaths and departures 
15 withdrawn from study 
43 incorrect people completed 
8 returned addresses unknown 
 
Study population mailed  
baseline health survey 
= 9,926 
Eligible for baseline health survey 
= 9,676 
Patients to be invited into 2C study 
= 10,064 
138 pre-mailout exclusions 
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7.9.1. Characteristic of the eligible study sample 
The characteristics of each of the disease cohorts are provided in Table 7.8. The breakdown 
by disease cohort of the 9,676 people aged 40 years and over who were identified as the 
eligible study sample was as follows: 2,535 (26%) without CVD or OA; CVD index groups 
without OA – 1,322 (14%) with hypertension, 2,036 (21%) with ischaemic heart disease, 259 
(3%) with heart failure; 1,317 (14%) in OA index group without CVD, and CVD groups with 
comorbid OA – 1,644 (17%) with hypertension, 490 (5%) with ischaemic heart disease, 73 
with heart failure (1%). 
 
The reference group, those without CVD or OA, was composed of the younger population, and 
around 69% were aged 59 years or younger. It had an equivalent number of men and women, 
and around 20% in the top or bottom categories of deprivation. Of the index CVD cohorts 
without OA, the youngest age groups were in the hypertension cohort (30% aged 59 years 
and younger), and the oldest groups were in the heart failure cohort (69% aged 70 years and 
over). There were more men than women in both the IHD and heart failure cohorts, and a 
quarter of the heart failure cohort had the most deprived status. Most of the index OA 
category was aged between 50 and 80 years of age, and there were more women than men. 
The age figures were in contrast to the index CVD cohorts who had a higher number in the 
age group 70 year and over, but the deprivation figures were similar. 
 
The comorbid groups were relatively older than the index groups and the age proportion for 
the group 70 years and over were: 57% in the hypertension comorbid group, 73% in the IHD 
comorbid group and 93% in the heart failure comorbid group. There were more women than 
men with CVD and comorbid OA for all three groups, and IHD comorbid group had relatively 
fewer numbers in the top and bottom deprivation categories. 
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7.10. Summary 
Through a pilot study, the design of the 2C study was tested and refined. This was particularly 
necessary due to need for identifying comorbidity cohorts. The final eligible study sample 
included over 9,500 general practice patients across all of the disease cohorts. From this 
eligible study sample the next chapter will examine the cross-sectional associations between 
cardiovascular disease severity and OA comorbidity and physical health.  
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Table 7.8: Characteristics of the 2C eligible study population (n = 9,676) 
 
*Deprivation status calculated for: 2,530 of –CVD –OA, 1,315 for +Hyp –OA, 2,030 for +IHD –OA, 259 for +HF –OA, 1,312 for -CVD +OA, for 1,634 for +Hyp +OA, 485 
for +IHD +OA and 71 for +HF +OA cohorts
  Disease cohorts 
  Reference 
 cohort 
 Index cohorts  Comorbid cohorts 
Factors  -CVD -OA 
n= 2535 (%) 
 +Hyp -OA 
n= 1322 (%) 
+IHD -OA 
n= 2036 (%) 
+HF -OA 
n= 259 (%) 
-CVD +OA 
n= 1317 (%) 
 +Hyp +OA 
n= 1644 (%) 
+IHD +OA 
n= 490 (%) 
+HF +OA 
n= 73 (%) 
            
Age group  
(years) 
40-49 892 (35.2)  106 (8.0) 72 (3.5) 5 (1.9) 138 (10.5)  33 (2.0) 4 (0.8) 0 (0) 
50-59 848 (33.5)  291 (22.0) 275 (13.5) 22 (8.5) 309 (23.5)  172 (10.5) 22 (4.5) 1 (1.4) 
60-69 513 (20.2)  416 (31.5) 617 (30.3) 54 (20.8) 445 (33.8)  499 (30.4) 106 (21.6) 4 (5.5) 
70-79 195 (7.7)  329 (24.9) 677 (33.3) 82 (31.7) 278 (21.1)  554 (33.7) 203 (41.4) 23 (31.5) 
80≥ 87 (3.4)  180 (13.6) 395 (19.4) 96 (37.1) 147 (11.2)  386 (23.5) 155 (31.6) 45 (61.6) 
            
Gender Male 1245 (49.1)  609 (46.1) 1334 (65.5) 142 (54.8) 563 (42.7)  611 (37.2) 205 (41.8) 31 (42.5) 
 Female 1290 (50.9)  713 (53.9) 702 (34.5) 117 (45.2) 754 (57.3)  1033 (62.8) 285 (58.2) 42 (57.5) 
            
Deprivation  
Status* 
Category 0  
(most affluent) 
525 (20.8)  266 (20.2) 368 (18.1) 38 (14.7) 267 (20.3)  327 (20.0) 86 (17.7) 13 (18.3) 
Category 1 1521 (60.1)  786 (59.8) 1251 (61.6) 156 (60.2) 808 (61.6)  980 (60.0) 310 (63.9) 43 (60.6) 
Category 2  
(most deprived) 
484 (19.1)  263 (20.0) 411 (20.3) 65 (25.1) 237 (18.1)  327 (20.0) 89 (18.4) 15 (21.1) 
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Chapter 8: Association between comorbidity and physical 
health: 2C cross-sectional study 
 
Following on from the 2C methods detailed in the previous chapter, this chapter will explore 
the baseline relationship between cardiovascular disease (CVD) severity & comorbid 
osteoarthritis (OA) and physical health. This chapter will provide an understanding of how 
index diseases interact with comorbidity in the general practice population and how disease 
severity influences the association with physical health. 
 
8.1. Introduction 
Though previous research has demonstrated the importance of comorbidity in both CVD and 
OA populations, there has been little evidence on the specific interactions between these two 
common disease combinations, and how it influences health outcomes. Therefore, the 
interest here was in understanding, for the measure of physical health, whether the comorbid 
interaction was the sum of individual ‘effects’ (additive) or more than the sum of individual 
‘effects’ (synergistic). Furthermore, it is also unclear how having conditions of differing 
severity within a chronic disease population, for example CVD, combined with comorbidity 
may influence the physical health of the patient. Previously, Kadam et al found that in their 
OA sample drawn from general practice, increasing comorbid severity was associated with 
poorer physical health, and such interaction appeared to be synergistic (Kadam, Croft 2007). 
 
In the majority of previous studies, CVD or OA comorbidity was based on overall morbidity 
counts and not a specific disease combination. As a result of using such a method, identifying 
the contribution of each disease to the health experience within those forming the 
comorbidity was not possible. However, these studies have demonstrated the negative 
influence of comorbidity on the physical health of CVD or OA samples. There are few studies 
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which have examined interaction between comorbid conditions, and each has its limitations, 
either examining wide disease concepts (i.e. arthritis) (Verbrugge, Lepkowski & Imanaka 
1989), in a specific sample group (i.e. women only) (Fried et al. 1999) or defining 
comorbidity as morbidity index rather than disease pair (Kadam, Croft 2007). 
 
These results suggest that not only does the presence of CVD & OA impact negatively on the 
health of the patient population, but that this impact may vary depending on the combination 
of conditions. However, previous research has not examined (i) the associations between 
different CVD & OA comorbidity and the physical health of a general practice population nor 
ii) how the severity of different CVD populations may influence these associations.  
 
Using the baseline survey of the 2C study allowed for cross-sectional analysis of CVD severity 
and comorbid OA. The hypothesis tested was that, as CVD severity increased, physical health 
would be worse and that, for those with CVD severity groups & OA comorbidity, the self-
reported physical health would be worse than for those with index CVD groups. 
 
8.2. Aim & objectives 
8.2.1. Aim 
The aim of this cross-sectional study was to examine the association of defined comorbid 
chronic disease groups from general practice, and physical health and examine the role of 
relative severity on this association. 
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8.2.2. Objectives 
The objectives of this study were: 
1) To investigate the association between CVD & OA comorbidity and physical health 
2) To investigate the association between CVD severity and OA comorbidity and physical 
health 
 
8.3. Methods 
8.3.1. Study design 
Full study methods were reported in the previous Chapter 7. In brief, the 2C study population 
were aged 40 years and over, sampled from clinical records using specific standard clinical 
codes in their records over three years (staged over November 2006 – November 2009, 
mailed January 2010). The selected disease groups were ordered a priori, with three CVD 
categories ranging in severity from hypertension (least severe) to IHD to HF (most severe). In 
the same 3-year time period before baseline survey, patients with OA diagnoses in their 
clinical records were also identified. Using the presence or absence of CVD or OA diagnosis, a 
total of eight disease cohorts were constructed: 1) a random reference group of patients 
without CVD or OA, 2) three index CVD groups without OA (hypertension, IHD, HF), 3) a 
random index OA group without any of the CVD conditions, and 4) three CVD comorbid 
groups with OA. All index or CVD comorbid groups were mutually exclusive.  
 
The Physical Component Summary (PCS) score from the Short-Form-12 (SF-12) Health 
Survey, present in the baseline questionnaire was the primary ‘outcome’ measure (Ware, 
Kosinski & Keller 1996). This score is normalised to the general US population mean of 50 
(SD 10), scores below 50 indicate worse physical health than the general population (Ware et 
al. 2002). Other survey data included age, gender and deprivation status. The level of 
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neighbourhood deprivation for each patient was derived using the Index of Multiple 
Deprivation (IMD) 2007 (Communities and Neighbourhoods 2008). 
 
8.3.2. Data analysis 
The study sample was categorised by age, gender and deprivation status. Age was categorised 
into five groups 40-49, 50-59, 60-69, 70-79 or 80 years or older. The Index of Multiple 
Deprivation (IMD 2007) status was categorised into three groups, those with the 20% least 
deprived scores, the 20% most deprived scores and the middle 60% (Ashworth et al. 2007). 
 
The PCS score, generated from the SF-12 was used as the primary ‘outcome’ measure for this 
baseline analysis of the 2C study. For each disease group the mean PCS score with the 95% 
confidence interval (95% CI) was determined. The associations between index disease or 
CVD comorbid groups with physical health were analysed using linear regression. The PCS 
score was the dependent variable, the disease cohorts as the independent variables, and the 
cohort who had neither CVD nor OA acted as the reference group. Analyses were adjusted for 
age, gender and deprivation status. 
 
The potential interaction between CVD severity groups and OA was then assessed, by 
comparing the ‘observed’ PCS scores for each CVD and OA comorbid group from the linear 
regression with the estimated and ‘expected’ PCS score. Expected PCS scores for each of the 
three CVD and OA comorbid groups were calculated by combining the PCS scores from the 
index groups. For example, the ‘expected’ PCS score for the hypertension & comorbid OA 
group would be calculated by combining the PCS score of the index hypertension group 
(without OA) with the PCS score of the index OA group. If the observed estimate was greater 
than ‘expected’, then the interaction was greater than additive, and if the observed estimate 
was less than ‘expected’, then the interaction was less than additive. 
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8.4. Results 
8.4.1. Study sample 
5,426 (56%) patients responded to the baseline 2C survey. 1,165 (21%) of these patients 
formed the reference cohort and had not consulted for either CVD or OA (-CVD -OA) in the 
three years before baseline. Of the index CVD cohort, 720 (13%) had index hypertension, 
1,196 (22%) had index IHD, 149 (3%) had index HF and 828 (15%) of patients had a 
previous consultation for OA but no CVD. From CVD cohorts with comorbid OA, 1,017 (19%) 
had hypertension & OA, 305 (6%) had IHD & OA and 46 (1%) had HF & OA. 
 
The socio-demographic characteristics of responders to the baseline survey with a Short-
Form 12 score (5,176) are given in Table 8.1. The mean age of this sample was 67 years of 
age (SD 12) and the reference cohort were the youngest, with a mean of 57 years of age (SD 
10). Over half of the patients from the IHD and HF index cohorts and all three comorbid 
cohorts were aged 70 years or older. Only the IHD and HF index cohorts had more men than 
women. In terms of deprivation status, only the OA index cohort were more likely to be from 
the least deprived category than the most deprived category. The socio-demographic 
characteristics between the CVD index without OA and CVD comorbid groups with OA were 
similar. 
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Table 8.1: Characteristics of baseline responders, with a Physical Component Summary score stratified by disease cohort (n = 5,176) 
CVD=Cardiovascular disease, OA=Osteoarthritis, Hyp=Hypertension, IHD=Ischaemic heart disease, HF=Heart failure. *Deprivation status is based on 5,151 and 
measured using the Index of Multiple Deprivation 
 
  Disease categories 
Factors  -CVD -OA 
n=1141 (%) 
+Hyp -OA 
n=688 (%) 
+IHD -OA 
n=1140 (%) 
+HF -OA 
n=141 (%) 
-CVD +OA 
n=788 (%) 
+Hyp +OA 
n=953 (%) 
+IHD +OA 
n=284 (%) 
+HF +OA 
n=41 (%) 
          
Age group  
(years) 
40-49 308 (27.0) 33 (4.8) 21 (1.8) 3 (2.1) 59 (7.5) 9 (1.0) 1 (0.3) 0 (0) 
50-59 409 (35.8) 132 (19.1) 123 (10.8) 9 (6.4) 176 (22.4) 90 (9.4) 11 (3.9) 0 (0) 
60-69 277 (24.3) 229 (33.3) 360 (31.6) 25 (17.7) 298 (37.8) 300 (31.5) 65 (22.9) 3 (7.3) 
70-79 113 (9.9) 209 (30.4) 426 (37.4) 49 (34.8) 172 (21.8) 345 (36.2) 128 (45.1) 14 (34.2) 
80≥ 34 (3.0) 85 (12.4) 210 (18.4) 55 (39.0) 83 (10.5) 209 (21.9) 79 (27.8) 24 (58.5) 
          
Gender Male 535 (46.9) 314 (45.6) 775 (68.0) 85 (60.3) 312 (39.6) 367 (38.5) 132 (46.5) 20 (48.8) 
 Female 606 (53.1) 374 (54.4) 365 (32.0) 56 (39.7) 476 (60.4) 586 (61.5) 152 (53.5) 21 (51.2) 
          
Deprivation  
Status* 
Category 0  
(most affluent) 
276 (24.2) 150 (21.9) 237 (20.9) 22 (15.6) 161 (20.5) 211 (22.3) 57 (20.3) 7 (17.5) 
Category 1 695 (61.0) 410 (60.0) 694 (61.1) 87 (61.7) 497 (63.4) 564 (59.6) 176 (62.9) 25 (62.5) 
Category 2  
(most deprived) 
169 (14.8) 124 (18.1) 205 (18.0) 32 (22.7) 126 (16.1) 171 (18.1) 47 (16.8) 8 (20.0) 
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8.4.2. Physical health of disease cohorts 
Patients who had consulted their general practice in the three years before the baseline 
survey, but had not consulted for a CVD or OA Read code had the highest mean baseline PCS 
score (best physical health) of 49.7 (95% confidence interval 49.1-50.2).  
 
All three of the index disease cohorts with CVD had worse physical health than patients 
without CVD or OA. Furthermore, as the relative morbidity severity of the CVD populations 
increased, the PCS score of these patients decreased (worsening physical health). A trend was 
apparent for these PCS scores, ranging from 43.3 (95% CI 42.4-44.2) for index hypertension, 
38.1 (95% CI 37.5-38.8) for index IHD and 30.6 (95% CI 28.9-32.3) for index HF. The disease 
cohort who had OA, but no CVD condition had worse physical health than those with no CVD 
or OA consultation and was comparable to the index IHD cohort, 38.8 (95% CI 38.0-39.7).  
 
Compared to the index disease cohorts, the CVD comorbid cohorts had worse PCS scores. As 
in the spectrum of index CVD cohorts, increasing CVD severity and OA was associated with 
worsening physical health. The mean PCS scores for these three comorbid cohorts ranged 
from 34.7 (34.0-35.5) for hypertension & OA, 31.2 (95% CI 30.0-32.5) for IHD & OA and 26.9 
(23.8-30.0) for HF & OA (Figure 8.1 & Table 8.2). 
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Figure 8.1: Mean Physical Component Summary score (95% confidence interval) by disease cohort  
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Table 8.2: Associations between disease cohorts and physical health  
     Linear regression analysis 
Disease  
groups  
Study sample (n=5,176) 
n (%) 
Age 
Mean (SD) 
 PCS score 
Mean (95% CI) 
Unadjusted  
Mean (95% CI) 
Adjusted*   
Mean (95% CI) 
 
Reference 
      
-CVD -OA 1141 (22.0) 57.2 (10.0)  49.7 (49.1, 50.2) Ref Ref 
       
 
Index 
      
+Hyp -OA 688 (13.3) 67.2 (10.5)  43.3 (42.4, 44.2) -6.3 (-7.4, -5.3) -3.1 (-4.2, -2.0) 
+IHD -OA 1140  (22.0) 70.6 (9.7)  38.1 (37.5, 38.8) -11.5 (-12.5, -10.6) -8.3 (-9.3, -7.2) 
+HF -OA 141 (2.7) 75.6 (11.1)  30.6 (28.9, 32.3) -19.0 (-21.0, -17.0) -13.8 (-15.8, -11.8) 
-CVD +OA 788 (15.2) 65.1 (10.5)  38.8 (38.0, 39.7) -10.8 (11.9, -9.8) -8.6 (-9.6, -7.5) 
       
 
Comorbid 
      
+Hyp +OA 953 (18.4) 71.4 (9.3)  34.7 (34.0, 35.5) -14.9 (-15.9, -13.9) -10.7 (-11.8, -9.6) 
+IHD +OA 284 (5.5) 74.5 (8.6)  31.2 (30.0, 32.5) -18.4 (-19.9, -16.9) -13.2 (-14.8, -11.7) 
+HF +OA 41 (0.8) 79.9 (7.6)  26.9 (23.8, 30.0) -22.8 (-26.3, -19.2) -16.0 (-19.3, -12.7) 
*Adjusted for age, gender and deprivation status; physical health measured by the Physical Component Summary score 
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8.4.3. Associations between disease cohorts and physical health 
Adjusting for age, gender and deprivation, reduced the strength of associations between all 
cohorts and poor physical health (Table 8.2). However, relative to the reference cohort, the 
PCS scores for the index and CVD comorbid cohorts were still lower. Increasing index CVD 
severity was associated with worse physical health and CVD comorbid groups with OA had 
the worst adjusted PCS scores. Compared to the reference cohort, the adjusted mean PCS 
score for the three CVD index cohorts without OA, hypertension was 3.1 points lower (95% CI 
-4.2 to -2.0), IHD was 8.3 points lower (-9.3 to -7.2) and HF was 13.8 points lower (-15.8 to -
11.8). The index OA cohort was 8.6 points lower (-9.6 to -7.5). Compared to the reference 
cohort, the hypertension group with comorbid OA had adjusted mean PCS score which was 
10.7 points lower (95% CI -11.8 to -9.6), the comorbid IHD group was 13.2 points lower 
(95% CI -14.8 to -11.7) and the comorbid HF cohort was 16.0 points lower (95% CI -19.3 to -
12.7). 
 
The observed interaction estimates for the CVD comorbid cohorts were less than expected by 
adding the individual estimates for the respective index CVD and index OA cohort. Based on 
combined estimates for the index CVD and index OA cohort, the expected estimate for 
hypertension comorbid cohort would be -3.1 (index hypertension) + -8.6 (index OA) = -11.7, 
for IHD comorbid cohort would be -8.3 (index IHD) + -8.6 (index OA) = -16.9 and for HF 
comorbid cohort would be -13.8 (index HF) + -8.6 (index OA) = -22.4. So whilst adding OA to 
CVD cohorts was associated with worse health, the observed comorbid ‘effect’ was less than 
additive when compared with expected estimates (Figure 8.2). 
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Figure 8.2: Observed vs. expected estimates of Physical Component Summary scores of index cardiovascular disease with comorbid OA 
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8.4.4. Responders vs. non-responders 
5,426 (56%) patients responded to the baseline health questionnaire and formed the cross-
sectional study sample of the 2C study The socio-demographic characteristics of baseline 
responders are given in Appendix 8.1. 4,250 (44%) patients were classified as non-
responders, by failing to respond to the baseline questionnaire, returning a blank 
questionnaire or specifically contacting the Centre and requesting to be removed from the 
study. Across the disease cohorts, index OA without CVD and the comorbid CVD & OA cohorts 
had the greatest proportions of responders, 62% - 63% in both. The lowest proportion of 
responders was from the reference cohort with no CVD or OA (46%) (Table 8.3). 
 
The socio-demographic characteristics of each response category are given in Table 8.4. 56% 
of responders to the baseline questionnaire were aged 69 years or under, making them an 
older sample than the original study sample (61% aged 69 years or under). There was no 
difference in the gender of the eligible sample and subsequent responders, but responders 
were more likely to have a more affluent deprivation status. There was no difference between 
those who responded to the baseline questionnaire and those who responded to the 
questionnaire but failed to complete the SF-12.  
 
The socio-demographic characteristics of non-responders are given in Appendix 8.2. Non-
responders to the baseline questionnaire were younger than responders (66% aged 69 years 
or under). Mean age of non-responders was 63.5 (SD 13.3), with over half of patients in the 
index HF and the three comorbid cohorts being aged 70 years or older. Except for the 
reference cohort and the index IHD cohort, women were more likely to be non-responders 
than men in each cohort, with women in the comorbid cohorts being twice as likely as men 
not to respond to the baseline questionnaire. Across all of the disease cohorts, non-
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responders were more likely to be from the most deprived category of deprivation status 
than from the most affluent category. 
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Table 8.3: Response of baseline population by each disease cohort  
 
CVD=Cardiovascular disease, OA=Osteoarthritis, Hyp=Hypertension, IHD=Ischaemic heart disease, HF=Heart failure. Disease categories (defined by study specific 
Read codes in the 3 years prior to baseline survey: -CVD -OA=Patients with no CVD condition or OA; +CVD -OA=Patients with CVD but no OA; +Hyp -OA= Patients 
with hypertension but no OA; +IHD -OA= Patients with ischaemic heart disease but no OA; +HF -OA= Patients with heart failure but no OA; +Hyp +OA= Patients 
with hypertension and OA;  +IHD +OA= Patients with ischaemic heart disease and OA;  +HF +OA= Patients with heart failure and OA   
 
 
Disease cohort  Study sample 
N = 9676 
n (%) 
 Non-responders 
n=4250 
n (%) 
 Responders 
n=5426 
n (%) 
      
-CVD -OA 2535  1370 (54)  1165 (46) 
      
+Hyp -OA 1322  602 (46)  720 (54) 
+IHD -OA 2036   840 (41)  1196 (59) 
+HF -OA 259  110 (42)  149 (58) 
      
-CVD +OA 1317   489 (37)  828 (63) 
       
+Hyp +OA 1644  627 (38)  1017 (62) 
+IHD +OA 490  185 (38)  305 (62) 
+HF +OA 73  27 (37)  46 (63) 
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Table 8.4: Characteristics across study response categories 
Factors  Eligible 2C study sample 
(N = 9676) 
n (%) 
Responders 
(n=5426) 
n (%) 
Responders with PCS score 
(n = 5176) 
n (%) 
Non-responders 
(n=4250) 
n (%) 
      
Age groups  
(years) 
40-49 1250 (13) 439 (8) 434 (8) 811 (19) 
50-59 1940 (20) 964 (18) 950 (19) 976 (23) 
60-69 2654 (28) 1613 (30) 1557 (30) 1041 (24) 
70-79 2341 (24) 1538 (28) 1456 (28) 803 (19) 
80≥ 1491 (15) 872 (16) 779 (15) 619 (15) 
      
Gender Male 4740 (49) 2653 (49) 2540 (49) 2087 (49) 
 Female 4936 (51) 2773 (51) 2636 (51) 2163 (51) 
      
Deprivation  
Status* 
Category 0 (most affluent) 1890 (20) 1157 (22) 1121 (22) 733 (17) 
Category 1 5855 (60) 3302 (61) 3148 (61) 2553 (60) 
Category 2 (most deprived) 1891 (20) 940 (17) 882 (17) 951 (23) 
*Deprivation status available for: 9,636 of 2C study sample, 4,237 non-responders, 5,599 responders and 5,151 responders with PCS score 
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8.5. Discussion 
This study shows that increasing CVD severity was associated with poorer physical health. 
The comorbid addition of OA increased the strength of association between exclusive index 
hypertension, IHD and heart failure cohorts and poor physical health. However, in this 
baseline analyses, the combined interaction ‘effect’ of CVD and OA was found to be less than 
additive, and other factors such as age, gender and deprivation status did not explain the 
associations. The implications of these findings are that both relative morbidity severity and 
comorbidity are associated with poor health, and therefore both need to be taken into 
account in strategies aimed at either health improvement or prevention of health 
deterioration. 
 
8.5.1. Index disease and physical health 
In the index CVD cohorts, the heart failure cohort had worse baseline health than the IHD 
cohort, which had worse health than the hypertension cohort. Estimates found in this study 
were comparable to other QOL studies. In hypertension, the PCS scores (43.3) reflected 
values recorded in studies conducted in general population samples from Spain (PCS score 
43.2), Germany (42.9) and the USA (43.7) (Cunillera et al. 2010, Wang et al. 2008, Ware, 
Kosinski & Keller 1994). The PCS score from the IHD cohort (38.1) was comparable to several 
general population samples from the USA (37.1), Italy (37.5), Germany (38.3) and Denmark 
(37.6) (Alonso et al. 2004) and a UK study found similar physical health experienced by heart 
failure patients from general practice (32.6) (Gott et al. 2006) as the 2C study (30.6). The 2C 
study, along with these external studies, show that ‘severity’ definition applied to diagnostic 
CVD and OA morbidity based on routine chronic disease recording is associated with 
population-level reporting of poor health. 
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OA patients had worse baseline physical health than the reference cohort, which was also 
comparable to other studies of individual OA on physical health as measured by the Short-
Form. In a Spanish sample drawn from general practice, OA patients reported a PCS score of 
35.1 (Loza et al. 2009) and in two general population samples from the Netherlands and the 
US, PCS scores were 39.8 and 38.9 respectively (Picavet, Hoeymans 2004, Ware, Kosinski & 
Keller 1994). The physical health estimate for the index OA cohort (38.8) was similar to the 
index IHD cohort (38.1), and this was similar to the results described in Chapter 5. 
 
8.5.2. Cardiovascular disease and comorbid osteoarthritis and physical 
health 
In terms of CVD severity comorbid with OA, these findings show that all CVD comorbid 
cohorts had much worse physical health than the index cohorts. There have been no previous 
studies which have been designed a priori to test the interaction between common chronic 
diseases such as CVD and OA. These findings are unique as the design tested the hypotheses 
of the combined ‘effect’ of CVD severity and comorbid OA on physical health. The combined 
‘effect’ appeared additive (Ahlbom, Alfredsson 2005) for the hypertension and OA cohort, but 
less than additive for the IHD & OA and HF & OA comorbid cohorts.  
 
Implications for the baseline comorbid interactions need to be interpreted in terms of age, 
health measurement and ‘true’ disease interaction. The HF cohort was the oldest, so the 
addition of a chronic disease such as OA may not lead to much worse health since the HF has 
already contributed to poor health. Instruments such as the Short-Form may also be prone to 
‘floor effects’, where patients with HF report such poor health that the instrument is unable 
to pick up any worse health with the addition of conditions. However, the study shows that 
the combined influence of CVD severity and comorbid OA was still greater than the index 
influences, which suggests that interaction was observed in relation to self-reported physical 
health. This was not explained by age, gender and deprivation, and previous evidence has 
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shown the possibility of such interaction (Kadam, Croft 2007). Furthermore, other types of 
comorbidity are an unlikely explanation since the index cohorts would, in general, also have 
‘other comorbidity’ and this provides the basis for assessing the individual influence of the 
specified CVD and OA diagnostic categories. Therefore, the clinical implications suggest that 
both the relative morbidity severity, which can be based on exclusive diagnostic categories 
and comorbidity, may provide the simple and practical basis of identifying patients with 
poorer physical health in routine general practice.  
 
8.5.3. Responders vs. non-responders 
The response rate to the baseline health survey was 56%. Patients who did not consult for a 
CVD or OA disease (reference cohort) were the least likely to respond to the baseline survey 
(46%). Based on previous Centre research, it was anticipated that this category would have a 
higher proportion of non-responders and the study sample was adjusted accordingly to 
recruit a larger proportion of this group (Chapter 7). Potential reasons for this cohort’s lower 
response may be that these patients have not taken part as they did not perceive the 
relevance of the study to their current circumstances. This could have been because, as the 
‘healthier’ cohort, they are not as likely to be presently experiencing symptoms at initial 
recruitment. 
 
This study found that the more severe the disease cohort the greater the response rate. In 
contrast to the reference cohort, refusals to take part in the study by these severe cohorts 
may be a reflection of poor health. Patients who are experiencing difficulties in their life due 
to poor health may not partake as they feel this places additional burden on themselves. Non-
responders were also younger than responders and a greater proportion of these were also 
categorised into the most deprived proportion of the study sample. 
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8.5.4. Strengths & limitations 
8.5.4.1. Strengths  
The Comorbidity Cohort (2C) study is a large scale population-based study that has been 
designed to test the specific interaction between CVD and OA. The disease cohorts were 
selected, in the case of CVD, on the basis of chronic disease registers which are part of 
performance incentives (Lester, Campbell 2010). Whilst OA is not part of chronic disease 
registers, the practices participating in the study are part of an active research network, and 
other studies have shown the validity of identifying chronic disease samples which were 
recorded in actual consultations using standard coding classifications. The 2C study is also 
designed to enable survey data to be linked with general practice records. 
 
8.5.4.2. Limitations 
The SF is a widely used and valid instrument to measure physical health, but may have 
limitations, such as a floor effect in the oldest populations with the poorest health (Andresen 
et al. 1999), which means that the study might not have captured the real influence of the 
chronic diseases on poor physical health. Population surveys are dependent on the number of 
people who participate, and responders and non-responders were compared. Baseline survey 
responders were older and had a more affluent status than non-responders which will limit 
the generalisability of the findings. Having a reduced response rate from those who are more 
deprived is a particular issue as this demographic have been shown to experience more 
morbidities and earlier in life than those who are more affluent (Verbrugge, Juarez 2008, 
Barnett et al. 2012). Finally, our study focused on physical health, and other measures of 
health, such as psychological health and healthcare outcomes may show different comorbid 
interactions.  
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8.6. Conclusions 
Increasing severity of CVD was associated with poorer physical health. The comorbid 
addition of OA increased the strength of association between CVD severity and poor physical 
health. Relative morbidity severity and comorbidity are both important physical health 
influences and management and treatment models need to be developed to address these. 
Though it is well known that chronic diseases are associated with worse physical health and 
progression of poor health, the comorbid impact and interaction of different diseases and 
their severity on health now needs further investigated, as do how such interactions may 
change physical health over time.            
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Chapter 9: Associations between comorbidity and physical 
health change: 2C cohort study - 4 months and 12 months 
follow-up 
 
In this chapter, the associations between baseline 2C disease cohorts and prospective 
physical health change at 4 month and 12 month time-points were examined. This study will 
test the interaction between cardiovascular disease (CVD) severity & osteoarthritis (OA) 
comorbidity and influence on health change over two different short-term time points. The 
hypothesis tested was that comorbid cohorts interact to cause a greater and more rapid 
deterioration in health compared to the reference and index cohorts. 
  
9.1. Introduction 
There are few prospective studies of CVD comorbidity or OA comorbidity in general practice 
samples (Table 2.1). Limitations of the existing prospective literature include; using wide 
definitions of comorbidity (i.e. counts measure) (Bayliss et al. 2004, White et al. 2011) or 
wide definitions of chronic disease (i.e. arthritis) (Kriegsman, Deeg & Stalman 2004), 
examining comorbidity ‘post-hoc’ (Peters et al. 2005) or examining comorbidity of 
concomitant diseases (Maatouk et al. 2012). Furthermore, all this previous research has 
examined the consequences of comorbidity over the long-term, with follow-up ranging from 
2-year to 5-year (Sherbourne et al. 1996). Only Ettinger et al has examined the prospective 
consequences of interaction of CVD & OA comorbidity in general practice. They showed a 
significant interaction between hypertension & OA on physical functioning at 10-year follow-
up compared to those with individual hypertension or individual knee OA. However, though 
there was a strong association between knee OA & comorbid heart disease and poor physical 
functioning after 10 years, there was no significant interaction of this comorbidity compared 
to those with individual knee OA or individual heart disease (Ettinger et al. 1994).  
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There is limited and specific research into potential short-term outcomes of chronic disease 
comorbidity. Though prospective research has investigated the consequence of chronic 
diseases on physical health change over a number of years (Brown et al. 1999, Dervin et al. 
2003, Roux et al. 2005, Boini et al. 2006), there has been little comorbidity research on 
whether physical health may change on a month-by-month basis. The extent to which a 
comorbidity impacts on the health of patients may not be consistent over the course of a 
chronic disease, and changes may occur in the short-term as well as over the long-term time-
period. 
 
Other literatures considered in relation to short-term physical health change are studies 
which focused on CVD only or OA only. Van Jaarsveld et al examined the longitudinal 
influence of individual CVD on change in physical functioning over the course of 12-months, 
across three follow-up time points and in different CVD conditions, in a general practice 
sample. The sample was recruited by either having a record of myocardial infarction (MI) or 
heart failure (HF). Change in physical functioning was recorded using the Groningen Activity 
Restriction Scale (GARS) which was included within a survey at each time-point. The mean 
GARS was recorded at 6 weeks, 6 months and 12 months. Those with MI experienced a 
decline in physical functioning 6-weeks after diagnosis, but there was no further significant 
change in physical functioning either 6-months or 12-months later. However, those with HF 
experienced significantly worse physical functioning from baseline to 6-weeks and a further 
significant decline from 6-weeks to 12-months (van Jaarsveld et al. 2001).  
 
In contrast to the findings of van Jaarsveld, a study by Sidorov et al observed no significant 
change in the PCS score of HF patients over 12-months. Using US data of patients with health 
insurance and a previous claim through their Health Maintenance Organisation (HMO) for HF, 
they found that even those who had undergone an intervention of education about their 
condition saw no change in their physical health (Sidorov et al. 2003). 
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Information on the rate at which OA progresses and the causes behind any physical health 
changes is also limited (Arden, Nevitt 2006). In a Canadian study of the general population 
seeking pain relief for knee pain from pharmacists, who were subsequently diagnosed with 
OA, physical health (PCS score) was shown to improve after 6 months (Grindrod et al. 2010). 
The contrasting influence of individual chronic disease on physical health change is an area of 
research which still requires investigation, and research examining the impact of chronic 
disease comorbidity on physical health change in the short-term time-period is even more 
limited.  
 
In the previous chapter, the cross-sectional associations showed that CVD severity was 
associated with poorer physical health. Given the lack of comorbidity evidence on short-term 
change in physical health, in this next stage of analysis, the hypothesis tested was that CVD 
and comorbid OA cohorts interact to cause a greater and more rapid deterioration in health 
compared to the reference and index cohorts 
  
9.2. Aim & objectives 
9.2.1. Aim 
The aim was to investigate the prospective association between CVD & OA comorbidity and 
two short-term physical health time-points. 
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9.2.2. Objectives 
1) To examine the association between comorbidity cohorts and change in physical 
health, compared to reference cohort, from baseline to 12-month follow-up  
2) To examine the association between comorbidity cohorts and change in physical 
health, compared to reference cohort, from baseline to 4-month follow-up 
3) To examine the association between comorbidity cohorts and change in physical 
health over 4 and 12 month follow-up. 
 
9.3. Methods 
9.3.1. Study design 
This is the prospective phase on i) those patients who had completed the baseline health 
survey and also completed a follow-up survey at 4 months and ii) those who had completed 
the baseline health survey and completed the 12-month follow-up survey. Whilst there were 
monthly questionnaires as part of the overall design of the study the following analyses 
focused on two time-points to provide a clear starting point on understanding short-term 
change in physical health. 
 
9.3.2. Study sample 
The NorStOP prospective study (Chapter 6) showed the 3-year long-term impact of individual 
chronic disease and comorbidity. In this chapter, the samples are organised to examine i) 
change over 12 months, then ii) change over 4 months, and then iii) change between 4 and 12 
months. This chapter is therefore framed from 12-month ‘longer-term’ to 4-month shorter-
term to reflect continuation from previous chapters. A summary of the different sections of 
analysis conducted within this, and the previous chapters can be found in Table 9.1. 
 
  
 
2
3
3
 
Table 9.1: Summary of the thesis studies and their overall socio-demographic characteristics  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ǂDeprivation status for NorStOP was categorised into quartiles, 2C study was categorised into 20% most affluent, 20% most deprived  
and the middle 60%. *NorStOP sample was aged 50 years of age or older, 2C sample was aged 40 years of age or older. 
Chapter Study Analysis Design Follow-up n Age* 
(% ≤69 years) 
Gender 
(% male) 
Deprivation statusǂ 
(% most affluent) 
         
5 
 
NorStOP Secondary Cross-sectional  - 7,799 64 46 26 
6 
 
NorStOP Secondary Cohort  3-year 4,672 72 54 28 
7 
 
2C Primary Descriptive  - 9,676 60 49 20 
8 
 
2C Primary Cross-sectional  - 5,176 57 49 22 
9 
 
2C Primary Cohort  12-month 3,266 59 49 24 
9 
 
2C Primary Cohort 4-month 2,167 61 49 26 
9 2C Primary Cohort 4 & 12-month 1,919 62 49 27 
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9.3.3. Data analysis 
The physical component summary (PCS) score, derived from the SF-12 was the primary 
outcome measure. From the eligible sample of patients with a baseline PCS score (5,176), 
patients were selected who had also responded to the survey at months 4 & 12.  
 
For each disease cohort, responders were categorised by age, gender and deprivation status. 
Age was separated by five groups, those aged 40-49, 50-59, 60-69, 70-79 or 80 years or older. 
The Index of Multiple Deprivation (IMD) status was divided into three categories, those with 
the 20% most affluent deprivation status, those with the 20% most deprived deprivation 
status and the 60% which remained. For each disease cohort the mean change in PCS score, 
along with the standard deviation (SD) was calculated, for parts 1 & 2 of the analysis this was 
used in linear regression analysis.  
 
In the first and second parts of analysis, the associations between the mean change in PCS 
score for six of the eight disease cohorts and physical health change were examined. The 
index heart failure (HF) and HF & OA comorbidity cohort were omitted from regression 
analysis as follow-up attrition of these cohorts meant that sample sizes were too small to use. 
As in the baseline analysis, the cohort with no CVD or OA was used as the reference cohort in 
the linear regression analysis; the associations between each disease cohort and the mean 
change in PCS score were compared against the mean change in PCS score of the reference 
cohort. These results are initially reported as unadjusted values and then adjusted for age, 
gender and deprivation status. 
 
In addition to the analysis of change, a separate approach was also taken to account for the 
baseline PCS score of the cohorts. Adjusted (age, gender and deprivation) linear regression 
analyses were stratified by the mean baseline PCS score. The baseline PCS score was 
stratified into ‘good’ or ‘poor’ by dichotomising at the mean, for those patients who had 
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completed both the baseline and 12-month follow-up (mean PCS score: 41.02) and the 
baseline and 4-month follow-up (mean PCS score: 41.24). 
 
In the third analysis, the physical health change of the sub-group who had responded at 
baseline, month 4 and month 12 was examined. Mean change in PCS score was considered 
separately for each disease cohort from i) baseline to month 4 (‘initial 4 months) and ii) then 
from month 4 to month 12. Change in PCS score consecutively between these time points was 
then examined expressed as a 2x2 table.  For each disease cohort, patients were allocated 
either; i) a change in PCS score greater than the mean change in PCS score (improved physical 
health) or ii) a change in PCS score less than the mean change in PCS score (worse physical 
health). Improved physical health from baseline to month 4 was defined by a PCS score 
greater than the mean change of -0.67 and improved physical health from month 4 to month 
12 was defined as a PCS score greater than the mean change of -0.30. This resulted in four 
possible physical health change states i) improvement in physical health in the initial 4 
months, and which continued from month 4 to month 12,  ii) improvement in physical health 
in the initial 4 months, but which was worse in the subsequent time-period, iii) physical 
health which worsened from baseline to month 4, but improved from month 4 to month 12 or 
iv) physical health which worsened from baseline to month 4 and which remained poor from 
month 4 to month 12 (Figure 9.1). The proportion of patients in each of the four categories of 
change was then compared. 
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Figure 9.1: 2x2 table of physical health change over follow-up time-periods  
 
 
9.4. Results – Physical health change over 12 months 
9.4.1. Disease cohort characteristics 
Of the 5,176 patients who had a baseline PCS score, 3,266 (63%) had also responded to the 
12-month follow-up questionnaire and had a PCS score. The characteristics of these 
responders are provided in Table 9.2. Just over half of the index hypertension and index OA 
cohorts, and 87% of the reference cohort were aged 69 years or younger. Those with index 
IHD (53%), index HF (73%) and all comorbid cohorts (hypertension 55%, IHD 71%, HF 90%) 
were more likely to be aged 70 years or older. Index IHD (70%), index HF (61%) and 
comorbid HF & OA (57%) comprised more men than women. The deprivation status of those 
forming the index HF and comorbid HF cohorts were more likely to be from the most 
deprived quintile than the most affluent quintile, which was in contrast to the other cohorts. 
  
 
2
3
7
 
Table 9.2: Characteristics of responders to both baseline and 12-month follow-up questionnaire (n = 3,266) 
CVD=Cardiovascular disease, OA=Osteoarthritis, Hyp=Hypertension, IHD=Ischaemic heart disease, HF=Heart failure. *Deprivation status is based on 3250 patients. 
 
 
  Disease cohorts 
Factors  -CVD -OA 
n = 722 
n (%) 
+Hyp -OA 
n = 439 
n (%) 
+IHD -OA 
n = 702 
n (%) 
+HF -OA 
n = 69 
n (%) 
-CVD +OA 
n = 515 
n (%) 
+Hyp +OA 
n = 614 
n (%) 
+IHD +OA 
n = 184 
n (%) 
+HF +OA 
n = 21 
n (%) 
          
Age group  
(years) 
40-49 171 (24) 18 (4) 8 (1) 2 (3) 43 (9) 5 (1) 1 (1) 0 (0) 
50-59 263 (36) 87 (20) 84 (12) 3 (4) 112 (21) 58 (9) 4 (2) 0 (0) 
60-69 194 (27) 151 (34) 234 (34) 14 (20) 211 (41) 214 (35) 49 (26) 2 (10) 
70-79 71 (10) 131 (30) 269 (38) 27 (39) 103 (20) 217 (35) 81 (44) 7 (33) 
80≥ 23 (3) 52 (12) 107 (15) 23 (34) 46 (9) 120 (20) 49 (27) 12 (57) 
          
Gender Male 323 (45) 206 (47) 490 (70) 42 (61) 205 (40) 232 (38) 88 (48) 12 (57) 
 Female 399 (55) 233 (53) 212 (30) 27 (39) 310 (60) 382 (62) 96 (52) 9 (43) 
          
Deprivation  
Status* 
Category 0 (most affluent) 197 (27) 107 (25) 159 (23) 9 (13) 116 (23) 139 (23) 42 (23) 2 (10) 
Category 1 436 (61) 265 (61) 421 (60) 42 (61) 321 (63) 365 (60) 115 (64) 15 (75) 
Category 2 (most deprived) 88 (12) 64 (14) 120 (17) 18 (26) 76 (14) 106 (17) 24 (13) 3 (15) 
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9.4.2. Physical health change over 12 months 
All cohorts experienced a decrease in mean PCS score (worse physical health) over the 12-
month time-period, with the exception of the IHD comorbidity and HF comorbidity cohorts 
(Table 9.3). Of cohorts that experienced worsening physical health, changes in the reference, 
index hypertension and index IHD cohorts were significant. A greater decline in PCS scores 
was observed in each of the index CVD cohorts compared to their CVD comorbid cohort 
groups with OA. 
 
9.4.3. Associations between cohorts and change in physical health over 
12 months  
Associations between disease cohort and physical health change over 12-months are shown 
in Table 9.4. Unadjusted linear regression analysis showed that the physical health of all 
cohorts improved after 12 months, compared to the mean change in PCS score of the 
reference cohort. This improvement was significant for the hypertension comorbidity and 
IHD comorbidity cohort groups. When these analyses were adjusted for age, gender and 
deprivation status, the change in PCS score estimates remained similar. 
 
This adjusted analysis was repeated, with the baseline sample stratified by a ‘good’ or ‘poor’ 
baseline PCS score. All cohorts, except index hypertension group, showed that the population 
with a ‘poor’ baseline PCS score had a worse PCS score after 12-months. When comparing the 
index CVD and CVD comorbid cohorts, the hypertension comorbidity group had worse 
physical health at 12 months than those with index hypertension, but only if their baseline 
PCS score was poor. Regardless of the baseline PCS score, those with index IHD experienced 
greater decline in physical health over the 12-month than the IHD comorbidity group. 
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Table 9.3: Change in Physical Component Summary scores over 12 months follow-up  
Disease cohorts  
 
Sample 
n=3,266 (%) 
Baseline age 
Mean (SD) 
Mean (95% Confidence interval) 
Baseline PCS score  12-month PCS score  PCS score difference 
           
-CVD -OA 722 (22) 57.9 (10) 50.1 (49.4, 50.8)  48.9 (48.2, 49.7)  -1.2 (-1.7, -0.7)* 
           
+Hyp -OA 439 (13) 67.2 (10) 44.3 (43.2, 45.4)  43.4 (42.3, 44.4)  -1.0 (-1.6, -0.3)* 
+IHD -OA 702 (21) 70.1 (9) 39.3 (38.4, 40.2)  38.3 (37.5, 39.2)  -1.0 (-1.6, -0.4)* 
+HF -OA 69 (2) 74.8 (11) 30.6 (28.2, 32.9)  30.2 (27.9, 32.5)  -0.4 (-2.1, 1.4) 
           
-CVD +OA 515 (16) 64.5 (10) 39.6 (38.6, 40.7)  39.2 (38.2, 40.2)  -0.5 (-1.2, 0.3) 
           
+Hyp +OA 614 (19) 70.7 (9) 35.6 (34.6, 36.5)  35.2 (34.3, 36.2)  -0.4 (-0.9, 0.2) 
+IHD +OA 184 (6) 74.1 (8) 31.6 (30.0, 33.2)  32.1 (30.5, 33.7)  0.5 (-0.6, 1.6) 
+HF +OA 21 (1) 80.1 (7) 26.1 (21.5, 30.7)  27.0 (22.6, 31.4)  0.8 (-1.7, 3.4) 
CVD=Cardiovascular disease, OA=Osteoarthritis, Hyp=Hypertension, IHD=Ischaemic heart disease, HF=Heart failure. *p≤ 0.05,  
SD=Standard Deviation, PCS=Physical Component Summary score 
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Table 9.4: Associations between disease cohorts and change in Physical Component Summary score over 12-months 
    Adjusted linear regression analysis, stratified by: 
Disease  
cohorts  
Study sample  
Good/poor 
(n = 3,266) 
Unadjusted linear  
regression  
Mean (95% CI) 
Adjusted linear  
regressionǂ 
Mean (95% CI) 
Good Baseline PCS score 
 (Mean (95% CI) 
Poor Baseline PCS score 
(Mean (95% CI) 
      
-CVD -OA 601/121 Ref  Ref Ref Ref 
      
-CVD +OA 244/271 0.7 (-0.1, 1.6) 0.8 (-0.1, 1.6) -0.7 (-1.7, 0.3) -0.8 (-2.5, 0.9) 
      
+Hyp -OA 289/150 0.3 (-0.6, 1.1) 0.3 (-0.6, 1.2) -0.3 (-1.3, 0.6) 0.1 (-1.8, 2.0) 
+Hyp +OA 203/411 0.9 (0.1, 1.7)* 0.9 (0.2, 1.8)* -0.3 (-1.4, 0.8) -1.5 (-3.2, 0.1) 
      
+IHD -OA   328/374 0.2 (-0.6, 0.1) 0.0 (-0.8, 0.9) -1.0 (-1.9, 0.1) -1.8 (-3.4, -0.1)* 
+IHD +OA 38/146 1.7 (0.5, 2.9)* 1.9 (0.6, 3.2)* 0.1 (-2.1, 2.4) -0.9 (-2.8, 1.0) 
ǂAdjusted for age, gender & deprivation status, *p ≤0.05,  
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9.5. Results – Physical health change over 4 months  
9.5.1. Disease cohort characteristics 
Of the 5,176 patients who had a baseline PCS score, 2,167 (42%) had also returned the month 
4 follow-up questionnaire and had a PCS score. The characteristics of these responders are 
provided in Table 9.5. Over half of the reference, index hypertension and index OA cohorts 
were aged 69 years or younger, responders in the index IHD, index HF and all comorbid 
cohorts were more likely to be aged 70 years or older. Index IHD (72%), index HF (67%) and 
comorbid HF & OA (64%) cohorts were comprised of more men than women. Except for 
index OA, the patients in each of the remaining cohorts were approximately twice as likely to 
be from the most affluent quintile as the most deprived quintile. 
 
9.5.2. Physical health change over 4 months 
All disease cohorts experienced a decrease in mean PCS score (worse physical health) from 
baseline to 4-month follow-up, with the exception of the index HF and HF comorbid cohorts 
(Table 9.6). The deterioration in physical health was significant in the reference, index IHD 
and index OA cohorts. Index hypertension and hypertension comorbidity cohorts 
experienced the same decline in PCS score, a greater decline in PCS score was observed in the 
index IHD cohort than in the IHD comorbidity cohort, and those with index HF experienced 
greater improvement in PCS, but those with HF comorbidity had a greater deterioration in 
physical health compared to the index HF group. 
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Table 9.5: Characteristics of responders to both baseline and month 4 questionnaire by disease cohort (n = 2,167) 
CVD=Cardiovascular disease, OA=Osteoarthritis, Hyp=Hypertension, IHD=Ischaemic heart disease, HF=Heart failure. *Deprivation status is based on 2159, ** with 
SF score 
 
 
 
  Disease cohorts 
Factors  -CVD -OA 
n = 470 
n (%) 
+Hyp -OA 
n = 284 
n (%) 
+IHD -OA 
n = 480 
n (%) 
+HF -OA 
n = 48 
n (%) 
-CVD +OA 
n = 358 
n (%) 
+Hyp +OA 
n = 404 
n (%) 
+IHD +OA 
n = 109 
n (%) 
+HF +OA 
n = 14 
n (%) 
          
Age group  
(years) 
40-49 107 (23) 14 (5) 7 (1) 2 (4) 26 (7) 4 (1) 1 (1) 0 (0) 
50-59 182 (37) 62 (22) 57 (12) 2 (4) 80 (23) 40 (10) 1 (1) 0 (0) 
60-69 125 (26) 104 (37) 166 (35) 13 (27) 154 (43) 143 (35) 28 (25) 1 (7) 
70-79 43 (9) 81 (28) 189 (39) 19 (40) 65 (18) 138 (34) 53 (49) 5 (36) 
80≥ 13 (3) 23 (8) 61 (13) 12 (25) 33 (9) 79 (20) 26 (24) 8 (57) 
          
Gender Male 211 (45) 134 (47) 347 (72) 32 (67) 139 (39) 148 (37) 51 (47) 9 (64) 
 Female 259 (55) 150 (53) 133 (28) 16 (33) 219 (61) 256 (63) 58 (53) 5 (36) 
          
Deprivation  
Status* 
Category 0 (most affluent) 135 (29) 76 (27) 127 (27) 8 (17) 86 (24) 104 (26) 32 (29) 4 (29) 
Category 1 291 (62) 163 (58) 283 (59) 30 (62) 223 (63) 244 (61) 68 (62) 8 (57) 
Category 2 (most deprived) 44 (9) 43 (15) 68 (14) 10 (21) 47 (13) 54 (13) 9 (9) 2 (14) 
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Table 9.6: Change in physical health over 4 months, by disease cohorts 
Disease  
cohorts  
Sample 
n=2167 
Baseline age 
(Mean, SD) 
Baseline PCS score 
Mean (95% CI) 
 PCS score at 4 months 
Mean 95% CI 
 Difference between baseline and 4 months 
Mean 95% CI 
        
-CVD -OA 470 57.6 (9.4) 50.3 (49.4, 51.2)  49.5 (48.6, 50.4)  -0.8 (-1.4, -0.1)* 
        
+Hyp -OA 284 66.1 (9.9) 44.6 (43.2, 45.9)  44.0 (42.6, 45.4)  -0.5 (-1.3, 0.2) 
+IHD -OA 480 69.7 (8.9) 39.5 (38.4, 40.5)  38.5 (37.4, 39.5)  -1.0 (-1.7, -0.3)* 
+HF -OA 48 72.6 (11.0) 32.2 (29.2, 35.2)  33.8 (30.7, 36.9)  1.6 (-0.2, 3.4) 
        
-CVD +OA 358 64.5 (10.2) 40.1 (38.8, 41.4)  38.9 (37.7, 40.2)  -1.2 (-1.9, -0.5)* 
        
+Hyp +OA 404 70.5 (9.2) 35.5 (34.3, 36.7)  35.0 (33.9, 36.1)  -0.5 (-1.3, 0.2) 
+IHD +OA 109 74.0 (8.0) 31.5 (29.4, 33.6)  31.4 (29.3, 33.5)  -0.1 (-1.4, 1.1) 
+HF +OA 14 80.7 (6.4) 28.9 (23.0, 34.7)  29.2 (23.1, 35.3)  0.3 (-4.1, 4.8) 
CVD=Cardiovascular disease, OA=Osteoarthritis, Hyp=Hypertension, IHD=Ischaemic heart disease, HF=Heart failure. *p≤0.05 
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9.5.3. Associations between cohorts and change in physical health over 4 
months   
Associations between disease cohorts and physical health change over 4-months are shown 
in Table 9.7. In unadjusted analysis, all disease cohorts, with the exception of index OA and 
index IHD cohorts, showed an improvement in physical health, compared to the reference 
group. When the analyses were adjusted for age, gender and deprivation status, the PCS 
scores remain similar. 
 
The adjusted analyses were repeated, with the 4-month sample stratified by ‘good’ or ‘poor’ 
baseline PCS score. There was a greater decrease in physical health within the ‘poor health’ 
baseline group than within the ‘good health’ baseline group for all disease cohorts. In this 
baseline stratified PCS analysis, the index OA group showed a significant decrease in PCS 
score over 4 months. In the baseline ‘good health’ group, hypertension comorbid with OA, 
showed a greater deterioration in physical health, compared to either the index hypertension 
or index OA groups. The extent of deterioration in the index hypertension and hypertension 
comorbid groups was similar over the four months for those with ‘poor’ baseline health. 
Finally, the index IHD group within the baseline ‘poor health’ sample, showed a decline in 
physical health over the 4 months, and this change was greater than that shown by the IHD 
comorbidity group. 
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Table 9.7: Associations between disease cohorts and change in Physical Component Summary score from baseline to 4-month follow-up (n = 2,167) 
    Stratified by: 
Disease  
cohorts  
Study sample  
Good/poor 
Unadjusted Mean  
(95% CI) 
Adjustedǂ 
Mean (95% CI) 
Good Baseline PCS score 
(Mean (95% CI) 
Poor Baseline PCS score 
(Mean (95% CI) 
      
-CVD -OA 393/77 Ref  Ref Ref Ref 
      
-CVD +OA 172/186 -0.4 (-1.4, 0.6) -0.3 (-1.3, 0.7) -1.5 (-2.7, -0.3)* -2.3 (-4.2, -0.3)* 
      
+Hyp -OA 185/99 0.2 (-0.8, 1.3) 0.4 (-0.7, 1.5) 0.7 (-0.5, 1.9) -1.8 (-4.4, 0.8) 
+Hyp +OA 132/272 0.3 (-0.7, 1.2) 0.3 (-0.9, 1.5) -1.7 (-3.2, -0.2)* -1.8 (-3.9, 0.3) 
      
+IHD -OA 226/254 -0.2 (-1.1, 0.7) 0.1 (-1.0, 1.2) -0.6 (-2.0, 0.7) -2.2 (-4.3, -0.1)* 
+IHD +OA 23/86 0.6 (-0.8, 2.1) 1.0 (-0.7, 2.8) -0.6 (-3.5, 2.3) -1.8 (-4.5, 1.0) 
ǂAdjusted for age, gender & deprivation status using linear regression analysis, *p≤0.05  
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9.6. Results – Physical health change over two follow-up time points 
9.6.1. Disease cohort characteristics  
Of the 5,176 baseline responders with PCS score, 1,919 (37%) had also completed the 
questionnaires at 4 and 12 months follow up and had a PCS score from each questionnaire. 
The characteristics of these responders are provided in Table 9.8. Over half of the index 
hypertension and index OA groups and 88% of the reference cohort were aged 69 years or 
younger. Responders in the index IHD, index HF and all CVD comorbid cohorts were more 
likely to be aged 70 years or older. Index IHD (73%), index HF (63%) and HF comorbid group 
(67%) had more males than females. Except for the index HF and HF comorbid cohorts, the 
patients in each of the remaining cohorts were more likely to be from the most affluent 
category than the most deprived category. 
 
9.6.2. Physical health change at two follow-up time-points 
Over the first 4 months, index HF, IHD comorbidity and HF comorbidity cohorts showed an 
improvement in physical health. The remaining cohorts showed deterioration in physical 
health, which was significant for the index IHD and index OA cohorts. From 4-month to 12-
month the reference cohort (significant change), index HF and IHD comorbid groups showed 
a continued deteriorating in PCS score (Table 9.9). 
 
In 2x2 comparisons, of change in physical health between baseline to 4 months and 4 months 
to 12 months (Table 9.10), there was variation in the way health was changing within each 
cohort. Broadly, in each cohort around a 20% had improved within both follow-up time-
periods and 20% had deteriorated in both time-periods. Of the remaining sample within each 
cohort, approximately 30% had improved in between 4 and 12 months follow-up and 30% 
had deteriorated between this time-period. The cohort that is however difficult to interpret is 
the heart failure comorbid cohort with OA, which was small in number.  
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Table 9.8: Characteristics of responders to 4- and 12-month follow-up questionnaires, by disease cohorts (n = 1,919) 
*Deprivation status based on sample of 1,912 that could be categorised 
 
  Disease cohorts 
Factors  -CVD -OA 
n = 416 
n (%) 
+Hyp -OA 
n = 257 
n (%) 
+IHD -OA 
n = 419 
n (%) 
+HF -OA 
n = 35 
n (%) 
-CVD +OA 
n = 324 
n (%) 
+Hyp +OA 
n = 358 
n (%) 
+IHD +OA 
n = 98 
n (%) 
+HF +OA 
n = 12 
n (%) 
          
Age group  
(years) 
40-49 91 (22) 13 (5) 6 (1) 2 (6) 25 (7) 3 (1) 1 (1) 0 (0) 
50-59 159 (38) 55 (21) 53 (13) 1 (3) 74 (23) 38 (11) 1 (1) 0 (0) 
60-69 116 (28) 99 (39) 146 (35) 10 (28) 140 (43) 132 (37) 28 (29) 1 (8) 
70-79 39 (9) 70 (27) 162 (39) 13 (37) 57 (18) 120 (33) 46 (47) 5 (42) 
80≥ 11 (3) 20 (8) 52 (12) 9 (26) 28 (9) 65 (18) 22 (22) 6 (50) 
          
Gender Male 187 (45) 124 (48) 305 (73) 22 (63) 122 (38) 129 (36) 48 (49) 8 (67) 
 Female 229 (55) 133 (52) 114 (27) 13 (37) 202 (62) 229 (64) 50 (51) 4 (33) 
          
Deprivation  
Status* 
Category 0 (most affluent) 121 (29) 70 (28) 110 (26) 6 (17) 77 (24) 95 (27) 31 (32) 2 (17) 
Category 1 257 (62) 149 (58) 250 (60) 22 (63) 205 (63) 209 (59) 60 (61) 8 (66) 
Category 2 (most deprived) 38 (9) 36 (14) 57 (14) 7 (20) 41 (13) 52 (14) 7 (7) 2 (17) 
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Table 9.9: Physical health change from baseline to month 4 and from month 4 to month 12, by disease cohorts  
   Mean change in PCS score (95% CI) 
Disease cohort  N = 1,919 (%) Baseline age 
Mean (SD) 
Baseline to Month 4  Month 4 to Month 12 
      
-CVD -OA 416 (21) 57.8 (9) -0.6 (-1.3, 0.0)  -0.8 (-1.4, -0.2)* 
      
+Hyp -OA 257 (13) 65.9 (10) -0.5 (-1.3, 0.2)  -0.4 (-1.2, 0.5) 
+IHD -OA 419 (22) 69.5 (9) -0.9 (-1.6, -0.2)*  -0.3 (-0.9, 0.3) 
+HF -OA 35 (2) 72.1 (11) 1.1 (-1.0, 3.2)  -0.6 (-3.0, 1.8) 
      
-CVD +OA 324 (17) 64.2 (10) -1.2 (-1.9, -0.4)*  -0.1 (-0.8, 0.7) 
      
+Hyp +OA 358 (19) 70.0 (9) -0.6 (-1.4, 0.3)  -0.0 (-0.7, 0.7) 
+IHD +OA 98 (5) 73.5 (8) 0.4 (-0.8, 1.7)  0.0 (-1.3, 1.3) 
+HF +OA 12 (1) 79.8 (7) 0.2 (-5.2, 5.5)  1.0 (-3.0, 5.1) 
*p ≤0.05 
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Table 9.10: Physical health change from first 4 months up to 12 months, by disease cohorts  
 Mean change in PCS score 
Disease cohort Improveda, improvedb 
n (%) 
Worsea, improvedb 
n (%) 
Improveda, worseb 
n (%) 
Worsea, worseb 
n (%) 
Total 
n 
      
-CVD -OA 93 (22) 123 (30) 128 (31) 72 (17) 416 
      
+Hyp -OA 58 (23) 75 (29) 80 (31) 44 (17) 257 
+IHD -OA 76 (18) 131 (31) 139 (33) 73 (17) 419 
+HF -OA 7 (20) 13 (37) 11 (31) 4 (11) 35 
      
-CVD +OA 70 (22) 95 (29) 103 (32) 56 (17) 324 
      
+Hyp +OA 74 (21) 109 (30) 124 (35) 51 (14) 358 
+IHD +OA 29 (30) 29 (30) 28 (29) 12 (12) 98 
+HF +OA 1 (8) 4 (33) 6 (50) 1 (8) 12 
Figures in brackets are % in rows; a=physical health change between baseline and 4 months; b=physical health change between 4 and 12 months.  
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9.7. Study sample 
The proportions of each disease cohort (as a total of the sampling population) in the baseline 
analysis were the same as the proportions of responders and non-responders in i) the 12-
month follow-up questionnaire, ii) the 4-month follow-up questionnaire and iii) the baseline, 
4-month & 12-month questionnaires (Appendix 9.1). In all three sets of analysis there was 
also no difference in patients who had responded and those who had responded and had a 
PCS score. The characteristics of responders and non-responders to each of the three sets of 
analysis are shown in Table 9.11.  
 
9.7.1. Responder vs. non-responder: 12-month follow-up 
Compared to the baseline sample, there was little difference in age of responders at 12-month 
follow-up, with 57% also being aged 69 years or under (Table 9.11). However, non-
responders were slightly older, with only 52% being aged 69 years or under. There were a 
greater proportion of females than males in both the responder and non-responder 
categories, and 12-month follow-up responders had a more affluent deprivation status (in-
line with the baseline sample) than non-responders. 
 
Characteristic of non-responders to 12-month follow-up in each disease cohort are shown in 
Appendix 9.2. As with responders, non-responders were more likely to be aged 69 years or 
younger in the reference, index hypertension and index OA cohorts, with those in the 
remaining cohorts more likely to be aged 70 years or older. However, in each disease cohort, 
patients were slightly older. Non-responders in the reference cohort were more likely to be 
women, whereas responders in this cohort had been evenly distributed between the genders. 
60% of non-responders in the comorbid HF cohort were female, in contrast to 57% of males 
who responded in the same disease cohort. The gender distribution was similar between 
responders and non-responders for the remaining disease cohorts. Non-responders across all 
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disease cohorts had a greater proportion of their sample in the most deprived quintile than 
was seen for responders. 
 
9.7.2. Responder vs. non-responder: 4-month follow-up 
Responders to the 4-month follow-up were younger than non-responders; the proportion of 
patients aged 69 years or younger was 59% and 53% respectively (Table 9.11). In all 
responder cohorts, there were more females than males. A greater proportion of non-
responders were from the most deprived category than the most affluent category. This was 
in contrast to responders, where twice the proportion was from the most affluent category 
(26%) than from the most deprived (13%). 
 
Characteristic of non-responders to month-4 follow-up in each disease cohort are shown in 
Appendix 9.3. Distribution of patients across the age categories was the same as responders 
but in each disease cohort, the proportions demonstrated slightly older patients. As with the 
responders, index IHD (65%) and index HF (56%) cohorts were comprised of more men than 
women, though a smaller proportion. Of those in the comorbid HF & OA cohort, non-
responders were more likely to be female (55%), where in contrast a greater proportion of 
responders in this cohort had been male (64%). A greater proportion of patients across all 
disease cohorts were in the most deprived quintile than those who responded. 
 
9.7.3. Responder vs. non-responder: Two different time-points 
When comparing the responders and part-responders (Responders to baseline but 
subsequent non-response to either month 4 or month 12), there was no difference in age, 
with over half of each group being aged 69 years or younger, or the proportion of males and 
females (Table 9.11). The proportion of responders were from the most affluent category 
was twice that of the least affluent category, whereas a greater proportion of part-responders 
were from the most deprived category. 
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Characteristic of part-responders in each disease cohort are shown in Appendix 9.4. Age 
distributions for the responders and non-responders were similar within each disease 
cohort. Non-responders in the index IHD (65%) and index HF (59%) cohorts were comprised 
of more males than females; the remaining disease cohorts had more females. In the HF 
comorbid group, part-responders were more likely to be female (58%) than male, but in 
contrast a greater proportion of responders in this cohort had been male (67%). A greater 
proportion of patients across all disease cohorts were in the most deprived category, this was 
in contrast to the responders who had higher proportions in the most affluent categories. 
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Table 9.11: Characteristics of different response types 
  Baseline Baseline & 12-month follow-up Baseline & 4-month follow-up  Baseline, month 4 and month 12 
Factors  Responders** 
n = 5176 (%)  
Responders**  
n = 3266 (%) 
Non-responders  
n = 1942 (%) 
Responders**  
n = 2167 (%) 
Non-responders  
n = 3128 (%) 
Responders**  
n = 1,919 (%) 
Part-respondersǂ 
n = 3,371 (%) 
Age group  
(years) 
40-49 434 (8) 248 (7) 183 (9) 161 (7) 274 (9) 141 (7) 295 (9) 
50-59 950 (19) 611 (19) 336 (17) 424 (20) 524 (17) 381 (20) 563 (17) 
60-69 1557 (30) 1069 (33) 500 (26) 734 (34) 856 (27) 672 (35) 911 (27) 
70-79 1456 (28) 906 (28) 561 (29) 593 (27) 905 (29) 512 (27) 982 (29) 
80≥ 779 (15) 432 (13) 362 (19) 255 (12) 569 (18) 213 (11) 620 (18) 
         
Gender Male 2540 (49) 1598 (49) 950 (49) 1071 (49) 1521 (49) 945 (49) 1640 (49) 
Female 2636 (51) 1668 (51) 992 (51) 1096 (51) 1607 (51) 974 (51) 1731 (51) 
         
Deprivation  
Status* 
Category 0  
(most affluent) 
1121 (22) 771 (24) 340 (18) 572 (26) 554 (18) 512 (27) 607 (18) 
Category 1 3148 (61) 1980 (61) 1199 (62) 1310 (61) 1919 (62) 1160 (60) 2071 (62) 
Category 2  
(most deprived) 
882 (17) 499 (15) 396 (20) 277 (13) 636 (20) 240 (13) 673 (20) 
12-month follow-up = *Deprivation status: calculated for study sample of 9,636, for baseline sample of 5,151, for non-responders to 12-month FU of 1,935, for 
responders to 12-month FU of 3,464, for responders with PCS at baseline and 12-month FU of 3,250.  
4-month follow-up = *Deprivation status: calculated for study sample of 9636, for baseline responder of 5399, for non-responders to 4-month follow-up of 3109, 
for responders to 12-month follow-up of 2290, for responders with PCS at baseline and 4-month follow-up of 2159. 
Baseline, 4-month & 12-month follow-up = ǂResponders to baseline, but subsequent non-response to either month 4 or month 12. *Deprivation status: calculated 
for study sample of 9636, for baseline responders of 5151, for non-responders of 3351, for responders to baseline, 4-month & 12-month follow-up of 2048, for 
responders to baseline, 4-month & 12-month follow-up of 1912. **responders with SF-score  
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9.8. Discussion 
In this chapter, the prospective analyses show that the combination of CVD & comorbid OA 
did change physical health from baseline to 4 months or 12 months, but the change that was 
measured was of small magnitude. The CVD severity also did not appear to influence the 
physical health outcome over this time-period.  When comparisons between change in the 
first 4 months was compared to the second time-period (between 4 months and 12 months), 
within all cohort groups, there appeared to be some patients who were improving and some 
who seemed to be deteriorating, but such change was similar across all cohort groups. In all 
analyses, whilst it was possible to draw some interpretation, the small numbers for the heart 
failure and comorbid OA group did not allow for fuller interpretation.  
 
In the previous chapter, the baseline 2C analyses, showed that increasing CVD severity and 
comorbid OA was associated with worse physical health, but prospectively over 12 months 
that does not translate into changing physical health. The hypothesis that CVD severity and 
comorbid OA would lead to greater deterioration in physical health was not met. These 
findings are, however notable that comorbidity and severity in chronic disease do not 
influence change in physical health over 12 months. The interpretation of these findings 
needs to be placed within the context of the baseline physical health of the cohort groups. The 
baseline PCS scores were lower with increasing CVD severity and with comorbid OA. This 
means that the poor health status of comorbid groups, did not allow for any further 
measurable change in physical health over the selected time points of 4 months and 12 
months. Whilst the analytic approach measured change at individual patient level, it is 
possible that more detailed time-point analyses (i.e. monthly) is required to fully test the 
prospective hypothesis. 
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It is not possible to fully place these findings within the context of limited other evidence on 
this type of prospective investigation. Previous local research has indicated interaction in the 
association between OA comorbidity and physical health (Kadam, Croft 2007). Furthermore 
detailed analyses that have investigated pain reported symptoms, suggest that there are 
trajectories which individuals may follow (Dunn et al. 2011) and that such change may be 
similar in physical health.  
 
9.8.1. Strengths & limitations 
In this chapter, there was a focus on two short-term follow-up time-periods, and this is one of 
the largest prospective investigations of its type with a priori constructed cohort groups. 
Whilst this is a strength, the ascertainment of the chronic disease was based on the 
‘prevalent’ status. It is possible that the prevalent status of the CVD and OA cohort definitions, 
meant that patient’s had already reached the associated poor physical health level (as 
indicated by the baseline physical health), and further prospective change in health was not 
possible. A true cohort design would incorporate ‘incident’ disease at the start of the potential 
influence of the disease on physical health. However such an approach in chronic disease 
comorbidity would not be feasible as incident follow up may involve many years of follow-up. 
Also arguably, an hypothesis test on whether prevalent comorbidity causes subtle physical 
health change is important in its own right, as even small changes may be the drivers behind 
progression of disease or the seeking of healthcare (Norris et al. 2008, Laux et al. 2008).     
 
Though the use of the SF-12 as a generic measure of physical health allows comparison 
between CVD and OA, it also introduces certain limitations to this study. The change in 
physical health over both time points was small and the SF-12 may not be a sensitive enough 
to measure subtle physical health change over relatively short time periods. In addition those 
patients in the more severe disease cohorts may have such poor health that SF-12 can’t 
record this due to a floor effect of the measure (Bennett et al. 2003). 
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Cohort analyses are also subject to losses to follow-up over time. Whilst the overall sample 
size were large at baseline and follow-up, there was attrition over the follow-up time-period. 
The responders and non-responders did not show notable differences in terms of age, gender 
and deprivation, but it is possible there may be ‘survivor bias’ effect (Glesby, Hoover 1996). It 
is possible that losses to follow-up were patients with the poorest health, or for example, in 
the heart failure cohort the losses were due to death. This means that within all cohort 
groups, evidence for little change in health was because of the patients who continued to 
participate were people in whom the physical health was relatively stable.  
 
Finally, the fuller 2C design has monthly physical health measurements, and the analytic 
approaches that were employed were simply focused on only two time-points. In the next 
phase of the analyses, outside the scope of the PhD, multi-level modelling methods will be 
used, and also within the context of the larger consultation data to assess changes in the 2C 
study cohorts. 
 
9.9. Conclusions 
This prospective investigation showed that CVD severity and comorbid OA were not 
associated with significant physical health change over 4 and 12 months. However, within all 
study cohorts there appears to be patients who are improving and others who are 
deteriorating.  The baseline physical health in the 2C prevalent chronic disease cohort may 
provide one point of identifying patients, but it does not appear in these analyses to be an 
indicator of prospective health. The overall interpretation of the prospective findings needs 
to be placed within issues of design, measurement of health and losses to follow-up. 
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Chapter 10: Discussion 
 
The thesis has examined and discussed how individual chronic conditions, relative morbidity 
severity and comorbidity influence physical health over the short and long-term, with the 
common chronic disease examples of cardiovascular disease (CVD) and osteoarthritis (OA). 
This chapter will now draw on each of these areas of work, briefly recapping their overall 
findings, discussing the current context of the findings placed in the wider literature, and the 
strengths and limitations of the selected methodological approaches. Finally, it will consider 
the key implications, both for research and general practice and suggestions for future 
research and the conclusions that can be drawn from the thesis findings. 
 
10.1. Overall findings of the thesis 
The primary aim of this thesis was to examine the consequences of CVD and OA comorbidity 
on short and long-term physical health in general practice. To address this question the thesis 
was orientated around five main hypotheses, which resulted in several key findings (Box 
10.1). The first hypothesis was that the association between individual chronic disease 
populations and physical health would be dependent on the type of health conditions. This 
hypothesis was confirmed. Through a systematic review, the influence of six conditions from 
two chronic diseases (three CVD and three MSK) were all shown to have an adverse influence 
on physical health, but the extent of this influence varied across conditions. In the CVD 
spectrum there was a distinction between the three conditions as relative morbidity severity 
increased. The MSK disorders did not display such a consistent difference across the 
spectrum. This work not only demonstrated the varying influence of chronic conditions on 
physical health but also presented the potential to define ‘severity’ in populations based on 
one health condition compared to another. 
 258 
 
Box 10.1: Key findings of the thesis 
Study Findings 
1  Individual chronic conditions (CVD: hypertension, ischaemic heart disease (IHD) 
& heart failure (HF). MSK: lower back pain (LBP), osteoarthritis (OA) & 
rheumatoid arthritis (RA)) are associated with poor physical health 
 Increasing severity in the CVD spectrum was associated with worse physical 
health. This association was not present for the MSK spectrum 
 Between different chronic conditions (CVD vs. MSK) the influence on physical 
health can be quite similar 
 
2  Diagnostic labels applied in general practice are markers of physical health  
 Ordering of CVD a priori showed increasing relative morbidity severity was 
associated with worse physical health 
 Ordering of MSK disorders a priori showed increasing relative morbidity 
severity was associated with worse physical health 
 
3  Ordering of CVD a priori showed increasing relative morbidity severity was 
associated with worse long-term physical health 
 Ordering of MSK disorders a priori showed increasing relative morbidity 
severity was not associated with long-term change of physical health 
 
4  Increasing severity of three a priori CVD (hypertension, IHD, HF) was 
associated with poor physical health 
 CVD and comorbid OA increased the association with poor physical health 
 The influence of having CVD & OA was less than additive 
 
5  CVD & OA comorbidity influences change in short-term physical health 
 Short-term change was small and dependent on the comorbid combination 
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In the systematic review, chronic conditions had been defined through several different 
methods and then compared relative to one another. The second hypothesis was that chronic 
disease populations, through diagnostic labels applied in general practice would act as 
markers of ‘relative morbidity severity’ for physical health. This hypothesis was confirmed. 
The cross-sectional analysis demonstrated that as severity of the a priori list of several 
conditions, in both spectrums (CVD & MSK) formed from the same study sample increased, 
then physical health was poorer. This was true for both the CVD and MSK spectrums. The 
third hypothesis was that increasing severity and comorbidity would be associated with 
greater deterioration in long-term physical health over 3-years. This hypothesis was 
confirmed for the CVD spectrum, but not the MSK spectrum. Longitudinal investigation of the 
influence of relative morbidity severity and comorbidity count showed variation between the 
two severity spectrums. Increasing relative morbidity severity was associated with 
increasingly adverse physical health change after 3 years in the CVD spectrum. Those with 
‘high’ comorbidity as measured by simple counts had worse physical health than those with 
‘low’ comorbidity. These associations were not observed in the MSK spectrum. 
 
The fourth and fifth hypotheses were based on the new study data (2C) part-used for this 
thesis. The 2C study expanded on the previous secondary analysis by using a prospective, a 
priori sample to examine the interaction between two common chronic diseases. Using three 
cardiovascular diseases (hypertension, IHD & HF) ordered a priori by relative morbidity 
severity, the fourth hypothesis was that combined CVD & OA comorbidity would be 
associated with worse physical health than index CVD or index OA groups. This hypothesis 
was also confirmed. In baseline 2C analysis, patients with CVD & OA comorbidity had worse 
physical health compared to populations with index CVD or index OA. Furthermore, as CVD 
severity increased across these comorbid combinations, physical health became worse. This 
interaction was less than additive. Although physical health was poorer when both CVD & OA 
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were present, this was less than would be expected by combining the individual ‘effects’ of 
the two index conditions. 
 
 The fifth hypothesis was that those populations with CVD & OA comorbidity would 
experience faster and greater deterioration in physical health than the populations with 
either index CVD or index OA. Furthermore this impact would increase with increasing 
morbidity severity. However, here the null hypothesis was confirmed. Though CVD & OA 
comorbidity did influence physical health change, the extent of this was limited, and non-
significant when compared to that of the index CVD or index OA cohorts. 
 
10.2. Individual chronic diseases & physical health 
To understand the influence of comorbidity on physical health, one must first understand the 
influence of individual chronic conditions. The systematic review described in Chapter 4 and 
secondary analysis of Chapter 5 demonstrated the adverse influence of several individual 
chronic conditions on physical health. Though chronic conditions have been shown to have 
an adverse influence on health experience, the extent to which one condition impacts upon 
the patient populations relative to another had remained unclear. Due to the wide use of the 
Short-Form survey, a comprehensive review of literature from many different countries using 
this quality-of-life (QOL) measure was possible to address this issue.  
 
The systematic review showed that there was an association between increasing CVD 
severity and deteriorating physical health. This was not as distinct in the MSK spectrum. In 
Chapter 5, defining conditions through general practice records and in the same general 
practice sample, showed an association between increasing severity as measured by 
diagnostic populations and poorer physical health for both CVD and MSK spectrums. The 
secondary analysis expanded on the systematic review, but with conditions defined from the 
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same sample and allowing adjustment for key confounders, such as age, gender and 
deprivation to present a more robust understanding of the influence of individual chronic 
disease populations on physical health.  
 
The examination of the relationship between individual chronic conditions and physical 
health had two roles. The first role was to estimate the physical health by chronic disease 
populations through a systematic review. No previous systematic review had compared 
chronic disease populations, either within the same spectrum or between spectrums, and 
used the z-score method. Second the role of the review and secondary analysis was also to 
test the use of diagnostic labels as markers of relative morbidity severity and finally, provided 
a context in which to compare physical health of those with chronic disease comorbidity.  
 
Two empirical choices must be highlighted within this work. The conclusions drawn from 
these two chapters (chapter 4 and 5) are specific to the conditions chosen and therefore 
further studies would be required to test the relationship with other measures in other CVD 
or MSK. Within both studies, common conditions were used in the construction of ‘chronic’ 
spectrums. Placing conditions such as hypertension or soft tissue disorder into the respective 
‘chronic’ spectrum was a specific choice. Here these conditions are described as a distinct 
chronic disease or disorder, but it is recognised that, for example, hypertension is more 
commonly described as a risk factor for CVD rather than a chronic condition (Giles et al. 
2005). No matter the true distinction, the interest of this work lies in those patients labelled 
as ‘hypertensive’ at consultation and therefore ‘What is hypertension?’, is not as important a 
question as, ‘What does the presence of a hypertension label from general practice mean for 
physical health?’. 
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10.3. Long-term physical health change 
In cross-sectional analysis (chapter 5), as the relative morbidity severity of CVD and MSK 
population categories increased, so physical health was poorer. Assessing the association 
between relative morbidity severity and physical health change over three years was an 
important examination of how chronic conditions may change over the long-term time-
period. The individual chronic conditions examined did not progress in the same way over 
the three years. The long-term analysis of Chapter 6 showed that the influence of chronic 
conditions on physical health change over a three year period increased with increasing CVD 
severity, but not MSK severity. 
 
The difference in findings between CVD and MSK spectrums may reflect the nature of the 
potentially stronger aetiological links between different cardiovascular diseases, in 
comparison with the links between the MSK disorders. For example, hypertension and heart 
failure (HF) affect the same bodily system but also HF can result from sustained 
hypertension. Therefore, HF would in general be considered a more severe condition in 
relation to its effects on physical health than hypertension. This same rationale can be 
applied to the other CVD used in this spectrum. The relationship between the MSK disorders 
may often only be that these conditions affect the same system of the body. Back pain and OA 
can both be severe, especially in their impact of physical health, but without any implication 
that one will lead to the other or that they will necessarily coexist.   
 
The relatively small changes observed in long-term physical health change in both spectrums 
could also be related to the choices of conditions used in both spectrums. Different conditions 
may result in different findings. However, the selection of the CVD and MSK spectrums was 
based on the most prevalent conditions within the wide ranging ‘severity’ defined by the 
Kadam Morbidity Index and examined as a priori spectrums. Another reason for the small 
changes in physical health may have been that the follow-up period of three years may have 
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been too short a time-period to examine change in either of these chronic diseases, especially 
MSK of which progression of symptoms may take many years.  
 
Chapter 6 also introduced the first assessment of comorbidity within the thesis. Stratification 
by comorbidity (defined by counts of any other morbidity) demonstrated an association 
between increasing relative morbidity severity on physical health in the CVD spectrum but 
not the MSK spectrum. This stratification demonstrated the important role of comorbidity. 
Firstly, patients’ experienced high comorbidity for both chronic diseases. Secondly for the 
CVD spectrum, high levels of comorbid counts were associated with poor physical health. 
However, whilst this analysis demonstrated the potential importance of considering 
comorbidity, this approach could not inform the specific influence of specified combinations 
of chronic diseases, nor the severity of the comorbid populations. 
 
10.4. Minimal Clinically Important Difference  
This thesis has considered both the cross-sectional ‘difference’ of physical health between 
disease groups and the ‘change’ in physical health within a disease group over time. Several 
summary scores have been shown to be significantly different across disease groups and such 
variation in health has formed the basis of understanding the results of the thesis. However, it 
is also possible to consider the variance between disease groups as ‘clinically’ meaningful as 
well as statistically significant. 
 
Minimal Clinically Important Difference (MICD) (Hays, Woolley 2000) is “the smallest 
difference in score in the domain of interest which patients perceive as beneficial and which 
would mandate, in the absence of troublesome side-effects and excessive cost, a change in the 
patient’s management” (Jaeschke, Singer & Guyatt 1989). Though research often strives to 
understand whether outcomes are statistically significantly, even when they are, this may not 
always reflect a difference perceived by the patient or clinician and therefore a significant 
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value may not be considered clinically meaningful. The MICD value/cut-off is increasingly 
being considered for each outcome measures. This is a value unique to an outcome measure 
which represents a point at which a difference or change in score is likely to be noticed by the 
patient or influence management by the clinician. For the SF-36, it has been indicated that a 
change of 3-5 points (Samsa et al. 1999) of the PCS score indicates a clinically meaningful 
difference. Though no research has assessed this value for the SF-12, the close correlation 
between the two measures would suggest a similar MICD range. 
 
Though the focus of this thesis was on statistical significance, MICD can be considered overall 
based on a minimum change of 3-points in the PCS score. In the cross-sectional chapters 
(Chapters 4, 5 & 8) the MICD varied between disease groups. Chapters 4 & 5 showed that the 
difference in PCS score between disease groups of increasing severity could be considered 
clinically meaning, whilst others were not. Chapter 8 found the difference between each 
disease group and the reference group to have a MICD. In chapters 6 & 9, which considered 
change in PCS score within the same group over time, no disease group experienced a change 
which was greater than 3 points.  
 
Though MICD is important it was not a specific focus of the thesis, which was based upon 
hypothesis testing. Literature on the MICD for the SF-12 is limited and though the threshold 
for the SF-36 has been placed from 3-5, anything below 3 may still be important to consider 
at an epidemiological level. MCID are not clear cut values and variation and limitations are 
present (Cook 2008). Furthermore, these values have not been examined for the specific 
disease groups examined in the thesis and therefore, statistical significance remains the focus 
of this thesis. 
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10.5. Comorbidity Cohort (2C) study 
The 2C study formed the original component of the thesis. This novel prospective cohort 
study examined a priori the interaction between specified CVD & OA comorbidity and 
association with physical health at baseline and physical health change over the short-term 
time-period of 12-months. 
 
10.5.1. Cross-sectional physical health 
General practice populations with index CVD and index OA had worse physical health than 
the reference cohort. When the PCS scores for each index CVD cohort (hypertension, IHD, HF) 
and the index OA cohort were compared to the results of the NorStOP study (Chapter 5), 
these scores were consistently higher in the 2C study (better physical health). With the 
exception of HF, each cohort in the 2C study had a PCS score approximately 5 points higher 
(HF, 2 points higher) than the NorStOP categories. This variation could be a result of 
differences between the 2C and NorStOP samples used, though both from the same local area, 
the 2C samples patients were aged 40 years or older compared to the NorStOP of 50 years or 
older.  
 
All CVD comorbid disease cohorts had poorer physical health than the index CVD and index 
OA cohorts. These findings were in line with other research  (Wesseling et al. 2012, van Dijk 
et al. 2008) which examined the outcomes of similar comorbidity. The interaction between 
each of the CVD & OA, though worse than the index cohorts was less than additive. These 
findings were different to the earlier work of Kadam et al, which found a synergistic 
(multiplicative) effect of OA comorbidity on physical functioning. This difference may be a 
result of the specific comorbid condition interaction examined in this thesis compared to the 
definition of comorbidity by Kadam et al. In this previous work, the synergistic effect of 
comorbidity was based on increasing severity of the comorbidity but did not consider a 
specific comorbid combination (Kadam, Croft 2007). Therefore, the synergistic effect may 
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have been related to other conditions included in the comorbidity. Other previous interaction 
research is limited; especially that of CVD & OA and that which has been conducted has often 
been ‘post-hoc’ in contrast to the a priori design of the 2C study. 
 
10.5.2. Short-term physical health change 
No research has previously examined the interaction prospectively between CVD & OA 
comorbidity and its impact on short-term physical health change in UK general practice. The 
2C study fills an important gap in the field of comorbidity research by investigating the 
influence of two common chronic diseases, which exist as a comorbid combination, and how 
this may influence the short-term changes in one of the most important aspects of patient 
day-to-day life, their physical health. By using a prospective cohort design, this study 
examined changes in physical health over a 12-month time-period. Previous prospective 
research examining interactions has been over much longer time periods, ranging from 2-
year follow-up to 10-year follow-up and either in; CVD comorbidity (Sherbourne et al. 1996, 
Maatouk et al. 2012), OA comorbidity or the interaction between wider chronic condition 
concepts (i.e. CVD & arthritis) (Kriegsman, Deeg & Stalman 2004). Only Ettinger et al had 
prospectively (10-year follow-up) examined the consequences of interaction between knee 
OA & CVD. This study found an association between this comorbidity and poor physical 
health (Ettinger et al. 1994).  
 
No association was observed between CVD & OA comorbidity and change in physical health 
over either the 4-month, 12-month, or for both time-periods. Limited change in physical 
health over these periods could be for two reasons. The first may be that the SF-12 is not able 
to measure change in such short time-periods. However, these measures have been shown to 
record health change in other studies (Garratt et al. 1994, Khanna et al. 2011). The second 
reason for the lack of change in physical health may be related to the use of patients with 
existing, prevalent conditions used within this study. The 2C study sampled from the records 
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of general practice. Patients were recruited based on a historical record for one of the 
diseases of interest and a priori cohort construction. Though such a method allows for access 
to a large sample with the diseases of interest, the duration of each respective disease may 
have varied. Therefore, such a prevalent sample may have had these long-term diseases and 
associated health problems for some time and in the trajectories of their disease, may well be 
far along these. It is still possible that two prevalent conditions may be along different points 
in their trajectory, and so it was still reasonable to posit a hypothesis as to whether the 
combination potentially causes faster and greater deterioration in physical health. 
 
10.5.3. 2C study strengths 
The Comorbidity Cohort (2C) study is a novel study in the area of comorbidity research. 
Research examining the interaction between a priori CVD cohorts & OA comorbidity provides 
new insight into the outcome of experiencing these two chronic diseases at the same time in 
direct comparison to index cohorts. The prospective nature of its design provides further 
information on how the interaction of two chronic conditions influences physical health 
change over the short-term. The survey-linkage design provides the potential for the 
combination of survey data with the medical records of the (consenting) samples. The 2C 
study also considers the severity of the chronic condition based on general practice records, 
which forms an epidemiological definition of conditions for research (Box 10.2). 
 
10.5.4. 2C study limitations 
Response to the baseline survey was 56%, which will limit the generalisability of the results. 
However, (ethically approved) access to the anonymised medical records of the denominator 
population (9,676 patients) means that the generalisability of the responder sample can be 
compared with the study sample in future analyses. Further, attrition must also be 
considered as a limitation in the short-term follow-up, at both 4-month and 12-month.  
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Chronic disease cohorts were defined using the diagnostic labels applied by health care 
professionals in general practice. Therefore, the application of labels to a given condition may 
be a source of measurement bias, due to the variation in the application of diagnostic or 
symptomatic labels. However, other work within this thesis (Chapter 5) has shown that the 
application of diagnostics labels does reflect the physical health experienced by these disease 
groups. Furthermore, monitoring systems such as the QOF have led to increased and 
improved quality of coding in general practice (Steel et al. 2007). 
 
The 2C sample was selected based on the presence of a specific diagnostic label present in the 
practice records, and this was based on the review of clinical records over three years prior 
to the baseline survey. Ascertainment based on clinical records may be prone to mis-
classification, especially for conditions such as OA. However, the design partly attenuates this 
issue by providing detailed cohorts, with reference, index and comorbid samples. 
 
The samples which form all disease cohorts within the 2C study may also have additional 
comorbidity. The presence of such comorbidity is a potential confounder to these results, as 
those with more chronic disease are likely to experience more comorbidity, which may in 
turn be influencing physical health. Where the secondary analysis in Chapters 5 & 6 was able 
to adjust for morbidity recorded in the general practice records with which the NorStOP 
survey had been linked, this process is not yet available for the 2C study and would reduce 
the sample to those consenting to record review. However, the design of the 2C study does 
allow for partial consideration of other comorbidity prior to the linkage of survey data with 
general practice records.  
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The 2C study design is likely to have ‘accounted’ for some of the other comorbidity from the 
analysis. By comparing large samples of index and comorbid categories from the same 
population, it is expected that similar proportions of morbidities will be experienced across 
both cohorts. For example, the proportion of the patients with index CVD and diabetes and 
index OA and diabetes would be similar to the proportion of patients with comorbid CVD & 
OA and diabetes. However, as the prevalence of comorbidity is frequently greater than that 
expected from the presence of the index condition, not all comorbidity may be accounted for. 
This design allows a more ‘isolated’ examination of each cohort of interest as any ‘other’ 
comorbidity which may be influencing physical health to a similar degree in both cohorts. 
This presents a clearer understanding of how specific comorbid pairing influences physical 
health change in the absence of general practice records. 
 
Further argument that the poor health of the CVD & OA comorbid category is not caused by 
confounding of ‘other’ comorbidity is related to the adjustment for age in the analysis. 
Comorbidity increases with age, but the baseline 2C data were adjusted for age. Age is 
therefore a proxy measure of comorbidity, and the design and this adjustment make it 
unlikely that ‘other’ comorbidity was an explanation for the 2C findings.  
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Box 10.2: Strengths & limitations of the 2C PhD studies 
Strengths  Limitations 
 Prospective survey-linkage cohort 
study 
 
 Quality-of-life outcomes measured over 
short-term time-period 
 
 Comorbidity of two common chronic 
conditions (CVD & OA) 
 
 A priori sample used to examine 
interaction  
 
 Examined the influence of the severity 
of comorbidity  
 Disease cohorts were defined using 
general practice records and not a 
standardised measurement tool 
 
 Response to baseline was lower than 
expected and follow-up phase introduced 
some attrition 
 
 Disease cohorts were formed from patients 
with already prevalent conditions  
 
 ‘Other’ comorbidity has not been adjusted 
for completely 
 
 
10.6. Conceptual framework of the thesis 
10.6.1. Measuring health in general practice 
To purposively select a sample from general practice with a condition of interest, one must be 
able to define that condition. There are several ways in which this could be achieved. Within a 
survey patients may be asked to recall their past medical history and inform the researcher 
whether they ever had the condition of interest. Such a method may remove the need to 
access medical records to define a health condition but may be influenced by recall bias 
(systematic error due to difference in accuracy or completeness of recall to memory of past 
events or experiences (Porta et al. 2008)) or a conscious effort by the patient not to disclose 
such information, perhaps due to embarrassment. Furthermore, if there is a need to construct 
a purposive sample, then patients cannot be asked before their health condition has been 
identified from the records. Health conditions can also be defined using clinical techniques or 
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research tools by health professionals during consultation. If a gold-standard tool is available 
then this may be able to produce an accurate and definitive condition diagnosis. However, 
this may not always be performed routinely by GPs or nurses and can be expensive to 
undertake for all patients in a large study. 
 
The use of general practice records to define populations with conditions of interest for 
research is a practical method. However, the accuracy with which such diagnostic labels are 
applied by GPs & nurses has been questioned in the past and even with the advent of 
monitoring programmes such as the QOF, issues around inaccurate or infrequent application 
of Read codes persist. That this thesis demonstrates the use of diagnostic labels as markers of 
physical health and that diagnostic labels reflect physical health, supports the argument that 
codes are applied consistently and appropriately by GPs/nurses. This in turn means that 
general practice disease groups can be defined using GP records for epidemiological research 
and using linkage methodology (for consenting patients) can be linked to research data (i.e. 
surveys). 
 
10.6.2. Relative morbidity severity 
This thesis adds to and supports existing research relating to the concept of ‘relative 
morbidity severity’ in populations. This method, to define conditions based on general 
practice records has previously been associated with physical health in English & Dutch 
general practice samples (Kadam et al. 2009). Using this index to examine the relative 
morbidity severity of diagnostic labels is supported by the association between the increasing 
severity of a priori ordered labels and poorer physical health.  
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10.7. Implications drawn from the thesis 
10.7.1. Implications for research 
Research into comorbidity has increased substantially in the previous decades. The presence 
of comorbidity has been established as an important factor to consider, or at least adjust for, 
in studies. However, research which has examined the interaction between specific comorbid 
disease combinations in general practice is extremely limited. This thesis, and specifically the 
2C study, is a novel examination into the interaction of two comorbid combinations. Not only 
is there limited research into the interaction between CVD & OA, but this has not been 
examined in either general practice or in the UK. This thesis therefore is an important 
addition to the field of comorbidity research. 
 
This thesis is an argument for further examination of different comorbid interactions 
because, though an interaction between CVD & OA was shown, this effect was less than 
expected. The true extent to which many comorbid pairs influence physical and other aspects 
of health needs to be established. Such information on the natural history of different 
combinations would form a basis to support clinical practice. Looking forward, this research 
presents a design which other studies could use. 
 
An important implication of this thesis for epidemiological research design, is the additional 
support to the use of diagnostic labels to define disease groups. This work adds support to 
that previously conducted by Kadam et al, by demonstrating that this morbidity index can be 
used to consider the relative severity of morbidities, as the labels applied in clinical practice 
are a marker of physical health. Relative morbidity severity is therefore a means of 
determining the severity of disease populations in general practice. There was previously a 
lack of general practice measures of severity for use in epidemiological research, this now 
provides an opportunity for the definition of large disease group samples, where defining 
conditions through tests may not be appropriate or conducted on a regular basis 
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Finally, an implication for research involving the SF-12 or SF-36 is the use of z-scores, as used 
in the systematic review. The SF surveys are widely used general health measures, with the 
PCS and MCS scores frequent choices of outcome. Use of both the PCS and MCS scores are a 
function of calculations based on US normative data. Though these summary scores allow 
comparison between datasets, these are limited by their standardisation around American 
data norms, introducing measurement bias when comparing samples from countries other 
than the US. The use of z-scores presents an alternative methodological choice when using SF 
surveys, allowing comparison between the general health of disease groups with normative 
data from the same country. As the number of normative datasets from different countries 
increases, the opportunity to test this further will also increase.  
 
10.7.2. Implications for clinical practice 
Clinical implications, range from those which contribute to general clinical knowledge, 
through to that which are directly applicable in general practice. The wider clinical 
implications of the results from the 2C study suggest that for chronic disease populations, 
severity and comorbidity are important issues to address. Clinicians should consider that 
increasing CVD severity is associated with worse physical health and furthermore, that 
populations with ‘more severe’ CVD would see greater deterioration in their physical health 
than those with ‘less severe’ CVD over a 3-year time-period. With CVD, the addition of OA will 
have a negative influence of physical health, greater than for those who consult with 
individual CVD or individual OA. 
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It is also useful for clinicians to understand that change in the physical health of patients with 
individual and comorbid chronic disease is not substantial over the periods examined in this 
thesis. Despite the change seen in the CVD group after three years, this was not so for MSK. 
Furthermore, no short-term change was seen for either CVD or OA. Contrary to the 
hypothesis, increasing morbidity severity did not lead to substantial alterations in the general 
health experience of these disease groups. Therefore, less intensive monitoring may be 
appropriate. 
 
Finally, the morbidity index not only has implications for research, but this is also directly 
applicable in clinical practice. By understanding that a diagnostic label can be used as a 
marker of disease group severity and health, general practices can use diagnostic labels as an 
indicator of health in comorbid groups. This may allow them to place greater importance on 
particular conditions more practically.  
 
10.7.3. Implications for health policy 
Patients with CVD & OA comorbidity will experience worse general physical health than those 
with these conditions individually. GPs & nurses need to consider this influence of CVD with 
OA and tailor management and treatment to account for this. Improved treatment may not 
only improve patient care but also reduce consultations. A consequence of comorbidity is 
increased health care expenditure. As general practice primarily deals with comorbidity, then 
this subsequently places a large burden on resources. In England, a record-based cohort 
study of approximately 100,000 general practice patients found that 16% had more than one 
chronic disease, but that these patients accounted for 32% of all consultations (Salisbury et 
al. 2011). 
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Despite growing awareness for a need to address comorbidity, research and health services 
have continued to neglect this problem. Much research continues to underestimate the 
importance of comorbidity or even excludes patients with it (as is often the practice in 
Randomised Control Trials (RCT)). This continues as comorbidity is seen to complicate the 
research question (Rijken et al. 2005). To counter this, a more holistic approach may be 
required. General practice is currently predominantly driven by a medical model of care of 
conditions in isolation and this approach has been strengthened by incentivised systems, 
such as the QOF to treat and monitor certain diseases (Tinetti, Fried 2004). 
 
The practice of focusing on individual conditions is driven in two main ways. Firstly, the NHS 
strives to perform evidence-based medicine, yet in research, patients are frequently excluded 
if other diseases are apparent. Patients with comorbidity are frequently excluded from 
clinical trials in favour of patients with only the disease of interest (Schellevis et al. 1993). 
Secondly, clinical guidelines inform clinicians of the best practice for a disease but these 
frequently fail to consider comorbidity with the guideline disease of interest (van Weel, 
Schellevis 2006). Even those which make reference to comorbidity dedicate little to this area 
and even fewer recommendations for management or treatment (Lugtenberg et al. 2011). 
The current management of diseases within general practice solely based on individual and 
isolated perspectives of conditions is not likely to be in the best interest of the patients or 
finite health service resources (Starfield et al. 2003). 
 
Finally, osteoarthritis is not currently included as part of the QOF. To ensure that those 
patients with OA & CVD are optimally managed those with CVD & OA comorbidity could be 
identified through CVD registries. Those with a CVD & OA could be identified as potentially in 
need of increasing support for physical health. 
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Box 10.3: Summary of thesis implications 
Research implications 
 The study design, to examine interaction between comorbid disease groups in 
comparison to individual morbidity, could be used with other disease combinations 
 Increasing morbidity severity, defined from general practice records, is associated 
with poorer physical health. This is further evidence that the Kadam morbidity 
index can be used as a method to define severity 
 In light of the increasing number of national datasets, use of z-scores provides an 
opportunity to consider the physical health of disease groups in the context of their 
own country’s normative population 
 
Clinical implications 
 Clinical knowledge is added by understanding that the way in which two chronic 
diseases interact may not be a purely additive effect 
 These findings are clinically useful as clinicians can be confident that these disease 
groups will not rapidly deteriorate either in the short-term or long-term (MSK only) 
 That clinicians can define the severity of disease groups by diagnostic labels applied 
in general practice consultations, is clinically applicable information as they can use 
such information to define groups for their own use  
  
Health policy implications 
 From a general perspective, and where appropriate, diseases should be considered 
more in combination and not always individually 
 Where disease registry groups are used by practices to see CVD patients, benefit 
may be gained in identifying a subgroup of those with OA, as physical health will 
likely be poorer 
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10.8. Strengths & limitations of the thesis 
10.8.1. Strengths 
This thesis presents findings from several novel aspects of research related to chronic disease 
and chronic disease comorbidity in general practice populations. This presents an elaborate 
systematic review which has collated research articles to form the current understanding of 
how individual chronic conditions influence physical health and expanded on a method to 
perform this in the form of z-scores. Secondary cross-sectional and cohort analysis has added 
to the concept of ‘relative morbidity severity’ as an epidemiological measurement of general 
population health, highlighting the appropriateness of using GP records formed from the 
diagnostic labels applied in general practice by GP and nurses. 
 
The original component of the thesis is a novel prospective cohort study which provides new 
understanding into the interaction of comorbid conditions, the role of severity and the 
influence on short-term change in physical health. 
 
10.8.2. Limitations 
Limitations related to specific chapters have already been highlighted. However, there are 
several points to be addressed for the thesis as a whole. One such issue relates to the use of 
the SF-12 as the primary outcome in testing for an additive or multiplicative interaction 
between CVD & OA on physical health. It is possible that any potential to measure a 
multiplicative effect would always be limited compared to measuring an additive effect by the 
initial poor health of this sample. In particular, there may have been a limited ability of 
patients, already with one chronic disease and the poorest baseline health (i.e. heart failure 
patients) to experience a multiplicative effect of poorer health with the combination of OA. 
However, the SF-12 has been used previously in an OA cohort, which found a multiplicative 
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effect of increasing comorbidity on poorer physical health (Kadam, Croft. 2007) and this 
limitation is not only related to the SF-12 and would influence any outcome measure. 
 
A further limitation is the use of a self-report outcome measure to assess QOL over time. Such 
measures, including the SF-12, are vulnerable to bias as a result of response shift. As defined 
by Schwartz & Sprangers in 1999, response shift is “a change in the meaning of one's self-
evaluation of a target construct as a result of: (a) a change in the respondent's internal 
standards of measurement; (b) a change in the respondent's values or (c) a redefinition of the 
target construct” (Schwartz, Sprangers 1999). An example of such a shift is the psychological 
adjustment to disease, despite long-term physiological deterioration. Schwartz found that in 
multiple sclerosis patients with functional deterioration over two years, self-reported health 
improved with the intervention of coping strategies, the health scores had been biased by the 
patients’ ability to adjust to their situation (Schwartz 1999). In this thesis, disease groups 
were defined using patients’ past medical records. As a result, patients may have had 
conditions for a long time, already adjusted to their condition and therefore health change 
would be minimal. This may be a reason for the small health changes observed in this work. 
 
Finally, across the primary and secondary data analysis, limitations may exist as a result of 
clustering of observations within each of the General Practices. As a result of local factors, for 
example, methods of disease coding in Practice, living standards or working environmental, 
Practice patients from a certain geographical area may share characteristics not experienced 
by patients living in other areas (Lawlor et al. 2003). Such clustering can mean that analysis, 
which assumes each observation (individual patient) as independent may have introduced 
some variance into the results.  However, the use of ten Practices, across three different local 
regions (Cheshire, North Staffordshire & Stoke-on-Trent) and the weighting of patient 
numbers by Practice size mean that a variety of patients would have been included and 
therefore reducing the chances of greatly different patients types. 
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10.9. Future research 
10.9.1. Further 2C study analysis 
The 2C study provides the potential for further research, with five main avenues of analysis.  
 
1) Linkage analysis, with the future linkage of 2C survey data with the general practice 
patient records of the consenting sample, there is the potential to expand on the 
questions examined in this thesis. Prescribing and referral histories of those with CVD 
& OA comorbidity compared to the index categories could inform on combined drug 
usage or patterns of secondary care use for comorbid patients.  
 
2) Health trajectories, due to the prospective design of the 2C study, with surveys 
completed on a monthly basis for a 12-month period, there is the potential to examine 
several different outcomes on a monthly basis to observe the trajectories of patient 
health in this sample.  
 
3) Disease specific outcome measures, the baseline and 12-month follow-up surveys 
contained many disease specific outcome measures, for CVD, MSK and pain. Similar or 
more expansive analysis to that performed in this thesis could be conducted with the 
data from these measures to assess the influence of CVD & OA comorbidity on 
condition-specific components of patient health. 
 
4) Relative morbidity severity, further assessment of this method to define severity can 
be conducted using any of the other health measures of the 2C study 
 
5) Minimal clinically important difference (MICD), longitudinal data can be assessed for 
clinically meaningful changes in patients, across different outcome measures of the 2C 
study, several time points and in different disease groups 
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10.9.2. Comorbidity research 
This thesis adds to research which has demonstrated that, though general comorbidity 
frequently has a negative consequence, specific disease pairs can have varying effects. 
Additional research into the interactions of different disease combinations would be 
beneficial. In the first instance, this would inform on the consequence of different chronic 
disease pairings within populations and their effect on patients. Expanding from that, such 
information would be useful to include in clinical guidelines. 
 
Though several prospective studies have been highlighted within the thesis there is much 
need for well-designed prospective studies, covering both short-term periods as in this thesis 
and much longer periods. This needs to be conducted in general practice samples to examine 
how different aspects of health or the course of life long conditions are changing. 
 
10.10. Conclusions 
The negative consequences of the presence of comorbidity have been established previously. 
Though the volume of research considering the influence of comorbidity has rapidly 
increased in recent decades, this research has remained general in approach, primarily 
considering wide disease concepts and overarching definitions of comorbidity, such as 
counts. Though some comorbidity research has examined paired diseases, these have failed 
to sufficiently consider how the physical health of these patients may alter over the short 
term. This thesis highlights that a more specific understanding of disease interactions is 
required, such as the type of conditions and their severity. If we are to offer practical 
mechanisms for clinicians to address patients’ needs, the difficult but essential questions of 
how specific diseases interact and the subsequent impact upon multiple aspects of patient 
health must be expanded upon.  
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James A Prior1,2*, Claire A Rushton1, Kelvin P Jordan2 and Umesh T Kadam1,2Abstract
Background: Two of the commonest chronic diseases experienced by older people in the general population are
cardiovascular diseases and osteoarthritis. These conditions also commonly co-occur, which is only partly explained
by age. Yet, there have been few studies investigating specific a priori hypotheses in testing the comorbid
interaction between two chronic diseases and related health and healthcare outcomes. It is also unknown whether
the stage or severity of the chronic disease influences the comorbidity impact. The overall plan is to investigate the
interaction between cardiovascular severity groups (hypertension, ischaemic heart disease and heart failure) and
osteoarthritis comorbidity, and their longitudinal impact on health and healthcare outcomes relative to either
condition alone.
Methods: From ten general practices participating in a research network, adults aged 40 years and over were
sampled to construct eight exclusive cohort groups (n = 9,676). Baseline groups were defined on the basis of
computer clinical diagnostic data in a 3-year time-period (between 2006 and 2009) as: (i) without cardiovascular
disease or osteoarthritis (reference group), (ii) index cardiovascular disease groups (hypertension, ischaemic heart
disease and heart failure) without osteoarthritis, (iii) index osteoarthritis group without cardiovascular disease, and
(vi) index cardiovascular disease groups comorbid with osteoarthritis. There were three main phases to longitudinal
follow-up. The first (survey population) was to invite cohorts to complete a baseline postal health questionnaire,
with 10 monthly brief interval health questionnaires, and a final 12-month follow-up questionnaire. The second
phase (linkage population) was to link the collected survey data to patient clinical records with consent for the
3-year time-period before baseline, during the 12-month survey period and the 12 months after final questionnaire
(total 5 years). The third phase (denominator population) was to construct an anonymised clinical data archive for
the study five year period for the total baseline cohorts, linking clinical information such as diagnosis, prescriptions
and referrals.
Discussion: The outcomes of the study will result in the determination of the specific interaction between
cardiovascular severity and osteoarthritis comorbidity on the change and progression of physical health status in
individuals and on the linked and associated clinical-decision making process in primary care.
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As people get older, they are more likely to experience a
chronic disease, such as cardiovascular disease (CVD) or
osteoarthritis (OA), and many will experience two or
more chronic diseases at the same time [1]. With in-
creasing life spans, each individual is more likely to
experience multiple chronic diseases. Yet, in the day-to-
day management of patients, the focus has often been
on single chronic disease [2]. Such approaches do not
acknowledge or address the common experience of older
populations with multiple chronic diseases such as CVD
and OA. Implications for the impact on health care and
health care systems lie, for example, in the variations in
the clinical decision-making process as exemplified by
referrals [3] and in mortality outcomes [4], which could
be explained by the presence of multiple chronic dis-
eases in the same individual. It has been argued that the
management of single diseases may distort the provision
of good health care by not addressing the potential inter-
actions of different conditions and therefore not appro-
priately assessing the management of each chronic
illness in the real clinical situation [5]. Consideration of
potential patterns of care in patients with comorbidity
requires a broader perspective on management and the
clinical pathways, and alternative approaches are
required to address this problem [6]. From an inter-
national perspective, in an ageing European population,
this issue is set to become an increasing public health
priority. Current estimates range up to 30 million
European sufferers with two or more chronic diseases, with
further increases likely as the number of older Europeans
expands by an estimated 30% in the next 25 years [7].
Two of the commonest chronic diseases experienced
by older people in the general population are CVD and
OA [8]. Cardiovascular disease, shares many of the
chronic disease characteristics shown by OA, and is an
important cause of disability as well as mortality. A
range of studies have shown that CVD is associated with
poor physical health, and this relationship influences
management progression and health care outcomes. For
example, people with poor physical health are likely to
report greater CVD health needs [9], the progression of
CVD symptoms is likely to be associated with poor
physical health [10] and this in consequence is likely to
lead to higher hospital admissions and mortality [11]. In
a similar pattern to OA, co-existing depression adversely
influences symptoms of CVD and is more likely to be
associated with poor physical health [12]. Specific stud-
ies have also shown that poor physical health is asso-
ciated with CVD that range from hypertension, atrial
fibrillation, angina, myocardial infarction to heart failure.
Some studies indicate that poor health in hypertension
is unexplained by socio-demographic factors or comor-
bidity [13], in atrial fibrillation is dependent on theseverity of symptoms [14], in angina patients is asso-
ciated with depression and anxiety [15], and in myocar-
dial infarction or heart failure is associated with poor
health care outcomes [16,17].
Osteoarthritis is the most frequent reason for
restricted activity in daily life [18] and has a high im-
pact on health care use and costs [19], both in hos-
pital (for example, joint replacements [20]) and in
primary care in relation to consultations and drug use
[21]. The prevalence of many other disabling condi-
tions also rises with age, and some common chronic
conditions can be found alongside OA, including CVD
[22]. We have previously shown that there are specific
associations in OA sufferers in general practice [23]
and that the combination of OA and comorbidity is
associated with much poorer physical health [24]. Sev-
eral studies have shown that OA and specific CVD are
associated together and this co-occurrence is independ-
ent of age [25,26]. Explanations for this finding include
pathologic links, similar and shared risk factors or inter-
mediary links, such as drugs (anti-inflammatories). In
addition to adverse mortality outcomes, previous OA
studies have also shown that people with CVD comor-
bidity have poor quality of life, and that co-existing
conditions such as depression can influence similar
outcomes [27,28].
In primary care, where multiple morbidity is the rule
rather than the exception [29,30], general practitioners
and primary care by definition deal with many different
morbidities presented by the same individual. As each
encounter contributing to multiple morbidity is rou-
tinely recorded during consultations and subsequently
in historical records, so a catalogue of health states
emerges through which an individual passes over time.
Such health events might be linked to each other [31],
because they represent overlapping syndromes [32] or
are a result of shared causes or mechanisms, and their
interactions might help to explain different patterns in
health course or progression. Studies of multiple mor-
bidity in primary care, based on a limited number of
empirically selected chronic conditions, have shown
that it is negatively associated with overall health [33]
and that it is associated with increased referral to sec-
ondary care and increased health care costs [1,34].
Whilst, studies of the association between specific
chronic diseases and overall health have been com-
pleted, especially in relation to changes within interven-
tion studies, very few studies have examined the
patterns of change in health that leads to consultation
[35] and in those with specific dual chronic diseases at
the same time. How comorbidity influences short and
longer-term health status in CVD or OA, how it causes
changes in health status, and how it influences health
care management decisions is unknown.
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be spectrum of different disease categories for each in-
dividual chronic disease. So for example, the term ‘CVD’
encapsulates a spectrum ranging from hypertension to
chronic congestive heart failure as outlined, and ‘OA’
encapsulates a spectrum of joint-specific problems. In
each spectrum, each stage implicitly carries the notion of
the process of disease severity related to a specific out-
come. For example, in people with OA, impact on mobil-
ity will be dependent on the joint site and whether there
is pain with or without radiographic change, whereas, the
stage of CVD will determine outcomes, such as health
status and mortality. In the course of chronic disease de-
velopment in populations, it is the stages within each dis-
ease process that offers one definition of ‘severity’.
Studies, for example, in the CVD field, suggest that the
lifetime risk of different CVD varies with age and the
related risk factors [36-38]. So instead of simply using
broad disease categories, the spectrum of CVD ‘severity’
potentially offers an empirical way of exploring the dis-
ease gradient to investigate whether the interaction be-
tween two individual chronic diseases and its impact on
health is over and above that which we might expect
from simply combining the individual effects.
Using an empirically defined order of disease severity
we intend to use hypertension, ischaemic heart disease
(angina or myocardial infarction) and heart failure as
indicators of CVD severity with comorbid OA defined
as a single broad category. In this study we propose to
investigate the specific interaction of CVD severity and
OA comorbidity on:
(i) the progression of physical health (with the null
hypothesis: that the adverse influence on physical
health is the same for CVD and comorbid OA
compared to those with either index condition
alone), and
(ii) the associated clinical decisions in consulting adult
general practice populations aged 40 years and over
compared to consulters with either condition alone
or without either condition (with the null
hypothesis: that clinical decisions are the same for
CVD and comorbid OA compared to those with
either index chronic disease).
Methods
Setting
Our study will be carried out in ten general practices,
from North Staffordshire, Stoke-on-Trent and Cheshire.
These practices are part of a local research network, the
Primary Care Musculoskeletal Research Consortium.
These practices, supported by the Primary Care
Research West Midlands North (PCR WMN) network,
cover a wide range of socio-economic groups and includespractices that have actively participated in routine collec-
tion of clinical data using computer records for the pur-
poses of epidemiological study. Clinical information
relating to all morbidity and drug therapies is recorded
using standard classifications of Read codes [39] and BNF
(British National Formulary) respectively [40]. Ethics
permission was sought and given by the Cheshire
Research Ethics Committee (REC ref no: 09/H1017/40).
Study population
The cohort study is based on the recruitment of four main
groups aged 40 years and over who have either a record
or consultation for: (i) No CVD or OA (reference); (ii)
CVD without OA; (iii) OA without CVD and (iv) CVD
and OA (comorbid cohort). The sampling of these groups
from the ten general practices was in a three-year period
beginning November 2006 and ending January 2010.
Identifying cohort samples
CVD cohorts: Using the CVD registers and historical
information, all adults aged 40 years and over who had
a record (main Read code Chapter G: “Cardiovascular
system diseases”) and on active registration at the end
of the 3-year study time-period will be identified.
Cohorts will then be based on the three CVD severity
categories of hypertension (Read and daughter codes
beginning with G20), ischaemic heart disease (Read and
daughter codes beginning with G3.) and heart failure
(Read and daughter codes beginning with G58 and
heart failure codes related New York Heart Association
(NYHA) classification), as these conditions are cur-
rently part of the national Quality Framework of clin-
ical recording, a means by which General Practitioners
(GP) are reimbursed as part of chronic disease manage-
ment. The CVD groups will be organised into three ex-
clusive severity groups, which means that allocation to
a cohort group will be based on the most severe cat-
egory e.g. if an individual had consulted for hyperten-
sion and heart failure, they would be in the heart
failure cohort. Previous studies have indicated that the
recording quality of such information is likely to be
high [41,42]. These three cohorts will be separated into
two sub-groups of (i) patients who had not consulted
for OA in the same time period (index CVD cohort)
and (ii) patients who had also consulted for OA in the
same time period (comorbid cohort). All those in the
three CVD severity groups who had comorbid OA
were sampled, as were those with heart failure or is-
chaemic heart disease but no OA. However, those with
hypertension but without OA were randomly sampled
(stratified by practice) given the high prevalence of this
group (see Sample size).
OA cohort: Using the general practice records for the
same time period (2006–2010), all adults aged 40 years
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have a historical record or consultation for OA (Read
and daughter codes beginning with N05, and codes
related to OA joint replacement (7 K2 or 7 K3)) will be
identified. This cohort group will be exclusive of those
patients who had also consulted for any CVD-related
diagnosis (as stated above) in the same time period.
Non-index cohort: Using the general practice records
for the same time period (2006–2010), a random sample
stratified by practice of all adults aged 40 years and over
without a historical record or consultation for the study
specific CVD and OA codes will be identified. This sam-
ple will provide a random reference group for the other
main cohort categories.
Data collection
There are 3 phases to the study data collection. The first
phase (survey population) will use postal questionnaires
to obtain self-reported health information at baseline,
monthly interval and 12-month follow-up. The second
phase (linkage population) will link the survey data to
consultation data, for patients who will give written con-
sent to access their clinical records from general practice
in the baseline questionnaire. The third phase (denomin-
ator population) will construct an anonymised database
for the whole cohort for the total five-year time-period.
So the denominator cohort constitutes the whole sample
from which the survey sample will be drawn. The de-
nominator sample will provide the basis for a distinct
cohort sample in its own right, as well as addressing se-
lection comparisons between people who took part in3-year and historical GP records 
Reference: Without CVD or OA 
3 Index CVD groups without OA 
Index OA group without CVD  
3 CVD comorbid groups with OA 
P
I
L
O
T
Baseline main 
questionnaire (Q1)  
General measures 
Cardiovascular measures 
Pain and OA measures 
Lifestyle measures 
Socio-demographic
Consent to monthly survey 
Consent to record review 
review to identify cohorts   :
Figure 1 2C study design.the survey and those who did not, and people who gave
consent to record review and who did not.Phase 1: Survey population
Overall, study participants will be invited to complete
12 questionnaires – baseline and 12-month follow up,
and between these time-points, 10 monthly short-
interval questionnaires (Figure 1). A pilot study in one
practice on 500 patients was carried out to test the
feasibility of sampling and testing of the questionnaire
methods.Baseline survey
The identified sampled cohorts will be sent a baseline
questionnaire (Q1), which will include generic and
specific-health measures (Table 1). Measures have been
identified on the basis of the primary focus on CVD and
OA diseases and other specific measures selected on the
basis of conceptual links between the disease and out-
come of interest in the follow-up phase.
For the primary outcome of interest, we will use the
Short-Form-12 (SF-12) (version 2) health survey as a
generic measure of physical health, specifically the Phys-
ical Component Summary (PCS) score [43]. We will also
include an assessment of physical activity [44] and Hos-
pital Anxiety and Depression (HAD) questionnaire will
be included as a measure of psychological status, that
influences both CVD and OA [45].
The CVD-specific measures will include the: Seattle
Angina Questionnaire [46], Kansas City Cardiomyopathy12 months
12-month Follow-up 
questionnaire (Q12) 
(Repeat main questionnaire) 
10 monthly-short 
questionnaires 
Table 1 Comorbidity Cohort (2C) study measures
Survey measures
Data source Factors Baseline & 12-month follow-up Short monthly**
Clinical records 8 disease cohorts • Read code classification*
Consultation comorbidity • Kadam severity classification
Blood tests & investigations • Read code classification*
Drugs prescribed • British National Formulary (BNF)
Referrals • Read code classification*
Survey data General measures • Short form 12 (SF-12) health survey • SF-12
• Short form 36 (SF-36) health survey – Q2 only • SF-36, Q2
• EuroQol (EQ-5D)
• Hospital Anxiety and Depression (HAD) scale
• Medical Outcomes Study (MOS) - Sleep Scale • Qs 1 & 2 only
• Functional Assessment of Chronic Illness (FACIT) – • Qs 5 & 6 only
Fatigue
• Brief Illness Perception Questionnaire (B-IPQ)
• Social Networks
Cardiovascular measures • Seattle Angina Questionnaire (SAQ), UK version • Qs 2 & 3 only
• Kansas City Cardiomyopathy Questionnaire (KCCQ) • Qs 3 & 7 only
• Rose Angina Questionnaire
• Palpitations (based on [50]) • Q1 only
• Vertigo Severity Scale (VSS) • Q1 only
Pain and OA measures • Pain manikin, pain frequency & pain intensity • Pain frequency
• Knee Injury & Osteoarthritis Outcome Score (KOOS) –
Physical Function Shortform
• Hip Injury & Osteoarthritis Outcome Score (HOOS) –
Physical Function Shortform
Lifestyle • Body Mass Index (BMI), Alcohol, Smoking
• Short Questionnaire to Assess Health Enhancing • Qs 2a, 2c, 2e only
Physical Activity (SQUASH)
Other • Eyesight/hearing
• Body shape
Survey & clinical records Socio-demographic • Age, Gender, Deprivation
*Read code classification is a standard clinical coding system used in British general practice; **question numbers refer to the original questionnaire.
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symptoms of palpitations [49] and dizziness [50].
The OA-specific measures will include the: Knee injury
and Osteoarthritis Outcome Score (KOOS – physical
function component) [51], Hip injury and Osteoarthritis
Outcome Score (HOOS – physical function component)
[52], pain scale, pain manikin [53], joint pain, and other
links previously reported in chronic disease literature in
relation to the symptoms of tiredness [54] and sleep [55].
Survey participants will also be requested for consent
to the monthly short-interval questionnaires and for per-
mission to the subsequent review of their clinical
records. Participants will be “tagged” in their general
practice registers as ‘2C’ study participants.Measurement of health in the 12-month follow-up period
With baseline consent, participants will be sent 10
monthly short-interval questionnaires (4 pages), including
the SF-12, pain measures and CVD symptom measures.
At the end of the study period, all study participants
will be sent a 12-month follow-up postal questionnaire
(Q12) using the same measures as used in the baseline
survey.
Phase 2: Survey-consultation linkage population
The linked consultation data covers a total five-year
time-period, for 3 years before the baseline survey,
12 months of the survey, and the 12 months after the
full follow-up survey. We will measure the clinical
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vey cohort follow-up. Using the same study samples for
both phases allows the linkage of the self-reported health
status, morbidity and the decision process experienced
by that individual patient in the 12-month period.
After the completion of the survey phase, the clinical
record data for cohort groups will be downloaded with
prior patient consent. Clinical decisions in consenting
patients will be measured following the baseline survey
on the basis of: (i) drug treatment changes (new, repeat,
dose, type), (ii) investigations such as blood tests or
X-rays, (iii) referrals (in-practice and external, investiga-
tion or second-opinion) or (iv) no change in any of these
measures. Drug use will be measured on the basis of
new index-related treatments (i.e. analgesia for OA and
CVD-related therapies), or change in doses used for
those on pre-existing drug treatments. Investigations will
cover index-specific indications, cardiological (e.g. Elec-
trocardiogram (ECG), Cholesterol) or rheumatological
(e.g. X-Rays). Referrals will include those relevant to the
index conditions (i.e. physiotherapists and allied thera-
pists, rheumatologists, orthopaedics and cardiologists)
and all other referrals. Other measurements for the
cohorts will include all other comorbidity using the
Kadam severity classification [56,57], specific morbidities
such as cerebrovascular disease and peripheral arterial
disease, and co-drug therapies used.
Phase 3: Anonymised denominator population
Phase 1, survey population method is defined by the
responders who take part in the study, phase 2, the
survey-consultation method is subject to the consenters
who will give permission for this link to occur. There-
fore, phase 3 will focus on the total cohort denominator
population and the anonymised clinical data within the
medical records of each individual patient to allow
methodological assessment of response biases in the co-
hort samples. Patients who explicitly stated to their gen-
eral practice that they did not wish to take part in any
research or share their clinical data are excluded from
this phase.
For the total denominator population, invited to take
part at baseline, anonymised clinical data with patient
diagnostic information, prescribed drugs, blood tests and
investigations, referrals and linked healthcare activity
will be collected. This anonymised data archive covers a
total five year time-period (between 2006 and 2011)
from 3 years prior to the baseline survey to 12 months
after the 12 month follow-up survey (Figure 2).
Sample size
The pilot study was used to guide the sample size
needed. The primary outcome of the study is the mean
change in PCS score from baseline to 12-month follow-up. In order to compare the change in PCS score be-
tween the whole comorbid (OA and CVD) cohort and
the OA index cohort we estimated that at least 394
patients responding at 12 months per cohort were
needed (confidence level 0.05; power 80%) to detect a
between cohort effect size of 0.2. Based on expected
responses of 60% at baseline and 70% at 12 months, this
required 939 patients to be invited with comorbid OA
and CVD and 939 with OA alone. Assuming 75% con-
sent to medical record review, this number would also
give 423 people in each cohort responding at baseline
and consenting to record review. However, to maximize
numbers in the index CVD cohorts (hypertension, is-
chaemic heart disease and heart failure), OA index and
comorbid groups and in order to allow comparison be-
tween the CVD severity comorbid cohorts with their
related index CVD cohorts, we invited all eligible
patients with these conditions to participate. The excep-
tions were the index hypertension cohorts and index OA
cohorts where we randomly sampled patients stratified
by practice due to the large size of these groups. Simi-
larly, we also randomly sampled patients from the refer-
ence group without CVD or OA.
Analysis
Phase 1: Survey population
The initial analysis will use independent t-tests to com-
pare the OA and CVD comorbid cohorts with mean
change in PCS over the 12-month period. We will then
examine the influence of CVD severity, comorbidity and
baseline covariates on mean change in PCS score using
multiple linear regression methods, including cohort
group, anxiety and depression, Body Mass Index (BMI),
and socio-demographic characteristics (i.e. age, gender,
neighborhood level deprivation [58]) as explanatory vari-
ables. These analyses will be repeated with change in the
Mental Summary Component (MCS) score of the SF-12
as the outcome.
The monthly PCS scores from the SF-12 will be used
as time-dependent repeated outcomes in the 12-month
follow up period, to determine the association of base-
line measures and time on monthly PCS score. This ana-
lysis will use repeated measures multilevel modelling,
with a 2-level model (repeated PCS score within
patients) with the same explanatory variables as for the
12-month analysis.
Phase 2: Survey-consultation linkage
We will also determine cumulative onset of disability
defined on the basis of the generic and disease-specific
health measures. The rate of progression to severe dis-
ability in the comorbid groups will be estimated com-
pared to the other groups using Cox regression.
Attributable fractions for health status and clinical
Anonymised denominator cohort (total study population) N=9,676 
Survey responders cohort n=5,426 
Survey-consultation linkage consenters cohort n=4,030 
Baseline
Questionnaire 1 
Follow-up 
Questionnaire 12 
Baseline
Questionnaire 1 
Follow-up 
Questionnaire 12 
12 months consultations 12months consultations
12 months consultations/clinical data from GP records 12months consultations 
Total time-period 5 years (2006-2011) 
3 years consultations 
3 years consultations 
Monthly short questionnaires 
Figure 2 Comorbidity Cohort (2C) design.
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(age, gender, deprivation, obesity, consultation comor-
bidity) for onset or progression of disability will be
determined. We will also assess time to change in clin-
ical decisions.
Phase 3: Denominator population
We will compare consultation patterns and management
for the anonymised denominator cohort to the survey-
consultation cohort to assess generalisability of our find-
ings and estimate the likely extent of response bias.
Preliminary data
Initial data collection has already been completed and the
following data is presented to follow the sequence of sam-
pling stages in an epidemiological cohort study (Figure 2).
Denominator population
In the denominator cohort population, there were 9,676
people aged 40 years and over (Table 2) who wereidentified as baseline participants. The denominator study
groups were as follows: 2,535 (26%) without CVD or OA;
CVD index groups without OA – 1,322 (14%) with hyper-
tension, 2,036 (21%) with ischaemic heart disease, 259
(3%) with heart failure; 1,317 (13%) in OA index group
without CVD, and CVD groups with comorbid OA –
1,644 (17%) with hypertension, 490 (5%) with ischaemic
heart disease, 73 with heart failure (1%).
Reference cohort: The reference cohort without CVD
or OA (Table 3) was composed of the younger popula-
tion, and around 69% were aged 59 years or younger. It
had an equivalent number of men and women, and
around 20% in the top or bottom tertiles of deprivation.
Index CVD cohorts without OA: The youngest age
groups were in the hypertension cohort (30% aged
59 years and younger), and the oldest groups were in the
heart failure cohort (69% aged 70 years and over)
(Table 3). There were more men than women in both
the IHD and heart failure cohorts, and a quarter of the
heart failure cohort had the most deprived status.
Table 2 2C baseline cohorts
Disease
cohort
Cohort
ID
Denominator cohort
N = 9676 n
Responders cohort
n= 5426 n* (%)
Non-responders
cohort n =4250
n* (%)
Linkage consenters
cohort n =4030
n** (%)
-CVD -OA 0 2535 1165 (45.9) 1370 (54.1) 820 (70.4)
+Hyp -OA 1 1322 720 (54.5) 602 (45.5) 525 (72.9)
+IHD -OA 2 2036 1196 (58.7) 840 (41.3) 915 (76.5)
+HF -OA 3 259 149 (57.5) 110 (42.5) 108 (72.5)
-CVD+OA 4 1317 828 (62.9) 489 (37.1) 617 (74.5)
+Hyp+OA 5 1644 1017 (61.9) 627 (38.1) 773 (76.0)
+IHD+OA 6 490 305 (62.2) 185 (37.8) 237 (77.8)
+HF+OA 7 73 46 (63.0) 27 (37.0) 35 (76.1)
CVD=Cardiovascular disease, OA=Osteoarthritis, Hyp =Hypertension, IHD= Ischaemic heart disease, HF =Heart failure.
Disease categories (defined by study specific Read codes in the 3 years prior to baseline survey.
-CVD -OA= no record of CVD (hypertension, IHD or HF) condition or OA; -CVD +OA= record of OA but not CVD (hypertension, IHD or HF).
+Hyp -OA= record of hypertension without OA; +IHD -OA= record of IHD without OA; +HF -OA= record of HF without OA.
+Hyp+OA= record of hypertension and OA; +IHD+OA= record of IHD and OA; +HF +OA= record of HF and OA.
*percentage of denominator population; **percentage of responder population.
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was aged between 50 and 80 years of age, and there were
more women than men (Table 3). The age figures were
in contrast to the index CVD cohorts who had a higher
number in the age group 70 years and over, but the
deprivation figures were similar.
Comorbid CVD & OA cohort: The comorbid groups
were relatively older than the index groups and the age
proportion for the group 70 years and over were: 57% in
the hypertension comorbid group, 73% in the IHD
comorbid group and 93% in the heart failure comorbid
group (Table 3). There were more women than menTable 3 Socio-demographic characteristics of the 2C study de
Disease cohorts
Reference Index CVD cohorts
Factors -CVD -OA (0)
n = 2535
(%)
+Hyp -OA (1)
n = 1322
(%)
+IHD -OA (2)
n = 2036
(%)
+HF -
n =25
(%)
Age group
(years)
40-49 892 (35.2) 106 (8.0) 72 (3.5) 5 (1.9)
50-59 848 (33.5) 291 (22.0) 275 (13.5) 22 (8.5
60-69 513 (20.2) 416 (31.5) 617 (30.3) 54 (20
70-79 195 (7.7) 329 (24.9) 677 (33.3) 82 (31
80≥ 87 (3.4) 180 (13.6) 395 (19.4) 96 (37
Gender Men 1245 (49.1) 609 (46.1) 1334 (65.5) 142 (5
Women 1290 (50.9) 713 (53.9) 702 (34.5) 117 (4
Deprivation
Status*
Category 0
(most
affluent)
525 (20.8) 266 (20.2) 368 (18.1) 38 (14
Category 1 1521 (60.1) 786 (59.8) 1251 (61.6) 156 (6
Category 2
(most
deprived)
484 (19.1) 263 (20.0) 411 (20.3) 65 (25
CVD=Cardiovascular disease, OA =Osteoarthritis, Hyp =Hypertension, IHD= Ischaem
Multiple Deprivation score and available for 9,636 patients and ‘most affluent’ as thewith CVD and comorbid OA for all three groups, and
IHD comorbid group had relatively fewer numbers in
the top and bottom deprivation tertiles.
Survey participation and consent
In the baseline survey population, there were 5,426 (56%)
people aged 40 years and over who responded to the ques-
tionnaire. The lowest response was in the reference cohort
(46%) and the highest was in the comorbid heart failure
cohort (63%). The proportion of responders in the index
OA cohort and the CVD comorbid cohorts were higher
than the index CVD cohorts (Table 2).nominator population (n =9,676)
Index OA cohort CVD comorbid cohorts
OA (3)
9
-CVD+OA (4)
n = 1317
(%)
+Hyp+OA (5)
n = 1644
(%)
+IHD+OA (6)
n = 490
(%)
+HF+OA (7)
n = 73
(%)
138 (10.4) 33 (2.0) 4 (0.8) 0 (0)
) 309 (23.5) 172 (10.4) 22 (4.5) 1 (1.4)
.8) 445 (33.8) 499 (30.4) 106 (21.7) 4 (5.5)
.7) 278 (21.1) 554 (33.7) 203 (41.4) 23 (31.5)
.1) 147 (11.2) 386 (23.5) 155 (31.6) 45 (61.6)
4.8) 563 (42.7) 611 (37.2) 205 (41.8) 31 (42.5)
5.2) 754 (57.3) 1033 (62.8) 285 (58.2) 42 (57.5)
.7) 267 (20.3) 327 (20.0) 86 (17.7) 13 (18.3)
0.2) 808 (61.6) 980 (60.0) 310 (63.9) 43 (60.6)
.1) 237 (18.1) 327 (20.0) 89 (18.4) 15 (21.1)
ic heart disease, HF =Heart failure. *Deprivation status is based on Index of
top 20% of the sample and ‘most deprived’ as the bottom 20% of the sample.
Table 4 Socio-demographic characteristics of baseline responders stratified by study groups (n =5,426)
Disease cohorts
Reference Index CVD cohorts Index OA cohort CVD comorbid cohorts
Factors -CVD -OA (0)
n = 1165
(%)
+Hyp -OA (1)
n = 720
(%)
+IHD -OA (2)
n = 1196
(%)
+HF -OA (3)
n =149
(%)
-CVD+OA (4)
n = 828
(%)
+Hyp+OA (5)
n = 1017
(%)
+IHD+OA (6)
n = 305
(%)
+HF+OA (7)
n = 46
(%)
Age group
(years)
40-49 313 (26.8) 33 (4.6) 21 (1.7) 3 (2.0) 59 (7.1) 9 (0.9) 1 (0.3) 0 (0)
50-59 413 (35.5) 132 (18.3) 127 (10.6) 9 (6.1) 180 (21.7) 92 (9.0) 11 (3.6) 0 (0)
60-69 282 (24.2) 239 (33.2) 369 (30.9) 26 (17.4) 312 (37.7) 318 (31.3) 64 (21.0) 3 (6.5)
70-79 119 (10.2) 219 (30.4) 446 (37.3) 53 (35.6) 180 (21.8) 369 (36.3) 136 (44.6) 16 (34.8)
80≥ 38 (3.3) 97 (13.5) 233 (19.5) 58 (38.9) 97 (11.7) 229 (22.5) 93 (30.5) 27 (58.7)
Gender Men 547 (47.0) 324 (45.0) 807 (67.5) 89 (59.7) 332 (40.1) 391 (38.4) 140 (45.9) 23 (50.0)
Women 618 (53.0) 395 (55.0) 389 (32.5) 60 (40.3) 496 (59.9) 626 (61.6) 165 (54.1) 23 (50.0)
Deprivation
Status*
Category 0
(most
affluent)
279 (24.0) 155 (21.7) 243 (20.4) 23 (15.4) 168 (20.4) 222 (22.0) 59 (19.6) 8 (18.2)
Category 1 712 (61.2) 425 (59.4) 732 (61.4) 90 (60.4) 521 (63.2) 605 (59.9) 190 (63.1) 27 (61.3)
Category 2
(most
deprived)
173 (14.8) 135 (18.9) 217 (18.2) 36 (24.2) 135 (16.4) 183 (18.1) 52 (17.3) 9 (20.5)
CVD=Cardiovascular disease, OA =Osteoarthritis, Hyp =Hypertension, IHD= Ischaemic heart disease, HF =Heart failure. *Deprivation status is based on Index of
Multiple Deprivation score and available for 5,399 patients and ‘most affluent’ as the top 20% of the sample and ‘most deprived’ as the bottom 20% of the sample.
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of age, gender and deprivation characteristics, compared
to the denominator population (Table 3 and 4). When
comparing the responder and non-responder groups
(Tables 4 and 5), non-responders were likely to be the
younger groups, women and those people with the most
deprived status. In the reference cohort, 74% of the non-Table 5 Socio-demographic characteristics of baseline non-re
Disease cohorts (Cohort ID)
Reference Index CVD groups
Factors -CVD -OA (0)
n = 1370
(%)
+Hyp -OA (1)
n = 602
(%)
+IHD -OA (2)
n = 840
(%)
+HF -
n = 11
%)
Age group
(years)
40-49 579 (42.2) 73 (12.1) 51 (6.1) 2 (1.8)
50-59 435 (31.8) 159 (26.4) 148 (17.6) 13 (11
60-69 231 (16.9) 177 (29.4) 248 (29.5) 28 (25
70-79 76 (5.5) 110 (18.3) 231 (27.5) 29 (26
80≥ 49 (3.6) 83 (13.8) 162 (19.3) 38 (34
Gender Men 698 (50.9) 285 (47.3) 527 (62.7) 53 (48
Women 672 (49.1) 317 (52.7) 313 (37.3) 57 (51
Deprivation
Status*
Category 0
(most
affluent)
246 (18.0) 111 (18.5) 125 (14.9) 15 (13
Category 1 809 (59.2) 361 (60.2) 519 (61.9) 66 (60
Category 2
(most
deprived)
311 (22.8) 128 (21.3) 194 (23.2) 29 (26
CVD=Cardiovascular disease, OA =Osteoarthritis, Hyp =Hypertension, IHD= Ischaem
Multiple Deprivation score and available for 4,327 patients and ‘most affluent’ as theresponder group were 59 years or younger. The age pro-
portions of the index hypertension and index OA cohort
were similar, but the proportions of age groups 70 years
and over were higher in index IHD (47%) and heart fail-
ure (61%) cohorts, and highest in the IHD (70%) and
heart failure (93%) comorbid cohorts. Apart from the
reference cohort and the index IHD cohort, there weresponders stratified by study groups (n = 4,250)
Index OA Groups CVD comorbid groups
OA (3)
0 (
-CVD+OA (4)
n = 489
(%)
+Hyp+OA (5)
n = 627
(%)
+IHD+OA (6)
n = 185
(%)
+HF+OA 7)
n = 27
(%)
79 (16.2) 24 (3.8) 3 (1.6) 0 (0)
.8) 129 (26.4) 80 (12.8) 11 (5.9) 1 (3.7)
.5) 133 (27.2) 181 (2.9) 42 (22.7) 1 (3.7)
.4) 98 (20.0) 185 (29.5) 68 (36.8) 7 (25.9)
.5) 50 (10.2) 157 (25.0) 61 (33.0) 18 (66.7)
.2) 231 (47.2) 220 (35.1) 65 (35.1) 8 (29.6)
.8) 258 (52.8) 407 (64.9) 120 (64.9) 19 (70.4)
.6) 99 (20.3) 105 (16.8) 27 (14.7) 5 (18.5)
.0) 287 (58.8) 375 (60.1) 120 (65.2) 16 (59.3)
.4) 102 (20.9) 144 (23.1) 37 (20.1) 6 (22.2)
ic heart disease, HF =Heart failure. *Deprivation status is based on Index of
top 20% of the sample and ‘most deprived’ as the bottom 20% of the sample.
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quarter of the most deprived groups were non-
responders in all study cohorts.
Of the survey responders, 4,030 (74%) gave permission
to access and link their clinical records (Table 2), and
this linked clinical data will be anonymised for the pur-
poses of analyses. The lowest consent proportion was in
the reference group (70%) and the highest in the CVD
comorbid groups (76%).
Discussion
There are very few comorbidity cohort studies [59] and
this is the first study of its kind which has been con-
structed with a priori hypotheses, identifying two com-
mon chronic diseases (CVD and OA) in the general
practice population, and testing their interaction in rela-
tion to self-reported health and health care outcomes.
The innovative epidemiological design incorporates
comorbid interaction, interaction as influenced by sever-
ity (in this example of CVD), and potential cohort im-
pact both in the short-term and longer-term. The
innovative methodological design also incorporates a de-
nominator cohort, from which a survey population was
sampled, allowing the assessment of selection and data
issues. The linkage between survey data and consultation
data provides the investigation of population symptoms
and health, and their impact on short and longer-term
healthcare outcomes.
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Abstract
Purpose To investigate the influence of disease severity
within cardiovascular disease (CVD) and musculoskeletal
(MSK) disorder spectrums on physical health change over
3 years.
Methods Consultation records of 4,672 patients aged
50 years and above from six general practices were linked
to their baseline and 3-year Short-Form-12 (SF-12) phys-
ical component summary (PCS) scores. Associations
between exclusive diagnostic categories and comorbid
counts with physical health change over 3 years were
examined.
Results There were 1,371 (29.3%) CVD and 1,972
(42.2%) MSK consulters. Adjusted additional change in
PCS scores relative to hypertension ranged from -0.43
(95% confidence interval -2.5, 1.7) for atrial fibrillation to
-2.09 (-4.2, 0.0) for heart failure. In the MSK spectrum,
changes relative to soft tissue disorder ranged from -0.63
(-3.0, 1.8) for soft tissue pain to -1.09 (-4.1, 2.0) for
inflammatory polyarthropathy. A trend in association
between increasing disease severity and deterioration in
physical health was only observed within the CVD spec-
trum, and this trend was retained in those with CVD and
higher levels of comorbidity.
Conclusions CVD severity with higher levels of comor-
bidity was associated with greater relative deterioration in
long-term physical health. Such findings were not found for
the MSK cohorts, suggesting the differing health impact of
different chronic diseases.
Keywords Cardiovascular diseases  Musculoskeletal
diseases  Comorbidity  Cohort studies  Family practice 
Quality of life
Abbreviations
CVD Cardiovascular disease
IMD Index of Multiple Deprivation
MCS Mental component summary score
MSK Musculoskeletal
OA Osteoarthritis
PCS Physical component summary score
RA Rheumatoid arthritis
SF-12 Short-Form-12 health survey
Introduction
At population level, health-related quality of life instru-
ments can be used as measures of changing health service
need [1], but at individual patient level, clinical needs are
dependent on the stage of disease. Care is often driven by
the ‘severity’ of the disease, or ‘severity’ of health associ-
ated with the disease, or the ‘severity’ as measured from the
perspective of the patients. An additional distinct approach
is the notion of ‘relative severity’ [2–4], where different
stages of the same chronic disease imply changing severity,
or the fact that clinicians allocate different levels of care
input dependent on different categories of morbidity [5].
With disease management often being a continual pro-
cess, an understanding of how different chronic diseases
influence change in health over time is important [6]. As
the numbers of patients living with chronic diseases are
increasing [7], it is essential to understand how these
conditions relate to physical health over time and whether
their influence on health is distinct to each type of chronic
J. A. Prior (&)  K. P. Jordan  U. T. Kadam
Arthritis Research UK Primary Care Centre, Primary Care
Sciences, Keele University, Staffordshire ST5 5BG, UK
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disease. Such information would not only enhance health
professionals’ understanding of how chronic diseases
influence physical health relative to one another but also
highlight the relationships between the development of a
long-term condition and providing optimum quality of life
for the patient.
Cardiovascular disease (CVD) and musculoskeletal
(MSK) disorders are two of the commonest chronic dis-
eases in developed countries [8, 9], the former impacting
on patients’ mortality [10, 11] and both influencing mor-
bidity [12, 13]. Both these chronic diseases include several
disease and symptom conditions, which can form spec-
trums based on relative severity of disease. However, it is
not clearly understood how the different conditions within
the same chronic disease spectrum influence health relative
to one another longitudinally.
Previous cohort studies have shown the influence that
individual CVD [14, 15] and MSK disorders [16, 17] have
on deterioration of physical health over time. However,
studying individual conditions within chronic diseases
provides only variable, time-dependant information on how
physical health deteriorates. In contrast, studies investi-
gating the association between different conditions within
chronic disease spectrums and their impact on physical
health have mostly been cross-sectional for CVD [18] and
MSK disorders [19, 20]. These studies have shown an
adverse influence of chronic diseases on physical health,
for example, a study by Alonso et al. [21] found that in
comparison with general populations, patients with differ-
ent categories of CVD had progressively worse physical
health. However, it is currently unclear whether, across a
number of conditions within a chronic disease, the degree
of poor health remains the same or changes over time.
Longitudinal observational research comparing the relative
influence of different chronic diseases on physical health
remains limited, especially of how conditions of differing
severities in the same chronic disease spectrum relate to
long-term physical health change in general practice
populations.
In a cross-sectional precursor to this study [22], we
investigated whether CVD and MSK spectrums could be
allocated to an a priori ordered group by testing it against
self-reported physical health. The cross-sectional study and
a previous clinician consensus study [2, 3] provided the
basis in this work of investigating two specific objectives
for CVD and MSK cohorts in general practice populations
aged 50 years and above. First, we investigated whether
disease severity influenced self-reported physical health
change over 3 years, and second, whether disease severity
and comorbidity influenced self-reported physical health
change over 3 years. It was hypothesised for both CVD and
MSK disorders that those patients recorded in general
practice with the more severe diagnostic categories in
either chronic disease spectrum would show greater dete-
rioration of health over the long term and furthermore that
comorbidity would be a separate influence on deteriorating
physical health.
Methods
Design
This cohort study used a larger data set linking primary
care consultation records to self-reported health status from
a population aged 50 years and above, from six general
practices who participated in two population health surveys
[23]. In this study, the local general practices routinely
coded morbidity data in actual consultations for their reg-
istered populations, and cross-sectional general health
surveys were conducted in 2001 (baseline) and a further
follow-up 3 years later.
Study sample
Full details of sampling and response rates from the larger
study have been previously published [23]. All registered
patients aged 50 and above were invited to take part in a
baseline survey. From this original survey sample, 7,799
patients responded to the baseline postal health question-
naire and had given consent for their clinical consultation
records to be linked to their survey data. Of this baseline
study population, 4,672 (59.9%) patients had also
responded to the 3-year follow-up questionnaire (Fig. 1).
Local research ethics committee (REC) approval was
obtained.
Cohort groups: disease definition
We used the computer-recorded primary care consultations
in the 2 years before the baseline questionnaire survey to
construct the study cohort groups. Morbidity data were
collected routinely by the practices in actual consultations
using a standard coding classification called Read codes
[24]. This coding has been shown to produce high-quality
data [25, 26]. Using the Read codes, we identified a CVD
cohort group (six categories) and MSK cohort group (nine
categories) on the basis of patient consultation in the
2 years before baseline.
Cohort groups: severity definition
The six CVD and nine MSK categories to be placed into
an a priori severity order were based on a previous focus
group and consensus studies [2] and further validation
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work [3–5]. In the GP focus groups, the criteria for
severity classification using clinical data were developed.
Following this, a further 118 GPs took part in the con-
sensus study, to agree the severity definitions for a total
of 188 morbidities [3]. These methods were then tested
in both English and Dutch general practice populations
[4, 5].
Six exclusive CVD cohorts were ordered by severity
from: (1) hypertension: Read code G20 (least severe), (2)
atrial fibrillation: G57, (3) ischaemic heart disease: G3,
(4) angina: G33, (5) myocardial infarction: G30 and (6)
heart failure: G58 (most severe). The nine exclusive
MSK cohorts were also ordered by severity from: (1) soft
tissue disorder: Read code N22 (least severe), (2) soft
tissue pain: N24, (3) peripheral enthesopathies: N21, (4)
joint disorders: N14, (5) back pain: N14, (6) neck pain:
N11, (7) osteoarthritis: N05, (8) osteoporosis: N33 and
(9) inflammatory polyarthropathy: N04/N20 (most
severe).
The a priori order of these diagnostic categories was
initially tested in a cross-sectional study, which investi-
gated whether such ‘diagnostic severity’ was associated
with severity as measured by self-reported health status
[22]. The results showed that using these same ordered
categories for the two spectrums, there was an association
with poor self-reported physical health, and furthermore,
there was a statistically significant and increasing trend i.e.
increasing ‘diagnostic severity’ associated with increasing
poorer health. This cross-sectional study further provided
the basis for the prospective hypotheses on whether there
was a significant change across diagnostic categories
within two chronic illness spectrums.
Comorbidity measure
We also used the morbidity consultations to measure
comorbidity. In addition to the CVD and MSK cohort
categories, we constructed comorbidity count levels, which
were based on the number of different morbidities con-
sulted for in the same 2-year time period before the base-
line survey. These 2-year comorbidity counts refer to at
least one consultation for any given morbidity, including
the CVD or MSK categories, but do not include any repeat
consultations for the same morbidity.
Self-reported health measure: baseline and 3-year
follow-up
The Short-Form-12 (SF-12) Health Survey [27] was used to
measure physical health at baseline and 3-year follow-up. It
is a widely used measure of health-related quality of life,
which had been shown to be valid in assessing the general
health of chronic disease groups [28, 29]. From these sub-
scales, two summary scores, the physical component sum-
mary (PCS) score and the mental component summary
(MCS) score, can be produced. These scores are normalised
to the general population mean of 50 (SD 10). Scores below
50 indicate worse physical or mental health than the general
population [30]. The primary outcome was change in
physical health as measured by the PCS score of the SF-12,
from baseline to the 3-year follow-up survey, with a minus
score indicating deterioration in physical health.
The mental component summary (MCS) score of the
SF-12 was used as a measure of psychological health sta-
tus; other survey data included age, gender and deprivation.
Responders to the general population study baseline questionnaire that consented to medical record 
review and had consulted in the previous two years  
= 7,799 
Consulted for  
CVD 
= 2,447 (31.4%) 
Consulted for  
MSK 
= 3,321 (42.6%) 
Consulted for neither  
CVD or MSK 
= 3,068 (39.3%) 
Eligible population : Responders to general population study baseline and 3-years follow-up 
questionnaire that consented to medical record review and had consulted in the previous two years 
= 4,672 (59.9%) 
Consulted for  
CVD & MSK 
= 1,037 (13.3%)
Consulted for  
CVD 
= 1,371 (17.6%) 
Consulted for  
MSK 
= 1,972 (25.3%) 
Consulted for neither  
CVD or MSK 
= 1,890 (24.2%) 
Consulted for  
CVD & MSK 
= 561 (7.2%)
Fig. 1 Sample flowchart
including: baseline responders
only (dashed line) and those
responding at baseline and
3-year follow-up (solid line).
For each of these responder
groups, those who consulted for
a CVD, MSK or neither CVD
nor MSK condition in the
2 years prior to baseline survey
are displayed. Those who
consulted for both a CVD and
MSK disorder in the 2 years
prior to baseline are also shown
(circles)
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The level of neighbourhood deprivation for each patient
was produced using the Index of Multiple Deprivation
(IMD). This is an area-level measure of deprivation, based
on the patients’ postcode, and is a weighted score of seven
subdomains relating to income; employment; health; edu-
cation, skills and training; barriers to housing and access to
local services; crime; and living environment [31].
Statistical analysis
Age was categorised into four groups: 50–59 years,
60–69 years, 70–79 years and 80 years and above, and
deprivation status into quartiles from category 1 (least
deprived) to category 4 (most deprived). Psychological
health status was dichotomised into ‘low’ or ‘high’, using the
mean baseline MCS score (48.59, SD 11.4) from the cross-
sectional study sample [22]. Comorbidity level was also
dichotomised using the mean count, with individuals defined
as consulting with either ‘low’ (B7) or ‘high’ (C8) morbidity
counts in the 2-year period before the baseline survey.
Within both the CVD and MSK spectrums, the results for
each cohort were summarised by age, gender, deprivation
status, psychological health status and comorbidity levels.
For each diagnostic cohort within the CVD and MSK
spectrums, change in physical health over 3 years was first
examined using paired t-tests. Associations between cohort
and physical health change were then examined using linear
regression with adjustments made separately for: (1) age,
gender and deprivation status, (2) age, gender, deprivation
status and baseline psychological health status (MCS score)
and (3) all factors and baseline physical health status (PCS
score). This final adjustment was then stratified by ‘low’ or
‘high’ comorbidity levels. All analyses were performed
using SPSS version 15.0 (SPSS Inc., Chicago, Illinois).
Results
Overall study cohorts
In the study population of 4,672, there were 1,371 (29.3%)
patients who had consulted for one of the six CVD cohorts
and 1,972 (42.2%) patients who had consulted for one of
the nine MSK cohorts, with 561 (12.0%) of these having
consulted for both chronic conditions. There were 1,890
(40.5%) patients who had consulted for neither a CVD nor
MSK diagnostic category in the 2 years prior to the base-
line survey.
Characteristics of CVD cohorts
More than half of CVD cohort samples were aged 69 years
or younger in each of the six subgroups, with the exception
of the heart failure cohort, who had a greater proportion of
older patients (Table 1). More women than men consulted
for hypertension, atrial fibrillation and heart failure, and
there were no specific deprivation patterns across the dif-
ferent categories. For each cohort, except heart failure,
more patients had a ‘high’, rather than ‘low’ psychological
health status at baseline survey, with more than two-thirds
having high comorbidity levels in the 2 years before the
baseline survey.
Characteristics of MSK disorder cohorts
More than half of MSK cohort samples were aged 69 years
or younger in all of the nine subgroups (Table 2). More
men than women consulted for peripheral enthesopathies
or back pain, and there were no specific patterns of
deprivation across different cohorts. Except for the
inflammatory polyarthropathy category, more patients had
a ‘high’, rather than ‘low’ baseline psychological health
status, with more than half of the patients (except soft
tissue disorder) having high comorbidity levels in the
2 years before the baseline survey.
Associations between CVD cohorts and physical health
change
Absolute physical health change in individual cohorts over
the 3 years was only significant (p \ 0.001) for hyperten-
sion, with the PCS score deteriorating by -0.86 (95% CI -
1.4, -0.3) over 3 years (Table 3).
In multivariable analysis, increasing disease severity
was associated with greater relative deterioration of long-
term physical health, particularly for the most severe
cohorts (Table 4). For example, when unadjusted, the
atrial fibrillation cohort showed an improvement in phys-
ical health after 3 years of 0.96 relative to change in the
hypertension cohort, but when adjusted, physical health in
this group deteriorated by -0.43. Associations for more
severe CVD cohorts compared with the reference cohort
(hypertension) on physical health change were as follows
(unadjusted vs. full adjustment): atrial fibrillation (0.96 vs.
-0.43), ischaemic heart disease (1.02 vs. -0.92), angina
(1.42 vs. -0.45), myocardial infarction (-0.48 vs. -2.31)
and heart failure (0.23 vs. -2.09).
Associations between MSK cohorts and physical
health change
There were no significant associations for any individual
cohort within the MSK spectrum and change in absolute
physical health score, even for the most severe cohort
(Table 3). In multivariable analysis, increasing disease
Qual Life Res
123
severity was not associated with greater relative deterio-
ration of long-term physical health.
More severe cohorts within the MSK spectrum
(Table 4) compared to the reference cohort (soft tissue
disorder) were as follows (unadjusted vs. full adjustment):
soft tissue pain (1.41 vs. -0.63), peripheral enthesopathies
(2.58 vs. 0.78), joint disorder (1.09 vs. -1.21), back pain
(1.56 vs. -1.22), neck pain (2.77 vs. -0.66), osteoarthritis
(2.09 vs. -1.54), osteoporosis (2.98 vs. -0.04), and
inflammatory polyarthropathy (3.59 vs. -1.09).
Influence of comorbidity levels on physical
health change
All CVD cohorts with a higher comorbidity level showed
greater deterioration in physical health over 3 years com-
pared to those with lower comorbidity levels, with the
exception of ischaemic heart disease (Table 5). Further-
more, increasing disease severity, compared to the refer-
ence category (hypertension), was associated with a trend
in deteriorating physical health, but for those with CVD
and high comorbidity only. Associations between disease
severity and change in physical health by comorbidity
levels were as follows (low comorbidity levels vs. high
comorbidity levels): atrial fibrillation (2.84 vs. -1.41),
ischaemic heart disease (-1.17 vs. -0.88), angina (1.04
vs. -0.99), myocardial infarction (-1.88 vs. -2.28) and
heart failure (-0.99 vs. -2.54). Within the MSK spec-
trum, there was no association with either the ‘low’ or
‘high’ levels of comorbidity and change in long-term
physical health (Table 5).
Sample selection issues
Of the baseline study population of 7,799 patients, there
were 3,127 (40.1%) patients who had participated only in
the baseline survey and 4,672 (59.9%) patients who had
responded to both baseline and 3-year follow-up ques-
tionnaire. Of these baseline-only responders, 1,076 (34.4%)
patients had consulted for CVD categories, 1,349 (43.1%)
for MSK categories and 476 (15.2%) for both CVD and
MSK categories. The remaining baseline-only responders
of 1,178 (37.7%) had consulted for neither CVD nor MSK
categories.
For both chronic disease spectrums, the proportions of
baseline-only responders for each diagnostic category were
similar to those who responded to both baseline and 3-year
follow-up questionnaire. For example, of those responding
to baseline only, 10.7% were classified in the ischaemic
heart disease category. A similar proportion of those
responding to baseline and 3-year follow-up (10.4%) were
also classified into the ischaemic heart disease category.
Table 1 Characteristics of cardiovascular disease (CVD) cohorts
Study factor Category Hypertension Atrial
fibrillation
Ischaemic heart
disease
Angina Myocardial
infarction
Heart
failure
Total
n = 936 n = 58 n = 142 n = 152 n = 24 n = 59 n = 1371
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Age group (years) 50–59 242 (25.9) 9 (15.5) 23 (16.2) 24 (15.8) 5 (20.8) 2 (3.4) 305 (22.2)
60–69 367 (39.2) 23 (39.7) 61 (43.0) 60 (39.5) 8 (33.3) 11 (18.6) 530 (38.7)
70–79 260 (27.8) 17 (29.3) 50 (35.2) 57 (37.5) 9 (37.5) 29 (49.2) 422 (30.8)
80? 67 (7.2) 9 (15.5) 8 (5.6) 11 (7.2) 2 (8.3) 17 (28.8) 114 (8.3)
Gender Male 413 (44.1) 27 (46.6) 101 (71.1) 88 (57.9) 22 (91.7) 29 (49.2) 680 (49.6)
Female 523 (55.9) 31 (53.4) 41 (28.9) 64 (42.1) 2 (8.3) 30 (50.8) 691 (50.4)
Deprivation statusa Category 1
(affluent)
220 (23.5) 14 (24.1) 32 (22.5) 33 (21.7) 10 (41.7) 18 (30.5) 327 (23.9)
Category 2 199 (21.3) 14 (24.1) 37 (26.1) 30 (19.7) 6 (25.0) 19 (32.2) 305 (22.3)
Category 3 229 (24.5) 18 (31.0) 34 (23.9) 51 (33.6) 3 (12.5) 11 (18.6) 346 (25.3)
Category 4
(deprived)
287 (30.7) 12 (20.7) 39 (27.5) 38 (25.0) 5 (20.8) 11 (18.6) 392 (28.6)
Psychological
health statusb
High 587 (62.7) 34 (58.6) 89 (62.7) 76 (50.0) 15 (62.5) 26 (44.1) 827 (60.3)
Low 349 (37.3) 24 (41.4) 53 (37.3) 76 (50.0) 9 (37.5) 33 (55.9) 544 (39.7)
Comorbidity levelc Low (B 7) 277 (29.6) 13 (22.4) 46 (32.4) 34 (22.4) 6 (25.0) 6 (10.2) 382 (27.9)
High (C 8) 659 (70.4) 45 (77.6) 96 (67.6) 118 (77.6) 18 (75.0) 53 (89.9) 989 (72.1)
a Based on Index of Multiple Deprivation (IMD)
b Based on mental component summary (MCS) score from SF-12
c Based on number of consultations in the 2 years prior to the baseline survey
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For no disease category was the proportion of patients
responding after 3 years markedly different from those
responding to baseline only.
Discussion
Key findings
Our study showed within the CVD spectrum that increasing
disease severity was associated with deteriorating long-term
physical health, but such an association was not observed
within the MSK disorder spectrum. These findings were
independent of socio-demographic characteristics and
baseline psychological health status. After adjusting for the
baseline physical health status, all cohorts showed deteri-
oration in physical health compared to their unadjusted
values. In CVD cohorts, higher levels of comorbidity and
increasing severity of disease were associated with greater
deterioration in long-term physical health, but such asso-
ciations were not observed for CVD cohorts with lower
comorbidity levels. These findings suggest that health care
professionals may need to identify more severe CVD
patients with higher levels of comorbidity to target health
care and potentially prevent the likelihood of long-
term worsening in physical health. In contrast, for MSK
cohorts, there was little influence of disease severity and
comorbidity levels on long-term physical health change.
Here, the potential implication for long-term health, as
defined within the study spectrum, could be that patients are
assessed according to the respective MSK condition, with
less emphasis required on the overall status of disease
severity or associated comorbidity as these may not impact
on the long-term change in physical health.
CVD findings
Previous studies have shown the adverse influence of
individual CVD on long-term physical health change [14].
Boini et al. found that in a general population, people with
coronary artery disease were likely to have poorer physical
health when followed up around 3 years later [15]. How-
ever, we were interested in the influence of a range of
conditions within the same chronic disease spectrum,
which constitutes one definition of ‘severity’.
Previous cross-sectional works have shown that hyper-
tension, myocardial infarction, ischaemic heart disease and
congestive heart failure are associated with progressively
poorer physical health [18, 21]. We found that increasing
disease severity influenced the long-term deterioration in
physical health, with the myocardial infarction and heart
failure cohorts showing greater deterioration relative to the
hypertension cohort over 3 years. Our study adds to the
picture by showing that across the CVD spectrum in
Table 3 Mean physical component summary (PCS) scores for cardiovascular disease (CVD) or musculoskeletal (MSK) cohorts
Chronic disease Cohort Samplea
No. (%)
Baseline PCSb
Mean (95% CI)
3-year follow-up PCSc
Mean (95% CI)
Change in PCSd
Mean (95% CI)
CVD Hypertension 936 (68.3) 39.94 (39.1, 40.7) 39.08 (38.3, 39.8) -0.86 (-1.4, -0.3)
Atrial fibrillation 58 (4.2) 34.96 (32.3, 37.7) 35.05 (32.0, 38.1) 0.09 (-2.5, 2.7)
Ischaemic heart disease 142 (10.3) 34.88 (32.9, 36.8) 35.04 (33.1, 37.0) 0.16 (-1.2, 1.5)
Angina 152 (11.1) 33.44 (31.9, 34.9) 34.00 (32.4, 35.6) 0.56 (-0.7, 1.8)
Myocardial Infarction 24 (1.8) 35.77 (30.4, 41.1) 34.43 (30.2, 38.7) -1.34 (-6.2, 3.6)
Heart failure 59 (4.3) 29.43 (27.3, 31.5) 28.80 (26.6, 31.0) -0.63 (-2.9, 1.7)
MSK Soft tissue disorder 47 (2.4) 46.24 (43.6, 48.9) 44.52 (41.5, 47.5) -1.72 (-4.1, 0.7)
Soft tissue pain 309 (15.7) 40.40 (39.0, 41.8) 40.08 (38.7, 41.5) -0.32 (-1.4, 0.8)
Peripheral enthesopathies 166 (8.4) 42.77 (41.0, 44.5) 43.63 (42.0, 45.2) 0.86 (-0.4, 2.1)
Joint disorder 282 (14.3) 40.52 (39.1, 41.9) 39.89 (38.5, 41.3) -0.63 (-1.6, 0.3)
Back pain 391 (19.8) 39.21 (38.0, 40.4) 39.04 (37.9, 40.2) -0.17 (-1.1, 0.7)
Neck pain 156 (7.9) 36.12 (34.1, 38.1) 37.17 (35.3, 39.0) 1.05 (-0.4, 2.5)
Osteoarthritis 509 (25.8) 34.01 (33.0, 35.0) 34.37 (33.5, 35.3) 0.36 (-0.4, 1.1)
Osteoporosis 55 (2.8) 36.35 (33.2, 39.5) 37.60 (34.3, 40.9) 1.25 (-1.3, 3.8)
Inflammatory polyarthropathy 57 (2.9) 29.81 (26.9, 32.7) 31.68 (29.0, 34.3) 1.87 (-0.4, 4.2)
a Number of patients classified by study defined exclusive diagnostic categories
b Physical component summary (PCS) score of the SF-12 recorded in the baseline survey
c Physical component summary (PCS) score of the SF-12 recorded in the follow-up survey, 3 years after the baseline survey
d Change in PCS score after 3 years, calculated by subtracting the 3-year follow-up PCS score from the baseline PCS score
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general practice populations, there are differing influences
on long-term physical health change, reflecting the
importance of ‘severity’ as indicated by diagnostic cate-
gories that constitute the stages of a chronic disease.
Higher comorbidity levels were also a separate influence
on long-term physical health change within the CVD
spectrum, with CVD cohorts and higher comorbidity levels
showing greater deterioration in physical health change.
This supports the concept that comorbidity needs be con-
sidered as a separate issue in the clinical management of
patients.
MSK disorder findings
The influence of the spectrum of MSK cohorts on long-
term change in physical health was distinct to those of the
CVD cohorts. In our study, there was no trend in the
association between increasing severity of MSK cohort and
long-term change in physical health. Previous longitudinal
studies have investigated specific and single MSK cate-
gories, which showed long-term deterioration in physical
health [16, 32–34], but these studies have not compared the
relative influence of different MSK categories within a
spectrum over time. In one cross-sectional study, Fortin
et al. [35] found that in a Canadian primary care popula-
tion, physical health deteriorated in more severe categories
within MSK disease categories, but with ‘severity’ classi-
fied using the Cumulative Illness Rating Scale (CIRS) [36].
An explanation for these MSK cohorts may relate to the
chosen reference category or the way the spectrum was
defined, with a range of different MSK disorders. However,
this is an unlikely explanation for the lack of long-term
Table 4 Associations between cohorts and physical health change, by cardiovascular disease (CVD) or musculoskeletal (MSK) disorder
Cohort Total
numbera
Exclusive
numberb
(%)
Physical
healthc
Unadjusted linear
regression. Mean
(95% CI)
Adjusted linear regression. Mean (95% CI)
Age, Gender and
Deprivation
statusd
Age, Gender,
Deprivation statusd
and Baseline MCS
scoree
Age, Gender,
Deprivation statusd,
MCSe and Baseline
PCS scoref
High Low
Cardiovascular disease
Hypertension 1047 936 (89.4) 479 457 Ref Ref Ref Ref
Atrial
fibrillation
84 58 (69.0) 20 38 0.96 (-1.4, 3.3) 1.05 (-1.3, 3.4) 1.18 (-1.2, 3.5) -0.43 (-2.5, 1.7)
Ischaemic heart
disease
202 142 (70.3) 46 96 1.02 (-0.6, 2.6) 0.88 (-0.7, 2.5) 0.95 (-0.6, 2.5) -0.92 (-2.3, 0.5)
Angina 168 152 (90.5) 37 115 1.42 (-0.1, 3.0) 1.42 (-0.1, 3.0) 1.73 (-0.2, 3.3) -0.45 (-1.8, 0.9)
Myocardial
infarction
25 24 (96.0) 7 17 -0.48 (-4.1, 3.1) -0.73 (-4.4, 2.9) -0.58 (-4.2, 3.0) -2.31 (-5.5, 0.9)
Heart failure 59 59 (100.0) 7 52 0.23 (-2.1, 2.6) 0.65 (-1.8, 3.1) 1.09 (-1.3, 3.5) -2.09 (-4.2, 0.0)
Musculoskeletal disorder
Soft tissue
disorder
87 47 (54.0) 36 11 Ref Ref Ref Ref
Soft tissue pain 634 309 (48.7) 160 149 1.41 (-1.3, 4.1) 1.23 (-1.5, 3.9) 1.39 (-1.3, 4.1) -0.63 (-3.0, 1.8)
Peripheral
enthesopathies
301 166 (55.1) 99 67 2.58 (-0.3, 5.4) 2.21 (-0.7, 5.1) 2.28 (-0.6, 5.1) 0.78 (-1.7, 3.3)
Joint disorder 482 282 (58.5) 148 134 1.09 (-1.6, 3.8) 0.80 (-1.9, 3.5) 0.94 (-1.8, 3.6) -1.21 (-3.6, 1.2)
Back pain 511 391 (76.5) 191 200 1.56 (-1.1, 4.2) 1.12 (-1.6, 3.8) 1.37 (-1.3, 4.0) -1.22 (-3.6, 1.1)
Neck pain 192 156 (81.3) 60 96 2.77 (-0.1, 5.7) 2.60 (-0.3, 5.5) 2.92 (0.1, 5.8) -0.66 (-3.2, 1.9)
Osteoarthritis 524 509 (97.1) 146 363 2.09 (-0.6, 4.7) 2.19 (-0.4, 4.8) 2.50 (-0.1, 5.1) -1.54 (-3.9, 0.8)
Osteoporosis 59 55 (93.2) 20 35 2.98 (-0.5, 6.4) 3.27 (-0.2, 6.7) 3.53 (0.1, 6.9) -0.04 (-3.1, 3.0)
Inflammatory
polyarthropathy
58 57 (98.3) 10 47 3.59 (0.2, 7.0) 3.69 (0.3, 7.1) 4.20 (0.8, 7.6) -1.09 (-4.1, 2.0)
a Number of patients in the study sample with at least one consultation for this diagnostic category in the 2-year time period of observation
b Number of patients classified by study defined exclusive diagnostic categories
c Dichotomy based on the mean physical component summary (PCS) score of SF-12 from previous cross-sectional study [21]
d Deprivation score as measured by Index of Multiple Deprivation (IMD)
e Based on mental component summary (MCS) score from SF-12
f Physical component summary (PCS) score from SF-12
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MSK effects on physical health, as previous cross-sectional
analyses had shown that the more ‘severe’ MSK cohorts
had poorer health at baseline relative to the reference cat-
egory [22].
MSK cohorts and associated comorbidity levels also
showed a lack of influence on long-term physical health
change. Whilst a cross-sectional study has shown the
synergistic adverse influence of osteoarthritis and comor-
bidity on physical health [37], more detailed long-term
studies of MSK-specific outcomes and comorbidity may be
required.
Comparing CVD and MSK findings
Part of the reason that the differences observed for the
CVD spectrum compared to the MSK spectrum within this
study may be because the CVD cohorts share a patholog-
ical link in aetiology [38, 39], compared to the categories
within the MSK spectrum. MSK cohorts encompass a
range of ‘pain disorders’, which may represent diffuse
symptom disorders such as neck or back pain or be distinct
pathological processes i.e. osteoarthritis (OA) or rheuma-
toid arthritis (RA). MSK cohorts in this study were based
on an interlinking spectrum of disorders, albeit with an
a priori order that influences the pain expression through
different physiological mechanisms and subjective patient
experience.
Lack of associations for the MSK cohort could be
related to confounding issues, other than those factors
considered in the study. Such factors could include the
chronicity of MSK categories, factors such as psychosocial
influences [40] or reduced physical activity, which may
mediate the relationship between MSK disorders and
overall physical health [41].
In terms of clinical relevance, the objective of the study
was to understand whether there was a measureable change
in physical health across the two chronic spectrums. The
results did show that such change (as an average) was small
over time; thus, these results convey more with regard to
the relevance of clinically applied diagnostic categories
rather than the measurement of minimal clinical impor-
tance difference (MCID) that may be important to infer
change in practice.
Study design: strengths and limitations
Our study expands on the limited research investigating the
influence of different conditions within two common
chronic disease spectrums on long-term physical health
change. This large prospective study allows comparisons to
Table 5 Associations between cohorts and change in physical health by cardiovascular disease (CVD) or musculoskeletal (MSK) disorder,
stratified by low or high comorbidity levels
Chronic disease Cohorts Samplea
No. (%)
Adjusted linear regression
Low comorbidity levelb High comorbidity levelc
Mean (95% CI) Mean (95% CI)
CVD Hypertension 936 (68.3) Refd Refd
Atrial fibrillation 58 (4.2) 2.84 (-1.9, 7.5) -1.41 (-3.7, 0.9)
Ischaemic heart disease 142 (10.3) -1.17 (-3.9, 1.6) -0.88 (-2.5, 0.8)
Angina 152 (11.1) 1.04 (-2.1, 4.2) -0.99 (-2.5, 0.5)
Myocardial Infarction 24 (1.8) -1.88 (-8.8, 5.0) -2.28 (-5.9, 1.3)
Heart failure 59 (4.3) -0.99 (-8.0, 6.0) -2.54 (-4.8, -0.3)
MSK Soft tissue disorder 47 (2.4) Refd Refd
Soft tissue pain 309 (15.7) -0.28 (-3.7, 3.2) -1.09 (-4.5, 2.3)
Peripheral enthesopathies 166 (8.4) -0.27 (-3.9, 3.4) 1.52 (-2.0, 5.1)
Joint disorder 282 (14.3) -0.72 (-4.2, 2.8) -1.60 (-5.0, 1.8)
Back pain 391 (19.8) -1.28 (-4.7, 2.1) -1.25 (-4.6, 2.1)
Neck pain 156 (7.9) 0.21 (-3.7, 4.1) -1.13 (-4.6, 2.4)
Osteoarthritis 509 (25.8) -1.07 (-4.5, 2.4) -1.79 (-5.1, 1.5)
Osteoporosis 55 (2.8) 1.05 (-4.2, 6.4) -0.41 (-4.4, 3.5)
Inflammatory polyarthropathy 57 (2.9) -1.87 (-7.5, 3.7) -1.08 (-5.0, 2.8)
a Number of patients classified by study defined exclusive diagnostic categories
b Patients with B 7 different consultations in the 2 years prior to the baseline survey
c Patients with 8 C different consultations in the 2 years prior to the baseline survey
d Reference category
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be made between several conditions within chronic dis-
eases as seen in routine general practice and their influence
of health change. Physical health was measured with a
widely used and validated measure of general health [42],
and this work investigated the potential impact of comor-
bidity in primary care, which is an increasingly important
clinical issue in ageing populations [43]. Whilst our study
considered many different morbidities, additional studies
would be needed to consider the role of changing disease
status and interventions that patients routinely receive, in
relation to overall health change.
However, in addition to survey and consultation record
consent selection issues previously addressed [44], we also
considered ‘dropout’ bias from the CVD and MSK cohorts,
i.e. those participants who only took part in the baseline
survey but not in the 3-year follow-up survey. Compara-
tively, the study sample with both baseline and follow-up
measurements was younger, more affluent and had
improved psychological health status compared to those
only responding at baseline. This subsampling reduces the
generalisability of findings but will still allow the test of
internal comparisons of the cohorts.
In considering the influence of comorbidity on physi-
cal health change, the method of defining comorbidity is
also important. We chose to define comorbidity levels as
the counts of morbidities in the 2 years prior to baseline
survey. This was a relatively crude measure and may
have underestimated the role of comorbidity on physical
health [35]. Defining comorbidity by specific, chronic
combinations of disease may provide clarification into the
role of this important factor in assessing long-term
physical health change. Finally, the number of partici-
pants in some groups was low and hence reduced the
power of the study to detect small differences compared
to the reference groups. It is unclear whether these small
differences would equate to ‘clinically’ important chan-
ges in physical health.
Conclusions
Over a 3-year period, higher CVD severity and high levels
of comorbidity were associated with a greater deterioration
in physical health. In contrast, such findings were not
observed for the MSK spectrum. Our results suggest that
health professionals should consider that CVD severity and
comorbidity may need to be addressed together in the
management of long-term changes in physical health.
Further research on how each chronic disease, comorbidity
and quality of life of general practice populations change
over time is still required. An improved understanding of
both disease severity and comorbidity will allow clinicians
to provide more tailored treatment and management.
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Accepted 1 June 2010AbstractObjective: Family practitioner diagnostic labels applied in consultation provide a signpost for treatment and management. Yet, it is
unknown whether each label reflects the health of the respective patient group.
Study Design and Setting: Consultation records of 7,799 patients aged 50 years and older from six family practices were linked to
a cross-sectional baseline health survey. Associations between six mutually exclusive cardiovascular disease and nine mutually exclusive
musculoskeletal disorder categories, and physical health severity as measured by the Short Form-12 questionnaire were examined.
Results: There were 2,447 (31.4%) cardiovascular disease and 3,321 (42.6%) musculoskeletal disorder consulters. The mean physical
health scores ranged from 38.38 (95% confidence interval [CI]: 37.8e39.0) for hypertension to the poorest score of health 28.98 (95% CI:
27.5e30.5) for consulters with heart failure, whereas in the musculoskeletal disorder group, scores ranged from 44.85 (95% CI: 42.2e47.5)
for soft tissue disorder to 28.79 (95% CI: 26.8e30.8) for consulters with inflammatory polyarthropathy (trend P! 0.001). This trend in the
association between diagnostic categories and physical health severity within both spectrums remained after adjustment for confounders.
Conclusion: Specific diagnostic labels for selected chronic illness indicate the severity of physical health for the corresponding
consulting population.  2010 Elsevier Inc. All rights reserved.
Keywords: Cardiovascular diseases; MSK diseases; Diagnosis; Quality of life; Epidemiological studies1. Introduction
A visit to family practice is marked by the application of
a label summarizing the main presenting complaint. This
label, usually attributed by the family practitioner (FP), de-
termines the course of health care management or treatment
[1]. For example, routine chronic disease clinics that mon-
itor individual patients with conditions, such as diabetes [2]
and ischemic heart disease [3], have their respective labels
that provide key signposts for the health care management
pathway of the patient [4].
The presenting complaint of the patient can fall within
a wide spectrum of health, including nonspecific and self-
limiting symptoms such as pain or infections or specificPrior presentations: Society for Academic Primary Care annual scien-
tific meeting, July 8e10, 2009.
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0895-4356/$ e see front matter  2010 Elsevier Inc. All rights reserved.
doi: 10.1016/j.jclinepi.2010.06.002disorders such as anxiety or depression. Complaints can
also relate to specific chronic conditions, including a num-
ber of potentially interlinking diseases affecting the same
system (e.g., cardiovascular), a series of unrelated disorders
(musculoskeletal), or spectrums which can include both
disease and disorder.
The variation in the use of labels [5] can be dependent
on both patient-related [6] and clinician-related [7] factors.
Patients may present at different points as a result of
changes in their health and clinical histories that may be
specific or complex. Clinician choices can relate to (1) in-
tegration of complex information from a variety of sources,
(2) imperfect or incomplete information, (3) the presence of
uncertainty, and (4) complex interactions between the clini-
cian and the patient [8]. In the end, the final choice of label
at one time point could therefore relate to any stage along
a disease or disorder spectrum (between onset and end
stage). These labels in themselves will be either a ‘‘working
diagnosis’’ (e.g., symptom-related only) or a definitive ‘‘di-
agnostic label’’ based on a combination of clinical assess-
ment and further information, such as investigation.
However, whether the choice of this label within the same
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ARTICLE IN PRESSWhat is new?
Key finding
Diagnostic labels applied in family practice can indi-
cate the severity of physical health within categories
of cardiovascular disease and musculoskeletal
disorder.
What this adds to what was known
Although diagnostic variability has been shown to
exist in family practice, our results support the con-
cept that groups of consulters with the same diagnos-
tic label as recorded in clinical encounters could be
grouped into exclusive measures of severity.
What is the implication, what should change now?
Our findings show the usefulness of routinely col-
lected morbidity data as implicit indicators of
severity. This method shows the potential for epide-
miological construction of populations using
morbidity data, the clinical implication supporting
the potential for testing this method in clinical
decision-making research.
spectrum of ‘‘diagnostic’’ possibilities reflects the severity
as measured by health is unknown.
Chronic disease or disorder spectrums may comprise
symptoms and pathologies that are related or unrelated to
each other [9]. For example, in musculoskeletal disorders,
diagnostic labels can range from pain symptoms that are re-
gional [10] or widespread [11] to pathology that is localized
such as osteoarthritis [12] or to more systemic conditions
such as rheumatoid arthritis [13]. Notably the pain symp-
toms could either be self-limiting [14] or be part of an es-
tablished chronic disease such as osteoarthritis [15]. In
contrast, within cardiovascular diseases, current evidence
has more clearly focused on a linked pathway in relation
to development of this disease spectrum [16,17]. Therefore,
hypertension may be a preceding risk factor to myocardial
infarction, which in turn can progress to end-stage heart
failure in some individuals [18]. Yet, even within this spec-
trum, it is not clear as to how the stages of disease develop-
ment can affect the patient population and whether this
reflects the associated severity of general health [19].
From this current perspective of clinical encounters in
family practice, we have taken two examples of chronic ill-
ness spectrums to identify two distinct questions: (1) do dif-
ferent labels that form the stages of a disease spectrum, that
is, cardiovascular disease, reflect the associated health se-
verity of the corresponding patient group, and (2) do differ-
ent labels that form the stages of a disorder spectrum, that
is, musculoskeletal disorder, also reflect the associated
health severity of the corresponding patient group.2. Methods
2.1. Design
Using a consultation-survey linkage data set from six
family practices, the study hypotheses were investigated
in the population aged 50 years and older. These partici-
pants had completed a cross-sectional survey that was sub-
sequently linked with consent to their clinical records for
the 2 years before the baseline survey. The study was given
local research ethics committee approval.
2.2. Study population
The study practices are part of the North Staffordshire
General Practice Research Network, and the practices rou-
tinely use the Read classification [20] to code clinical en-
counters with their patients. The registered practice
populations aged 50 years and older had taken part in
a larger general population survey [21], which included
a subsurvey focusing on joint pain symptoms in the popu-
lation. The larger survey was sent to 20,293 people and
13,986 (68.9%) responded, with nonresponders showing
similar characteristics to previous surveys [22]. From these
responders, 10,432 consented to the review of their comput-
erized clinical records, and of these consenters, 8,962 peo-
ple had had a morbidity consultation in the 2 years before
the baseline survey. However, only 7,779 had completed
the Short Form (SF) questionnaire, and it was this group
that formed the study sample, and their survey data were
linked to the morbidity data coded by FPs as the patients
had presented their problems during consultation.
2.3. Baseline survey measures
In the baseline health questionnaire survey, the physical
component summary (PCS) score of the SF-12 provided the
primary outcome measure of physical health severity [23].
The SF-12 also provides the mental component summary
(MCS) score, which was used as a measure of psychologi-
cal health. Other survey data included were age, gender,
and Index of Multiple Deprivation (IMD) based on the
2004 census as an area-level measure of deprivation [24].
An IMD score combines a number of indicators, including
economic, social, and housing issues, into a single depriva-
tion score for each small area in England.
2.4. Selection of cardiovascular diseases and
musculoskeletal disorders
In clinical consultations, FPs had used the Read classifi-
cation to code the morbidity as presented by patients. Read
classifications have a main chapter heading, for example,
Chapter G for cardiovascular disease and Chapter N for
musculoskeletal disorders. Within each chapter, there are
four sublevels of coding, and we used the third hierarchical
level to define diagnostic categories for the study. For the
cardiovascular disease and musculoskeletal disorder
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ori order of hypothesized severity, with these labels being
selected on the basis of a clinically validated severity clas-
sification [25] and clinical judgment of an experienced FP
(U.T.K.). All patients who had consulted for any cardiovas-
cular disease or musculoskeletal disorder in the 2 years be-
fore baseline survey were identified from the study sample.
Within these consulters, we categorized individuals into ex-
clusive diagnostic categories, and these were ordered by
a priori severity ranging from ‘‘least severe’’ to ‘‘most se-
vere.’’ The six exclusive cardiovascular ‘‘disease’’ cate-
gories selected were (1) hypertension (least severe), (2)
atrial fibrillation, (3) ischemic heart disease, (4) angina,
(5) myocardial infarction, and (6) heart failure (most se-
vere). The nine exclusive musculoskeletal ‘‘disorder’’ cate-
gories were (1) soft tissue disorder (least severe), (2) soft
tissue pain, (3) peripheral enthesopathies, (4) joint disor-
ders, (5) back pain, (6) neck pain (7) osteoarthritis, (8)
osteoporosis, and (9) inflammatory polyarthropathy (most
severe). The exclusiveness of severity categories means that
allocation of an individual to one of these was based on the
most severe category; for example, if an individual had
consulted for hypertension and heart failure, they would
be classified into the heart failure category.
The remaining patients from the study sample formed
a comparator group, who were people who had not con-
sulted for one of the study-specific Read codes (cardiovas-
cular or musculoskeletal), and they represent the wider
consulting sample.2.5. Statistical analysis
For the main outcome measure, we used the dichoto-
mized mean PCS score (39.80, standard deviation [SD]:
12.5) for the study sample to investigate our primary hy-
potheses. Within both study groups, the results for each
of the exclusive diagnostic categories were summarized
by age, gender, deprivation and psychological status (also
dichotomized using the mean score: 48.59, SD: 11.4), and
morbidity counts. Morbidity counts categorized individuals
in the 2-year period of observation into consulters for (1)
one morbidity only, (2) two to four morbidities, (3) five
to eight morbidities, (4) 9e13 morbidities, and (5) 14 or
more morbidities. These counts refer to at least one consul-
tation for any given morbidity and do not include repeat
consultations for the same morbidity. Age was categorized
into four groups: 50e59, 60e69, 70e79, and 80 years and
older, and IMD deprivation status was categorized into
quartiles from category 1 (affluent) to category 4 (de-
prived). The mean PCS score (with 95% confidence inter-
vals [CIs]) for each diagnostic category within the two
spectrums is presented graphically. Associations between
diagnostic categories and physical health were estimated
as odds ratios (with 95% CIs) using logistic regression
methods. Associations were adjusted separately for (1)
age, gender, and deprivation status; (2) age, gender, anddeprivation and psychological status; and (3) all factors
and morbidity counts. A statistical trend in the estimates
within the ordered spectrums was assessed using the null
hypothesis in relation to a linear trend. Statistical signifi-
cance in analyses was defined as P! 0.05, all hypothesis
testing was two tailed, and analyses were performed using
SPSS version 15.0 (SPSS Inc, Chicago, IL).3. Results
In the study population of 7,799, there were 2,447
(31.4%) patients who had consulted for one of the specified
cardiovascular diseases and 3,321 (42.6%) patients who
had consulted for one of the specified musculoskeletal dis-
orders, with 1,037 (13.3%) of these having consulted for
both chronic problems. There were 3,068 (39.3%) people
with a mean PCS score of 43.73 (SD: 12.0) who had not
consulted for any one of the cardiovascular or musculoskel-
etal diagnostic categories.
3.1. Characteristics of cardiovascular disease group
Of the 2,447 cardiovascular disease consulters (Table 1),
just less than half were men or aged 70 years and older.
This group had a higher proportion with those who were
deprived or had a good psychological status, with 42%
consulting for 14 or more morbidities in the 2-year time
period.
There were 1,606 (65.6%) exclusive consulters with hy-
pertension, 115 (4.7%) with atrial fibrillation, and 139
(5.7%) with heart failure. The lowest numbers were ob-
served for myocardial infarction (44 [1.8%]). There were
more women than men in the hypertension and atrial fibril-
lation groups, but the situation was reversed for the other
diagnostic categories. There were no clear differences be-
tween the groups in relation to deprivation status, but the
heart failure group had the poorer psychological status
and two-thirds of these had consulted for 14 morbidities
or more. The highest proportion (41%) of those aged 80
years and older was also in the heart failure group.
3.2. Characteristics of musculoskeletal disorder group
Of the 3,321 patients with a musculoskeletal disorder
(Table 2), more than half were women aged 69 years or
younger. There was no difference in deprivation and most
had a good psychological status, with 34% consulting for
14 or more morbidities in the 2-year time period.
The highest number of exclusive consulters was 850
(25.6%) for osteoarthritis, followed by 650 (19.6%) with
back pain, and then 556 (16.7%) with soft tissue pain. Only
102 (3%) patients had consulted for an inflammatory poly-
arthropathy. With the exception of peripheral enthesopa-
thies, women were more likely to have consulted for any
of the other musculoskeletal categories than men. There
were no distinct differences in relation to deprivation status,
Table 1
Characteristics of cardiovascular disease group
Study factor
Hypertension
(n51,606)
Atrial
fibrillation
(n5115)
Ischemic
heart disease
(n5257)
Angina
(n5286)
Myocardial
infarction
(n544)
Heart
failure
(n5139)
Total
(n52,447)
Comparator
group
(n53,068)
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Age group (yr)
50e59 353 (22.0) 11 (9.6) 38 (14.8) 44 (15.4) 11 (25.0) 5 (3.6) 462 (18.9) 1,250 (40.7)
60e69 546 (34.0) 34 (29.6) 91 (35.4) 91 (31.8) 9 (20.5) 26 (18.7) 797 (32.6) 918 (29.9)
70e79 507 (31.6) 44 (38.3) 99 (38.5) 104 (36.4) 18 (40.9) 51 (36.7) 823 (33.6) 646 (21.1)
80þ 200 (12.5) 26 (22.6) 29 (11.3) 47 (16.4) 6 (13.6) 57 (41.0) 365 (14.9) 254 (8.3)
Gender
Male 669 (41.7) 51 (44.3) 170 (66.1) 152 (53.1) 36 (81.8) 72 (51.8) 1,150 (47.0) 1,462 (47.7)
Female 937 (58.3) 64 (55.7) 87 (33.9) 134 (46.9) 8 (18.2) 67 (48.2) 1,297 (53.0) 1,606 (52.3)
Deprivation status, categories
1 (affluent) 345 (21.5) 27 (23.5) 51 (19.8) 49 (17.1) 15 (34.1) 35 (25.2) 522 (21.3) 840 (27.3)
2 321 (20.0) 24 (20.9) 59 (23.0) 54 (18.9) 14 (31.8) 41 (29.5) 513 (21.0) 842 (27.5)
3 406 (25.3) 39 (33.9) 65 (25.3) 100 (35.0) 6 (13.6) 33 (23.7) 649 (26.5) 714 (23.3)
4 (deprived) 533 (33.2) 25 (21.7) 82 (31.9) 83 (29.0) 9 (20.5) 30 (21.6) 762 (31.1) 671 (21.9)
Psychological status
Good 939 (58.5) 59 (51.8) 135 (52.5) 125 (43.7) 23 (52.3) 54 (38.8) 1,335 (54.6) 1,933 (63.0)
Poor 667 (41.5) 55 (48.2) 122 (47.5) 161 (56.3) 21 (47.7) 85 (61.2) 1,111 (45.4) 1,134 (37.0)
Morbidity count
1 17 (1.1) 2 (1.7) 4 (1.6) 1 (0.3) 0 (0) 1 (0.7) 25 (1.0) 607 (19.8)
2e4 182 (11.3) 16 (13.9) 37 (14.4) 23 (8.0) 5 (11.4) 6 (4.3) 269 (11.0) 1,181 (38.5)
5e8 371 (23.1) 18 (15.7) 59 (23.0) 54 (18.9) 7 (15.9) 15 (10.8) 524 (21.4) 718 (23.4)
9e13 404 (25.2) 23 (20.0) 69 (26.8) 73 (25.5) 8 (18.2) 24 (17.3) 601 (24.6) 329 (10.7)
>14 632 (39.4) 56 (48.7) 88 (34.2) 135 (47.2) 24 (54.5) 93 (66.9) 1,028 (42.0) 233 (7.6)
Read code classifications used by family practitioners: G205 hypertension; G575 atrial fibrillation; G35 ischemic heart disease; G335 angina;
G305myocardial infarction; G585 heart failure. The ‘‘comparator group’’ represents those without a study-specific (cardiovascular or musculoskeletal)
Read code.
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cal status for neck pain, osteoporosis, and inflammatory
polyarthropathy categories. More than 40% of consulters
with neck pain, osteoarthritis, osteoporosis, or inflamma-
tory polyarthropathy categories had the highest morbidity
count of 14 or more.
3.3. Associations between cardiovascular categories
and physical health
The mean PCS scores with 95% CIs for this group are
shown in Fig. 1. Mean PCS scores decreased across the hy-
pothesized severity spectrum, ranging from 38.38 (95% CI:
37.8e39.0) for hypertension to the lowest score of 28.98
(95% CI: 27.5e30.5) for consulters with heart failure
(trend P! 0.001). The estimated odds ratios were as fol-
lows (unadjusted vs. adjusted for age, gender, deprivation
and psychological status, and morbidity count): atrial
fibrillation (1.8 vs. 1.5), ischemic heart disease (2.6 vs.
3.0), angina (3.6 vs. 3.2), myocardial infarction (2.5 vs.
2.8), and heart failure (6.1 vs. 3.5). These estimates dimin-
ished when fully adjusted with morbidity counts (Table 3),
but the trend in the association between the ordered diag-
nostic categories and poorer physical health remained
significant (P! 0.001).3.4. Associations between musculoskeletal categories
and physical health
The mean PCS scores with 95% CIs for this group are
shown in Fig. 2. Mean PCS scores decreased across the hy-
pothesized severity spectrum and ranged from 44.85 (95%
CI: 42.2e47.5) for soft tissue disorder to 28.79 (95% CI:
26.8e30.8) for consulters with inflammatory polyarthrop-
athy (trend P! 0.001). The estimated odds ratios were as
follows (unadjusted vs. adjusted for age, gender, depriva-
tion and psychological status, and morbidity count): soft
tissue pain (2.8 vs. 2.6), peripheral enthesopathies (1.6
vs. 1.8), joint disorder (2.7 vs. 2.7), back pain (3.0 vs.
3.0), neck pain (4.4 vs. 3.8), osteoarthritis (6.6 vs. 5.4),
osteoporosis (7.2 vs. 5.3), and inflammatory polyarthrop-
athy (14.2 vs. 9.8). These estimates diminished with
full adjustment with morbidity counts (Table 3), but the
trend in the association between the ordered diagnostic cat-
egories and poorer physical health remained significant
(P! 0.001).3.5. Comparison of the two chronic illness spectrums
The overall mean PCS score for the cardiovascular
disease group was 36.3 (SD: 12.0), and the score for the
Table 2
Characteristics of musculoskeletal disorder group
Study factor
Soft tissue
disorder (n562)
Soft tissue
pain (n5556)
Peripheral
enthesopathies
(n5259)
Joint disorder
(n5467)
Back pain
(n5650)
Neck pain
(n5262)
Osteoarthritis
(n5850)
Osteoporo s
(n5113)
Inflammatory
polyarthropathy
(n5102)
Total
(n53,321)
Comparator
group
(n53,068)
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Age group (yr)
50e59 22 (35.5) 166 (29.9) 104 (40.2) 186 (39.8) 258 (39.7) 72 (27.5) 166 (19.5) 25 (22.1) 15 (14.7) 1,014 (30.5) 1,250 (40.7)
60e69 15 (24.2) 188 (33.8) 90 (34.7) 138 (29.6) 191 (29.4) 93 (35.5) 288 (33.9) 37 (32.7) 36 (35.3) 1,076 (32.4) 918 (29.9)
70e79 18 (29.0) 146 (26.3) 55 (21.2) 101 (21.6) 139 (21.4) 71 (27.1) 263 (30.9) 36 (31.9) 29 (28.4) 858 (25.8) 646 (21.1)
80þ 7 (11.33) 56 (10.1) 10 (3.9) 42 (9.0) 62 (9.5) 26 (9.9) 133 (15.6) 15 (13.3) 22 (21.6) 373 (11.2) 254 (8.3)
Gender
Male 18 (29.0) 239 (43.0) 131 (50.6) 187 (40.0) 316 (48.6) 118 (45.0) 306 (36.0) 15 (13.3) 33 (32.4) 1,363 (41.0) 1,462 (47.7)
Female 44 (71.0) 317 (57.0) 128 (49.4) 280 (60.0) 334 (51.4) 144 (55.0) 544 (64.0) 98 (86.7) 69 (67.6) 1,958 (59.0) 1,606 (52.3)
Deprivation status, categories
1 (affluent) 17 (27.4) 138 (24.8) 68 (26.3) 99 (21.2) 155 (23.8) 73 (27.9) 227 (26.7) 33 (29.2) 21 (20.6) 831 (25.0) 840 (27.3)
2 15 (24.2) 111 (20.0) 74 (28.6) 127 (27.2) 160 (24.6) 66 (25.2) 233 (27.4) 28 (24.8) 24 (23.5) 838 (25.2) 842 (27.5)
3 15 (24.2) 148 (26.6) 58 (22.4) 131 (28.1) 166 (25.5) 61 (23.3) 178 (20.9) 31 (27.4) 39 (38.2) 827 (24.9) 714 (23.3)
4 (deprived) 15 (24.2) 159 (28.6) 59 (22.8) 110 (23.6) 169 (26.0) 62 (23.7) 212 (24.9) 21 (18.6) 18 (17.6) 825 (24.8) 671 (21.9)
Psychological status
Good 37 (59.7) 307 (55.2) 169 (65.3) 260 (55.7) 353 (54.3) 126 (48.1) 425 (50.0) 47 (41.6) 44 (43.1) 1,768 (53.2) 1,933 (63.0)
Poor 25 (40.3) 249 (44.8) 90 (34.7) 207 (44.3) 297 (45.7) 136 (51.9) 425 (50.0) 66 (58.4) 58 (56.9) 1,553 (46.8) 1,134 (37.0)
Morbidity counts
1 4 (6.5) 27 (4.9) 13 (5.0) 18 (3.9) 25 (3.8) 4 (1.5) 11 (1.3) 1 (0.9) 1 (1.0) 104 (3.1) 607 (19.8)
2e4 16 (25.8) 113 (20.3) 54 (20.8) 91 (19.5) 124 (19.1) 38 (14.5) 94 (11.1) 11 (9.7) 9 (8.8) 550 (16.6) 1,181 (38.5)
5e8 19 (30.6) 129 (23.2) 69 (26.6) 127 (27.2) 152 (23.4) 55 (21.0) 178 (20.9) 17 (15.0) 17 (16.7) 763 (23.0) 718 (23.4)
9e13 16 (25.8) 130 (23.4) 52 (20.1) 95 (20.3) 145 (22.3) 55 (21.0) 233 (27.4) 26 (23.0) 17 (16.7) 769 (23.2) 329 (10.7)
>14 7 (11.3) 157 (28.2) 71 (27.4) 136 (29.1) 204 (31.4) 110 (42.0) 334 (39.3) 58 (51.3) 58 (56.9) 1,135 (34.2) 233 (7.6)
Read code classifications used by family practitioners: N225 soft tissue disorder; N245 soft tissue pain; N215 peripheral enthesopathies; N09 joint disorder; N145 back pain; N115 neck pain;
N055 osteoarthritis; N335 osteoporosis; N04/N205 inflammatory polyarthropathy. The ‘‘comparator group’’ represents those without a study-speci (cardiovascular or musculoskeletal) Read code.
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Fig. 1. Mean physical component summary score (95% CI) for cardiovascular disease group. CI, confidence interval; SF, short form.
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ARTICLE IN PRESSmusculoskeletal disorder group was 36.6 (SD: 12.2). Con-
sulters with hypertension had a lower PCS score of 38.38
(95% CI: 37.8e39.0) than people who had consulted with
symptoms of a soft tissue disorder with a score of 44.85
(95% CI: 42.2e47.5). For the hypothesized ‘‘most severe’’
categories, the PCS scores were 28.98 (95% CI: 27.4e30.4)
for heart failure and 28.79 (95% CI: 26.7e30.8) for inflam-
matory polyarthropathy. Other diagnostic categories within
both the spectrums also showed similar PCS scores; for
example, ischemic heart disease (33.36 [95% CI: 32.0e
34.7]) was comparable to osteoarthritis (33.15 [95% CI:
32.4e33.9]).4. Discussion
Our study results confirm an a priori hypothesis that di-
agnostic labels applied in family practice can indicate the
severity of physical health, within categories of cardiovas-
cular disease and musculoskeletal disorder. Age, gender,
deprivation and psychological status, and morbidity counts
in a 2-year time period do not fully explain these associa-
tions. Although diagnostic variability exists in family prac-
tice [5,6], our results support the concept that groups of
consulters with the same diagnostic label as recorded in
clinical encounters could be grouped into exclusive mea-
sures of severity. Our findings for the selected cardiovascu-
lar disease labels showed that exclusive consulters with
heart failure are most likely to have poorer physical health
compared with hypertension-only consulters [26], and that
consulters with an exclusive category of angina [27] willdiffer in health severity compared with atrial fibrillation
consulters [28]. All those with a cardiovascular diagnostic
category had poorer physical health than the study compar-
ator group [29]. Although we selected only six diagnostic
categories for cardiovascular disease, they were based on
potentially illustrating the idea that the different categories
convey the stages of disease pathology development in
populations [30,31].
Our findings for the selected musculoskeletal disorders
showed that consulters with exclusive inflammatory poly-
arthropathy have poorer physical health compared with
those who consult for the symptoms of soft tissue disorders
[32]. All musculoskeletal diagnostic categories, except soft
tissue disorders, had poorer physical health than the com-
parator group. In the musculoskeletal group, there were
nine separate categories, and they had been selected on
the basis of potentially illustrating the idea that different
categories convey a spectrum of severity disorders that
may be interrelated in populations. So our categories re-
lated to nonspecific (soft tissue disorder and soft tissue
pain) and specific regional symptoms ( peripheral entheso-
pathies, joint disorders, back pain, and neck pain) and pa-
thology (osteoarthritis, osteoporosis, and inflammatory
polyarthropathy). It is possible, for example, that our exclu-
sive consulters with osteoarthritis may include people who
also had a joint disorder diagnosis [33] or that neck pain
may be part of the symptom complex of inflammatory poly-
arthropathy [34]. In contrast to the hypothesis for the clear
pathological links between different cardiovascular dis-
eases, here the hypothesis is related to undifferentiated
and differentiated stages of illness within the same
Table 3
Associations between diagnostic categories and poor physical health by cardiovascular disease and musculoskeletal disorder groups
Diagnostic category
Total
numbera
Exclusive
numberb (%)
Physical healthc
Unadjusted
OR (95% CI)
Adjusted OR (95% CI)
Good Poor
Age, gender, and
deprivation statusd
Age, gender,
deprivation status,d
and MCSe
Age, gender,
deprivation status,d
MCS,e and
morbidity countf
Cardiovascular disease
Hypertension 1,824 1,606 (88.0) 736 870 1.0g 1.0g 1.0g 1.0g
Atrial fibrillation 168 115 (68.5) 37 78 1.78 (1.1e2.6) 1.63 (1.1e2.5) 1.55 (1.0e2.4) 1.51 (1.0e2.3)
Ischemic heart disease 357 257 (72.0) 64 193 2.55 (1.8e3.4) 2.78 (2.0e3.8) 2.74 (2.0e3.8) 2.98 (2.1e4.1)
Angina 327 286 (87.5) 55 231 3.55 (2.6e4.8) 3.62 (2.6e5.0) 3.30 (2.4e4.6) 3.18 (2.3e4.4)
Myocardial infarction 50 44 (88.0) 11 33 2.53 (1.2e5.0) 3.17 (1.6e6.4) 3.02 (1.5e6.3) 2.81 (1.3e6.0)
Heart failure 139 139 (100.0) 17 122 6.07 (3.6e10.1) 5.02 (3.0e8.5) 4.35 (2.5e7.5) 3.54 (2.1e6.1)
Musculoskeletal disorder
Soft tissue disorder 119 62 (52.1) 43 19 1.0g 1.0g 1.0g 1.0g
Soft tissue pain 1,119 556 (49.7) 251 305 2.75 (1.6e4.8) 2.91 (1.6e5.2) 2.97 (1.6e5.5) 2.62 (1.4e4.9)
Peripheral enthesopathies 462 259 (56.1) 152 107 1.59 (0.9e2.9) 1.95 (1.1e3.6) 2.11 (1.1e4.0) 1.79 (0.9e3.4)
Joint disorder 836 467 (55.9) 214 253 2.67 (1.5e4.7) 3.09 (1.7e5.6) 3.17 (1.7e5.8) 2.73 (1.5e5.1)
Back pain 876 650 (74.2) 279 371 3.00 (1.7e5.3) 3.47 (1.9e6.2) 3.53 (1.9e6.5) 2.99 (1.6e5.5)
Neck pain 325 262 (80.6) 89 173 4.39 (2.4e8.0) 4.95 (2.7e9.2) 4.77 (2.5e9.1) 3.76 (2.0e7.2)
Osteoarthritis 882 850 (96.4) 218 632 6.56 (3.7e11.5) 6.74 (3.8e12.1) 6.86 (3.8e12.5) 5.38 (2.9e9.9)
Osteoporosis 118 113 (95.8) 27 86 7.20 (3.6e14.4) 7.77 (3.8e15.9) 7.34 (3.5e15.3) 5.34 (2.5e11.3)
Inflammatory polyarthropathy 102 102 (100.0) 14 88 14.22 (6.5e31.1) 13.90 (6.2e31.0) 13.37 (5.9e30.4) 9.77 (4.2e22.5)
Abbreviations: OR, odds ratio; CI, confidence interval; MCS, mental component summary; SF, short form.
a Number of patients in the study sample with at least one morbidity consultation for this diagnostic category in the 2-year time period of observation.
b Number of patients classified by study-defined exclusive severity categories.
c Based on physical component summary score from SF-12.
d Deprivation score as measured by Index of Multiple Deprivation [24].
e Based on MCS score from SF-12.
f Morbidity count is the number of different morbidities consulted for in a 2-year period before health survey.
g Reference group.
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ARTICLE IN PRESSspectrum of musculoskeletal disorders. So, although there
were distinct hypotheses for the two examples chosen, the
study findings are consistent in reflecting the overall idea
that diagnostic labels can act as a measure of the corre-
sponding physical health severity. Such empirical findings
from a large population-based study of family practice pro-
vide the basis for clinical construction of populations with
relatively poor physical health, the implication being that
this may aid clinical management [35]. Potential benefits
may include an improved ability for the FP to provide more
selective or staged treatment referral mechanisms depend-
ing on the label or developing management approaches that
use information from diagnostic labels as proxy measures
of general physical health. This method may also provide
the basis of an epidemiological construction of the stages
of disease that populations may develop and pass through
over time.
Although specific examples were chosen for the study,
the analyses allowed the comparison of physical health
for consulters with different, but exclusive, diagnostic cat-
egories between the disease and disorder spectrums
[36,37]. Consulters with angina or heart failure have com-
parable poor health to consulters with osteoarthritis, osteo-
porosis, or inflammatory polyarthropathy. Consulters for
osteoarthritis have poorer physical health than consulterswith back pain [32]. Age, gender, and deprivation and psy-
chological status do not explain these associations, and
even the co-occurrence of other morbidity did not explain
the associations between diagnostic categories and severity
as measured by self-reported physical health.
The interpretation of study results is based on the notion
of severity that relates to the population of consulters with
a diagnostic category, for example, of either angina or
osteoarthritis. Previous evidence has highlighted that there
is variation in the diagnostic coding by family physicians in
primary care [5,38]. However, this study provides the evi-
dence that the clinical judgment that underpins the applica-
tion of diagnostic labels (and arguably the decision-making
process), at least at a population level can distinguish
between different severities of physical health.
Because the study measurement is also based on the
consulting population, it will not include people who had
one of the study conditions but did not consult during the
study period. However, with a 2-year time window of ob-
servation, our study would have captured most of the study
conditions, which are persistent and chronic in duration.
Our study was also based on people who had agreed to par-
ticipate in the health survey, consented to the record review
and had consulted, which introduces the possibility of other
selection issues [39e41]. However, overall response to the
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Fig. 2. Mean physical component summary score (95% CI) for musculoskeletal disorder group. CI, confidence interval; SF, short form.
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ARTICLE IN PRESSsurvey was high (68.9%), and our previous analyses have
shown that such a bias is unlikely [42] (see Table 1 on
the journal’s Web site at www.elsevier.com). Internal com-
parisons remain valid as they were based on a priori
hypotheses, and although the use of ‘‘exclusive’’ groups
categorized patients by their most severe consultation, the
adjustment by morbidity counts reduces the explanation
of comorbidity as a marker of poor physical health. Finally,
other cardiovascular and musculoskeletal conditions could
have been chosen, but study categories were based on pre-
vious work, although other diagnostic categories may re-
quire further validation against physical health measures.
In conclusion, using the examples of cardiovascular dis-
ease and musculoskeletal disorders, our study shows that
exclusive diagnostic labels can be used as a basis of indicat-
ing severity as measured by physical health. These findings
were not explained by sociodemographic factors or comor-
bidity. In family practice populations, this method provides
the evidence for using diagnostic labels as a basis for
developing clinical decision aids for the potential provision
of public health interventions and for the epidemiological
investigation of change in chronic disease or disorder
over time.Acknowledgments
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Appendix 4.1: Systematic review – Search criteria  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 4.1: Cardiovascular disease search strategy 
  Hits 
No. Search MEDLINE EMBASE CINAHL 
 [Date search performed] 08/03/11 08/03/11 08/03/11 
     
 OUTCOME    
1. "quality of life*".ti,ab 103062 132545 28902 
2. "health survey*".ti,ab 13024 13934 3389 
3. "short form*".ti,ab 11938 13749 3529 
4. sf-36*.ti,ab 9223 11493 2702 
5. sf36*.ti,ab 531 768 2702 
6. sf-12*.ti,ab 1396 1780 435 
7. sf12*.ti,ab 123 185 435 
8. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 120042 151257 33634 
 SETTING    
9. exp GENERAL PRACTICE 
(*FAMILY PRACTICE/ for Cinahl) 
57526 59807 4683 
10. "general population*".ti,ab 47004 56083 7006 
11. “general practice*” 27433 31795 4500 
12. "primary care*".ti,ab 54762 64476 22540 
13. "family practice*".ti,ab 6867 6775 1222 
14. "family medicine*".ti,ab 5493 6028 912 
15. 9 OR 10 OR 11 OR 12 OR 13 OR 14 164441 187589 36841 
 POPULATION    
16. exp CARDIOVASCULAR DISEASES/  1614790 2274253 182295 
17. cardiovascular*.ti,ab 207581 252284 27365 
18. CVD*.ti,ab 10695 13437 2094 
19. hypertensi*.ti,ab 265548 315187 20370 
20. "high blood pressure*".ti,ab  8630 10417 1375 
21. "heart disease*".ti,ab  104238 120778 13117 
22. angina*.ti,ab  41356 48061 2944 
23. "myocardial infarction*".ti,ab  111170 130901 11860 
24. "heart attack*".ti,ab 3264 3776 1457 
25. "heart failure*".ti,ab 83119 102791 12542 
26. 16 OR 17 OR 18 OR 19 OR 20 OR 21 
OR 22 OR 23 OR 24 OR 25 
1816439 2414107 201412 
 COMBINED SEARCHES    
27. 8 AND 15 AND 26 1042 1525 276 
 LIMITED SEARCHES*     
28. 27 644 1215 167 
*Final searches limited by; date (Medline and Embase: 1990-current, Cinahl: 1990-2011); human studies 
only (available only for Medline & Embase); age (Medline and Cinahl: All adults, Embase: 18-64, 65+) and 
language (English). 
 
 
 
 
Appendix 4.1: Musculoskeletal disorder search strategy 
  Hits 
No. Search MEDLINE EMBASE CINAHL 
 [Date search performed] 08/03/11 08/03/11 08/03/11 
     
 OUTCOME    
1. "quality of life*".ti,ab 103062 132545 28902 
2. "health survey*".ti,ab 13024 13934 3389 
3. "short form*".ti,ab 11938 13749 3529 
4. sf-36*.ti,ab 9223 11493 2702 
5. sf36*.ti,ab 531 768 2702 
6. sf-12*.ti,ab 1396 1780 435 
7. sf12*.ti,ab 123 185 435 
8. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 120042 151257 33634 
 SETTING    
9. exp GENERAL PRACTICE 
(*FAMILY PRACTICE/ for Cinahl) 
57526 59807 4683 
10. "general population*".ti,ab 47004 56083 7006 
11. “general practice*” 27433 31795 4500 
12. "primary care*".ti,ab 54762 64476 22540 
13. "family practice*".ti,ab 6867 6775 1222 
14. "family medicine*".ti,ab 5493 6028 912 
15. 9 OR 10 OR 11 OR 12 OR 13 OR 14 164441 187589 36841 
 POPULATION    
16. exp MUSCULOSKELETAL DISEASES/ 721821 1232186 76877 
17. "musculoskeletal*".ti,ab 19847 23738 6969 
18. MSK*.ti,ab 758 1051 68 
19. arthritis*.ti,ab 104649 120246 11496 
20. disorder*.ti,ab 558177 665965 60062 
21. "neck pain*".ti,ab 4024 4826 1674 
22. "back pain*".ti,ab 22675 28284 9008 
23. osteoarthritis*.ti,ab 25753 31869 5255 
24. “rheumatoid arthritis*”.ti,ab 65110 74627 5901 
25. “joint disease*”.ti,ab 5943 6726 443 
26. 16 OR 17 OR 18 OR 19 OR 20 OR 21  
OR 22 OR 23 OR 24 OR 25 
1284273 1857903 145249 
 COMBINED SEARCHES    
27. 8 AND 15 AND 26 1645 2300 406 
 LIMITED SEARCHES*     
28. 27 1096 1886 250 
*Final searches limited by; date (Medline and Embase: 1990-current, Cinahl: 1990-2011); human studies 
only (available only for Medline & Embase); age (Medline and Cinahl: All adults, Embase: 18-64, 65+) and 
language (English). 
 
 
 
 
 
Appendix 4.1: Chronic disease search strategy 
  Hits 
No. Search MEDLINE EMBASE CINAHL 
 [Date search performed] 08/03/11 08/03/11 08/03/11 
     
 OUTCOME    
1. "quality of life*".ti,ab 103062 132545 28902 
2. "health survey*".ti,ab 13024 13934 3389 
3. "short form*".ti,ab 11938 13749 3529 
4. sf-36*.ti,ab 9223 11493 2702 
5. sf36*.ti,ab 531 768 2702 
6. sf-12*.ti,ab 1396 1780 435 
7. sf12*.ti,ab 123 185 435 
8. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 120042 151257 33634 
 SETTING    
9. exp GENERAL PRACTICE 
(*FAMILY PRACTICE/ for Cinahl) 
57526 59807 4683 
10. "general population*".ti,ab 47004 56083 7006 
11. “general practice*” 27433 31795 4500 
12. "primary care*".ti,ab 54762 64476 22540 
13. "family practice*".ti,ab 6867 6775 1222 
14. "family medicine*".ti,ab 5493 6028 912 
15. 9 OR 10 OR 11 OR 12 OR 13 OR 14 164441 187589 36841 
 POPULATION    
16. exp CHRONIC DISEASE/ 195728 132276 21376 
17. chronic*.ti,ab 681346 786110 64469 
18. 16 OR 17  735554 826533 72875 
 COMBINED SEARCHES    
19. 8 AND 15 AND 18 1476 1788 384 
 LIMITED SEARCHES*     
20. 19 930 1437 228 
*Final searches limited by; date (Medline and Embase: 1990-current, Cinahl: 1990-2011); human studies 
only (available only for Medline & Embase); age (Medline and Cinahl: All adults, Embase: 18-64, 65+) and 
language (English). 
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Appendix 4.2: Systematic review – National normative data studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 4.2: Reference studies and normative PCS values from individual countries for calculation of country-specific z-scores 
 
Country  Author, year  
[reference] 
n Method of data collection  PCS score  
Mean (SD) 
Europe     
France 
 
Gandek et al, 
1998 
2743 Nationally representative sample (≥15 years of age), stratified by age 
occupation, household size, regions and community size 
 
52.2 (8.0) 
Germany 
 
Gandek et al, 
1998 
2453 Separate, multistage samples, representative of both East & West Germany, 
aged 14 years or over were randomly selected. These were stratified by 
age, gender and region 
 
50.7 (9.8) 
Italy 
 
Gandek et al, 
1998 
1413 Multistage, stratified random sample of adults aged 18 years and older. 
This sample was drawn from electoral lists of regions selected at random. 
 
52.7 (7.8) 
Netherlands 
 
Gandek et al, 
1998 
1479 The study sample was drawn from all residents of Amsterdam aged 12 and 
over. These were selected from the municipal population registry and data 
was collected as part of a larger household survey 
 
49.7 (9.3) 
Spain 
 
Gandek et al, 
1998 
 
8494 Interviews were conducted with a nationally representative sample.  
This sample was weighted for the age and gender 
51.0 (9.8) 
Turkey 
 
Demiral et al , 
2006 
 
1271 SF36 (version 1) data was collected during interviews of randomly selected 
households from two districts of Izmir. Data was weighted for age. Gender 
and educational structure was shown to be similar to urban population 
figures 
 
47.9 (8.9) 
UK 
 
Gandek et al, 
1998 
1751 From a random sample of 100 areas in England, Wales and Scotland, 30 
addresses were selected at random. A sampling weight was constructed to 
represent the age, gender and regional composition of the UK 
 
50.8 (10.2) 
 
 
Appendix 4.2 cont. 
 
Country  Author, year n Sampling frame PCS score  
Mean (SD) 
     
Scandinavia     
Denmark 
 
Gandek et al, 
1998 
 
3242 SF-36 was completed by a nationally representative sample aged 16 or 
older, drawn from the Central Person Registry.  
51.5 (8.6) 
Norway 
 
Gandek et al, 
1998 
 
1885 Sample aged from 19-80 representing the general population of Norway by 
age and gender were mailed an SF36. 
51.2 (9.3) 
Sweden 
 
Gandek et al, 
1998 
 
7175 SF36 mailed to residents aged 15 or over from several different 
communities types across Sweden. 
50.8 (9.1) 
North America     
Canada 
 
Hopman et al, 
2000 
6495 SF36 data was collected as part of prospective cohort study of adults aged 
25 years or older from in and around 9 Canadian cities. Participants were 
selected at random from telephone listings and were weighted by 12 age 
and gender stratifications. 
 
49.7 (9.4) 
US 
 
Gandek et al, 
1998 
2105 SF36 data collected as part of an ongoing survey of the adult U.S. 
population and consisted of a core sample plus an elderly sample. 
Weighting of the sample reflected the age, gender and racial compositions 
of this population.  
50.8 (9.4) 
Asia     
China Lam et al, 2005 2410 Cross-sectional telephone survey was conducted within a random sample 
of the Chinese population in Hong Kong. A trained interviewer conducted 
interviews with householders aged 18 years or over.   
52.8 (7.3) 
 
 
 
 324 
 
Appendix 4.3: Systematic review – Hypertension studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 4.3: Hypertension studies  
 
Author, year n Mean age 
(SD) 
Country  Health Setting Case definition  Outcome 
measure 
Reference 
data* 
(Alonso et al. 2004) 665 53.5 (17.3) US Nationally representative 
general population  
Self-report checklist SF-36   (Gandek et al. 
1998) 
 448 59.4 (15.7) Italy     
 618 60.6 (14.4) France     
 599 56.9 (16.2) Germany     
 308 52.6 (15.8) Norway     
 489 54.2 (18.3) Netherlands     
 316 57.1 (16.0) Denmark     
 502 58.7 (13.0) Japan 
 
   (Lam et al. 
2005) 
(Aydemir, Ozdemir & 
Koroglu 2005)                                                                                                                                                   
 
938 58.1 (11.2) Turkey Primary care centres across four 
different geographical regions 
 
Clinical classification with 
the JNC VI 
SF-36   Demiral et al., 
2006 
(Cunillera et al. 
2010) 
917 61.1 (18.5) Spain Representative general 
population health survey in the 
autonomous area of Catalonia 
 
Common chronic condition 
self-report checklist 
SF-12 (Gandek et al. 
1998) 
(Erickson, Williams & 
Gruppen 2001)                                                                                                                                                 
125 59.0 (11.2) US Attendance at either a 
university general health clinic 
or a hypertension clinic 
Previous diagnosis of 
hypertension and 
prescribed anti-
hypertensive medication 
 
SF-36   (Gandek et al. 
1998) 
US: United States of America; JNC VI: Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 7: SD: Standard 
Deviation; *Article which provides the ‘national average’ Physical Component Summary (PCS) score to compare against the study sample of interest. 
 
 
 
Appendix 4.3: Hypertension studies continued 
 
Author, year n Mean age 
(SD) 
Country  Health setting Case definition  Outcome 
measure 
Reference  
data* 
(Hobbs et al. 
2002) 
1203 65.1 (10.0) UK 16 general practices from across 
the West Midlands region of 
England 
 
Diagnosis in practice 
records 
SF-36   (Gandek et al. 
1998) 
(Johnson, Coons 
1998) 
81 - US Representative general 
population sample drawn from 
White pages and driving licence 
registrations 
 
 
Common chronic condition 
self-report checklist 
SF-12 (Gandek et al. 
1998) 
(Lam et al. 
2005) 
271 - 
 
China Randomly selected sample of 
Hong Kong general population  
 
Self-report of Hypertension 
during telephone survey 
SF-36   (Lam et al. 
2005) 
(Lima et al. 
2009) 
941 69.9 (12.3) Brazil Multicentre health survey sent to 
stratified general population of 
the state of Sao Paulo 
 
Chronic disease self-report 
checklist  
SF-36 (Gandek et al. 
1998) 
(Mena-Martin et 
al. 2003) 
104 59.3 (12.9) Spain Random sample of the general 
population from Valladolid 
 
Self-report of other chronic 
diseases and physical 
examination 
  
SF-36   (Gandek et al. 
1998) 
UK: United Kingdom; US: United States of America; SD: Standard Deviation; *Article which provides the ‘national average’ Physical Component Summary (PCS) 
score to compare against the study sample of interest. 
 
 
 
 
 
 
Appendix 4.3: Hypertension studies continued 
 
Author, year n Mean age 
 (SD) 
Country  Health setting Case definition  Outcome 
measure 
Reference  
data* 
(Prior, Kadam 
2011) 
1606 68.1 (9.5) UK 6 general practices from the 
north Staffordshire region of 
England 
 
Diagnosis by clinician, 
defined by Read code in 
practice records 
SF-12 (Gandek et al. 
1998) 
 
(Quercioli et al. 
2009) 
218 64.8 (12.8) Italy General practices in two 
Italian cities (Turin & Siena) 
 
 
Self-report of a history of 
hypertension 
 
SF-36   (Gandek et al. 
1998) 
 
(Schmidt et al. 
2008) 
3410 - 
 
Germany Multiple general practices 
 
Clinician selected 
patients with 
uncontrolled arterial 
hypertension 
 
SF-12 (Gandek et al. 
1998) 
(Wang et al. 
2008) 
217 61.5 (13.2) Germany Cross-sectional survey across 
20 general practices  
 
Record chronic diseases 
at consultation and self-
reported severe illness 
experience 
 
SF-36   (Gandek et al. 
1998) 
(Ware, Kosinski 
& Keller 1994)                                                                                                                                  
1689 58.4 US Representative and stratified 
general population survey 
 
Chronic condition self-
report checklist  
SF-12 (Gandek et al. 
1998) 
UK: United Kingdom; US: United States of America; SD: Standard Deviation; *Article which provides the ‘national average’ Physical Component Summary (PCS) 
score to compare against the study sample of interest. 
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Appendix 4.4: Systematic review – Ischaemic Heart Disease studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 4.4: Ischaemic Heart Disease (IHD) studies 
Author, year  
 
n Mean age 
(SD) 
Country  Health setting Case definition  Outcome 
measure 
Reference  
data* 
(Alonso et al. 
2004) 
 
141 60.46 (16.30) US Nationally representative 
general population  
Self-reported checklist SF-36 (Gandek et al. 
1998) 
 104 66.58 (16.21) Italy     
 103 65.56 (15.18) France     
 289 64.05 (14.32) Germany     
 47 64.06 (11.24) Norway     
 190 55 (20.62) Netherlands     
 78 63.88 (11.75) Denmark     
 100 59.26 (14.51) Japan 
 
   (Lam et al. 
2005) 
 
(Buckley, 
Murphy 2009) 
449 65.0 (9.09) Ireland 37 general practices in the 
west and north-west of 
Ireland 
 
IHD diagnosis (excluding 
angina) in medical records 
 
SF-36 (Gandek et al. 
1998) 
(Prior, Kadam 
2011) 
257 69.4 (8.3) UK 6 general practices from the 
north Staffordshire region of 
England 
 
Defined by IHD Read code in 
practice records 
SF-12 (Gandek et al. 
1998) 
UK: United Kingdom; US: United States of America; SD: Standard Deviation; *Article which provides the ‘national average’ Physical Component Summary (PCS) 
score to compare against the study sample of interest. 
 
 
 
 
 
Appendix 4.4: Ischaemic Heart Disease (IHD) studies continued 
Author, year n Mean age 
(SD) 
Country  Health setting Case definition  Outcome 
measure 
Reference  
data 
(Buckley, 
Murphy 2009) 
 
275 67.2 (9.01) Ireland 37 general practices in the west 
and north-west of Ireland 
Angina diagnosis in medical 
records 
SF-36 (Gandek et al. 
1998) 
 
(Hobbs et al. 
2002) 
 
531 68.04 (9.58) UK 16 general practices from 
across the West Midlands 
region of England 
 
Previous diagnosis of angina in 
practice records 
SF-36 (Gandek et al. 
1998) 
(Prior, Kadam 
2011) 
 
286 70.2 (9.5) UK 6 general practices from the 
north Staffordshire region of 
England 
 
Angina diagnosis by clinician, 
defined by Read code in practice 
records 
 
SF-12 (Gandek et al. 
1998) 
(Cunillera et al. 
2010) 
 
105 67.25 (14.96) Spain Representative general 
population health survey in the 
autonomous area of Catalonia 
 
Self-report of previous MI on 
common chronic condition 
checklist 
 
SF-12 (Gandek et al. 
1998) 
(Hobbs et al. 
2002) 
396 67.18 (9.7) UK 16 general practices from 
across the West Midlands 
region of England 
 
Previous diagnosis of MI in 
practice records 
SF-36 (Gandek et al. 
1998) 
(Prior, Kadam 
2011) 
 
44 68.9 (9.4) UK 6 general practices from the 
north Staffordshire region of 
England 
 
Defined by MI Read code in 
practice records 
SF-12 (Gandek et al. 
1998) 
MI: Myocardial Infarction; UK: United Kingdom; SD: Standard Deviation; *Article which provides the ‘national average’ Physical Component Summary (PCS) score 
to compare against the study sample of interest. 
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Appendix 4.5: Systematic review – Heart Failure studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 4.5: Heart Failure studies 
Author, year  
 
n Mean age 
(SD) 
Country  Health setting Case definition  Outcome 
measure 
Reference 
data 
        
(Alonso et al. 
2004) 
 
83 64.74 (11.38) US Nationally representative 
general population  
Self-report checklist 
 
SF-36 (Gandek et al. 
1998) 
 127 66.72 (13.15) Italy     
 142 67.97 (12.62) France     
 250 64.43 (14.30) Germany     
 91 63.52 (12.79) Norway     
 170 62.16 (17.48) Netherlands     
 35 65.26 (12.50) Denmark     
 50 57.40 (14.73) Japan 
 
   (Lam et al. 
2005) 
 
(Brostrom et al. 
2004) 
 
223 75 (9): males 
78 (9): females  
Sweden 1 university hospital 
medical ward, 2 heart 
failure clinics, 5 primary 
health care centre in the 
southeast 
 
Diagnosis of HF based on 
symptoms, signs or valid 
clinical measures  
SF-36 (Gandek et al. 
1998) 
(Faller et al. 
2007) 
231 64 (13) Germany 2 Wurzburg university 
medical centres 
 
Diagnosis of HF confirmed by 
clinical, laboratory or 
echocardiographic criteria 
SF-36 (Gandek et al. 
1998) 
HF: Heart Failure; US: United States of America; SD: Standard Deviation; *Article which provides the ‘national average’ Physical Component Summary (PCS) score to 
compare against the study sample of interest. 
 
 
 
Appendix 4.5: Heart Failure studies continued 
 
Author, year  
 
n Mean age 
(SD) 
Country  Health setting Case definition  Outcome 
measure 
Reference 
data* 
        
(Gott et al. 
2006) 
542 76.46 UK 16 general practices across 
four geographical areas 
HF Read codes within the medical 
records or prescription for HF 
related drugs 
 
SF-36 (Gandek et al. 
1998) 
(Hobbs et al. 
2002) 
 
399 72.71 (9.49) UK 16 general practices from 
across the West Midlands 
region of England 
 
Previous diagnosis in practice 
records 
SF-36 (Gandek et al. 
1998) 
(Prior, Kadam 
2011) 
 
139 76.5 (8.2) UK 6 general practices from 
the north Staffordshire 
region of England 
 
Diagnosis by clinician, defined by 
Read code in practice records 
SF-12 (Gandek et al. 
1998) 
(Sidorov et al. 
2003) 
268 75.2 US Primary care based, HMO 
sponsored patient 
education  programme 
 
Health plan members with 
diagnosis of HF 
 
SF-36 (Gandek et al. 
1998) 
(Wyrwich et al. 
2007) 
80  US Primary care outpatients 
 
Medical records detailed a 
previous diagnosis of HF, 
prescription of HF medication 
 
SF-36 (Gandek et al. 
1998) 
HF: Heart Failure; HMO: Health Maintenance Organisation; UK: United Kingdom; US: United States of America; SD: Standard Deviation;  
*Article which provides the ‘national average’ Physical Component Summary (PCS) score to compare against the study sample of interest. 
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Appendix 4.6: Systematic review – Lower Back Pain studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 4.6: Lower Back Pain studies  
Author, year  
 
n Mean age 
(SD) 
Country  Health setting Case definition  Outcome 
measure 
Reference  
data* 
(Carmona et al. 
2001)  
325 ≥20 Spain General population survey 
across all geographic regions 
  
Self-report 
 
SF-12 (Gandek et al. 
1998) 
(Cunillera et al. 
2010) 
 
1277 50.7 (21.4) Spain Representative general 
population health survey in 
the autonomous area of 
Catalonia 
 
Self-report of previous 
LBP on common 
chronic condition 
checklist 
SF-12 (Gandek et al. 
1998) 
(Depont et al. 
2010) 
796 52.9 (11.3) 
 
France Random sample of primary 
care physicians from across 
the country  
 
LBP at least once a 
week for at least 3 
months at a time 
SF-12 (Gandek et al. 
1998) 
(Ekman et al. 
2005) 
302 48.9 (14.2) Sweden 10 primary care centres and 4 
orthopaedic outpatient clinics 
in 5 regions of Sweden 
 
Experienced LBP at 
least 50% of the days 
during last 3 months  
SF-12 (Gandek et al. 
1998) 
(Hicks et al. 2008) 140 81.0 (5.5) 
 
US Population-based survey to 
residential population in 
Maryland & North Virginia 
  
Self-report, indicating 
experience pain on 
diagram  
SF-36 (Gandek et al. 
1998) 
(Lima et al. 2009) 
 
621 69.6 Brazil Multicentre health survey sent 
to stratified general 
population of the state of Sao 
Paulo 
 
Chronic disease self-
report checklist 
SF-36 (Gandek et al. 
1998) 
US: United States of America; SD: Standard Deviation; *Article which provides the ‘national average’ Physical Component Summary (PCS) score to compare against 
the study sample of interest. 
 
Appendix 4.6: Lower Back Pain studies continued 
Author, year  n Mean age 
(SD) 
Country  Health setting Case definition  Outcome 
measure 
Reference  
data* 
(Prior, Kadam 
2011) 
 
650 64.4 (10.0) UK 6 general practices from the 
north Staffordshire region of 
England 
Diagnosis by clinician, defined 
by Read code in practice 
records 
 
SF-12 (Gandek et al. 
1998) 
(Salaffi et al. 
2005) 
 
127 ≥18 Italy 16 general practices from the 
Marche region of Italy  
 
 
Defined by pain localized in 
lower back, either radiating or 
not 
 
SF-36 (Gandek et al. 
1998) 
(Suarez-Almazor 
et al. 2000) 
46 49.9 (14.8) Canada Consecutive patients seen by 2 
physicians at outpatient clinics 
 
Consulters for LBP SF-36 (Hopman et al. 
2000) 
 
(Wang et al. 
2008) 
 
193 51.1 (15.2) Germany Cross-sectional survey across 
20 general practices  
 
Record chronic diseases at 
consultation and self-reported 
severe illness experience 
 
SF-36 (Gandek et al. 
1998) 
LBP: Lower Back Pain; UK: United Kingdom; SD: Standard Deviation; *Article which provides the ‘national average’ Physical Component Summary (PCS) score to 
compare against the study sample of interest. 
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Appendix 4.7: Systematic review – Osteoarthritis studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 4.7: Osteoarthritis studies 
Author, year n Mean age 
(SD) 
Country  Health setting Case definition  Outcome  
measure 
Reference 
data* 
(Carmona et al. 
2001) 
 
233 ≥20 Spain General population survey 
across all geographic regions 
 
Symptomatic knee OA, defined 
with ACR criteria 
 
SF-12 (Gandek et 
al. 1998) 
(Carmona et al. 
2001) 
 
136 ≥20 Spain General population survey 
across all geographic regions 
 
Symptomatic hand OA, defined 
with ACR criteria 
 
SF-12 (Gandek et 
al. 1998) 
(Loza et al. 2009) 
 
1071 71 (9) 
 
Spain 
 
Patients consulting general 
practices in 11 geographic 
regions  
 
Symptomatic and radiologic 
knee or hip OA  
 
SF-12 (Gandek et 
al. 1998) 
(Picavet, Hoeymans 
2004) 
 
547 64 
 
Netherlands Random general population 
sample from 1998 population 
register 
 
Reporting of knee OA via 
musculoskeletal disease self-
report checklist 
 
SF-36 (Gandek et 
al. 1998) 
(Picavet, Hoeymans 
2004) 
 
354 67 
 
Netherlands Random general population 
sample from 1998 population 
register 
 
Reporting of hip OA via 
musculoskeletal disease self-
report checklist 
 
SF-36 (Gandek et 
al. 1998) 
(Prior, Kadam 
2011) 
 
850 68.9 (9.7) 
 
UK 6 general practices from the 
north Staffordshire region of 
England 
 
Diagnosis by clinician,  
defined by Read code in  
practice records 
SF-12 (Gandek et 
al. 1998) 
UK: United Kingdom; SD: Standard Deviation; *Article which provides the ‘national average’ Physical Component Summary (PCS) score to compare against the 
study sample of interest. 
 
 
 
 
 
Appendix 4.7: Osteoarthritis studies continued 
Author, year  
 
n Mean age 
(SD) 
Country  Health setting Case definition  Outcome 
measure 
Reference 
data* 
(Rannou et al. 2007) 2540 67 (10) 
 
France  National sample of general practices 
by geographical stratification 
Consulting for, and 
radiographic evidence of 
knee OA 
 
SF-36 (Gandek et al. 
1998) 
(Rannou et al. 2007) 1581 67 (10) France  National sample of general practices 
by geographical stratification 
 
Consulting for, and 
radiographic evidence of 
hip OA 
 
SF-36 (Gandek et al. 
1998) 
(Salaffi et al. 2005) 
 
193 ≥18 Italy 16 general practices from the 
Marche region of Italy  
 
Hand, knee or hip OA 
defined using ACR criteria 
 
SF-36 (Gandek et al. 
1998) 
(Slatkowsky-
Christensen et al. 2007) 
190 61.6  
(49.9-70.9) 
 
Norway Referred to an outpatient 
rheumatology department in last 
two years 
 
Reported OA pain in last 
month before screening  
SF-36 (Gandek et al. 
1998) 
(Ware, Kosinski & 
Keller 1994)                                                                                         
 
994 60.8 US Representative and stratified 
general population survey 
 
Chronic condition self-
report checklist  
SF-12 (Gandek et al. 
1998) 
(Woo et al. 2004) 574  China 4 different clinic types (family 
medicine, rheumatology, 
orthopaedics & geriatric)  in 3 
different regions of Hong Kong 
 
Consecutive patients with a 
diagnosis of OA 
SF-36 Lam et al., 
2005  
(Zakaria et al. 2009) 151 65.6 (10.8) Malaysia Two outpatient clinics in Hulu 
Langat, Selangor 
Symptomatic knee OA, 
defined with ACR criteria 
 
SF-36 Lam et al., 
2005 
ACR: American College of Rheumatology; OA: Osteoarthritis; US: United States of America; SD: Standard Deviation; *Article which provides the ‘national average’ 
Physical Component Summary (PCS) score to compare against the study sample of interest. 
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Appendix 4.8: Systematic review – Rheumatoid Arthritis studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 4.8: Rheumatoid arthritis studies  
 
Author, year n Mean age 
(SD) 
Country  Health setting Case definition  Outcome 
measure 
Reference 
data* 
        
(Kahn et al. 2007) 
 
490 54 (11)  
{mean age is of  
study sample: 586} 
 
US Patients consulting across 4 
Californian medical centres  
 
At least 3 insurance claims for 
RA and meeting clinical and 
laboratory criteria 
 
SF-12 (Gandek et al. 
1998) 
(Picavet, Hoeymans 
2004) 
156 66 Netherlands Random general population 
sample from 1998 
population register 
 
Reporting of RA via 
musculoskeletal disease self-
report checklist 
 
SF-36 (Gandek et al. 
1998) 
(Salaffi et al. 2009) 
 
693 53.9 (12.9) Italy Outpatient clinic from two 
Rheumatology departments 
 
Diagnosis of RA defined by ARA 
criteria 
 
SF-36 (Gandek et al. 
1998) 
(Slatkowsky-
Christensen et al. 
2007) 
 
194 61.1 (49.6-70.0) 
 
Norway Female patients on Oslo  
RA register 
 
 
Patients examined in outpatient 
rheumatology department in 
preceding two years  
 
SF-36 (Gandek et al. 
1998) 
(Uhlig et al. 2007) 936 61.3 (14.1) 
{mean age is of 
study sample: 1052} 
Norway Representative sample of 
RA patients in Oslo from 
local register 
 
Diagnosis of RA defined by ARA 
criteria 
SF-36 (Gandek et al. 
1998) 
(Ware, Kosinski & 
Keller 1994)                                                                                 
501 57.6 US Representative and 
stratified general 
population survey 
 
Chronic condition self-report 
checklist  
SF-12 (Gandek et al. 
1998) 
ARA: American Rheumatism Association; RA: Rheumatoid Arthritis; UK: United Kingdom; US: United States of America; SD: Standard Deviation; *Article which 
provides the ‘national average’ Physical Component Summary (PCS) score to compare against the study sample of interest. 
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Appendix 4.9: Systematic review – Comparison of z-scores from SF-
36 only (Cardiovascular disease & Musculoskeletal graphs)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 4.9: The z-score of each study including only studies using SF-36 measure and with a defined CVD condition in descending order. 
Hyp=Hypertension, IHD = Ischaemic health disease, HF = Heart failure. SD = Standard Deviation 
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Study samples ordered by descending z-score 
Hyp (Mean -0.61, SD 0.4)
IHD (Mean -1.29, SD 0.4)
HF (Mean -1.64, SD 0.3)
 
Appendix 4.9: Z-scores of each article which used the SF-36 and with a defined MSK condition in descending order.  
LBP = Lower Back Pain, OA = Osteoarthritis, RA = Rheumatoid Arthritis. SD = Standard Deviation 
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Study samples order by decreasing z-score 
LBP (Mean -1.31, SD 0.7)
OA (Mean -1.92, SD 0.7)
RA (Mean -1.89, SD 0.5)
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Appendix 4.10: Systematic review – Graphs comparing z-scores 
against US norms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Appendix 4.10: Comparison of z-scores generated for each hypertension study using either each countries normative data (blue) or normative data 
from the USA (red), ordered by decreasing difference in score. 
Bra = Brazil, Chi = China, Den = Denmark, Fra = France, Ger = Germany, Ita = Italy, Jap = Japan, Net = Netherlands, Nor = Norway, Spa = Spain, UK = United Kingdom 
and US = United States of America (Alonso et al. 2004). Parenthesis after a country represents alterative country used to generate z-score 
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Appendix 7.1: 2C Methods – Ethical approval 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Cheshire Research Ethics Committee 
Research Ethics Office 
Victoria Building 
Bishop Goss Complex 
Rose Place 
Liverpool 
L3 3AN 
Telephone: 0151 330 2070  
Facsimile: 0151 330 2075 
19 March 2009 
 
Dr Umesh T Kadam 
Senior Lecturer in General Practice (Epidemiology)  
Keele University 
arc National Primary Care Centre 
Keele University 
Staffordshire 
ST5 5BG 
 
 
Dear Dr Kadam 
 
Full title of study: The consequences of cardiovascular disease and 
osteoarthritis comorbidity on short and long-term health 
status and health care in primary care 
REC reference number: 09/H1017/40 
 
The Research Ethics Committee reviewed the above application at the meeting held on 11 
March 2009. Thank you for attending to discuss the study. 
 
Ethical opinion 
 
Thank you for your reassurance that should participants die during the study period, the 
matter would be dealt with sensitively based on procedures developed as a result of a 
similar study. 
 
The members of the Committee present gave a favourable ethical opinion of the above 
research on the basis described in the application form, protocol and supporting 
documentation, subject to the conditions specified below. 
 
Ethical review of research sites 
 
The Committee agreed that all sites in this study should be exempt from site-specific 
assessment (SSA).  There is no need to submit the Site-Specific Information Form to any 
Research Ethics Committee.  The favourable opinion for the study applies to all sites 
involved in the research.  
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of 
the study. 
 
Management permission or approval must be obtained from each host organisation prior to 
the start of the study at the site concerned. 
 
Management permission at NHS sites (“R&D approval”) should be obtained from the 
relevant care organisation(s) in accordance with NHS research governance arrangements.  
Guidance on applying for NHS permission is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk. 
 
Approved documents 
 
The documents reviewed and approved at the meeting were: 
  
Document    Version    Date    
CV James Prior    17 February 2009  
Participant Consent Form  5  17 February 2009  
Participant Information Sheet  3  13 February 2009  
Letter of invitation to participant  1  11 February 2009  
Questionnaire: General Health Monthly  3  13 February 2009  
Questionnaire: General Health  5  17 February 2009  
Peer Review       
Letter from Sponsor    17 February 2009  
Summary/Synopsis       
Covering Letter       
Protocol  4  17 February 2009  
Investigator CV       
Application  2.0  17 February 2009  
 
Membership of the Committee 
 
The members of the Ethics Committee who were present at the meeting are listed on the 
attached sheet. 
 
Statement of compliance  
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
 
After ethical review 
 
Now that you have completed the application process please visit the National Research 
Ethics Website > After Review  
 
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure.  If you wish to make your views 
known please use the feedback form available on the website. 
 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
• Notifying substantial amendments 
• Progress and safety reports 
• Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
 
We would also like to inform you that we consult regularly with stakeholders to improve our 
service. If you would like to join our Reference Group please email 
referencegroup@nres.npsa.nhs.uk. 
 
09/H1017/40 Please quote this number on all correspondence 
 
With the Committee’s best wishes for the success of this project 
 
Yours sincerely 
 
 
 
 
Mr Jonathan Deans, FRCS 
Chair Cheshire REC 
 
Email: rob.emmett@liverpoolpct.nhs.uk 
 
Enclosures: List of names and professions of members who were present at the 
meeting and those who submitted written comments 
“After ethical review – guidance for researchers”  
 
 
Copy to: Professor Peter R Croft 
[R&D office for NHS care organisation at lead site] 
 
 
Cheshire Research Ethics Committee 
 
Attendance at Committee meeting on 11 March 2009 
 
 
  
 
Cheshire Research Ethics Committee 
 
LIST OF SITES WITH A FAVOURABLE ETHICAL OPINION 
 
For all studies requiring site-specific assessment, this form is issued by the main REC to the Chief Investigator and sponsor with the favourable opinion letter and 
following subsequent notifications from site assessors.  For issue 2 onwards, all sites with a favourable opinion are listed, adding the new sites approved. 
 
 
REC reference number: 
 
 
09/H1017/40 
 
Issue number: 
 
1 
 
Date of issue: 
 
19 March 2009 
 
Chief Investigator: 
 
 
Dr Umesh T Kadam 
 
Full title of study: 
 
 
The consequences of cardiovascular disease and osteoarthritis comorbidity on short and long-term health status and health care in 
primary care 
 
This study was given a favourable ethical opinion by Cheshire Research Ethics Committee on [##SF1ClockStopDate##]. The favourable opinion is extended to each 
of the sites listed below.  The research may commence at each NHS site when management approval from the relevant NHS care organisation has been confirmed. 
 
 
Principal Investigator 
 
Post 
 
Research site 
 
Site assessor 
 
Date of favourable 
opinion for this site 
 
 
Notes (1) 
 
Approved by the Chair on behalf of the REC: 
 
.……………………………………………… (Signature of Chair/Co-ordinator)  
(delete as applicable) 
 
………………………………………………. (Name) 
 
 
(1) The notes column may be used by the main REC to record the early closure or withdrawal of a site (where notified by the Chief Investigator or sponsor), 
the suspension of termination of the favourable opinion for an individual site, or any other relevant development.  The date should be recorded. 
 
[##IfMultisiteOrContainNoObjection##] 
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Appendix 7.2: 2C Methods – Baseline 2C questionnaire 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LREC Number: 09/H1017/40 
 
 
 
 
 
 
 
 
 
General Health 
Questionnaire 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 30/11/09, version 8 2 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 30/11/09, version 8 3 
 
 
 
 
 
 
 
Instructions 
 
 
 
The aim of this questionnaire is to find out how your health has been 
recently. The answers you give will be treated in the strictest confidence. 
 
Please answer the questions, even if you have no current 
problems with your health. Unless stated, most questions 
are answered by putting a cross in a box, like this: 
 
 
When you have finished, please check that all questions have been 
answered and then return the completed questionnaire back to us as soon 
as you can. An envelope is provided and you do not need a stamp. 
 
Details about this project are available in the information sheet enclosed. If 
you would like further information please contact the study coordinator  
James Prior on 01782 734863 
 
 
 
THANK YOU FOR YOUR HELP  
 
 
 
 
 
 
 
 
X 
 30/11/09, version 8 4 
SECTION A – YOUR HEALTH 
 
Part 1 – Your general health 
 
Please answer every question. Some questions may look similar to others 
but each one is different. Please take the time to read and answer each 
question carefully by placing a cross in the box of your choice. 
 
 
1. In general, would you say your health is…… 
     (Please put a cross in one box only) 
 
Excellent Very good Good Fair Poor 
     
 
 
    
 
 
 
2. Compared to a year ago, how would you rate your health in general 
now? (Please put a cross in one box only) 
 
Much better 
than a year 
ago 
Somewhat 
better than a 
year ago 
 
About the 
same 
Somewhat 
worse now than 
a year ago 
Much worse 
now than a year 
ago 
     
 
 
    
 
 
 
3. The following questions are about activities you might do during a typical 
day. Does your health now limit you in these activities? If so, how 
much? (Please put a cross in one box on each line) 
 
  Yes, 
limited 
a lot 
Yes, 
limited 
a little 
No, not 
limited 
at all 
     
 
a. 
 
Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling or playing golf 
 
   
     
 
b. 
 
Climbing several flights of stairs 
 
   
 
 
 
 
 
 
     
 
  
 
     
 30/11/09, version 8 5 
4. During the past 4 weeks, how much of the time have you had any of the 
following problems with your work or other regular daily activities as a 
result of your physical health?  
(Please put a cross in one box on each line) 
 
 All  
of the 
time 
Most  
of the 
time 
Some  
of the 
time 
A little  
of the 
time 
None 
of the 
time 
       
 
a. 
 
Accomplished less 
than you would like 
 
     
       
 
b. 
 
Were limited in the 
kind of work or other 
activities 
 
     
 
 
 
5. During the past 4 weeks, how much of the time have you had any of the 
following problems with your work or other regular daily activities as a 
result of any emotional problems (such as feeling depressed or 
anxious)? 
     (Please put a cross in one box on each line) 
  
 All  
of the 
time 
Most  
of the 
time 
Some  
of the 
time 
A little  
of the 
time 
None 
of the 
time 
       
 
a. 
 
Accomplished less 
than you would like 
 
     
       
 
b. 
 
Didn’t do work or other 
activities as carefully 
as usual 
 
     
 
 
 
6. During the past 4 weeks, how much did pain interfere with your normal 
work (including both work outside the home and housework)? 
     (Please put a cross in one box only) 
 
Not at all A little bit Moderately Quite a bit Extremely 
     
 
 
    
     
     
     
     
     
 30/11/09, version 8 6 
7. These questions are about how you feel and how things have been with  
     you during the past 4 weeks. For each question, please give the one   
     answer that comes closest to the way you have been feeling. 
     (Please put a cross in one box on each line) 
 
     How much of the time during the past 4 weeks… 
  
 All  
of the  
time 
Most  
of the 
time 
Some  
of the 
time 
A little  
of the 
time 
None 
of the 
time 
       
 
a. 
 
Have you felt calm and 
peaceful? 
 
     
       
 
b. 
 
Did you have a lot of 
energy? 
 
     
       
 
c. 
 
Have you felt downhearted 
and low? 
 
     
 
 
 
8. During the past 4 weeks, how much of the time has your physical  
    health or emotional problems interfered with your social activities (like  
    visiting with friends, relatives, etc.)?  
    (Please put a cross in one box only) 
 
All of the  
time 
Most of the 
time 
Some of the 
time 
A little of the 
time 
None of the 
time 
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Part 2 – Your health today 
 
For each of the five sets of statements below, please put a cross in the 
one box that best describes your own health state today. 
 
1. Mobility 
 
I have no problems  
in walking about  
I have some problems  
in walking about 
I am confined 
to bed 
   
 
 
  
 
2. Self-care 
 
I have no problems 
with self-care 
I have some problems  
washing and dressing myself 
I am unable to wash  
or dress myself 
   
 
 
  
 
3. Usual activities (e.g. work, study, housework, family or leisure activities) 
 
I have no problems  
with performing  
my usual activities 
I have some problems  
with performing my  
usual activities 
I am unable to perform 
my usual activities 
   
 
 
  
 
4. Pain/discomfort 
 
I have no pain  
or discomfort 
I have moderate pain or 
discomfort 
I have extreme pain  
or discomfort 
   
 
 
  
 
5. Anxiety/depression 
 
I am not anxious 
or depressed 
I am moderately  
anxious or depressed 
I am extremely  
anxious or depressed 
   
 
 
  
 
 
 
 
   
   
   
   
   
 30/11/09, version 8 8 
 
 
6. To help people say how good or bad their health is, we have drawn a  
     scale (rather like a thermometer) on which the best health state you can 
     imagine is marked 100 and the worst health state you can imagine is    
     marked 0. 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         
 
 
 
 
 
 
Your own health 
state today 
     
 
We would like you to indicate on this 
scale how good or bad you think your 
own health is today.   
 
Please do this by drawing a line from 
the box below to whichever point on 
the scale indicates how good or bad 
your health state is today. 
 
Worst Imaginable 
Health State  
Best Imaginable 
Health State 
0 
 
10 
20 
30 
 
40 
 
50 
60 
80 
 100 
5 
15 
25 
35 
45 
55 
65 
75 
85 
90 
95 
70 
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Part 3 – How you’ve been feeling 
 
The next sets of questions are about how you feel at the moment. Please 
read each item and put a cross in the box that comes closest to how you 
have been feeling in the past 4 weeks. Don’t take too long over your 
replies; your immediate reaction to each item will usually be more accurate 
than a long thought out response. 
 
1. I feel tense or ‘wound up’: 
 
 
Most of the time 
 
A lot of the time 
From time to time, 
occasionally 
 
Not at all 
    
 
 
   
 
2. I still enjoy the things I used to enjoy: 
 
Definitely  
as much 
Not quite  
as much 
 
Only a little 
 
Hardly at all 
    
 
 
   
 
3. I get a sort of frightened feeling as if something awful is about to happen: 
 
Very definitely 
and quite badly 
Yes, but not 
too badly 
A little, but it 
doesn’t worry me 
 
Not at all 
    
 
 
   
 
4. I can laugh and see the funny side of things: 
 
As much as I 
always could 
Not quite so 
much now 
Definitely not 
so much now 
 
Not at all 
    
 
 
   
 
5. Worrying thoughts go through my mind: 
 
A great deal of 
the time 
A lot of  
the time 
From time to time, 
but not too often 
Only  
occasionally 
    
 
 
   
 
    
    
    
    
    
 30/11/09, version 8 10 
6. I feel cheerful: 
 
Not at all Not often Sometimes Most of the time 
    
 
 
   
 
7. I can sit at ease and feel relaxed: 
 
Definitely  Usually Not often Not at all 
    
 
 
   
 
8. I feel as if I am slowed down: 
 
Nearly all the time  Very often Sometimes Not at all 
    
 
 
   
 
9. I get a sort of frightened feeling like ‘butterflies’ in my stomach: 
 
Not at all Occasionally Quite often Very often 
    
 
 
   
 
10. I have lost interest in my appearance: 
 
 
Definitely 
I don’t take as much  
care as I should 
I may not take 
quite as much care 
I take just as much 
care as ever 
    
 
 
   
 
11. I feel restless as if I have to be on the move: 
 
Very much indeed Quite a lot Not very much Not at all 
    
 
 
   
 
12. I look forward with enjoyment to things: 
 
As much  
as I ever did 
Rather less  
than I used to 
Definitely less  
than I used to 
 
Hardly at all 
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13. I get sudden feelings of panic: 
 
Very often indeed Quite often Not very often Not at all 
    
 
 
   
 
14. I can enjoy a good book or radio or television programme: 
 
Often Sometimes Not often Very seldom 
    
 
 
   
 
 
 
Part 4 – Your daily activities 
 
These questions ask you about activities you may perform at home, work or 
for leisure. Below is an example of how each part should be completed. 
Please note you are asked to write in the ‘time per day’ box and for 
questions 2 & 3 (Pg12) please place a cross in one of the effort boxes.  
 
 
EXAMPLE: Days 
per week 
 
 Time  
per day 
 Effort 
slow/light moderate fast/intense 
      
 
Walking 
 
 
 
    
 
 
 
Think about an average week in the past 4 weeks. Please indicate how 
many days per week you did the following activities and how much time 
on average you did these for. Please place a 0 in the ‘Days per week’ box if 
you DID NOT do one of the stated activities. 
 
 
1. HOUSEHOLD ACTIVITIES 
Days  
per week 
 
 Time  
per day 
   
 
a. Light household work 
    (e.g. cooking, washing, ironing) 
 
    
    
 
b. Intense household work 
    (e.g. walking with heavy shopping bags) 
 
   
 
 
    
    
 
  3 1hr 10min X 
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Now please let us know on average over the past 4 weeks how often, for 
how long and at what effort you have done any of the below activities. 
 
2. LEISURE  
    ACTIVITIES 
Days 
per week 
 
 Time 
per day 
 Effort 
slow/light moderate fast/intense 
      
 
a. Walking 
 
 
 
    
      
 
b. Cycling 
 
     
      
 
c. Gardening 
 
     
      
 
d. Vigorous activities  
    (e.g. dancing) 
 
      
 
  Yes No  
     
 
3. 
 
Are you retired? 
 
  
 
 
 
If yes please go to Part 5 (Pg 13) 
 
 
If you travel to and from work please let us know for an average week, over 
the past 4 weeks, how often you did this and at what level of effort. 
 
4. COMMUTING     
ACTIVITIES 
Days 
per week 
 
 Time  
per day 
 Effort 
slow/light moderate fast/intense 
        
 
a. Walk to/from work 
 
 
 
 
    
      
 
b. Drive to/from work 
 
     
 
If you work, please let us know, on average over the past 4 weeks how 
much of your time per week has involved doing light and/or intense work. 
 
 
5. ACTIVITY AT WORK 
Time  
per week 
 
  
 
a. Light work (sitting/standing with some walking e.g. a desk job) 
 
 
  
 
b. Intense work (regularly lifting heavy objects at work) 
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Part 5 – Your sleep and tiredness 
 
This section asks you about your ability to rest day-to-day over the past 4 
weeks. Please put a cross in one box per line to answer each question. 
 
  0-15 
mins 
16-30 
mins 
31-45 
mins 
46-60 
mins 
61+ 
mins 
       
 
1. 
 
How long on average did it usually 
take for you to fall asleep during the 
past 4 weeks?  
 
     
       
  0-3  
hours  
4-6  
hours 
7-8  
hours 
9-12  
hours 
13+ 
hours 
       
 
2. 
 
How many hours on average did 
you sleep each night during the 
past 4 weeks?  
 
     
 
3. How often during the 
past 4 weeks did you… 
All of 
the 
time 
Most 
of the  
time 
A good  
bit of  
the time 
Some  
of the 
time 
A little  
of the  
time 
None  
of the 
time 
        
 
a. 
 
get enough sleep to feel 
rested upon waking in the 
morning? 
 
      
        
 
b. 
 
awaken short of breath or 
with a headache? 
 
      
        
 
c. 
 
have trouble falling 
asleep? 
 
      
        
 
d. 
 
awaken during your sleep 
time and have trouble 
falling asleep again? 
 
      
        
 
e. 
 
have trouble staying 
awake during the day? 
 
      
        
 
f. 
 
get the amount of sleep 
you needed? 
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4. How true do you find each statement 
below. In the past 4 weeks I have 
found that... 
 
Not  
at all 
 
A little 
bit 
 
Some
what 
 
Quite  
a bit 
 
Very 
much 
       
 
a. 
 
I feel fatigued 
 
     
       
 
b. 
 
I feel weak all over 
 
     
       
 
c. 
 
I feel listless (“washed out”) 
 
     
       
 
d. 
 
I feel tired 
 
     
       
 
e. 
 
I have trouble starting things  
because I’m tired 
 
     
       
 
f. 
 
I have trouble finishing things  
because I’m tired 
 
     
       
 
g. 
 
I have energy 
 
     
       
 
h. 
 
I am able to do my usual activities 
 
     
       
 
i. 
 
I need to sleep during the day 
 
     
       
 
j. 
 
I am too tired to eat 
 
     
       
 
k. 
 
I need help doing my  
usual activities 
 
     
       
 
l. 
 
I am frustrated by being too  
tired to do the things I want to do 
 
     
       
 
m. 
 
I have to limit my social  
activity because I’m tired 
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SECTION B – YOUR PAIN 
 
Part 1 – Your general pain 
 
This question is about any recent pain you may have had in any part of 
your body. By pain we mean ache, discomfort or stiffness. Please do not 
include pain due to feverish illness such as flu and if you are a woman 
please do not include pain related to your monthly period. 
 
1. In the past 4 weeks, have you had pain that lasted for one day or longer  
    in any part of your body? (Please put a cross in one box) 
 
 
Yes 
 
   
Please shade in these areas on the diagram below  
    
 
No 
 
   
Please continue and go to question 3 (Pg 16) 
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2. Thinking back over the past 12 months, on how many days 
approximately have you had your pain? 
 
 
None 
Less than  
7 days 
1-4  
weeks 
More than 1 month,  
but less than 3 months 
More than  
3 months 
     
 
 
    
 
 
3. We are interested to know whether you have any finger nodes.  A finger 
node is a firm, knobbly swelling on the back of a finger joint. 
 
For example:  
 
A finger without nodes: 
 
 
 
 
A finger with nodes 
 
A finger with nodes: 
Please look at your hands and then on the diagrams below circle any finger 
joints on which you have nodes or swellings (you may have several of 
these). 
         Left                                          Right   
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Part 2 – Your specific pain 
 
This is about pain in different parts of your body. Please complete each of 
the following questions even if you have not suffered pain in any of these 
areas in the past 4 weeks.  
 
The first question is about HOW OFTEN you have had pain in different parts 
of your body. 
 
1. In the past 4 weeks, on average how many times (if at all) did you have.. 
    (Please put a cross in one box on each line) 
 
   
None 
1-3 times 
a week 
Once  
a day 
Several  
times a day 
All the 
time 
       
 
a. 
 
Headache 
 
     
       
 
b. 
 
Neck pain 
 
     
       
 
c. 
 
Shoulder pain 
 
     
       
 
d. 
 
Elbow pain 
 
     
       
 
e. 
 
Hand pain 
 
     
       
 
f. 
 
Chest pain 
 
     
       
 
g. 
 
Abdominal pain 
 
     
       
 
h. 
 
Back pain 
 
     
       
 
i. 
 
Hip pain 
 
     
       
 
j. 
 
Knee pain 
 
     
       
 
k. 
 
Foot pain 
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On this page we want you to think about HOW INTENSE (how bad) the 
pain in different parts of your body has been. 
 
2. In the past 4 weeks, on average, how intense were each of these pains  
    rated on a 0-10 scale, where 0 is “no pain” and 10 is “pain as bad as  
    could be”? 
 
    (For each question, please put a cross in one box. For pains that do  
     not apply to you please put a cross in box 0 to indicate No Pain.) 
 
       No  
    Pain 
          Pain as bad  
       as could be 
   
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
      
 
a. 
 
Headache 
 
           
             
 
b. 
 
Neck pain 
 
           
             
 
c. 
 
Shoulder pain 
 
           
             
 
d. 
 
Elbow pain 
 
           
             
 
e. 
 
Hand pain 
 
           
             
 
f. 
 
Chest pain 
 
           
             
 
g. 
 
Abdominal pain 
 
           
             
 
h. 
 
Back pain 
 
           
             
 
i. 
 
Hip pain 
 
           
             
 
j. 
 
Knee pain 
 
           
             
 
k. 
 
Foot pain  
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Part 3 – Your activities during pain 
 
1. For the past 4 weeks, please indicate the difficulty you have had in 
performing each of the following activities as a result of pain.  
         (For each line please put a cross in one box, even if you have not  
         experienced any problems) 
 
  No 
difficulty 
Mild 
difficulty 
Moderate 
difficulty 
Severe 
difficulty 
Extreme 
difficulty 
       
 
a. 
 
Rising from bed 
 
     
       
 
b. 
 
Putting on socks 
 
     
       
 
c. 
 
Rising from sitting 
 
     
       
 
d. 
 
Bending to floor 
 
     
       
 
e. 
 
Twisting on your knee 
 
     
       
 
f. 
 
Kneeling 
 
     
       
 
g. 
 
Squatting 
 
     
       
 
h. 
 
Going down stairs 
 
     
       
 
i. 
 
Getting in/out of the 
bath/shower 
 
     
       
 
j. 
 
Sitting 
 
     
       
 
k. 
 
Running 
 
     
       
 
l. 
 
 
Twisting your leg when 
you have your weight 
on it 
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SECTION C – YOUR SYMPTOMS 
 
Part 1 – Chest pain symptom 
 
1. This section asks you about different types of pain symptoms you may (or  
     may not) have had over the past 4 weeks. 
 
  Yes No  
     
 
a. 
 
Have you had any pain or discomfort in 
your chest in the past 4 weeks? 
 
   
If no please go to 
Part 2 (Pg 22) 
 
 
  Yes No 
    
 
b. 
 
Have you had a severe pain across the 
front of your chest lasting for half an 
hour or more? 
 
  
 
 
  Yes No 
    
 
c. 
 
Do you get this pain or discomfort when 
you walk uphill or hurry? 
 
  
 
 
  Yes No 
    
 
d. 
 
Do you get this pain when you walk at 
an ordinary pace on the level? 
 
  
 
 
   
Stop 
 
Slow down 
Continue at  
same pace 
     
 
e. 
 
When you get any pain or discomfort  
in your chest what do you do? 
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  Yes No 
    
 
f. 
 
Does the chest pain go away when you stand still? 
 
  
 
 
 
  10 minutes 
or less 
More than 10 
minutes 
    
 
g. 
 
How soon does the chest pain settle down? 
  
 
 
 
  
  
 
h. 
 
Where do you get this pain or discomfort?  
Please mark the place(s) with an X on the diagram below 
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Part 2 – Your chest symptoms 
 
The following questions refer to problems people may experience doing 
certain activities due to chest pain or chest tightness. 
 
 
 
 
2. Below is a list of activities that people often do during the week. For each  
    please indicate how limited you have been in performing these over the    
    past 4 weeks due to your chest pain or chest tightness.  
    (Please put a cross in one box on each line) 
 
 
  Severely 
limited 
Moderately 
limited 
Somewhat 
limited  
A little 
limited 
Not  
limited 
       
 
a. 
 
Dressing yourself 
 
     
       
 
b. 
 
Walking indoors 
on level ground 
 
     
       
 
c. 
 
Showering 
 
     
       
 
d. 
 
Climbing a hill or a 
flight of stairs 
without stopping 
 
     
       
 
e. 
 
Gardening, 
vacuuming, or 
carrying groceries 
 
     
       
 
f. 
 
Walking 100 yards 
or more 
 
     
       
 
g. 
 
Lifting heavy 
objects 
 
     
  Yes No  
     
 
1. 
 
Have you had any chest pain or tightness 
in the past 4 weeks? 
 
   
If no please go to 
Part 3 (Pg 25) 
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3. Compared with 4 weeks ago, how often do you have chest pain or  
    chest tightness when doing your most strenuous activities?  
    (Please put a cross in one box only) 
 
     I have had chest pain or chest tightness…… 
 
Much more  
often 
Slightly  
More often 
About 
the same 
Slightly 
less often 
Much less 
often 
     
 
 
    
 
 
 
4. Over the past 4 weeks, on average, how many times have you had  
    chest pain or chest tightness? (Please put a cross in one box only) 
 
     I have had chest pain or chest tightness… 
 
 
4 or more 
times a day 
 
1-3 times 
a day 
3 or more times  
a week but  
not every day 
 
1-2 times  
a week 
 
Less than  
once a week 
     
 
 
    
 
 
 
5. How satisfied are you that everything possible is being done to treat your  
    chest pain or chest tightness? (Please put a cross in one box only) 
 
Not satisfied  
at all 
Mostly 
dissatisfied 
Somewhat  
satisfied 
Mostly 
satisfied 
Highly 
satisfied  
     
 
 
    
 
 
 
6. How satisfied are you with the explanations your doctor has given you  
    about your chest pain or chest tightness?  
   (Please put a cross in one box only) 
 
Not satisfied  
at all 
Mostly 
dissatisfied 
Somewhat  
satisfied 
Mostly 
satisfied 
Highly 
satisfied  
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7. Overall, how satisfied are you with the current treatment of your chest   
    pain or chest tightness? (Please put a cross in one box only) 
 
Not satisfied  
at all 
Mostly 
dissatisfied 
Somewhat  
satisfied 
Mostly 
satisfied 
Highly 
satisfied  
     
 
 
    
 
 
 
8. Over the past 4 weeks, how much has your chest pain or chest   
     tightness limited your enjoyment of life? 
    (Please put a cross in one box only) 
 
It has  
severely 
limited my  
enjoyment  
of life 
 
It has 
moderately 
limited my  
enjoyment of life 
 
 
It has slightly 
limited my 
enjoyment of life 
 
It has barely 
limited my 
enjoyment of 
life 
 
It has not 
limited my 
enjoyment 
of life at all 
     
 
 
    
 
 
 
9. If you had to spend the rest of your life with your chest pain or chest   
     tightness the way it is right now, how would you feel about this?  
     (Please put a cross in one box only) 
 
Not satisfied  
at all 
Mostly 
dissatisfied 
Somewhat  
satisfied 
Mostly 
satisfied 
Highly 
satisfied  
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Part 3 – Your other symptoms 
 
The following questions refer to problems people may experience due to 
shortness of breath, fatigue or swelling. 
 
 
 
2. If you answered Yes to question 1 please indicate how limited you have    
    been by shortness of breath in the following activities over the past 4 
    weeks. (Please put a cross in one box on each line) 
 
   
Extremely 
limited 
Quite 
a bit 
limited 
 
Moderately 
limited 
 
Slightly 
limited 
Not 
at all  
limited 
       
 
a. 
 
Dressing yourself 
 
     
       
 
b. 
 
Showering or  
having a bath 
 
     
       
 
c. 
 
Walking 100 yards 
on level ground 
 
     
       
 
d. 
 
Doing gardening, 
housework or 
carrying groceries 
 
     
       
 
e. 
 
Climbing a flight of 
stairs without 
stopping 
 
     
       
 
f. 
 
Jogging or 
hurrying (as if to 
catch a bus) 
 
     
 
 
  Yes No  
     
 
1. 
 
Have you had any shortness of breath 
in the past 4 weeks? 
 
   
If no please go to 
question 3 (Pg 26) 
 
  
    
   
   
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 30/11/09, version 8 26 
3. Over the past 4 weeks, how many times did you have swelling in your  
    feet, ankles or legs when you woke up in the morning?  
    (Please put a cross in one box only) 
 
Every  
morning 
3 or more times a week, 
but not every day 
1-2 times  
a week 
Less than 
once a week 
Never over the 
past 4 weeks 
     
 
 
    
 
 
 
 
4. Over the past 4 weeks, how much has swelling in your feet, ankles or   
    legs bothered you? (Please put a cross in one box only) 
 
Extremely 
bothersome 
Quite a bit 
bothersome 
Moderately 
bothersome 
Slightly 
bothersome 
Not at all 
bothersome 
I’ve had no 
swelling 
      
 
 
     
 
 
 
 
5. Over the past 4 weeks, on average, how many times has fatigue limited 
   your ability to do what you wanted? (Please put a cross in one box only) 
 
 
All of  
the  
time 
 
Several  
times  
per day 
 
At least  
once  
a day 
3 or more 
times per 
week but not 
every day 
 
 
1-2 times  
per week 
 
Less than  
once a  
week 
 
Never over 
the past 4 
weeks 
       
 
 
      
 
 
 
 
6. Over the past 4 weeks, how much has your fatigue bothered you? 
    (Please put a cross in one box only) 
 
Extremely 
bothersome 
Quite a bit 
bothersome 
Moderately 
bothersome 
Slightly 
bothersome 
Not at all 
bothersome 
I’ve had  
no fatigue 
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7. Over the past 4 weeks, on average, how many times has shortness of    
    breath limited your ability to do what you wanted?  
    (Please put a cross in one box only) 
 
 
All of  
the  
time 
 
Several  
times  
a day 
 
At least  
once  
a day 
3 or more  
times a  
week but  
not every day 
 
 
1-2 times  
per week 
 
Less than  
once a  
week 
 
Never over 
the past 4 
weeks 
       
 
 
      
 
 
 
8. Over the past 4 weeks, how much has your shortness of breath   
    bothered you? (Please put a cross in one box only) 
 
 
Extremely 
bothersome 
 
Quite a bit 
bothersome 
 
Moderately 
bothersome 
 
Slightly 
bothersome 
 
Not at all 
bothersome 
I’ve had no 
shortness 
of breath 
      
 
 
     
 
 
 
9. Over the past 4 weeks, on average, how many times have you been    
      forced to sleep sitting up in a chair or with at least 3 pillows to prop you   
      up because of shortness of breath?  
      (Please put a cross in one box only) 
 
 
Every 
night 
3 or more 
 times a week, 
but not every night 
 
1-2 times  
a week 
 
Less than 
once a week 
 
Never over the  
past 4 weeks 
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Part 4 – Your dizziness  
 
Please answer every question. Some questions may look similar to others 
but each one is different. (Please put a cross in one box on each line) 
 
How often over the past 4 weeks have you had the following symptoms: 
 
 
1. A feeling that either you, or things around you, are spinning or moving? 
  
 
Never 
 
A few times 
 
Several times 
Quite often 
(every week) 
Very often 
(most days) 
     
 
 
    
 
 
 
2. A feeling of being dizzy, disoriented or "swimmy", lasting all day? 
 
 
Never 
 
A few times 
 
Several times 
Quite often 
(every week) 
Very often 
(most days) 
     
 
 
    
 
 
 
3. Feeling unsteady, about to lose balance? 
  
 
Never 
 
A few times 
 
Several times 
Quite often 
(every week) 
Very often 
(most days) 
     
 
 
    
 
 
 
4. Felt faint, about to lose consciousness (‘blacked out’)?  
  
 
Never 
 
A few times 
 
Several times 
Quite often 
(every week) 
Very often 
(most days) 
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Part 5 – Your heartbeat 
 
These questions ask you about your heartbeat in the past 4 weeks.  
(Please put a cross in one box for each line) 
 
 
  Yes No  
     
 
1. 
 
Have you felt your heart beating fast in the 
past 4 weeks? 
 
   
If no please go to  
Part 6 (Pg 30) 
 
 
 
  Yes No 
    
 
2. 
 
Are you on medication for your heart beat? 
 
  
 
 
 
  Exercise/ 
activity 
Psychological 
stress 
Could happen 
at anytime 
     
 
3. 
 
Was your heart beating 
fast mostly related to… 
 
   
 
 
 
  Regular Irregular 
    
 
4. 
 
When you feel your heart beating 
fast, does it feel as if it is…… 
 
  
 
 
 
  Sudden and  
immediately fast 
Gradually from  
slow to fast 
    
 
5. 
 
Did your fast heartbeat start…… 
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Part 6 – How you feel about any health problems 
 
  Yes No  
     
 
1. 
 
Do you have health problems that you 
feel have an impact on your life?   
 
   
If no please go to 
SECTION D (Pg 32) 
 
2. If yes, please write in the spaces below up to 3 of the problems that  
    have the biggest impact on your life.    
    
 
i. 
 
 
 
 
ii. 
 
 
 
 
iii. 
 
 
 
 
For the following questions, please put a cross in the box under the 
number that best corresponds to your views. 
 
3. How much does your illness affect your life? 
 
No affect 
at all 
Severely affects  
my life 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
          
 
4. How long do you think your illness will continue? 
 
A very 
short time 
 
Forever 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
          
 
5. How much control do you feel you have over your illness? 
 
Absolutely 
no control 
Extreme amount  
of control  
0 1 2 3 4 5 6 7 8 9 10 
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6. How much do you think your treatment can help your illness? 
 
Not 
at all 
Extremely 
helpful 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
          
 
 
7. How much do you experience symptoms from your illness? 
 
No symptoms 
at all 
Many severe 
symptoms 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
          
 
 
8. How concerned are you about your illness? 
 
Not at all 
concerned 
Extremely 
concerned 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
          
 
 
9. How well do you feel you understand your illness? 
 
Don’t understand 
at all 
Understand very 
clearly 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
          
 
 
10. How much does your illness affect you emotionally? (e.g. does it make  
      you angry, scared, upset or depressed?) 
 
Not at all affected  
emotionally 
Extremely affected 
emotionally 
0 1 2 3 4 5 6 7 8 9 10 
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SECTION D – ABOUT YOU 
 
Part 1 – Your eyesight and hearing 
 
 
1. How good is your eyesight for seeing things at a distance, like recognising  
    a friend across the street (using glasses or corrective lenses as usual)?  
    Would you say it is…… 
 
Excellent  Very good Good Fair Blind 
     
 
 
    
 
 
 
2. How good is your eyesight for seeing things up close, like reading a paper 
    (using glasses or corrective lenses as usual)? Would you say it is…… 
 
Excellent  Very good Good Fair Blind 
     
 
 
    
 
 
 
3. Is your hearing (using a hearing aid as usual)…… 
 
Excellent  Very good Good Fair Deaf 
     
 
 
    
 
 
 
4. Do you find it difficult to follow a conversation if there is background     
    noise, such as TV or radio (using a hearing aid as usual)? 
 
Yes No 
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Part 2 – Smoking 
 
1. Do you smoke tobacco now? (Please put a cross in one box only) 
 
 
Yes, on most or all days 
 Complete 
questions 2 & 3 
   
 
Only occasionally 
 
   
Complete 
questions 4 & 5   
 
No, not now 
 
 
   
 
Never smoked 
 
 Go to 
Part 3 (Pg 34) 
 
2.  About how many cigarettes do you currently smoke on average each  
     day (include hand-rolled cigarettes if smoked)?  
     (Please write a number in the box) 
 
Number 
  
 
 
 
3. Compared to 10 years ago do you currently smoke…….  
    (Please put a cross in one box only) 
 
More About the same Less 
   
 
 
  
 
4. If you are an ex-smoker or occasional smoker how long has it been  
    since you were smoking regularly? (Please write a number in the 
   “month(s)” OR “year(s)” box) 
 
Month(s)   Year(s)  
    
 
 
 
OR 
 
 
 
5. If you are an ex-smoker or occasional smoker how many cigarettes did 
you use to smoke on average each day (include hand-rolled cigarettes if 
smoked)? (Please write a number in the box) 
 
Number 
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Part 3 – Alcohol  
 
1. About how often do you drink alcohol? 
    (Put a cross in one box only) 
 
Daily or  
almost  
daily 
3 or 4 
 times  
a week 
Once or 
twice a  
week 
1 to 3  
times  
a month 
Special 
occasions  
only 
 
 
Never 
      
 
 
     
     
 
 
 
 
Go to Part 4 (Pg 35) 
 
 
 
2. In an average week how many…… 
    
   Number  
     
 
 a. 
 
regular (175ml) glasses of wine would you drink? 
(there are roughly four regular glasses in an average bottle) 
 
  
 
     
 
 b. 
 
pints of beer or cider would you drink? 
(Includes bitter, lager, stout, ale) 
 
  
 
     
 
 c. 
 
single measures (25ml) of spirits or liqueurs  
would you drink ? 
(Includes drinks such as whisky, gin & vodka) 
 
  
 
 
 
 
3. Compared to 10 years ago, do you drink……. 
    (Put a cross in one box only) 
 
More nowadays  About the same Less nowadays Don’t know 
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Part 4 – Your measurements 
 
1. Please fill in your weight and height in the boxes below. It doesn’t matter  
    whether you use the imperial OR metric systems. 
 
a. Weight  b. Height 
       
 
 
 
 
OR 
 
 
 
 
 
 
 
 
 
 
 
OR 
 
 
 
 
Stone & pounds  Kilograms  Feet & inches  Centimetres 
 
 
2. What size clothes do you wear? Please place a cross in one box on each 
     line to let us know what size clothes you would usually buy. 
 
 
 XS S M L XL XXL+ 
 
 
a. Jumper/ 
  t-shirt size 
 
      
        
 14-14.5 15-15.5 16-16.5 17-17.5 18-18.5 19 20+ 
 
b. Collar   
     size 
(inches) 
 
       
        
 30 or less 32 34 36 38 40 42+ 
 
c. Trouser 
   waist size 
(inches) 
 
       
 
 
 
 XS S M L XL XXL+   
 
d. Jumper/ 
  t-shirt size 
 
        
         
 8 10 12 14 16 18 20 22+ 
 
e. Blouse size 
 
        
         
 8 10 12 14 16 18 20 22+ 
 
f. Trouser/ 
     skirt size 
 
        
      
       
       
M
E
N
 
    
        
W
O
M
E
N
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Part 5 - About you and your life 
 
 
1. What is your date of birth?  
  
 
 
 
                /                /                      (example: 01/10/59) 
 
      (day)          (month)         (year) 
 
  
2. Are you? 
 
Male Female 
  
 
 
 
 
 
3. Do you live alone? 
 
Yes No  
  
 
 
 
 
 
4. What is your current marital status? 
    (Please put a cross in one box only) 
 
Married Widowed Separated Divorced Cohabiting Single 
      
 
 
 
     
 
 
5. What is your current employment status? 
   (Please put a cross in one box only) 
 
 
Employed  
Not working 
due to ill health 
 
Retired 
Unemployed/ 
seeking work 
 
Housewife 
 
Other 
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For the questions on this page (except question 8) please write the answers 
in the boxes provided. 
 
 
6. 
 
If you are working what is your job  
title (examples – factory worker, 
welder, office worker, lawyer)? 
 
 
 
 
 
6a. 
 
If you provided a job title in the  
question above please state in which 
field of employment this was  
(examples – manufacturing, civil  
service, health care). 
 
 
 
 
 
7. 
 
If you are not working or are retired, 
what job have you done for most of 
your working life? 
 
 
 
  
 
7a. 
 
If you provided a job title in the question 
above please state in which field of 
employment this was (examples – 
manufacturing, civil service, health care). 
 
 
 
 
  Yes No   
     
 
8. 
 
Do you have a spouse or partner who is 
currently living with you?           
      
 
 
  
If no please go to 
question 11 
 
 
9. 
 
If they are working what is their job title 
(examples – factory worker, welder, office 
worker, shop assistant, lawyer)? 
 
 
 
 
 
10. 
 
If they are not working or are  
retired, what job did they you do for 
most of their working life? 
 
 
 
 
 
11. 
 
If you are a widow, or widower, what  
was your spouse’s job title for most of 
their working life? 
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Part 6 – Your family & friends 
 
We are interested in the contact you may have with your friends and family. 
(Please answer each question and put a cross in one box on each line.) 
 
1. How many living children do you have? 
 
None 1 to 2 3 to 5 6 or more 
    
 
 
 
   
 
2. How many of your children do you see at least once a month? 
 
None 1 to 2 3 to 5 6 or more 
    
 
 
 
   
 
3. Apart from your children, how many relatives do you have with whom you 
    feel close? 
 
None 1 to 2 3 to 5 6 to 9 10 or more 
     
 
 
 
    
 
4. How many close relatives do you see at least once a month? 
 
None 1 to 2 3 to 5 6 to 9 10 or more 
     
 
 
 
    
 
5. How many close friends do you have? 
 
None 1 to 2 3 to 5 6 to 9 10 or more 
     
 
 
 
    
 
6. How many of these friends do you see at least once a month? 
 
None 1 to 2 3 to 5 6 to 9 10 or more 
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  Yes No  
    
 
7. 
 
Is there any one special person you know that you feel very 
close to; someone you feel you can share confidences and 
feelings with? 
 
 
 
 
 
 
7a. If yes, how often do you see or talk with this person? 
 
 
Daily  
 
Weekly 
 
Monthly 
Several times 
a year 
Once a year or 
less 
     
 
 
 
    
 
 
8. How often do you go to religious meetings or services? 
 
More than 
once a week 
 
Once a week 
1-3 times per 
month 
Less than 
once a month 
Never or  
almost never 
     
 
 
 
    
 
 
9. How many hours each week do you participate in any groups such as    
    a social or work group, church-connected group, self-help group, charity,  
    public service or community group? 
 
 
None 
 
1-2 hours 
 
3-5 hours 
 
6-10 hours 
 
11-15 hours 
16 or more 
hours 
      
 
 
 
     
 
 
10. Thinking about the cost of living as it affects you, which of these  
      descriptions best describes your situation?  
 
 
Find it a strain to get  
by from week to week 
 
Have to be careful 
with money 
Able to manage  
without much  
difficulty 
Quite  
comfortably 
off 
    
 
 
 
   
 
 
 
     
     
      
    
  
 30/11/09, version 8 40 
 
 
Please put in today’s date (example: 11/02/09) 
 
  
                         /                   / 
 
               (day)            (month)              (year) 
 
 
 
Please now continue and complete SECTION E on page 43.  
On this page could you please sign the CONSENT,  
date the questionnaire and then return it in  
the reply envelope provided.  
 
 
 
THANK YOU FOR YOUR HELP 
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SECTION E – YOUR CONSENT 
 
Thank you for your time. This section of the questionnaire signifies that you 
consent to take part in this study. You are reminded to read the 
information sheet about this study before giving consent to take part.  
 
We would also like your permission to contact you again, and to allow us to 
confidentially use your medical records for the purposes of this research. 
 
Please read and complete the following consent form, and then sign below. 
 
Part 1 - Consent Form 
 
I confirm that I have read and understood the study information sheet dated 
30/11/09 (version 5) and am willing to take part in the study. I understand 
that I can withdraw from the study at any time, and that this will not affect the 
care I receive in any way. 
 
Please answer each statement below  
by putting a cross in a box on each line 
 
 YES 
 
NO 
 
 I am willing to receive a much shorter (4 page) 
questionnaire each month 
 
     (this does not mean that you must take part in the future,  
      just that you are agreeing to be contacted again) 
 
  
   
 
 I give permission for my medical records to be  
     reviewed in confidence 
 
  
 
Even if you would prefer us not to review your medical records or 
contact you again, the answers you have given will still be very 
important to us. 
 
Signed…………………  Name……………………….………  Date……………. 
 
Address……………………………………………………………………………… 
 
……………………………………………………………. Post code: …………… 
 
 
Please return your questionnaire in the reply envelope provided 
(no stamp needed) 
 
Thank you for your help  
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Study ID 
 334 
 
Appendix 7.3: 2C Methods – Baseline 2C 12-month follow-up 
questionnaire 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LREC Number: 09/H1017/40 
 
 
 
 
 
 
 
 
12-Month Follow-up 
General Health 
Questionnaire 
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Instructions 
 
 
 
This is a follow-up questionnaire to the one that we sent you 12 months ago. 
The aim of this questionnaire is to find out how your health has been 
recently; the answers you give will be treated in the strictest confidence.  
 
 
Please answer the questions, even if you have no current 
problems with your health. Unless stated, most questions 
are answered by putting a cross in a box, like this: 
 
 
 
When you have finished, please check that all questions have been 
answered and then return the completed questionnaire back to us as soon 
as you can. An envelope is provided and you do not need a stamp. 
 
Details about this project are available in the information sheet enclosed. If 
you would like further information please contact the study coordinator  
James Prior on 01782 734863 
 
 
 
THANK YOU FOR YOUR HELP  
 
 
 
 
 
 
 
X 
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SECTION A – YOUR HEALTH 
 
Part 1 – Your general health 
 
Please answer every question. Some questions may look similar to others 
but each one is different. Please take the time to read and answer each 
question carefully by placing a cross in the box of your choice. 
 
 
1. In general, would you say your health is…… 
     (Please put a cross in one box only) 
 
Excellent Very good Good Fair Poor 
     
 
 
    
 
 
 
2. Compared to a year ago, how would you rate your health in general 
now? (Please put a cross in one box only) 
 
Much better 
than a year 
ago 
Somewhat 
better than a 
year ago 
 
About the 
same 
Somewhat 
worse now than 
a year ago 
Much worse 
now than a year 
ago 
     
 
 
    
 
 
 
3. The following questions are about activities you might do during a typical 
day. Does your health now limit you in these activities? If so, how 
much? (Please put a cross in one box on each line) 
 
  Yes, 
limited 
a lot 
Yes, 
limited 
a little 
No, not 
limited 
at all 
     
 
a. 
 
Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling or playing golf 
 
   
     
 
b. 
 
Climbing several flights of stairs 
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4. During the past 4 weeks, how much of the time have you had any of the 
following problems with your work or other regular daily activities as a 
result of your physical health?  
(Please put a cross in one box on each line) 
 
 All  
of the 
time 
Most  
of the 
time 
Some  
of the 
time 
A little  
of the 
time 
None 
of the 
time 
       
 
a. 
 
Accomplished less 
than you would like 
 
     
       
 
b. 
 
Were limited in the 
kind of work or other 
activities 
 
     
 
 
 
5. During the past 4 weeks, how much of the time have you had any of the 
following problems with your work or other regular daily activities as a 
result of any emotional problems (such as feeling depressed or 
anxious)? 
     (Please put a cross in one box on each line) 
  
 All  
of the 
time 
Most  
of the 
time 
Some  
of the 
time 
A little  
of the 
time 
None 
of the 
time 
       
 
a. 
 
Accomplished less 
than you would like 
 
     
       
 
b. 
 
Didn’t do work or other 
activities as carefully 
as usual 
 
     
 
 
 
6. During the past 4 weeks, how much did pain interfere with your normal 
work (including both work outside the home and housework)? 
     (Please put a cross in one box only) 
 
Not at all A little bit Moderately Quite a bit Extremely 
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7. These questions are about how you feel and how things have been with  
     you during the past 4 weeks. For each question, please give the one   
     answer that comes closest to the way you have been feeling. 
     (Please put a cross in one box on each line) 
 
     How much of the time during the past 4 weeks… 
  
 All  
of the  
time 
Most  
of the 
time 
Some  
of the 
time 
A little  
of the 
time 
None 
of the 
time 
       
 
a. 
 
Have you felt calm and 
peaceful? 
 
     
       
 
b. 
 
Did you have a lot of 
energy? 
 
     
       
 
c. 
 
Have you felt downhearted 
and low? 
 
     
 
 
 
8. During the past 4 weeks, how much of the time has your physical  
    health or emotional problems interfered with your social activities (like  
    visiting with friends, relatives, etc.)?  
    (Please put a cross in one box only) 
 
All of the  
time 
Most of the 
time 
Some of the 
time 
A little of the 
time 
None of the 
time 
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Part 2 – Your health today 
 
For each of the five sets of statements below, please put a cross in the 
one box that best describes your own health state today. 
 
1. Mobility 
 
I have no problems  
in walking about  
I have some problems  
in walking about 
I am confined 
to bed 
   
 
 
  
 
2. Self-care 
 
I have no problems 
with self-care 
I have some problems  
washing and dressing myself 
I am unable to wash  
or dress myself 
   
 
 
  
 
3. Usual activities (e.g. work, study, housework, family or leisure activities) 
 
I have no problems  
with performing  
my usual activities 
I have some problems  
with performing my  
usual activities 
I am unable to perform 
my usual activities 
   
 
 
  
 
4. Pain/discomfort 
 
I have no pain  
or discomfort 
I have moderate pain or 
discomfort 
I have extreme pain  
or discomfort 
   
 
 
  
 
5. Anxiety/depression 
 
I am not anxious 
or depressed 
I am moderately  
anxious or depressed 
I am extremely  
anxious or depressed 
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6. To help people say how good or bad their health is, we have drawn a  
     scale (rather like a thermometer) on which the best health state you can 
     imagine is marked 100 and the worst health state you can imagine is    
     marked 0. 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         
 
 
 
 
 
 
Your own health 
state today 
     
 
We would like you to indicate on this 
scale how good or bad you think your 
own health is today.   
 
Please do this by drawing a line from 
the box below to whichever point on 
the scale indicates how good or bad 
your health state is today. 
 
Worst Imaginable 
Health State  
Best Imaginable 
Health State 
0 
 
10 
20 
30 
 
40 
 
50 
60 
80 
 100 
5 
15 
25 
35 
45 
55 
65 
75 
85 
90 
95 
70 
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Part 3 – How you’ve been feeling 
 
The next sets of questions are about how you feel at the moment. Please 
read each item and put a cross in the box that comes closest to how you 
have been feeling in the past 4 weeks. Don’t take too long over your 
replies; your immediate reaction to each item will usually be more accurate 
than a long thought out response. 
 
1. I feel tense or ‘wound up’: 
 
 
Most of the time 
 
A lot of the time 
From time to time, 
occasionally 
 
Not at all 
    
 
 
   
 
2. I still enjoy the things I used to enjoy: 
 
Definitely  
as much 
Not quite  
as much 
 
Only a little 
 
Hardly at all 
    
 
 
   
 
3. I get a sort of frightened feeling as if something awful is about to happen: 
 
Very definitely 
and quite badly 
Yes, but not 
too badly 
A little, but it 
doesn’t worry me 
 
Not at all 
    
 
 
   
 
4. I can laugh and see the funny side of things: 
 
As much as I 
always could 
Not quite so 
much now 
Definitely not 
so much now 
 
Not at all 
    
 
 
   
 
5. Worrying thoughts go through my mind: 
 
A great deal of 
the time 
A lot of  
the time 
From time to time, 
but not too often 
Only  
occasionally 
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6. I feel cheerful: 
 
Not at all Not often Sometimes Most of the time 
    
 
 
   
 
7. I can sit at ease and feel relaxed: 
 
Definitely  Usually Not often Not at all 
    
 
 
   
 
8. I feel as if I am slowed down: 
 
Nearly all the time  Very often Sometimes Not at all 
    
 
 
   
 
9. I get a sort of frightened feeling like ‘butterflies’ in my stomach: 
 
Not at all Occasionally Quite often Very often 
    
 
 
   
 
10. I have lost interest in my appearance: 
 
 
Definitely 
I don’t take as much  
care as I should 
I may not take 
quite as much care 
I take just as much 
care as ever 
    
 
 
   
 
11. I feel restless as if I have to be on the move: 
 
Very much indeed Quite a lot Not very much Not at all 
    
 
 
   
 
12. I look forward with enjoyment to things: 
 
As much  
as I ever did 
Rather less  
than I used to 
Definitely less  
than I used to 
 
Hardly at all 
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13. I get sudden feelings of panic: 
 
Very often indeed Quite often Not very often Not at all 
    
 
 
   
 
14. I can enjoy a good book or radio or television programme: 
 
Often Sometimes Not often Very seldom 
    
 
 
   
 
 
 
Part 4 – Your daily activities 
 
These questions ask you about activities you may perform at home, work or 
for leisure. Below is an example of how each part should be completed. 
Please note you are asked to write in the ‘time per day’ box and for 
questions 2 & 3 (Pg12) please place a cross in one of the effort boxes.  
 
 
EXAMPLE: Days 
per week 
 
 Time  
per day 
 Effort 
slow/light moderate fast/intense 
      
 
Walking 
 
 
 
    
 
 
 
Think about an average week in the past 4 weeks. Please indicate how 
many days per week you did the following activities and how much time 
on average you did these for. Please place a 0 in the ‘Days per week’ box if 
you DID NOT do one of the stated activities. 
 
 
1. HOUSEHOLD ACTIVITIES 
Days  
per week 
 
 Time  
per day 
   
 
a. Light household work 
    (e.g. cooking, washing, ironing) 
 
    
    
 
b. Intense household work 
    (e.g. walking with heavy shopping bags) 
 
   
 
 
    
    
 
  3 1hr 10min X 
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Now please let us know on average over the past 4 weeks how often, for 
how long and at what effort you have done any of the below activities. 
 
2. LEISURE  
    ACTIVITIES 
Days 
per week 
 
 Time 
per day 
 Effort 
slow/light moderate fast/intense 
      
 
a. Walking 
 
 
 
    
      
 
b. Cycling 
 
     
      
 
c. Gardening 
 
     
      
 
d. Vigorous activities  
    (e.g. dancing) 
 
      
 
  Yes No  
     
 
3. 
 
Are you retired? 
 
  
 
 
 
If yes please go to Part 5 (Pg 13) 
 
 
If you travel to and from work please let us know for an average week, over 
the past 4 weeks, how often you did this and at what level of effort. 
 
4. COMMUTING     
ACTIVITIES 
Days 
per week 
 
 Time  
per day 
 Effort 
slow/light moderate fast/intense 
        
 
a. Walk to/from work 
 
 
 
 
    
      
 
b. Drive to/from work 
 
     
 
If you work, please let us know, on average over the past 4 weeks how 
much of your time per week has involved doing light and/or intense work. 
 
 
5. ACTIVITY AT WORK 
Time  
per week 
 
  
 
a. Light work (sitting/standing with some walking e.g. a desk job) 
 
 
  
 
b. Intense work (regularly lifting heavy objects at work) 
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Part 5 – Your sleep and tiredness 
 
This section asks you about your ability to rest day-to-day over the past 4 
weeks. Please put a cross in one box per line to answer each question. 
 
  0-15 
mins 
16-30 
mins 
31-45 
mins 
46-60 
mins 
61+ 
mins 
       
 
1. 
 
How long on average did it usually 
take for you to fall asleep during the 
past 4 weeks?  
 
     
       
  0-3  
hours  
4-6  
hours 
7-8  
hours 
9-12  
hours 
13+ 
hours 
       
 
2. 
 
How many hours on average did 
you sleep each night during the 
past 4 weeks?  
 
     
 
3. How often during the 
past 4 weeks did you… 
All of 
the 
time 
Most 
of the  
time 
A good  
bit of  
the time 
Some  
of the 
time 
A little  
of the  
time 
None  
of the 
time 
        
 
a. 
 
get enough sleep to feel 
rested upon waking in the 
morning? 
 
      
        
 
b. 
 
awaken short of breath or 
with a headache? 
 
      
        
 
c. 
 
have trouble falling 
asleep? 
 
      
        
 
d. 
 
awaken during your sleep 
time and have trouble 
falling asleep again? 
 
      
        
 
e. 
 
have trouble staying 
awake during the day? 
 
      
        
 
f. 
 
get the amount of sleep 
you needed? 
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4. How true do you find each statement 
below. In the past 4 weeks I have 
found that... 
 
Not  
at all 
 
A little 
bit 
 
Some
what 
 
Quite  
a bit 
 
Very 
much 
       
 
a. 
 
I feel fatigued 
 
     
       
 
b. 
 
I feel weak all over 
 
     
       
 
c. 
 
I feel listless (“washed out”) 
 
     
       
 
d. 
 
I feel tired 
 
     
       
 
e. 
 
I have trouble starting things  
because I’m tired 
 
     
       
 
f. 
 
I have trouble finishing things  
because I’m tired 
 
     
       
 
g. 
 
I have energy 
 
     
       
 
h. 
 
I am able to do my usual activities 
 
     
       
 
i. 
 
I need to sleep during the day 
 
     
       
 
j. 
 
I am too tired to eat 
 
     
       
 
k. 
 
I need help doing my  
usual activities 
 
     
       
 
l. 
 
I am frustrated by being too  
tired to do the things I want to do 
 
     
       
 
m. 
 
I have to limit my social  
activity because I’m tired 
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SECTION B – YOUR PAIN 
 
Part 1 – Your general pain 
 
This question is about any recent pain you may have had in any part of 
your body. By pain we mean ache, discomfort or stiffness. Please do not 
include pain due to feverish illness such as flu and if you are a woman 
please do not include pain related to your monthly period. 
 
1. In the past 4 weeks, have you had pain that lasted for one day or longer  
    in any part of your body? (Please put a cross in one box) 
 
 
Yes 
 
   
Please shade in these areas on the diagram below  
    
 
No 
 
   
Please continue and go to question 3 (Pg 16) 
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2. Thinking back over the past 12 months, on how many days 
approximately have you had your pain? 
 
 
None 
Less than  
7 days 
1-4  
weeks 
More than 1 month,  
but less than 3 months 
More than  
3 months 
     
 
 
    
 
 
3. We are interested to know whether you have any finger nodes.  A finger 
node is a firm, knobbly swelling on the back of a finger joint. 
 
For example:  
 
A finger without nodes: 
 
 
 
 
A finger with nodes 
 
A finger with nodes: 
Please look at your hands and then on the diagrams below circle any finger 
joints on which you have nodes or swellings (you may have several of 
these). 
         Left                                          Right   
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Part 2 – Your specific pain 
 
This is about pain in different parts of your body. Please complete each of 
the following questions even if you have not suffered pain in any of these 
areas in the past 4 weeks.  
 
The first question is about HOW OFTEN you have had pain in different parts 
of your body. 
 
1. In the past 4 weeks, on average how many times (if at all) did you have.. 
    (Please put a cross in one box on each line) 
 
   
None 
1-3 times 
a week 
Once  
a day 
Several  
times a day 
All the 
time 
       
 
a. 
 
Headache 
 
     
       
 
b. 
 
Neck pain 
 
     
       
 
c. 
 
Shoulder pain 
 
     
       
 
d. 
 
Elbow pain 
 
     
       
 
e. 
 
Hand pain 
 
     
       
 
f. 
 
Chest pain 
 
     
       
 
g. 
 
Abdominal pain 
 
     
       
 
h. 
 
Back pain 
 
     
       
 
i. 
 
Hip pain 
 
     
       
 
j. 
 
Knee pain 
 
     
       
 
k. 
 
Foot pain 
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On this page we want you to think about HOW INTENSE (how bad) the 
pain in different parts of your body has been. 
 
2. In the past 4 weeks, on average, how intense were each of these pains  
    rated on a 0-10 scale, where 0 is “no pain” and 10 is “pain as bad as  
    could be”? 
 
    (For each question, please put a cross in one box. For pains that do  
     not apply to you please put a cross in box 0 to indicate No Pain.) 
 
       No  
    Pain 
          Pain as bad  
       as could be 
   
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
      
 
a. 
 
Headache 
 
           
             
 
b. 
 
Neck pain 
 
           
             
 
c. 
 
Shoulder pain 
 
           
             
 
d. 
 
Elbow pain 
 
           
             
 
e. 
 
Hand pain 
 
           
             
 
f. 
 
Chest pain 
 
           
             
 
g. 
 
Abdominal pain 
 
           
             
 
h. 
 
Back pain 
 
           
             
 
i. 
 
Hip pain 
 
           
             
 
j. 
 
Knee pain 
 
           
             
 
k. 
 
Foot pain  
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Part 3 – Your activities during pain 
 
1. For the past 4 weeks, please indicate the difficulty you have had in 
performing each of the following activities as a result of pain.  
         (For each line please put a cross in one box, even if you have not  
         experienced any problems) 
 
  No 
difficulty 
Mild 
difficulty 
Moderate 
difficulty 
Severe 
difficulty 
Extreme 
difficulty 
       
 
a. 
 
Rising from bed 
 
     
       
 
b. 
 
Putting on socks 
 
     
       
 
c. 
 
Rising from sitting 
 
     
       
 
d. 
 
Bending to floor 
 
     
       
 
e. 
 
Twisting on your knee 
 
     
       
 
f. 
 
Kneeling 
 
     
       
 
g. 
 
Squatting 
 
     
       
 
h. 
 
Going down stairs 
 
     
       
 
i. 
 
Getting in/out of the 
bath/shower 
 
     
       
 
j. 
 
Sitting 
 
     
       
 
k. 
 
Running 
 
     
       
 
l. 
 
 
Twisting your leg when 
you have your weight 
on it 
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SECTION C – YOUR SYMPTOMS 
 
Part 1 – Chest pain symptom 
 
1. This section asks you about different types of pain symptoms you may (or  
     may not) have had over the past 4 weeks. 
 
  Yes No  
     
 
a. 
 
Have you had any pain or discomfort in 
your chest in the past 4 weeks? 
 
   
If no please go to 
Part 2 (Pg 22) 
 
 
  Yes No 
    
 
b. 
 
Have you had a severe pain across the 
front of your chest lasting for half an 
hour or more? 
 
  
 
 
  Yes No 
    
 
c. 
 
Do you get this pain or discomfort when 
you walk uphill or hurry? 
 
  
 
 
  Yes No 
    
 
d. 
 
Do you get this pain when you walk at 
an ordinary pace on the level? 
 
  
 
 
   
Stop 
 
Slow down 
Continue at  
same pace 
     
 
e. 
 
When you get any pain or discomfort  
in your chest what do you do? 
 
   
 
 
 
 
 
 
  
  
   
  
  
 15/09/10, version 1 21 
 
  Yes No 
    
 
f. 
 
Does the chest pain go away when you stand still? 
 
  
 
 
 
  10 minutes 
or less 
More than 10 
minutes 
    
 
g. 
 
How soon does the chest pain settle down? 
  
 
 
 
  
  
 
h. 
 
Where do you get this pain or discomfort?  
Please mark the place(s) with an X on the diagram below 
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Part 2 – Your chest symptoms 
 
The following questions refer to problems people may experience doing 
certain activities due to chest pain or chest tightness. 
 
 
 
 
2. Below is a list of activities that people often do during the week. For each  
    please indicate how limited you have been in performing these over the    
    past 4 weeks due to your chest pain or chest tightness.  
    (Please put a cross in one box on each line) 
 
 
  Severely 
limited 
Moderately 
limited 
Somewhat 
limited  
A little 
limited 
Not  
limited 
       
 
a. 
 
Dressing yourself 
 
     
       
 
b. 
 
Walking indoors 
on level ground 
 
     
       
 
c. 
 
Showering 
 
     
       
 
d. 
 
Climbing a hill or a 
flight of stairs 
without stopping 
 
     
       
 
e. 
 
Gardening, 
vacuuming, or 
carrying groceries 
 
     
       
 
f. 
 
Walking 100 yards 
or more 
 
     
       
 
g. 
 
Lifting heavy 
objects 
 
     
  Yes No  
     
 
1. 
 
Have you had any chest pain or tightness 
in the past 4 weeks? 
 
   
If no please go to 
Part 3 (Pg 25) 
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3. Compared with 4 weeks ago, how often do you have chest pain or  
    chest tightness when doing your most strenuous activities?  
    (Please put a cross in one box only) 
 
     I have had chest pain or chest tightness…… 
 
Much more  
often 
Slightly  
More often 
About 
the same 
Slightly 
less often 
Much less 
often 
     
 
 
    
 
 
 
4. Over the past 4 weeks, on average, how many times have you had  
    chest pain or chest tightness? (Please put a cross in one box only) 
 
     I have had chest pain or chest tightness… 
 
 
4 or more 
times a day 
 
1-3 times 
a day 
3 or more times  
a week but  
not every day 
 
1-2 times  
a week 
 
Less than  
once a week 
     
 
 
    
 
 
 
5. How satisfied are you that everything possible is being done to treat your  
    chest pain or chest tightness? (Please put a cross in one box only) 
 
Not satisfied  
at all 
Mostly 
dissatisfied 
Somewhat  
satisfied 
Mostly 
satisfied 
Highly 
satisfied  
     
 
 
    
 
 
 
6. How satisfied are you with the explanations your doctor has given you  
    about your chest pain or chest tightness?  
   (Please put a cross in one box only) 
 
Not satisfied  
at all 
Mostly 
dissatisfied 
Somewhat  
satisfied 
Mostly 
satisfied 
Highly 
satisfied  
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7. Overall, how satisfied are you with the current treatment of your chest   
    pain or chest tightness? (Please put a cross in one box only) 
 
Not satisfied  
at all 
Mostly 
dissatisfied 
Somewhat  
satisfied 
Mostly 
satisfied 
Highly 
satisfied  
     
 
 
    
 
 
 
8. Over the past 4 weeks, how much has your chest pain or chest   
     tightness limited your enjoyment of life? 
    (Please put a cross in one box only) 
 
It has  
severely 
limited my  
enjoyment  
of life 
 
It has 
moderately 
limited my  
enjoyment of life 
 
 
It has slightly 
limited my 
enjoyment of life 
 
It has barely 
limited my 
enjoyment of 
life 
 
It has not 
limited my 
enjoyment 
of life at all 
     
 
 
    
 
 
 
9. If you had to spend the rest of your life with your chest pain or chest   
     tightness the way it is right now, how would you feel about this?  
     (Please put a cross in one box only) 
 
Not satisfied  
at all 
Mostly 
dissatisfied 
Somewhat  
satisfied 
Mostly 
satisfied 
Highly 
satisfied  
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Part 3 – Your other symptoms 
 
The following questions refer to problems people may experience due to 
shortness of breath, fatigue or swelling. 
 
 
 
2. If you answered Yes to question 1 please indicate how limited you have    
    been by shortness of breath in the following activities over the past 4 
    weeks. (Please put a cross in one box on each line) 
 
   
Extremely 
limited 
Quite 
a bit 
limited 
 
Moderately 
limited 
 
Slightly 
limited 
Not 
at all  
limited 
       
 
a. 
 
Dressing yourself 
 
     
       
 
b. 
 
Showering or  
having a bath 
 
     
       
 
c. 
 
Walking 100 yards 
on level ground 
 
     
       
 
d. 
 
Doing gardening, 
housework or 
carrying groceries 
 
     
       
 
e. 
 
Climbing a flight of 
stairs without 
stopping 
 
     
       
 
f. 
 
Jogging or 
hurrying (as if to 
catch a bus) 
 
     
 
 
  Yes No  
     
 
1. 
 
Have you had any shortness of breath 
in the past 4 weeks? 
 
   
If no please go to 
question 3 (Pg 26) 
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3. Over the past 4 weeks, how many times did you have swelling in your  
    feet, ankles or legs when you woke up in the morning?  
    (Please put a cross in one box only) 
 
Every  
morning 
3 or more times a week, 
but not every day 
1-2 times  
a week 
Less than 
once a week 
Never over the 
past 4 weeks 
     
 
 
    
 
 
 
 
4. Over the past 4 weeks, how much has swelling in your feet, ankles or   
    legs bothered you? (Please put a cross in one box only) 
 
Extremely 
bothersome 
Quite a bit 
bothersome 
Moderately 
bothersome 
Slightly 
bothersome 
Not at all 
bothersome 
I’ve had no 
swelling 
      
 
 
     
 
 
 
 
5. Over the past 4 weeks, on average, how many times has fatigue limited 
   your ability to do what you wanted? (Please put a cross in one box only) 
 
 
All of  
the  
time 
 
Several  
times  
per day 
 
At least  
once  
a day 
3 or more 
times per 
week but not 
every day 
 
 
1-2 times  
per week 
 
Less than  
once a  
week 
 
Never over 
the past 4 
weeks 
       
 
 
      
 
 
 
 
6. Over the past 4 weeks, how much has your fatigue bothered you? 
    (Please put a cross in one box only) 
 
Extremely 
bothersome 
Quite a bit 
bothersome 
Moderately 
bothersome 
Slightly 
bothersome 
Not at all 
bothersome 
I’ve had  
no fatigue 
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7. Over the past 4 weeks, on average, how many times has shortness of    
    breath limited your ability to do what you wanted?  
    (Please put a cross in one box only) 
 
 
All of  
the  
time 
 
Several  
times  
a day 
 
At least  
once  
a day 
3 or more  
times a  
week but  
not every day 
 
 
1-2 times  
per week 
 
Less than  
once a  
week 
 
Never over 
the past 4 
weeks 
       
 
 
      
 
 
 
8. Over the past 4 weeks, how much has your shortness of breath   
    bothered you? (Please put a cross in one box only) 
 
 
Extremely 
bothersome 
 
Quite a bit 
bothersome 
 
Moderately 
bothersome 
 
Slightly 
bothersome 
 
Not at all 
bothersome 
I’ve had no 
shortness 
of breath 
      
 
 
     
 
 
 
9. Over the past 4 weeks, on average, how many times have you been    
      forced to sleep sitting up in a chair or with at least 3 pillows to prop you   
      up because of shortness of breath?  
      (Please put a cross in one box only) 
 
 
Every 
night 
3 or more 
 times a week, 
but not every night 
 
1-2 times  
a week 
 
Less than 
once a week 
 
Never over the  
past 4 weeks 
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Part 4 – Your dizziness  
 
Please answer every question. Some questions may look similar to others 
but each one is different. (Please put a cross in one box on each line) 
 
How often over the past 4 weeks have you had the following symptoms: 
 
 
1. A feeling that either you, or things around you, are spinning or moving? 
  
 
Never 
 
A few times 
 
Several times 
Quite often 
(every week) 
Very often 
(most days) 
     
 
 
    
 
 
 
2. A feeling of being dizzy, disoriented or "swimmy", lasting all day? 
 
 
Never 
 
A few times 
 
Several times 
Quite often 
(every week) 
Very often 
(most days) 
     
 
 
    
 
 
 
3. Feeling unsteady, about to lose balance? 
  
 
Never 
 
A few times 
 
Several times 
Quite often 
(every week) 
Very often 
(most days) 
     
 
 
    
 
 
 
4. Felt faint, about to lose consciousness (‘blacked out’)?  
  
 
Never 
 
A few times 
 
Several times 
Quite often 
(every week) 
Very often 
(most days) 
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Part 5 – Your heartbeat 
 
These questions ask you about your heartbeat in the past 4 weeks.  
(Please put a cross in one box for each line) 
 
 
  Yes No  
     
 
1. 
 
Have you felt your heart beating fast in the 
past 4 weeks? 
 
   
If no please go to  
Part 6 (Pg 30) 
 
 
 
  Yes No 
    
 
2. 
 
Are you on medication for your heart beat? 
 
  
 
 
 
  Exercise/ 
activity 
Psychological 
stress 
Could happen 
at anytime 
     
 
3. 
 
Was your heart beating 
fast mostly related to… 
 
   
 
 
 
  Regular Irregular 
    
 
4. 
 
When you feel your heart beating 
fast, does it feel as if it is…… 
 
  
 
 
 
  Sudden and  
immediately fast 
Gradually from  
slow to fast 
    
 
5. 
 
Did your fast heartbeat start…… 
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Part 6 – How you feel about any health problems 
 
  Yes No  
     
 
1. 
 
Do you have health problems that you 
feel have an impact on your life?   
 
   
If no please go to 
SECTION D (Pg 32) 
 
2. If yes, please write in the spaces below up to 3 of the problems that  
    have the biggest impact on your life.    
    
 
i. 
 
 
 
 
ii. 
 
 
 
 
iii. 
 
 
 
 
For the following questions, please put a cross in the box under the 
number that best corresponds to your views. 
 
3. How much does your illness affect your life? 
 
No affect 
at all 
Severely affects  
my life 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
          
 
4. How long do you think your illness will continue? 
 
A very 
short time 
 
Forever 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
          
 
5. How much control do you feel you have over your illness? 
 
Absolutely 
no control 
Extreme amount  
of control  
0 1 2 3 4 5 6 7 8 9 10 
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6. How much do you think your treatment can help your illness? 
 
Not 
at all 
Extremely 
helpful 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
          
 
 
7. How much do you experience symptoms from your illness? 
 
No symptoms 
at all 
Many severe 
symptoms 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
          
 
 
8. How concerned are you about your illness? 
 
Not at all 
concerned 
Extremely 
concerned 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
          
 
 
9. How well do you feel you understand your illness? 
 
Don’t understand 
at all 
Understand very 
clearly 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
          
 
 
10. How much does your illness affect you emotionally? (e.g. does it make  
      you angry, scared, upset or depressed?) 
 
Not at all affected  
emotionally 
Extremely affected 
emotionally 
0 1 2 3 4 5 6 7 8 9 10 
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SECTION D – ABOUT YOU 
 
Part 1 – Your eyesight and hearing 
 
 
1. How good is your eyesight for seeing things at a distance, like recognising  
    a friend across the street (using glasses or corrective lenses as usual)?  
    Would you say it is…… 
 
Excellent  Very good Good Fair Blind 
     
 
 
    
 
 
 
2. How good is your eyesight for seeing things up close, like reading a paper 
    (using glasses or corrective lenses as usual)? Would you say it is…… 
 
Excellent  Very good Good Fair Blind 
     
 
 
    
 
 
 
3. Is your hearing (using a hearing aid as usual)…… 
 
Excellent  Very good Good Fair Deaf 
     
 
 
    
 
 
 
4. Do you find it difficult to follow a conversation if there is background     
    noise, such as TV or radio (using a hearing aid as usual)? 
 
Yes No 
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Part 2 – Smoking 
 
1. Do you smoke tobacco now? (Please put a cross in one box only) 
 
 
Yes, on most or all days 
 Complete 
questions 2 & 3 
   
 
Only occasionally 
 
   
Complete 
questions 4 & 5   
 
No, not now 
 
 
   
 
Never smoked 
 
 Go to 
Part 3 (Pg 34) 
 
2.  About how many cigarettes do you currently smoke on average each  
     day (include hand-rolled cigarettes if smoked)?  
     (Please write a number in the box) 
 
Number 
  
 
 
 
3. Compared to 10 years ago do you currently smoke…….  
    (Please put a cross in one box only) 
 
More About the same Less 
   
 
 
  
 
4. If you are an ex-smoker or occasional smoker how long has it been  
    since you were smoking regularly? (Please write a number in the 
   “month(s)” OR “year(s)” box) 
 
Month(s)   Year(s)  
    
 
 
 
OR 
 
 
 
5. If you are an ex-smoker or occasional smoker how many cigarettes did 
you use to smoke on average each day (include hand-rolled cigarettes if 
smoked)? (Please write a number in the box) 
 
Number 
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Part 3 – Alcohol  
 
1. About how often do you drink alcohol? 
    (Put a cross in one box only) 
 
Daily or  
almost  
daily 
3 or 4 
 times  
a week 
Once or 
twice a  
week 
1 to 3  
times  
a month 
Special 
occasions  
only 
 
 
Never 
      
 
 
     
     
 
 
 
 
Go to Part 4 (Pg 35) 
 
 
 
2. In an average week how many…… 
    
   Number  
     
 
 a. 
 
regular (175ml) glasses of wine would you drink? 
(there are roughly four regular glasses in an average bottle) 
 
  
 
     
 
 b. 
 
pints of beer or cider would you drink? 
(Includes bitter, lager, stout, ale) 
 
  
 
     
 
 c. 
 
single measures (25ml) of spirits or liqueurs  
would you drink ? 
(Includes drinks such as whisky, gin & vodka) 
 
  
 
 
 
 
3. Compared to 10 years ago, do you drink……. 
    (Put a cross in one box only) 
 
More nowadays  About the same Less nowadays Don’t know 
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Part 4 – Your measurements 
 
1. Please fill in your weight and height in the boxes below. It doesn’t matter  
    whether you use the imperial OR metric systems. 
 
a. Weight  b. Height 
       
 
 
 
 
OR 
 
 
 
 
 
 
 
 
 
 
 
OR 
 
 
 
 
Stone & pounds  Kilograms  Feet & inches  Centimetres 
 
 
2. What size clothes do you wear? Please place a cross in one box on each 
     line to let us know what size clothes you would usually buy. 
 
 
 XS S M L XL XXL+ 
 
 
a. Jumper/ 
  t-shirt size 
 
      
        
 14-14.5 15-15.5 16-16.5 17-17.5 18-18.5 19 20+ 
 
b. Collar   
     size 
(inches) 
 
       
        
 30 or less 32 34 36 38 40 42+ 
 
c. Trouser 
   waist size 
(inches) 
 
       
 
 
 
 XS S M L XL XXL+   
 
d. Jumper/ 
  t-shirt size 
 
        
         
 8 10 12 14 16 18 20 22+ 
 
e. Blouse size 
 
        
         
 8 10 12 14 16 18 20 22+ 
 
f. Trouser/ 
     skirt size 
 
        
      
       
       
M
E
N
 
    
        
W
O
M
E
N
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Part 5 - About you and your life 
 
 
1. What is your date of birth?  
  
 
 
 
                /                /                      (example: 01/10/59) 
 
      (day)          (month)         (year) 
 
  
2. Are you? 
 
Male Female 
  
 
 
 
 
 
3. Do you live alone? 
 
Yes No  
  
 
 
 
 
 
4. What is your current marital status? 
    (Please put a cross in one box only) 
 
Married Widowed Separated Divorced Cohabiting Single 
      
 
 
 
     
 
 
5. What is your current employment status? 
   (Please put a cross in one box only) 
 
 
Employed  
Not working 
due to ill health 
 
Retired 
Unemployed/ 
seeking work 
 
Housewife 
 
Other 
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For the questions on this page (except question 8) please write the answers 
in the boxes provided. 
 
 
6. 
 
If you are working what is your job  
title (examples – factory worker, 
welder, office worker, lawyer)? 
 
 
 
 
 
6a. 
 
If you provided a job title in the  
question above please state in which 
field of employment this was  
(examples – manufacturing, civil  
service, health care). 
 
 
 
 
 
7. 
 
If you are not working or are retired, 
what job have you done for most of 
your working life? 
 
 
 
  
 
7a. 
 
If you provided a job title in the question 
above please state in which field of 
employment this was (examples – 
manufacturing, civil service, health care). 
 
 
 
 
  Yes No   
     
 
8. 
 
Do you have a spouse or partner who is 
currently living with you?           
      
 
 
  
If no please go to 
question 11 
 
 
9. 
 
If they are working what is their job title 
(examples – factory worker, welder, office 
worker, shop assistant, lawyer)? 
 
 
 
 
 
10. 
 
If they are not working or are  
retired, what job did they you do for 
most of their working life? 
 
 
 
 
 
11. 
 
If you are a widow, or widower, what  
was your spouse’s job title for most of 
their working life? 
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Part 6 – Your family & friends 
 
We are interested in the contact you may have with your friends and family. 
(Please answer each question and put a cross in one box on each line.) 
 
1. How many living children do you have? 
 
None 1 to 2 3 to 5 6 or more 
    
 
 
 
   
 
2. How many of your children do you see at least once a month? 
 
None 1 to 2 3 to 5 6 or more 
    
 
 
 
   
 
3. Apart from your children, how many relatives do you have with whom you 
    feel close? 
 
None 1 to 2 3 to 5 6 to 9 10 or more 
     
 
 
 
    
 
4. How many close relatives do you see at least once a month? 
 
None 1 to 2 3 to 5 6 to 9 10 or more 
     
 
 
 
    
 
5. How many close friends do you have? 
 
None 1 to 2 3 to 5 6 to 9 10 or more 
     
 
 
 
    
 
6. How many of these friends do you see at least once a month? 
 
None 1 to 2 3 to 5 6 to 9 10 or more 
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  Yes No  
    
 
7. 
 
Is there any one special person you know that you feel very 
close to; someone you feel you can share confidences and 
feelings with? 
 
 
 
 
 
 
7a. If yes, how often do you see or talk with this person? 
 
 
Daily  
 
Weekly 
 
Monthly 
Several times 
a year 
Once a year or 
less 
     
 
 
 
    
 
 
8. How often do you go to religious meetings or services? 
 
More than 
once a week 
 
Once a week 
1-3 times per 
month 
Less than 
once a month 
Never or  
almost never 
     
 
 
 
    
 
 
9. How many hours each week do you participate in any groups such as    
    a social or work group, church-connected group, self-help group, charity,  
    public service or community group? 
 
 
None 
 
1-2 hours 
 
3-5 hours 
 
6-10 hours 
 
11-15 hours 
16 or more 
hours 
      
 
 
 
     
 
 
10. Thinking about the cost of living as it affects you, which of these  
      descriptions best describes your situation?  
 
 
Find it a strain to get  
by from week to week 
 
Have to be careful 
with money 
Able to manage  
without much  
difficulty 
Quite  
comfortably 
off 
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Please put in today’s date (example: 12/01/11) 
 
  
                         /                   / 
 
               (day)            (month)              (year) 
 
 
 
Please now continue and complete SECTION E on page 43.  
Once you have completed this final page please return 
the questionnaire in the reply envelope provided.  
 
 
 
THANK YOU FOR YOUR HELP 
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SECTION E – Helping us in the future 
 
 
Thank you very much for your time. In this final section of the questionnaire 
we ask you about your willingness to be contacted again in the future. 
  
Please answer the statement below  
by putting a cross in one box only 
 
 YES 
 
NO 
 
 I am willing to be contacted in the future to help with 
further work related to this study 
 
      (this does not mean that you must take part in the future, 
       just that you are agreeing to be contacted again) 
 
   
 
 
Finally, please provide your details below and then return your 
questionnaire in the reply envelope provided (no stamp needed) 
 
 
Name…………………….……….………….………… Date……………………… 
 
Address……………………………………………………………………………… 
 
…………………………………………………………. Post code: ………………. 
 
 
 
 
Thank you for your help 
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Study ID 
 335 
 
Appendix 7.4: 2C Methods –2C monthly interval questionnaire 
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General Health  
Monthly Questionnaire 
 
Instructions 
 
The aim of this short follow-up questionnaire, to the main survey you completed 
recently is to find out about your health in the past 4 weeks. The answers you 
give in the questionnaire will be treated in the strictest confidence. 
 
Please answer the questions, even if you have  
no current problems with your health 
by putting a cross in a box, like this: 
 
When you have finished, please check that all questions have been answered 
and then return the completed questionnaire back to us as soon as you can. An 
envelope has been provided and you do not need a stamp. 
 
Details about this project are available in the information sheet enclosed. If you 
would like further information please contact the study coordinator  
James Prior on 01782 734863 
 
Your date of birth (example: 01/10/59) Today’s date  
  
 
                    /              /     
 
 
                 /              / 
 
         (day)            (month)           (year)            (day)            (month)         (year) 
X 
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Part 1 – Your general health 
 
Please answer every question. Some questions may look similar to others 
but each one is different. Please take the time to read and answer each 
question carefully by placing a cross in the box of your choice. 
 
 
1. In general, would you say your health is: 
(Please put a cross in one box only) 
 
Excellent Very good Good Fair Poor 
     
 
 
    
 
 
 
2. Compared to 4 weeks ago, how would you rate your health in general now? 
     (Please put a cross in one box only) 
 
Much better 
than 4  
weeks ago 
Somewhat 
better than 4 
weeks ago 
 
About the 
same 
Somewhat 
worse now than 
4 weeks ago 
Much worse 
now than 4 
weeks ago 
     
 
 
    
 
 
 
3. The following questions are about activities you might do during a typical 
day. Does your health now limit you in these activities? If so, how much? 
(Please put a cross in one box on each line) 
 
  Yes, 
limited 
a lot 
Yes, 
limited 
a little 
No, not 
limited 
at all 
     
 
a 
 
Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling or playing golf 
 
   
     
 
b 
 
Climbing several flights of stairs 
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4. During the past 4 weeks, have you had any of the following problems with  
     your work or other regular daily activities as a result of your physical  
     health? (Please put a cross in one box on each line) 
 
 All  
of the 
time 
Most  
of the 
time 
Some  
of the 
time 
A little  
of the 
time 
None 
of the  
time 
       
 
a. 
 
Accomplished less 
than you would like 
 
     
       
 
b. 
 
Were limited in the 
kind of work or other 
activities 
 
     
 
 
5. During the past 4 weeks, have you had any of the following problems with  
your work or other regular daily activities as a result of any emotional  
problems (such as feeling depressed or anxious)?  
(Please put a cross in one box on each line) 
  
 All  
of the 
time 
Most  
of the 
time 
Some  
of the 
time 
A little  
of the 
time 
None 
of the 
time 
       
 
a. 
 
Accomplished less 
than you would like 
 
     
       
 
b. 
 
Didn’t do work or other 
activities as carefully 
as usual 
 
     
 
 
6. During the past 4 weeks, how much did pain interfere with your normal 
work (including both work outside the home and housework)? 
    (Please put a cross in one box only) 
 
Not at all A little bit Moderately Quite a bit Extremely 
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7. These questions are about how you feel and how things have been with        
     you during the past 4 weeks. For each question, please give the one    
     answer that comes closest to the way you have been feeling. 
     (Please put a cross in one box on each line) 
 
How much of the time  
during the past 4 weeks… 
All  
of the  
time 
Most  
of the 
time 
Some  
of the 
time 
A little  
of the 
time 
None 
of the 
time 
       
 
a. 
 
Have you felt calm and 
peaceful? 
 
     
       
 
b. 
 
Did you have a lot of 
energy? 
 
     
       
 
c. 
 
Have you felt downhearted 
and depressed? 
 
     
 
 
 
8. During the past 4 weeks, how much of the time has your physical health    
     or emotional problems interfered with your social activities (like visiting  
     with friends, relatives, etc.)? (Please put a cross in one box only) 
  
 
All of the  
time 
Most of  
the time 
Some of  
the time 
A little of  
the time 
None of 
the time 
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Part 2 – Your daily life 
 
This section asks about how you’ve been in your day-to-day life in the past 4 
weeks. Please place a cross in one box per line to answer each question. 
 
  0-15 
mins 
16-30 
mins 
31-45 
mins 
46-60 
mins 
61+ 
mins 
       
 
1. 
 
How long on average did it usually 
take for you to fall asleep during the 
past 4 weeks?  
 
     
       
  0-3  
hours  
4-6  
hours 
7-8  
hours 
9-12  
hours 
13+ 
hours 
       
 
2. 
 
How many hours on average did 
you sleep each night during the 
past 4 weeks?  
 
     
 
 
3. In the past 4 weeks I have found   
     that... 
Not at 
all 
A little 
bit 
Some
what 
Quite 
a bit 
Very 
much 
      
 
a. I have trouble starting things  
      because I’m tired 
 
     
      
 
b. I have trouble finishing things  
      because I’m tired 
 
     
 
 
4. How often, in the past 4 weeks  
     have you done any of  
     these activities? 
 
 
None 
 
 
Monthly 
 
 
Weekly 
 
More than  
once a week 
     
 
a. Walking 
 
    
     
 
b. Gardening 
 
    
     
 
c. Vigorous activities  
    (e.g. dancing, swimming, bowling) 
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Part 3 – Your Pain 
 
This is about pain in different parts of your body. Please complete each of the 
following questions even if you have not had pain in any of these areas in 
the past 4 weeks.  
 
1. If you think about an average week over the past 4 weeks, for how many  
    days (if at all) did you have..?  
    (For each line please put a cross in one box only) 
 
  None 
 
1-3 times 
a week 
Once  
a day 
Several  
times a day 
All the 
time 
       
 
a. 
 
Headache 
 
     
       
 
b. 
 
Neck pain 
 
     
       
 
c. 
 
Shoulder pain 
 
     
       
 
d. 
 
Elbow pain 
 
     
       
 
e. 
 
Hand pain 
 
     
       
 
f. 
 
Chest pain 
 
     
       
 
g. 
 
Abdominal pain 
 
     
       
 
h. 
 
Back pain 
 
     
       
 
i. 
 
Hip pain 
 
     
       
 
j. 
 
Knee pain 
 
     
       
 
k. 
 
Foot pain 
 
     
 
    
    
    
    
    
    
   
    
    
    
    
 
 
 
 
 
 
 
 
 
 
 
 
20/11/09, version 5 7 
 Part 4 - Your Symptoms 
 
This is about other symptoms you may have experienced. Please complete 
each of the following questions even if you have not experienced the 
symptom in the past 4 weeks. 
 
1.  How often (if at all) have you had any of the below symptoms over the 
past 4 weeks? (For each line please put a cross in one box only) 
 
  Not  
at all 
For 1 week  
or less 
For 2 
weeks 
For 3  
weeks 
For 4  
weeks 
       
 
a. 
 
Chest pain 
 
i) At rest 
 
ii) During activity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
b. 
 
Shortness of breath: 
 
i) At rest 
 
ii) During light activity 
 
     
       
 
c. 
 
Swelling (feet, ankles 
and/or legs) 
 
     
       
 
d. 
 
Heartbeat racing  
(Palpitations) 
 
     
       
 
e. 
 
Dizziness  
 
     
 
 
Please check that you have answered all of the questions and return in 
the envelope provided (no stamp is required) 
  
 
THANK YOU FOR YOUR HELP 
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Study ID 
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Appendix 7.5: 2C Methods – List of measures included in the 2C 
questionnaires 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 7.5: Study measures  
  Survey measures  
Data source Factors Baseline & 12-month follow-up  Monthly 
Clinical records 8 disease cohorts  Read code classification  
Consultation comorbidity  Read code classification (Kadam severity classification)  
Blood tests & investigations  Read code classification  
Drugs prescribed  British National Formulary (BNF)  
Referrals  Read code classification  
Survey data General measures  Short form 12 (SF-12) health survey 
 Short form 36 (SF-36) health survey – Q2 only 
 EuroQol (EQ-5D) 
 Hospital Anxiety and Depression (HAD) scale 
 Medical Outcomes Study (MOS) - Sleep Scale 
 Functional Assessment of Chronic Illness (FACIT) – Fatigue 
 Brief Illness Perception Questionnaire (B-IPQ) 
 Social Networks 
 SF-12 
 SF-36, Q2 
 
 
 Qs 1 & 2 only 
 Qs 5 & 6 only 
 
Cardiovascular measures  Seattle Angina Questionnaire (SAQ), UK version 
 Kansas City Cardiomyopathy Questionnaire (KCCQ)  
 Rose angina 
 Palpitations (based on [ref]) 
 Vertigo Severity Scale (VSS) 
 Qs 2 & 3 only 
 Qs 3 & 7 only 
 
 Q1 only 
 Q1 only 
Pain and OA measures  Pain manikin, pain frequency & pain intensity 
 Knee Injury & Osteoarthritis Outcome Score (KOOS) – 
Physical Function Shortform 
 Hip Injury & Osteoarthritis Outcome Score (HOOS) –  
Physical Function Shortform 
 Pain frequency 
 Lifestyle  BMI, Alcohol, Smoking 
 Short Questionnaire to Assess Health Enhancing Physical Activity  
(SQUASH) 
 Eyesight/hearing 
 Body shape 
 
 Qs 2a, 2c, 2e only 
Survey & clinical  records Socio-demographic  Age, Gender, Deprivation  
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Appendix 7.6: 2C Methods – Patient invitation letter 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30/11/09, version 3 
 
 
 
 
 
 
Dear Patient, 
 
GENERAL HEALTH QUESTIONNAIRE 
 
Your general practice is working with Primary Care Sciences at Keele University and 
we would like your help with the start of a new research study.  
 
As a registered patient at this practice, and also a local resident we are interested in 
your views about your health, even if you are currently well. In this research we are 
trying to find out about how many people suffer with both joint pain and heart disease, 
how they live with these combined problems over time, and then compare them to 
people who have other problems or who are well. It is important that we ask different 
people about their health to make sure that we are providing the right types of 
services. 
 
We hope that you are able to help with our research and can spare a short amount of 
time to complete the questionnaire enclosed, which should take about 25-30 minutes. 
All of the answers will be dealt with in the strictest confidence. We can also assure 
you that whether or not you answer the questionnaire will not in any way affect the 
care you receive from your practice or elsewhere. 
 
We would be grateful if you would return the questionnaire in the envelope provided in 
the next two weeks or as soon as you can. You do not need a stamp. Further details 
of the project are on the accompanying information sheet. If you would like to know 
more about this study, please contact James Prior, Project Coordinator, at Keele 
University on 01782 734863. 
 
Thank you very much for your help in supporting our research project. 
 
Yours faithfully  
 
 
 
 
Practice GP  
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Appendix 7.7: 2C Methods – Patient baseline information sheet 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30/11/09, version 5 1 
Primary Care Sciences   working with     PRACTICE NAME        
Keele University         ADDRESS 1 
Staffordshire         ADDRESS 2 
ST5 5BG         ADDRESS 3 
01782 734863                    GP Name 1 
            GP Name 2 
            GP Name 3 
INFORMATION SHEET 
 
You are being invited to take part in a research study. Before you decide, it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully. 
 
What is the purpose of the study? 
It is important that we ask people about their health to make sure we are providing the 
right types of services. Joint pain and heart disease are very common problems in the 
UK and the likelihood of suffering both at the same time increases with age. In this 
research we are trying to find out about how many people suffer with both joint pain 
and heart disease and how they live with these combined problems over time, and 
then compare them to people with other types of problems or those who are well. 
 
Why have I been invited? 
As a local resident we are interested in your views about your health. If you could 
spare time to fill in the enclosed questionnaire you would provide information that will 
be of great benefit.  We are interested in your views even if you are currently well. 
 
Do I have to take part? 
Whether or not you take part in this research is voluntary. If you do decide to take 
part, you are free to withdraw at any time without giving a reason. A decision to 
withdraw, or not to take part will not affect your rights to access any health services. 
 
How long will it take? 
Taking part means that you are asked to complete the enclosed questionnaire and 
that we would send you another similar questionnaire in 12 months. We think it 
should take 25-30 minutes to complete each questionnaire.  
 
In between these two questionnaires and with your permission we would also like to 
send you a much shorter questionnaire (only 4 pages) each month. If you agree to be 
contacted in the future, this does not mean that you must take part, only that you will 
be contacted again.  
  
What are the possible benefits of taking part? 
Although any direct benefit to you is unlikely, what we learn from the study will help 
people who experience multiple health problems in the future. 
30/11/09, version 5 2 
Will my taking part in this study be kept confidential? 
The answers you give in the questionnaire will be dealt with in strictest confidence.  
Each person who responds to the questionnaire will be given a unique identification 
number, so the data from the study will not have any identifiable names and 
addresses, and cannot be traced back to you. On this basis, the data may be used in 
other research studies but will always be stored in a secure way. 
 
Medical record review 
We also want to find out what types of treatments and tests people have.  We can do 
this by reviewing your medical records, and we ask your permission to do this on the 
last page of the questionnaire. When reviewing records, your name will not be used 
so that you cannot be identified personally. All information will be held in confidence. 
 
What will happen if I don’t want to carry on with this study? 
You can withdraw from this study by telephoning us on 01782 734863.  Withdrawing 
means that we would no longer contact you directly, but we would still keep and use 
the information you have provided up to the point of your withdrawal. If you contact us 
to withdraw from the study, and you have consented to medical record review, we will 
check whether you also want us to stop reviewing your medical records. 
 
What will happen to the results of the research study? 
Because this is a large study, the results will not be available for about two years, and 
will then be published in medical journals and reports. The main findings from the 
study will be displayed on a poster in your practice but if you would like any other 
information after seeing these we will be happy to help. 
 
Who is overseeing this research? 
This research is organised by the Arthritis Research Campaign National Primary Care 
Centre at Keele University and has been reviewed by the Cheshire Research Ethics 
Committee (Research Ethics Committee Reference Number: 09/H1017/40). 
 
Contact for further information 
If you have any questions or would like further information about this study please 
contact our Study Coordinator, James Prior, on 01782 734863.  
 
If you have any questions or concerns about taking part you can also contact the 
Patient Advice and Liaison Service (PALS).  Your local PALS office phone number for 
Stoke-on-Trent is 0800 783 2865, for North Staffordshire this is 0800 389 8832 and 
for Cheshire it is 01606 544444. 
 
 
Thank you for taking time to read this information leaflet 
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Appendix 7.8: 2C Methods – Reminder postcard 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 GENERAL HEALTH QUESTIONNAIRE REMINDER 
 
We are writing to remind you of a questionnaire that we recently sent to 
you, as we are still interested in your response.  We know that you may be 
busy, but it would be very helpful to us if you would take the time to 
complete the questionnaire and return it to us in the envelope that we 
previously provided, you do not need a stamp.  We would be grateful if 
you could return the questionnaire in the next two weeks and would like to 
remind you that all answers are strictly confidential. 
 
If you have returned the questionnaire in the last few days, please ignore 
this postcard and we apologise for troubling you again. This study is being 
carried out by Keele researchers working with your practice and if you 
have any questions please contact James Prior on 01782 734863.  
 
Thank you very much for your help with this research. It is greatly 
appreciated. 
 
Practice GP 
GENERAL HEALTH QUESTIONNAIRE REMINDER 
 
We are writing to remind you of a questionnaire that we recently sent to 
you, as we are still interested in your response.  We know that you may be 
busy, but it would be very helpful to us if you would take the time to 
complete the questionnaire and return it to us in the envelope that we 
previously provided, you do not need a stamp.  We would be grateful if 
you could return the questionnaire in the next two weeks, and would like to 
remind you that all answers are strictly confidential. 
 
If you have returned the questionnaire in the last few days, please ignore 
this postcard and we apologise for troubling you again. This study is being 
carried out by Keele researchers working with your practice and if you 
have any questions please contact James Prior on 01782 734863.  
 
Thank you very much for your help with this research. It is greatly 
appreciated. 
 
Practice GP 
 
GENERAL HEALTH QUESTIONNAIRE REMINDER 
 
We are writing to remind you of a questionnaire that we recently sent to 
you, as we are still interested in your response.  We know that you may be 
busy, but it would be very helpful to us if you would take the time to 
complete the questionnaire and return it to us in the envelope that we 
previously provided, you do not need a stamp.  We would be grateful if 
you could return the questionnaire in the next two weeks, and would like to 
remind you that all answers are strictly confidential. 
 
If you have returned the questionnaire in the last few days, please ignore 
this postcard and we apologise for troubling you again. This study is being 
carried out by Keele researchers working with your practice and if you 
have any questions please contact James Prior on 01782 734863.  
 
Thank you very much for your help with this research. It is greatly 
appreciated. 
 
Practice GP 
 
GENERAL HEALTH QUESTIONNAIRE REMINDER 
 
We are writing to remind you of a questionnaire that we recently sent to 
you, as we are still interested in your response.  We know that you may be 
busy, but it would be very helpful to us if you would take the time to 
complete the questionnaire and return it to us in the envelope that we 
previously provided, you do not need a stamp.  We would be grateful if 
you could return the questionnaire in the next two weeks, and would like to 
remind you that all answers are strictly confidential. 
 
If you have returned the questionnaire in the last few days, please ignore 
this postcard and we apologise for troubling you again. This study is being 
carried out by Keele researchers working with your practice and if you 
have any questions please contact James Prior on 01782 734863.  
 
Thank you very much for your help with this research. It is greatly 
appreciated. 
 
Practice GP 
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Appendix 7.9: 2C Methods – Reminder letter 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30/11/09, version 2 
 
 
 
 
 
 
 
 
Dear Patient, 
 
GENERAL HEALTH QUESTIONNAIRE 
 
We are writing to remind you of our new research study that we are carrying out with 
Keele University. In this research we are trying to understand the local population’s 
views on their health, and also find out how this is affected in people with 
combinations of problems, such as joint pain and heart disease. We have not yet 
received a response from you but are still very interested to hear about your health.  
 
We have therefore enclosed another copy of the questionnaire we recently sent you 
and would be grateful if you could complete this, which should take about 25-30 
minutes. Once complete please return the questionnaire in the envelope provided in 
the next two weeks or as soon as you can. You do not need a stamp. 
 
If you have returned a questionnaire in the last few days we apologise for troubling 
you again. If you have not returned the questionnaire, we hope that you will be able to 
help with our research and spare a short amount of time to complete the one we have 
sent today. 
 
Further details of the project are on the accompanying information sheet. If you would 
like to know more about this study please contact James Prior, Project Coordinator 
at Keele University on 01782 734863. 
 
Thank you very much for your help in supporting our research project. 
 
Yours faithfully  
 
 
 
 
Practice GP 
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Appendix 7.10: 2C Methods – Patient exclusions from sample 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 7.10: Number of patients lost at each level of exclusion, stratified by each disease cohort  
   Exclusions 
Disease cohort   Total population  Pre-mailout 
n (%) 
 During mailout 
n (%) 
-CVD -OA 2624  27 (1.0)  62 (2.4) 
+Hyp -OA 1363  14 (1.0)  27 (2.0) 
+IHD -OA 2137  39 (1.8)  62 (2.9) 
+HF -OA 286  10 (3.5)  17 (5.9) 
-CVD +OA 1369  20 (1.5)  32 (2.3) 
+Hyp +OA 1699  17 (1.0)  38 (2.2) 
+IHD +OA 508  8 (1.6)  10 (2.0) 
+HF +OA 78  3 (3.8)  2 (2.6) 
Total   138 (1.4)  250 (2.5) 
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Appendix 8.1: 2C Cross-sectional – Characteristics of baseline 
responders 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 8.1: Characteristics of baseline responders stratified by disease cohort (n = 5,426) 
 
 
CVD=Cardiovascular disease, OA=Osteoarthritis, Hyp=Hypertension, IHD=Ischaemic heart disease, HF=Heart failure. *Deprivation status is based on 5,399 
 
 
 
 
 
 
 
 
  Disease cohorts 
Factors  -CVD -OA 
n=1165 (%) 
+Hyp -OA 
n=720 (%) 
+IHD -OA 
n=1196 (%) 
+HF -OA 
n=149 (%) 
-CVD +OA 
n=828 (%) 
+Hyp +OA 
n=1017 (%) 
+IHD +OA 
n=305 (%) 
+HF +OA 
n=46 (%) 
          
Age group  
(years) 
40-49 313 (27) 33 (5) 21 (2) 3 (2) 59 (7) 9 (1) 1 (1) 0 (0) 
50-59 413 (36) 132 (18) 127 (11) 9 (6) 180 (22) 92 (9) 11 (3) 0 (0) 
60-69 282 (24) 239 (33) 369 (31) 26 (17) 312 (37) 318 (31) 64 (21) 3 (6) 
70-79 119 (10) 219 (30) 446 (37) 53 (36) 180 (22) 369 (36) 136 (45) 16 (35) 
80≥ 38 (3) 97 (14) 233 (19) 58 (39) 97 (12) 229 (23) 93 (30) 27 (59) 
          
Gender Male 547 (47) 324 (45) 807 (67) 89 (60) 332 (40) 391 (38) 140 (46) 23 (50) 
 Female 618 (53) 395 (55) 389 (33) 60 (40) 496 (60) 626 (62) 165 (54) 23 (50) 
          
Deprivation  
Status* 
Category 0 (most affluent) 279 (24) 155 (22) 243 (20) 23 (15) 168 (21) 222 (22) 59 (20) 8 (18) 
Category 1 712 (61) 425 (59) 732 (62) 90 (61) 521 (63) 605 (60) 190 (63) 27 (61) 
Category 2 (most deprived) 173 (15) 135 (19) 217 (18) 36 (24) 135 (16) 183 (18) 52 (17) 9 (21) 
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Appendix 8.2: 2C Cross-sectional – Characteristics of baseline non-
responders 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 8.2: Characteristics of baseline non-responders, stratified by disease cohort (n = 4,250) 
 
 
CVD=Cardiovascular disease, OA=Osteoarthritis, Hyp=Hypertension, IHD=Ischaemic heart disease, HF=Heart failure. *Deprivation status is based on 4,237 
 
  Disease cohorts 
Factors  -CVD -OA 
n=1370 (%) 
+Hyp -OA 
n=602 (%) 
+IHD -OA 
n=840 (%) 
+HF -OA 
n=110 (%) 
-CVD +OA 
n=489 (%) 
+Hyp +OA 
n=627 (%) 
+IHD +OA 
n=185 (%) 
+HF +OA 
n=27 (%) 
          
Age group  
(years) 
40-49 579 (42) 73 (12) 51 (6) 2 (1) 79 (16) 24 (4) 3 (1) 0 (0) 
50-59 435 (31) 159 (27) 148 (17) 13 (12) 129 (27) 80 (13) 11 (6) 1 (4) 
60-69 231 (17) 177 (29) 248 (30) 28 (26) 133 (27) 181 (29) 42 (23) 1 (4) 
70-79 76 (6) 110 (18) 231 (28) 29 (26) 98 (20) 185 (29) 68 (37) 7 (26) 
80≥ 49 (4) 83 (14) 162 (19) 38 (35) 50 (10) 157 (25) 61 (33) 18 (66) 
          
Gender Male 698 (51) 285 (47) 527 (63) 53 (48) 231 (47) 220 (35) 65 (35) 8 (30) 
 Female 672 (49) 317 (53) 313 (37) 57 (52) 258 (53) 407 (65) 120 (65) 19 (70) 
          
Deprivation  
Status* 
Category 0 (most affluent) 246 (18) 111 (19) 125 (15) 15 (14) 99 (20) 105 (17) 27 (15) 5 (19) 
Category 1 809 (59) 361 (60) 519 (62) 66 (60) 287 (59) 375 (60) 120 (65) 16 (59) 
Category 2 (most deprived) 311 (23) 128 (21) 194 (23) 29 (26) 102 (21) 144 (23) 37 (20) 6 (22) 
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Appendix 9.1: 2C Cohort – Proportion of responders & non-
responders at each time-point 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 9.1: Comparison of baseline and 12-month follow-up responders by disease cohorts 
 Baseline Baseline & month 12 Baseline & month 4 baseline, month 4 & month 12 
Disease cohort  Responders  
n=5176 
n (%) 
Responders  
n = 3266 
n (%) 
Non-responders  
n = 1942 
n (%) 
Responders  
n = 2,167 
n (%) 
Non-responders  
n = 3,128 
n (%) 
Responders  
n = 1,919 
n (%) 
Part-responders* 
n = 3,371 
n (%) 
        
-CVD -OA 1141 (22) 722 (22) 410 (21) 470 (22) 674 (21) 416 (21) 726 (22) 
        
+Hyp -OA 688 (13) 439 (13) 257 (13) 284 (13) 420 (13) 257 (13) 447 (13) 
+IHD -OA 1140 (22) 702 (21) 440 (23) 480 (22) 687 (22) 419 (22) 747 (22) 
+HF -OA 141 (3) 69 (2) 71 (4) 48 (2) 96 (3) 35 (2) 111 (3) 
        
-CVD +OA 788 (15) 515 (16) 282 (15) 358 (16) 453 (15) 324 (17) 484 (14) 
        
+Hyp +OA 953 (18) 614 (19) 356 (18) 404 (19) 583 (19) 358 (19) 626 (19) 
+IHD +OA 284 (6) 184 (6) 106 (5) 109 (5) 186 (6) 98 (5) 197 (6) 
+HF +OA 41 (1) 21 (1) 20 (1) 14 (1) 29 (1) 12 (1) 33 (1) 
CVD=Cardiovascular disease, OA=Osteoarthritis, Hyp=Hypertension, IHD=Ischaemic heart disease, HF=Heart failure*Responders to baseline but subsequent non-
response to either month 4 or month 12. 
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Appendix 9.2: 2C Cohort – Characteristics of non-responders to 12-
month follow-up  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 9.2: Characteristics of non-responders to 12-month follow-up (n=1,942) 
 
  Disease Cohorts 
Factors  -CVD -OA 
n = 410 
n (%) 
+Hyp -OA 
n = 257 
n (%) 
+IHD -OA 
n = 440 
n (%) 
+HF -OA 
n = 71 
n (%) 
-CVD +OA 
n = 282 
n (%) 
+Hyp +OA 
n = 356 
n (%) 
+IHD +OA 
n = 106 
n (%) 
+HF +OA 
n = 20 
n (%) 
          
Age group  
(years) 
40-49 135 (33) 15 (6) 12 (3) 1 (1) 16 (6) 4 (1) 0 (0) 0 (0) 
50-59 142 (34) 45 (17) 40 (9) 6 (8) 63 (22) 33 (9) 7 (7) 0 (0) 
60-69 79 (19) 81 (32) 127 (29) 11 (16) 90 (32) 95 (27) 16 (15) 1 (5) 
70-79 43 (11) 81 (32) 159 (36) 22 (31) 71 (25) 130 (37) 48 (45) 7 (35) 
80≥ 11 (3) 35 (13) 102 (23) 31 (44) 42 (15) 94 (26) 35 (33) 12 (60) 
          
Gender Male 206 (50) 110 (43) 285 (65) 43 (61) 110 (39) 142 (40) 46 (43) 8 (40) 
Female 204 (50) 147 (57) 155 (35) 28 (39) 172 (61) 214 (60) 60 (57) 12 (60) 
          
Deprivation  
Status* 
Category 0 (most affluent) 70 (17) 45 (17) 76 (17)  13 (18) 44 (16) 73 (21) 14 (13) 5 (25) 
Category 1 261 (64) 150 (59) 276 (63) 41 (58) 183 (65) 212 (60) 66 (62) 10 (50) 
Category 2 (most deprived) 79 (19) 61 (24) 87 (20) 17 (24) 53 (19) 68 (19) 26 (25) 5 (25) 
*Deprivation status based on 1,935 patients
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Appendix 9.3: 2C Cohort – Characteristics of non-responders to 4-
month follow-up  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 9.3: Characteristics of non-responders to 4-month follow-up (n =3,128)  
 
  Disease cohorts 
Factors  -CVD -OA 
n = 674 
n (%) 
+Hyp -OA 
n = 420 
n (%) 
+IHD -OA 
n = 687 
n (%) 
+HF -OA 
n = 96 
n (%) 
-CVD +OA 
n = 453 
n (%) 
+Hyp +OA 
n = 583 
n (%) 
+IHD +OA 
n = 186 
n (%) 
+HF +OA 
n = 29 
n (%) 
          
Age group  
(years) 
40-49 203 (30) 19 (5) 14 (2) 1 (1) 32 (7) 5 (1) 0 (0) 0 (0) 
50-59 226 (33) 69 (16) 68 (10) 7 (7) 95 (21) 49 (8) 10 (5) 0 (0) 
60-69 152 (23) 133 (32) 200 (29) 12 (13) 152 (34) 168 (29) 37 (20) 2 (7) 
70-79 72 (11) 131 (31) 249 (36) 32 (33) 114 (25) 219 (38) 78 (42) 10 (34) 
80≥ 21 (3) 68 (16) 156 (23) 44 (46) 60 (13) 142 (24) 61 (33) 17 (59) 
          
Gender Male 327 (49) 182 (43) 446 (65) 54 (56) 185 (41) 231 (40) 83 (45) 13 (45) 
Female 347 (51) 238 (57) 241 (35) 42 (44) 268 (59) 352 (60) 103 (55) 16 (55) 
          
Deprivation 
Status* 
Category 0 (most affluent) 137 (20) 76 (18) 112 (16) 14 (15) 76 (17) 109 (19) 26 (14) 4 (15) 
Category 1 412 (61) 255 (61) 430 (63) 57 (59) 289 (64) 345 (60) 114 (63) 17 (63) 
Category 2 (most deprived) 124 (19) 86 (21) 143 (21) 25 (26) 86 (19) 124 (21) 42 (23) 6 (22) 
CVD=Cardiovascular disease, OA=Osteoarthritis, Hyp=Hypertension, IHD=Ischaemic heart disease, HF=Heart failure. *Deprivation status based on 3,109 patient
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Appendix 9.4: Characteristics of part-responders to baseline, 4-month and 12-month follow-up (n = 3,371) 
  Disease cohorts 
Factors  -CVD -OA 
n = 726 
n (%) 
+Hyp -OA 
n = 447 
n (%) 
+IHD -OA 
n = 747 
n (%) 
+HF -OA 
n = 111 
n (%) 
-CVD +OA 
n = 484 
n (%) 
+Hyp +OA 
n = 626 
n (%) 
+IHD +OA 
n = 197 
n (%) 
+HF +OA 
n = 33 
n (%) 
          
Age group  
(years) 
40-49 220 (30) 20 (4) 15 (2) 1 (1) 33 (7) 6 (1) 0 (0) 0 (0) 
50-59 246 (34) 76 (17) 72 (10) 8 (7) 100 (20) 51 (8) 10 (5) 0 (0) 
 60-69 159 (22) 137 (31) 218 (29) 15 (14) 164 (34) 179 (29) 37 (19) 2 (6) 
 70-79 76 (11) 143 (32) 274 (37) 38 (34) 120 (25) 236 (38) 84 (43) 11 (33) 
 80≥ 25 (3) 71 (16) 168 (22) 49 (44) 67 (14) 154 (24) 66 (33) 20 (61) 
          
Gender Male 349 (48) 193 (43) 483 (65) 65 (59) 201 (41) 249 (40) 86 (44) 14 (42) 
 Female 377 (52) 254 (57) 264 (35) 46 (41) 283 (59) 377 (60) 111 (56) 19 (58) 
          
Deprivation  
Status* 
Category 0 (most affluent) 146 (20) 83 (19) 126 (17) 16 (14) 84 (17) 119 (19) 27 (14) 6 (19) 
Category 1 449 (62) 268 (60) 466 (63) 67 (61) 306 (64) 375 (60) 122 (63) 18 (58) 
 Category 2 (most deprived) 130 (18) 93 (21) 153 (20) 28 (25) 91 (19) 127 (21) 44 (23) 7 (23) 
*Deprivation status based on 3,351 
 
 
 
 
 
